{ "dataset": "PFS-PSSD-Post-Drug-Syndromes-Corpus", "version": "1.17", "created": "2026-10-11", "count": 536, "counts_by_source": { "peer_reviewed": 28, "reddit": 9, "youtube": 5, "youtube_transcripts": 8, "icd_codes": 6, "medications": 15, "datasets": 14, "glossary": 64, "timeline": 45, "mechanism_matrix": 12, "open_questions": 10, "gene_library": 28, "powers_gene_list": 17, "pssd_discord_papers": 26, "pssd_discord_videos": 2, "powers_history_curated": 42, "pssd_discord_duplicates_updated": 1, "literature_sweep": 77, "epigenetics_supplement": 15, "sidefxhub": 11, "systems_review": 48, "powers_tranche2": 39, "researcher_list": 4, "powers_tranche3": 5, "powers_tranche4": 1, "powers_tranche5": 2, "curator_additions": 3 }, "counts_by_collection_tag": { "core": 261, "pssd-discord": 28, "powers-reddit-history": 89, "literature-sweep-2026-10": 77, "epigenetics-supplement-2026-10": 15, "sidefxhub": 11, "systems-review-2026-10": 48, "researcher-list-2026-10": 4, "curator-additions": 3 }, "collection_tags": { "core": "Original corpus content (peer-reviewed lit, Powers commentary, transcripts, ICD codes, medications, datasets, glossary, timeline, mechanism matrix, open questions, gene library records, Powers gene findings). Includes PSSD-003, which is additionally flagged starred/curated_source='PSSD discord'.", "pssd-discord": "Curated from the PSSD Discord 'Papers & Resources Mentioned' list (Oct 2026); all carry starred: true and curated_source: 'PSSD discord'.", "powers-reddit-history": "Curated from the user-provided u/drwillpowers Reddit history export (Oct 2026); all carry starred: true and curated_source: 'Powers Reddit history (John-provided export)'.", "literature-sweep-2026-10": "Systematic literature sweep of 2026-10-07 (5 axes: PFS clinical/neurosteroid, PSSD, post-retinoid/post-drug syndromes, mechanistic pillars, regulatory/gray); not starred; carries sweep_date.", "epigenetics-supplement-2026-10": "Targeted 2026-10-07 follow-up sweep filling the persistence-mechanism gap (finasteride/SSRI/isotretinoin epigenetics, SRD5A2 methylation, DNA-damage/integrity, antidepressant-epigenetics background); not starred; carries sweep_date; verified via OpenAlex + Crossref.", "sidefxhub": "SIDEfxHUB cross-check intake (Oct 2026): 11 new verified candidates from the SIDEfxHUB Research & Insights list, all starred", "systems-review-2026-10": "Systems literature review (Oct 2026): 48 verified papers across 8 bodily/mechanistic systems, each with system_classification + justification for causal-pathway and treatment-candidate branching. Not starred.", "researcher-list-2026-10": "Researcher-supplied paper list (Oct 2026): 4 papers missing from the corpus, verified and staged (RES-001…004). Not starred.", "curator-additions": "Curator additions (Oct 2026 onward): sources the curator adds one at a time between sweeps, from user submissions, the news scout and the curator's own finds; each drafted and approved in corpus-build/additions/. Not starred." }, "gene_library": { "count": 575, "index": "gene-library/index.json", "pages": "gene-library/{SYMBOL}.md", "families": "gene-library/families.md", "note": "575 per-gene reference pages (stable hotlinkable URLs gene-library/{SYMBOL}.md) plus INDEX.md and families.md: 564 NCBI-verified on 2026-10-07, and 11 retinoid-signaling pages added 2026-10-11 (NCBI Gene, Ensembl, UniProt). Extends the 28-gene narrative library (v1.3 section 12); not inlined into entries." }, "entries": [ { "type": "peer-reviewed review", "title": "Post-finasteride syndrome: a surmountable challenge for clinicians", "authors": [ "Traish, Abdulmaged M." ], "journal": "Fertility and Sterility", "year": 2020, "volume": "113(1)", "pages": "21-50", "doi": "10.1016/j.fertnstert.2019.11.030", "url": "https://www.fertstert.org/article/S0015-0282(19)32599-3/fulltext", "citation": "Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21-50.", "tags": [ "finasteride", "5-alpha-reductase-inhibitor", "dutasteride", "post-finasteride-syndrome", "epigenetics", "endocrine-disruption", "neurosteroids", "androgen-receptor", "sexual-dysfunction", "depression", "suicidality", "review" ], "_source_file": "peer_reviewed", "item_id": "PFS-001", "collection_tag": "core" }, { "type": "peer-reviewed review", "title": "The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption", "authors": [ "Traish, Abdulmaged M." ], "journal": "Current Sexual Health Reports", "year": 2018, "volume": "10(3)", "pages": "88-103", "url": "https://www.springermedizin.de/the-post-finasteride-syndrome-clinical-manifestation-of-drug-ind/15983152", "citation": "Traish AM. The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption. Curr Sex Health Rep. 2018;10(3):88-103.", "tags": [ "finasteride", "post-finasteride-syndrome", "epigenetics", "endocrine-disruption", "DNA-methylation", "histone-modification", "review", "hypothesis" ], "_source_file": "peer_reviewed", "item_id": "PFS-002", "collection_tag": "core" }, { "type": "peer-reviewed review", "title": "Post-Finasteride Syndrome And Post-SSRI Sexual Dysfunction: Two Clinical Conditions Apparently Distant, But Very Close", "authors": [ "Giatti, Silvia", "Diviccaro, Silvia", "Cioffi, Lucia", "Melcangi, Roberto Cosimo" ], "journal": "Frontiers in Neuroendocrinology", "year": 2024, "volume": "72", "article": "101114", "doi": "10.1016/j.yfrne.2023.101114", "url": "https://www.sciencedirect.com/science/article/pii/S0091302223000626", "citation": "Giatti S, Diviccaro S, Cioffi L, Melcangi RC. Post-Finasteride Syndrome And Post-SSRI Sexual Dysfunction: Two Clinical Conditions Apparently Distant, But Very Close. Front Neuroendocrinol. 2024;72:101114.", "tags": [ "post-finasteride-syndrome", "PSSD", "SSRI", "shared-mechanisms", "neurosteroids", "neurotransmitters", "gut-microbiota", "gut-brain-axis", "review" ], "_source_file": "peer_reviewed", "item_id": "PFS-003", "collection_tag": "core", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "PFS and PSSD: similar symptoms, a possible link" }, { "type": "peer-reviewed original-research", "title": "Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology", "authors": [ "Melcangi, Roberto Cosimo", "Caruso, Donatella", "Abbiati, Federico", "Giatti, Silvia", "Calabrese, Donato", "Piazza, Fabrizio", "Cavaletti, Guido" ], "journal": "The Journal of Sexual Medicine", "year": 2013, "volume": "10(10)", "pages": "2598-2603", "url": "https://ouci.dntb.gov.ua/works/lxqE5029/", "citation": "Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, Cavaletti G. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013;10(10):2598-2603.", "tags": [ "finasteride", "post-finasteride-syndrome", "neurosteroids", "cerebrospinal-fluid", "allopregnanolone", "DHT", "testosterone", "LC-MS-MS", "biomarkers" ], "_source_file": "peer_reviewed", "item_id": "PFS-004", "collection_tag": "core", "doi": "10.1111/jsm.12269", "pmid": "23890183", "abstract_or_summary": "Using liquid chromatography-tandem mass spectrometry on paired plasma and cerebrospinal fluid samples, the authors compared three men with persistent sexual side effects and anxious/depressive symptoms after stopping finasteride (prescribed for androgenic alopecia) against five healthy controls. In CSF, tetrahydroprogesterone, isopregnanolone and dihydrotestosterone were lower than in controls while testosterone and 17β-estradiol were higher; in plasma, dihydroprogesterone was lower and 5α-androstane-3α,17β-diol plus 17β-estradiol higher. The patients also reported muscular stiffness, cramps, tremors and chronic fatigue without any diagnosable muscular disorder, alongside a persistent neuropsychiatric pattern. The authors conclude that disrupted neuroactive-steroid levels outlast finasteride discontinuation.", "relevance": "The first human CSF evidence that neuroactive-steroid disruption persists after finasteride withdrawal — the founding observation of the neurosteroid pillar of this corpus and the direct predecessor of the Caruso 2014 follow-up (RES-002).", "keywords": [ "neuroactive steroids", "cerebrospinal fluid", "post-finasteride syndrome", "dihydrotestosterone", "tetrahydroprogesterone", "LC-MS/MS" ], "verification_status": "verified — OpenAlex + Crossref-indexed + EuropePMC record (title/authors/year/PMID match)", "study_type": "case-control (n=3 patients, n=5 controls)", "also_listed_in": [ "researcher-list-2026-10" ], "note": "Merged in v1.14 with RES-001 (same title, authors, journal and year (J Sex Med 2013)); RES-001 is now a tombstone pointing here." }, { "type": "peer-reviewed original-research", "title": "Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma", "authors": [ "Caruso, Donatella", "Abbiati, Federico", "Giatti, Silvia", "Romano, S.", "Fusco, L.", "Cavaletti, Guido", "Melcangi, Roberto Cosimo" ], "journal": "Journal of Steroid Biochemistry and Molecular Biology", "year": 2015, "volume": "146", "pages": "74-79", "pmid": "24717976", "url": "https://www.medscape.com/medline/abstract/24717976", "citation": "Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, Melcangi RC. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74-79.", "tags": [ "finasteride", "post-finasteride-syndrome", "neurosteroids", "cerebrospinal-fluid", "pregnenolone", "progesterone", "DHT", "LC-MS-MS" ], "_source_file": "peer_reviewed", "item_id": "PFS-005", "collection_tag": "core", "doi": "10.1016/j.jsbmb.2014.03.012", "abstract_or_summary": "Extending the 2013 CSF findings, the Milan group profiled neuroactive steroids by LC-MS/MS in paired plasma and CSF from post-finasteride patients versus healthy controls. In CSF, progesterone and its 5α-reduced metabolites dihydroprogesterone and tetrahydroprogesterone were reduced while the precursor pregnenolone rose; dihydrotestosterone fell as testosterone and 3α-diol rose. Plasma showed the same directional pattern: higher pregnenolone, testosterone, 3α-diol, 3β-diol and 17β-estradiol with lower dihydroprogesterone and tetrahydroprogesterone. The pattern reads as a persistent 5α-reductase-blockade signature — precursor buildup upstream, downstream metabolite depletion — still present after the drug was stopped. A 2023 corrigendum (DOI 10.1016/j.jsbmb.2023.106405) is attached to the record.", "relevance": "Maps the full precursor-buildup/downstream-depletion signature of persistent 5α-reductase blockade in human CSF and plasma — the biochemical fingerprint Powers' intracellular-trapping model and the glucuronidation thread build on.", "keywords": [ "neuroactive steroids", "cerebrospinal fluid", "post-finasteride syndrome", "progesterone metabolites", "5α-reductase blockade signature" ], "verification_status": "verified — OpenAlex + Crossref-indexed + EuropePMC record (title/authors/year/PMID match); corrigendum confirmed via Europe PMC", "study_type": "case-control", "also_listed_in": [ "researcher-list-2026-10" ], "note": "Merged in v1.14 with RES-002 (same PMID 24717976 and title); RES-002 is now a tombstone pointing here." }, { "type": "peer-reviewed review", "title": "Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?", "authors": [ "Giatti, Silvia", "Diviccaro, Silvia", "Panzica, Giancarlo", "Melcangi, Roberto Cosimo" ], "journal": "Endocrine", "year": 2018, "url": "https://doi.org/10.1007/s12020-018-1593-5", "citation": "Giatti S, Diviccaro S, Panzica G, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine. 2018;61(2):180-193.", "tags": [ "post-finasteride-syndrome", "PSSD", "neurosteroids", "dopamine", "serotonin", "review" ], "_source_file": "peer_reviewed", "item_id": "PFS-006", "collection_tag": "core", "volume": "61(2)", "pages": "180-193", "doi": "10.1007/s12020-018-1593-5", "pmid": "29675596", "note": "Corrected in v1.17: earlier releases gave this record the authors, year and findings of DISC-013 (Melcangi et al. 2017, the 16-patient study with pudendal nerve testing). Its title, journal and link were always this 2018 review." }, { "type": "peer-reviewed original-research", "title": "Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia", "authors": [ "Cauci, Sabina", "Chiriacò, Giovanni", "Cecchin, Erika", "Toffoli, Giuseppe", "Xodo, Serena", "Stinco, Giuseppe", "Trombetta, Carlo" ], "journal": "Sexual Medicine", "year": 2017, "volume": "5(1)", "pages": "e61-e71", "pmid": "28024997", "pmcid": "PMC5302381", "url": "http://pmc.ncbi.nlm.nih.gov/articles/PMC5302381/", "citation": "Cauci S, Chiriacò G, Cecchin E, Toffoli G, Xodo S, Stinco G, Trombetta C. Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia. Sex Med. 2017;5(1):e61-e71.", "tags": [ "finasteride", "post-finasteride-syndrome", "androgen-receptor", "CAG-repeat", "GGN-repeat", "polymorphism", "genetic-susceptibility", "pharmacogenetics", "precision-medicine" ], "_source_file": "peer_reviewed", "item_id": "PFS-007", "collection_tag": "core", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "Androgen Receptor Gene Variants and PFS Symptoms", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/exploring-androgen-receptor-gene-polymorphisms-and-symptoms-in-pfs/", "note": "From the same Trieste group as SIDE-011 (2014, 69 PFS patients); the cohorts may overlap." }, { "type": "conference-report", "title": "Differential Gene Expression in Post-Finasteride Syndrome Patients (Baylor College of Medicine)", "authors": [ "Howell, S.", "et al.", "(Khera, Mohit — senior investigator)" ], "journal": "Conference presentation; summarized by PFS Network", "year": 2021, "url": "https://www.pfsnetwork.org/science/differential-gene-expression-in-post-finasteride-syndrome-patients", "citation": "Howell et al., Baylor College of Medicine (Khera M). Differential gene expression in post-finasteride syndrome patients. Conference report, 2021. Published as SIDE-009 (J Sex Med 2021).", "tags": [ "post-finasteride-syndrome", "gene-expression", "microarray", "androgen-receptor", "overexpression", "transcriptomics", "preliminary" ], "_source_file": "peer_reviewed", "item_id": "PFS-008", "collection_tag": "core", "note": "The conference report of the study published as SIDE-009 (Howell, Song, Pastuszak, Khera, J Sex Med 2021); cite SIDE-009." }, { "type": "peer-reviewed original-research", "title": "Persistent sexual side effects of finasteride for male pattern hair loss", "authors": [ "Irwig, Michael S.", "Kolukula, Swapna" ], "journal": "The Journal of Sexual Medicine", "year": 2011, "volume": "8(6)", "pages": "1747-1753", "doi": "10.1111/j.1743-6109.2011.02255.x", "url": "https://www.gwumc.edu/news/gw-study-shows-men-report-persistent-sexual-impairment-after-use-common-hair-loss-drugs", "citation": "Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747-1753.", "tags": [ "finasteride", "post-finasteride-syndrome", "persistent-sexual-dysfunction", "case-series", "libido", "erectile-dysfunction", "orgasm" ], "_source_file": "peer_reviewed", "item_id": "PFS-009", "collection_tag": "core" }, { "type": "peer-reviewed original-research", "title": "Persistent sexual side effects of finasteride: could they be permanent?", "authors": [ "Irwig, Michael S." ], "journal": "The Journal of Sexual Medicine", "year": 2012, "volume": "9(11)", "pages": "2927-2932", "doi": "10.1111/j.1743-6109.2012.02846.x", "url": "https://medicalxpress.com/news/2012-07-hair-loss-drug-long-term-sexual.html", "citation": "Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9(11):2927-2932.", "tags": [ "finasteride", "post-finasteride-syndrome", "persistent-sexual-dysfunction", "follow-up", "ASEX", "prognosis" ], "_source_file": "peer_reviewed", "item_id": "PFS-010", "collection_tag": "core" }, { "type": "peer-reviewed review", "title": "Post-SSRI Sexual Dysfunction: A Literature Review", "authors": [ "Bala, Areeg", "Nguyen, Hoang Minh Tue", "Hellstrom, Wayne J. G." ], "journal": "Sexual Medicine Reviews", "year": 2018, "volume": "6(1)", "pages": "29-34", "doi": "10.1016/j.sxmr.2017.07.002", "pmid": "28778697", "url": "https://pubmed.ncbi.nlm.nih.gov/28778697/", "citation": "Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI Sexual Dysfunction: A Literature Review. Sex Med Rev. 2018;6(1):29-34.", "tags": [ "PSSD", "SSRI", "persistent-sexual-dysfunction", "genital-anesthesia", "5-HT1A", "epigenetics", "dopamine", "review" ], "_source_file": "peer_reviewed", "item_id": "PSSD-001", "collection_tag": "core" }, { "type": "peer-reviewed review", "title": "Post-SSRI Sexual Dysfunction (PSSD): Biological Plausibility, Symptoms, Diagnosis, and Presumed Risk Factors", "authors": [ "Peleg, L. C.", "Rabinovitch, D.", "Lavie, Y.", "et al." ], "journal": "Sexual Medicine Reviews", "year": 2022, "volume": "10", "pages": "91-98", "pmid": "34627736", "url": "https://pubmed.ncbi.nlm.nih.gov/34627736/", "citation": "Peleg LC, Rabinovitch D, Lavie Y, et al. Post-SSRI Sexual Dysfunction (PSSD): Biological Plausibility, Symptoms, Diagnosis, and Presumed Risk Factors. Sex Med Rev. 2022;10:91-98.", "tags": [ "PSSD", "SSRI", "SNRI", "biological-plausibility", "risk-factors", "genetic-predisposition", "epigenetics", "dopamine-serotonin", "neurotoxicity", "hormones", "review" ], "_source_file": "peer_reviewed", "item_id": "PSSD-002", "collection_tag": "core" }, { "type": "peer-reviewed review", "title": "Post-SSRI Sexual Dysfunction (PSSD): A comprehensive review of epidemiology, pathophysiology, and clinical management", "authors": [ "Xie, M.", "Huang, P.", "Wang, S.", "Ma, J.", "Zeng, Y.", "Sun, J." ], "journal": "Journal (SAGE; 2026)", "year": 2026, "doi": "10.1177/09246479261468499", "pmid": "42430418", "url": "https://pubmed.ncbi.nlm.nih.gov/42430418/", "citation": "Xie M, Huang P, Wang S, Ma J, Zeng Y, Sun J. Post-SSRI Sexual Dysfunction (PSSD): A comprehensive review of epidemiology, pathophysiology, and clinical management. 2026. PMID: 42430418.", "tags": [ "PSSD", "SSRI", "epidemiology", "pathophysiology", "5-HT1A", "neurosteroids", "allopregnanolone", "5-alpha-reductase", "epigenetics", "dopaminergic-circuits", "review" ], "_source_file": "peer_reviewed", "item_id": "PSSD-003", "starred": true, "curated_source": "PSSD discord", "curated_list_item": 1, "curated_note": "Already in corpus as PSSD-003 (Xie 2026 PSSD review, DOI 10.1177/09246479261468499); appears in PSSD discord curated list.", "collection_tag": "core" }, { "type": "peer-reviewed original-research", "title": "Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors", "authors": [ "Csoka, Antonei B.", "Bahrick, Audrey", "Mehtonen, Olavi-Pekka" ], "journal": "The Journal of Sexual Medicine", "year": 2008, "volume": "5(1)", "pages": "227-233", "doi": "10.1111/j.1743-6109.2007.00630.x", "pmid": "18173768", "url": "https://pubmed.ncbi.nlm.nih.gov/18173768/", "citation": "Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med. 2008;5(1):227-233.", "tags": [ "PSSD", "SSRI", "persistent-sexual-dysfunction", "case-reports", "genital-anesthesia", "epigenetics-hypothesis" ], "_source_file": "peer_reviewed", "item_id": "PSSD-004", "collection_tag": "core" }, { "type": "peer-reviewed hypothesis", "title": "Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology", "authors": [ "Csoka, Antonei B.", "Szyf, Moshe" ], "journal": "Medical Hypotheses", "year": 2009, "volume": "73(5)", "pages": "770-780", "doi": "10.1016/j.mehy.2008.10.039", "pmid": "19501473", "url": "https://pubmed.ncbi.nlm.nih.gov/19501473/", "citation": "Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses. 2009;73(5):770-780.", "tags": [ "epigenetics", "pharmacology", "drug-side-effects", "DNA-methylation", "hypothesis", "PSSD", "post-drug-syndromes" ], "_source_file": "peer_reviewed", "item_id": "PSSD-005", "collection_tag": "core", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "Epigenetic Side-Effects of Common Pharmaceuticals" }, { "type": "peer-reviewed original-research", "title": "Post-SSRI Sexual Dysfunction: Clinical Characterization and Preliminary Assessment of Contributory Factors and Dose-Response Relationship", "authors": [ "Ben-Sheetrit, Joseph", "Aizenberg, Dov", "Csoka, Antonei B.", "Weizman, Abraham", "Hermesh, Haggai" ], "journal": "Journal of Clinical Psychopharmacology", "year": 2015, "volume": "35(3)", "pages": "273-278", "doi": "10.1097/JCP.0000000000000300", "pmid": "25815755", "url": "https://pubmed.ncbi.nlm.nih.gov/25815755/", "citation": "Ben-Sheetrit J, Aizenberg D, Csoka AB, Weizman A, Hermesh H. Post-SSRI Sexual Dysfunction: Clinical Characterization and Preliminary Assessment of Contributory Factors and Dose-Response Relationship. J Clin Psychopharmacol. 2015;35(3):273-278.", "tags": [ "PSSD", "SSRI", "SNRI", "clinical-characterization", "genital-anesthesia", "dose-response", "survey", "risk-factors" ], "_source_file": "peer_reviewed", "item_id": "PSSD-006", "collection_tag": "core", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "PSSD: Contributory Factors and Case Characterization", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/pssd-exploring-contributory-factors-and-case-characterization/" }, { "type": "peer-reviewed original-research", "title": "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases", "authors": [ "Healy, David", "Le Noury, Joanna", "Mangin, Dee" ], "journal": "International Journal of Risk & Safety in Medicine", "year": 2018, "volume": "29(3-4)", "pages": "125-134", "doi": "10.3233/JRS-180744", "pmid": "29733030", "pmcid": "PMC6004900", "url": "https://pubmed.ncbi.nlm.nih.gov/29733030/", "citation": "Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29(3-4):125-134.", "tags": [ "enduring-sexual-dysfunction", "PSSD", "post-finasteride-syndrome", "isotretinoin", "pharmacovigilance", "case-series", "genital-anesthesia", "cross-drug" ], "_source_file": "peer_reviewed", "item_id": "CROSS-001", "collection_tag": "core", "abstract_or_summary": "Drawing on reports submitted to the RxISK.org adverse-event site, the authors assembled 300 cases of persistent sexual difficulty from 37 countries after treatment with serotonin reuptake inhibiting antidepressants, finasteride-type drugs, or isotretinoin. Genital anesthesia, weak or pleasureless orgasm, loss of libido, and impotence appeared across all three drug groups, while some features (such as new-onset premature ejaculation and persistent genital arousal) were unique to the antidepressant cases. The authors concluded that the data pointed to one or more legacy (tardive) syndromes, said a next step was to establish whether there was a single syndrome, and noted that secondary harms included relationship breakdown and reduced quality of life. They called for diagnostic coding that recognizes these enduring conditions.", "relevance": "A landmark cross-drug case series (221 serotonin reuptake inhibitor, 54 isotretinoin and 25 5α-reductase inhibitor cases) showing overlapping features of enduring sexual dysfunction across the three drug classes; the authors leave open whether this is one shared syndrome or several. Foundational citation for the corpus's cross-drug axis.", "keywords": [ "PSSD", "post-finasteride syndrome", "isotretinoin", "genital anesthesia", "RxISK", "tardive syndrome", "pharmacovigilance" ], "verification_status": "verified: matching records in OpenAlex and Crossref", "study_type": "case series", "sample_size": "n=300 case reports from 37 countries", "quality_notes": "Peer-reviewed. Patient-reported case series from RxISK.org, a site the authors and colleagues set up and all three authors are linked to; the authors say its articles likely encouraged reporting (selection bias possible).", "fulltext_url": "https://journals.sagepub.com/doi/pdf/10.3233/JRS-180744", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc", "also_listed_in": [ "literature-sweep-2026-10" ], "note": "Merged in v1.14 with LIT-019 (same DOI 10.3233/JRS-180744, PMID 29733030 and title); LIT-019 is now a tombstone pointing here.", "fulltext_note": "Link updated 2026-10-09: IOS Press journals moved to SAGE", "plain": { "summary": "The authors collected 300 reports, sent to a drug-safety website they run, from people in 37 countries whose sexual problems lasted after they stopped certain antidepressants, the acne drug isotretinoin, or the hair-loss and prostate drugs finasteride and dutasteride. People in all three groups described similar problems: genital numbness, orgasms that felt weak or brought little pleasure, low sex drive and, in men, erection problems. For about 1 in 5, the problems started or got much worse only after stopping the drug, and 17 people said they had lasted 10 years or more.", "caveat": "It can't show how often this happens or prove that the drugs caused it: these are reports people chose to send in, with no comparison group and no medical check described, and only 25 came from men who had taken finasteride or dutasteride." }, "evidence": { "design": "Case series of patient reports to an online adverse-event reporting site (RxISK.org), selected and coded by the authors", "design_class": "case-series", "setting": "RxISK.org reports from 17 June 2012 to 17 December 2015 and 26 April 2016 to 21 August 2017 (3,033 reports in all); reporters from 37 countries", "population": "People reporting sexual dysfunction that persisted after stopping a serotonin reuptake inhibitor (SRI), a 5α-reductase inhibitor (5α-RI) or isotretinoin; 245 men and 55 women, aged 15–66 (age given by 295). The authors excluded 51 reports (2 unconvincing, 5 duplicates, 10 possible confounders, 14 ambiguous, 20 too little detail), and set aside 8 linked to antipsychotics or catecholamine reuptake inhibitors.", "n": 300, "n_note": "300 cases: 221 after SRIs (171 men, 50 women), 54 after isotretinoin (49 men, 5 women), 25 after 5α-RIs (24 finasteride, 1 dutasteride; all men). Group totals summed from Table 1; they match the denominators of Tables 3a–3b.", "exposure": "14 drugs: 11 SRIs (escitalopram, citalopram, paroxetine, sertraline, fluoxetine, venlafaxine, duloxetine, fluvoxamine, vortioxetine, clomipramine, desvenlafaxine), isotretinoin, finasteride, dutasteride. Treatment length, given for 226, ranged from a single dose to over 16 years; 19 took the drug for under two weeks.", "comparator": "None; drug groups described side by side", "outcome": "Features of enduring sexual dysfunction as described in structured and free-text reports; Naranjo causality score (0–4 more information needed, 5–8 likely link, 9+ strong possibility); impact on relationships and work.", "follow_up": "None; single reports. Some reported problems lasting 10 or more years after stopping", "results": [ { "text": "Men (245): erectile dysfunction 216 (88.2%), loss of libido 193 (78.8%), genital anaesthesia 113 (46.1%), pleasureless or weak orgasm 80 (32.7%). Genital anaesthesia by group: SRIs 84 of 171 (49.1%), isotretinoin 18 of 49 (36.7%), 5α-RIs 11 of 25 (44.0%)", "where": "p. 128, Table 3a" }, { "text": "Women (55): loss of libido 41 (74.5%), genital anaesthesia 33 (60.0%), difficulty achieving orgasm 32 (58.2%), emotional blunting 14 (25.5%)", "where": "p. 129, Table 3b" }, { "text": "Men on 5α-RIs (25) more often reported watery ejaculate 8 (32.0%), testicular atrophy 8 (32.0%), reduced penis size 7 (28.0%) and penile or testicular pain 5 (20.0%) than the other groups; new premature ejaculation (17 men) and persistent genital arousal disorder (6; 2 men, 4 women) were reported only after SRIs", "where": "pp. 128–129, Tables 3a–3b" }, { "text": "Dysfunction appeared, or became much worse, only after stopping in 41 SRI cases (18.6%), 9 isotretinoin cases (16.7%) and 7 5α-RI cases (28.0%)", "where": "p. 129" }, { "text": "17 reported the condition lasting at least 10 years after stopping (8 isotretinoin, 8 SRIs, 1 finasteride), 5 of them over 20 years; 25 reported a relationship breakup (9 marriages) and 90 said their work was affected (12 lost jobs)", "where": "p. 129" }, { "text": "Mean Naranjo causality scores were 8.9 (SRIs), 8.8 (5α-RIs) and 8.5 (isotretinoin); the authors consider these underestimates because the algorithm is not designed for lasting effects", "where": "pp. 126–127" } ], "limitations_stated": [ "Articles on enduring sexual dysfunction run on RxISK.org since 2013 likely encouraged reporting", "The Naranjo and similar algorithms are not geared to lasting effects, so causality scores are likely underestimates", "The reporting facility was unavailable for an extended period (December 2015 to April 2016)", "Not every report mentions genital anaesthesia, though the authors say every PSSD patient who contacted them directly has had it", "How often PSSD occurs is unknown", "Online communities' focus (for example on neurosteroids in PFS) may shape which features are reported and obscure shared ones; structured interviews are needed to test whether there is a single syndrome", "Earlier treatments, such as tetracycline-type antibiotics, were not explored" ], "design_notes": [ "Self-selected, self-reported online reports; no clinical examination or independent verification is described, and the counts are not rates", "The authors set up the reporting site and chose which reports to include; the number of reports found before exclusions is not given", "No comparison group of people who took the same drugs without lasting problems", "The 5α-RI group is small (25 men), so its percentages rest on few reports (32.0% is 8 men)", "Symptoms come from what reporters chose to describe, not a fixed checklist, so a missing symptom does not mean it was absent; denominators for fatigue (9%), muscle weakness (3%), brain fog (19%) and memory impairment (11%) are not given" ], "funding": "No specific grant from any funding agency in the public, commercial or not-for-profit sectors", "interests": "All three authors are linked to RxISK.org (the reporting site used); none declared consultancy or other links to groups with an interest in the results", "supports": "That people report a similar pattern of lasting sexual problems, especially genital numbness, weak or pleasureless orgasm, low libido and erection problems, after SRIs, 5α-reductase inhibitors and isotretinoin. It cannot show how common this is, establish causation, or show that it is one syndrome rather than several.", "extracted_from": "fulltexts/LIT-019-Enduring-sexual-dysfunction-after-treatment-with-a.pdf (full text filed under the merged duplicate's old id; publisher PDF, CC BY-NC 4.0, 10 pp.; page refs are the printed page numbers 125–134)", "extracted": "2026-10-10" } }, { "type": "peer-reviewed consensus", "title": "Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin", "authors": [ "Healy, David", "Bahrick, Audrey", "Bak, Maarten", "Barbato, Angelo", "Calabrò, Rocco Salvatore", "Chubak, Barbara M.", "Cosci, Fiammetta", "Csoka, Antonei B.", "D'Avanzo, Barbara", "Diviccaro, Silvia", "Giatti, Silvia", "Goldstein, Irwin", "Graf, Heiko", "Hellstrom, Wayne J.G.", "Irwig, Michael S.", "Jannini, Emmanuele A.", "Janssen, Paddy K.C.", "Khera, Mohit", "Kumar, Manoj Therayil", "Le Noury, Joanna", "Lew-Starowicz, Michał", "Linden, David E.J.", "Lüning, Celine", "Mangin, Dee", "Melcangi, Roberto Cosimo", "Muquebil Ali Al Shaban Rodríguez, Omar Walid", "Panicker, Jalesh N.", "Patacchini, Arianna", "Pearlman, Amy M.", "Pukall, Caroline F.", "Raj, Sanjana", "Reisman, Yacov", "Rubin, Rachel S.", "Schreiber, Rudy", "Shipko, Stuart", "Vašečková, Barbora", "Waraich, Ahad" ], "journal": "International Journal of Risk & Safety in Medicine", "year": 2022, "volume": "33(1)", "pages": "65-76", "doi": "10.3233/JRS-210023", "pmcid": "PMC8925105", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8925105/", "citation": "Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022;33(1):65-76.", "tags": [ "diagnostic-criteria", "PSSD", "post-finasteride-syndrome", "PRSD", "PGAD", "enduring-sexual-dysfunction", "consensus" ], "_source_file": "peer_reviewed", "item_id": "CROSS-002", "collection_tag": "core", "pmid": "34719438", "abstract_or_summary": "A multidisciplinary expert panel drafted formal diagnostic criteria for four enduring post-drug conditions: PSSD, persistent genital arousal disorder after serotonin reuptake inhibitors, post-finasteride syndrome, and post-retinoid sexual dysfunction. The drafts were built from the two largest published case collections (Hogan et al. 2014; Healy et al. 2018). Core shared features across PSSD, PFS, and post-retinoid dysfunction included reduced genital and orgasmic sensation, reduced desire, and erectile dysfunction, with variable non-sexual symptoms such as emotional blunting and cognitive impairment. The panel also proposed a fifth category with its own criteria, post-SSRI asexuality, a new term for dampened sexual interest and pleasure after exposure to a serotonin reuptake inhibitor before birth or before the teens. The criteria were intended to give clinicians and researchers a common case definition for a field that had lacked one.", "relevance": "The first proposed diagnostic criteria for PSSD and its sibling syndromes. Directly usable as the corpus's case-definition reference.", "keywords": [ "PSSD", "diagnostic criteria", "PFS", "persistent genital arousal disorder", "post-retinoid sexual dysfunction", "consensus" ], "verification_status": "verified: matching records in OpenAlex and Crossref", "study_type": "consensus / diagnostic criteria development", "sample_size": "n/a (expert panel; criteria derived from prior case series)", "quality_notes": "Peer-reviewed. Criteria are proposed, not yet validated in independent cohorts.", "fulltext_url": "https://journals.sagepub.com/doi/pdf/10.3233/JRS-210023", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc", "also_listed_in": [ "literature-sweep-2026-10" ], "note": "Merged in v1.14 with LIT-021 (same DOI 10.3233/JRS-210023 and title); LIT-021 is now a tombstone pointing here. LIT-021 dated this paper 2021 (online first); the 2022 issue year is kept.", "fulltext_note": "Link updated 2026-10-09: IOS Press journals moved to SAGE", "plain": { "summary": "A group of 37 doctors and researchers agreed on a set of rules (diagnostic criteria) for recognising lasting sexual problems after stopping certain antidepressants, finasteride-type drugs or the acne drug isotretinoin, and for unwanted, uncomfortable genital arousal that can start when antidepressants are stopped. The shared features they describe are reduced genital and orgasm feeling, low sex drive and erection problems that continue after stopping; problems lasting three months or more are treated as more likely to be one of these conditions. They also suggested a new term for a lifelong lack of sexual interest and pleasure in people exposed to these antidepressants before birth or as children.", "caveat": "It can't show how common these conditions are or prove that the drugs cause them: the rules come from experts' agreement and two collections of patient reports, and they have not yet been tested on patients." }, "evidence": { "design": "Expert consensus on diagnostic criteria; a draft built from two published case series was circulated to a multidisciplinary panel and revised until agreement", "design_class": "expert-consensus", "setting": "International panel; 37 authors from 10 countries (Canada, USA, UK, Italy, the Netherlands, Germany, Poland, Spain, Slovakia, India)", "population": "Not applicable (criteria paper). The criteria cover people with enduring sexual dysfunction after serotonin reuptake inhibitors (SRIs), 5α-reductase inhibitors or isotretinoin, and people exposed to SRIs before birth or before their teens.", "n": null, "n_note": "Not applicable. 37 listed authors. Starting data were two RxISK.org case series by three of the authors, of 120 (2014) and 300 (2018) cases; whether they overlap is not stated. RxISK holds about 1,000 reports of these conditions.", "exposure": "SRIs, defined broadly (SSRIs, SNRIs, SRI tricyclics, SRI antihistamines, tetracycline antibiotics such as doxycycline, tramadol); 5α-reductase inhibitors (finasteride, dutasteride, saw palmetto); isotretinoin", "comparator": "None", "outcome": "Diagnostic criteria for PSSD, post-SRI persistent genital arousal disorder (PGAD), PFS, post-retinoid sexual dysfunction (PRSD) and post-SSRI asexuality", "follow_up": "Not applicable", "results": [ { "text": "PSSD. Necessary: prior SRI treatment, and an enduring change in tactile or sexual genital sensation after stopping. Additional: reduced or lost desire; erectile dysfunction (males); inability to orgasm or less pleasure in orgasm; present 3 months or more after stopping. Exclusions: matching pre-drug dysfunction, or a current medical condition, medication or substance misuse that could explain it. The genital sensory change is what distinguishes PSSD from other enduring sexual dysfunction", "where": "pp. 68–69" }, { "text": "PGAD after SRIs. Necessary: persistent unwelcome genital arousal or irritability that is painful or altered rather than pleasurable, gets little or no relief from sexual activity, and can be triggered by non-sexual stimuli. Additional criteria include spontaneous unwanted orgasms, marked distress, a continuous course, onset on stopping (if linked to an SRI), and presence 3 months or more after stopping", "where": "pp. 70–71" }, { "text": "PFS. Necessary: prior 5α-reductase inhibitor treatment, and enduring sexual dysfunction after stopping. Additional: reduced desire, erectile dysfunction, reduced genital and orgasmic sensation, present 3 months or more after stopping. No prior isotretinoin or SRI use; dysfunction that clears after stopping is not PFS. Cognitive impairment, depression and suicidality may accompany it but are not diagnostic", "where": "pp. 71–72" }, { "text": "PRSD. Necessary: prior isotretinoin treatment, and enduring sexual dysfunction after stopping. Additional: reduced desire, erectile dysfunction (males) or loss of vaginal lubrication (females), reduced genital and orgasmic sensation, present 3 months or more after stopping. No prior finasteride or SRI use", "where": "p. 72" }, { "text": "Post-SSRI asexuality (new term). Maternal SRI use in pregnancy or extended pre-teen SRI use; no sexual interest in either sex; never any pleasure from masturbation or sexual activity; identification as asexual", "where": "p. 73" }, { "text": "Diagnostic interviewing. No upper time limit, as PSSD and PRSD have been reported to persist for over two decades; challenge-dechallenge-rechallenge is unsuitable; a current mental health diagnosis does not rule these conditions out; testosterone treatment has not been reported to help reliably and PDE5 inhibitors appear less effective; penile quantitative sensory testing may help assess tactile sensation", "where": "p. 74" } ], "limitations_stated": [ "As with all criteria, they will likely need modification as evidence develops; the authors hope diagnostic markers will eventually replace them", "The incidence of these conditions is unknown, and full recovery after stopping has never been properly studied", "There is no biomarker; sexual (erogenous) sensation is poorly understood and there are no tests for it", "Data on the delay between the last dose and onset are limited, so no cut-off for onset can be set", "It is unclear whether penile, neurosteroid, methylation and gut microbiota findings in PFS were present before treatment, or whether erectile tissue changes are part of PSSD", "It is not clear whether men are affected by post-SRI PGAD, or whether persistent dysfunction after other drugs (mirtazapine, aripiprazole, NOACs) forms a related syndrome" ], "design_notes": [ "The draft was built from two case series drawn from RxISK.org, a site three of the authors are linked to, and both series are by those authors", "The consensus process is described only briefly; no formal method (such as Delphi), number of rounds, voting rule or dissent is reported", "Panel members include authors of earlier work on these conditions and several who petitioned regulators for label warnings", "The criteria do not say how many Additional criteria are needed, and the 3-month duration is listed as Additional, not Necessary, for PSSD, PFS and PRSD", "No testing of the criteria's reliability or validity in patients is reported", "Post-SSRI asexuality rests on animal studies and one human study cited by the authors" ], "funding": "None to report. Acknowledgements list individual support: Jannini, Italian Ministry of University and Research grant PRIN #2017S9KTNE_002; Mangin, David Braley Chair in Family Medicine, McMaster University; Panicker, UK Department of Health NIHR Biomedical Research Centres.", "interests": "David Healy, Joanna Le Noury and Dee Mangin are linked to RxISK.org, which records patient-reported adverse events and has featured information on enduring sexual dysfunction; no other interests declared.", "supports": "A proposed, consensus-based case definition for PSSD, PFS, PRSD and post-SRI PGAD, for consistent diagnosis and research. It does not show how common these conditions are, establish causation, or validate the criteria.", "extracted_from": "fulltexts/LIT-021-Diagnostic-criteria-for-enduring-sexual-dysfunctio.pdf (full text filed under the merged duplicate's old id; publisher PDF, CC BY-NC 4.0, 12 pp.; page refs are the printed page numbers 65–76)", "extracted": "2026-10-10" } }, { "type": "peer-reviewed original-research", "title": "One hundred and twenty cases of enduring sexual dysfunction following treatment", "authors": [ "Hogan, C.", "Le Noury, J.", "Healy, D.", "Mangin, D." ], "journal": "International Journal of Risk & Safety in Medicine", "year": 2014, "volume": "26(2)", "pages": "109-116", "doi": "10.3233/JRS-140617", "pmid": "24902508", "url": "https://pubmed.ncbi.nlm.nih.gov/24902508/", "citation": "Hogan C, Le Noury J, Healy D, Mangin D. One hundred and twenty cases of enduring sexual dysfunction following treatment. Int J Risk Saf Med. 2014;26(2):109-116.", "tags": [ "enduring-sexual-dysfunction", "PSSD", "pharmacovigilance", "case-series", "RxISK" ], "_source_file": "peer_reviewed", "item_id": "CROSS-003", "collection_tag": "core" }, { "type": "peer-reviewed review", "title": "Sexual Consequences of Post-SSRI Syndrome", "authors": [ "Reisman, Yacov" ], "journal": "Sexual Medicine Reviews", "year": 2017, "volume": "5(4)", "pages": "429-433", "doi": "10.1016/j.sxmr.2017.05.002", "pmid": "28642048", "url": "https://pubmed.ncbi.nlm.nih.gov/28642048/", "citation": "Reisman Y. Sexual Consequences of Post-SSRI Syndrome. Sex Med Rev. 2017;5(4):429-433.", "tags": [ "PSSD", "post-SSRI-syndrome", "sexual-dysfunction", "review", "clinical" ], "_source_file": "peer_reviewed", "item_id": "PSSD-007", "collection_tag": "core" }, { "type": "peer-reviewed original-research", "title": "Post-SSRI sexual dysfunction: patient experiences of engagement with healthcare professionals", "authors": [ "Healy, David", "Le Noury, Joanna", "Mangin, Dee" ], "journal": "International Journal of Risk & Safety in Medicine", "year": 2019, "volume": "30", "pages": "167-178", "doi": "10.3233/JRS-191005", "url": "https://doi.org/10.3233/JRS-191005", "citation": "Healy D, Le Noury J, Mangin D. Post-SSRI sexual dysfunction: patient experiences of engagement with healthcare professionals. Int J Risk Saf Med. 2019;30:167-178.", "tags": [ "PSSD", "patient-experience", "healthcare", "qualitative", "clinical-recognition" ], "_source_file": "peer_reviewed", "item_id": "PSSD-008", "collection_tag": "core" }, { "type": "peer-reviewed original-research", "title": "Effects of paroxetine treatment and its withdrawal on neurosteroidogenesis", "authors": [ "Diviccaro, Silvia", "Giatti, Silvia", "Cioffi, Lucia", "Falvo, E.", "Caruso, Donatella", "Melcangi, Roberto Cosimo" ], "journal": "Psychoneuroendocrinology", "year": 2021, "volume": "132", "article": "105364", "doi": "10.1016/j.psyneuen.2021.105364", "url": "https://doi.org/10.1016/j.psyneuen.2021.105364", "citation": "Diviccaro S, Giatti S, Cioffi L, Falvo E, Caruso D, Melcangi RC. Effects of paroxetine treatment and its withdrawal on neurosteroidogenesis. Psychoneuroendocrinology. 2021;132:105364.", "tags": [ "paroxetine", "SSRI", "neurosteroidogenesis", "neurosteroids", "withdrawal", "preclinical", "rat-model" ], "_source_file": "peer_reviewed", "item_id": "PSSD-009", "collection_tag": "core" }, { "type": "peer-reviewed original-research", "title": "Identification of a novel off-target of paroxetine: Possible role in sexual dysfunction induced by this SSRI antidepressant drug", "authors": [ "Giatti, Silvia", "Di Domizio, A.", "Diviccaro, Silvia", "Cioffi, Lucia", "Marmorini, I.", "Falvo, E.", "Caruso, Donatella", "Contini, A.", "Melcangi, Roberto Cosimo" ], "journal": "Journal of Molecular Structure", "year": 2022, "volume": "1268", "article": "133690", "doi": "10.1016/j.molstruc.2022.133690", "url": "https://doi.org/10.1016/j.molstruc.2022.133690", "citation": "Giatti S, Di Domizio A, Diviccaro S, Cioffi L, Marmorini I, Falvo E, Caruso D, Contini A, Melcangi RC. Identification of a novel off-target of paroxetine: Possible role in sexual dysfunction induced by this SSRI antidepressant drug. J Mol Struct. 2022;1268:133690.", "tags": [ "paroxetine", "SSRI", "off-target", "molecular-docking", "sexual-dysfunction", "pharmacology" ], "_source_file": "peer_reviewed", "item_id": "PSSD-010", "collection_tag": "core", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "Paroxetine and Sexual Dysfunction" }, { "type": "peer-reviewed original-research", "title": "Paroxetine effects in adult male rat colon: Focus on steroidogenesis and microbiota", "authors": [ "Diviccaro, Silvia", "Giatti, Silvia", "Cioffi, Lucia", "Falvo, E.", "Piazza, R.", "Caruso, Donatella", "Melcangi, Roberto Cosimo" ], "journal": "Psychoneuroendocrinology", "year": 2022, "volume": "143", "article": "105828", "doi": "10.1016/j.psyneuen.2022.105828", "url": "https://doi.org/10.1016/j.psyneuen.2022.105828", "citation": "Diviccaro S, Giatti S, Cioffi L, Falvo E, Piazza R, Caruso D, Melcangi RC. Paroxetine effects in adult male rat colon: Focus on steroidogenesis and microbiota. Psychoneuroendocrinology. 2022;143:105828.", "tags": [ "paroxetine", "SSRI", "gut-microbiota", "steroidogenesis", "gut-brain-axis", "preclinical", "rat-model" ], "_source_file": "peer_reviewed", "item_id": "PSSD-011", "collection_tag": "core" }, { "type": "peer-reviewed original-research", "title": "Transcriptomic Profile of the Male Rat Hypothalamus and Nucleus Accumbens After Paroxetine Treatment and Withdrawal: Possible Causes of Sexual Dysfunction", "authors": [ "Giatti, Silvia", "Cioffi, Lucia", "Diviccaro, Silvia", "Chrostek, G.", "Piazza, R.", "Melcangi, Roberto Cosimo" ], "journal": "Molecular Neurobiology", "year": 2024, "doi": "10.1007/s12035-024-04592-9", "url": "https://doi.org/10.1007/s12035-024-04592-9", "citation": "Giatti S, Cioffi L, Diviccaro S, Chrostek G, Piazza R, Melcangi RC. Transcriptomic Profile of the Male Rat Hypothalamus and Nucleus Accumbens After Paroxetine Treatment and Withdrawal: Possible Causes of Sexual Dysfunction. Mol Neurobiol. 2024.", "tags": [ "paroxetine", "SSRI", "transcriptomics", "hypothalamus", "nucleus-accumbens", "gene-expression", "withdrawal", "epigenetics", "reward-circuits", "preclinical" ], "_source_file": "peer_reviewed", "item_id": "PSSD-012", "collection_tag": "core", "pmid": "39495228", "abstract_or_summary": "RNA-seq of hypothalamus and nucleus accumbens in male rats treated with paroxetine for 2 weeks and re-examined after 1 month of withdrawal. The nucleus accumbens showed 245 differentially expressed genes at end of treatment and 6 persisting at withdrawal, including dopamine-, glutamate-, GABA-, neurexin/neuroligin-, and BDNF-signaling genes, alongside an inflammatory/immune-activation signature. The authors interpret the persisting changes as a molecular substrate for PSSD.", "relevance": "Directly PSSD-focused: full transcriptome of paroxetine treatment and withdrawal in sexual-behavior brain circuits, one of the few animal models of PSSD etiopathogenesis. NOTE: discord label 'CYP2D and SSRI response' is incorrect; PMID 39495228 is this Giatti paroxetine transcriptomics paper.", "keywords": [ "paroxetine", "PSSD", "transcriptomics", "nucleus accumbens", "dopamine", "neuroinflammation", "BDNF", "withdrawal" ], "verification_status": "verified", "starred": true, "curated_source": "PSSD discord", "also_listed_in": [ "pssd-discord" ], "note": "Merged in v1.14 with DISC-014 (same DOI 10.1007/s12035-024-04592-9 and title); DISC-014 is now a tombstone pointing here. DISC-014 dated this paper 2025 (issue year); the 2024 online year is kept." }, { "type": "peer-reviewed systematic-review", "title": "5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes", "authors": [ "Rodríguez-Cerdeira, Carmen", "Freus, Marika", "Misiakiewicz-Has, Kamila", "Pilutin, Anna", "Kolasa, Agnieszka", "Maksym, Radoslaw", "Kajdy, Anna" ], "journal": "NeuroSci (systematic review; PRISMA 2020)", "year": 2025, "url": "https://ouci.dntb.gov.ua/works/loAynGp7/", "citation": "Rodríguez-Cerdeira C, et al. 5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes. Systematic review (PRISMA 2020). 2025.", "tags": [ "5-alpha-reductase", "SRD5A1", "SRD5A2", "SRD5A3", "neurosteroids", "allopregnanolone", "neuropsychiatry", "depression", "suicidality", "systematic-review", "genetics" ], "_source_file": "peer_reviewed", "item_id": "PFS-011", "collection_tag": "core" }, { "type": "peer-reviewed meta-analysis", "title": "5-α-reductase inhibitors and the risk of suicide and neuropsychiatric symptoms: a meta-analysis of observational studies", "authors": [ "Federica Fraenza", "Valerio Liguori", "Ciro Pentella", "Consiglia Riccardi", "Francesca Futura Bernardi", "Annalisa Capuano", "Cristina Scavone" ], "journal": "Frontiers in Urology", "year": 2026, "article": "10.3389/fruro.2026.1881635", "url": "https://www.frontiersin.org/journals/urology/articles/10.3389/fruro.2026.1881635/full", "citation": "5-α-reductase inhibitors and the risk of suicide and neuropsychiatric symptoms: a meta-analysis of observational studies. Front Urol. 2026. doi:10.3389/fruro.2026.1881635.", "tags": [ "5-alpha-reductase-inhibitor", "finasteride", "dutasteride", "suicidality", "neuropsychiatric", "meta-analysis", "allopregnanolone", "GABA", "epigenetics" ], "_source_file": "peer_reviewed", "item_id": "PFS-012", "collection_tag": "core", "doi": "10.3389/fruro.2026.1881635", "abstract_or_summary": "Following PRISMA guidance and a pre-registered protocol, the authors systematically\nreviewed observational studies of suicide and neuropsychiatric events (anxiety,\ndepression, intentional self-harm) in 5-ARI users with prostate enlargement or hair\nloss. Eleven studies entered the systematic review and nine the meta-analysis,\ncomparing users against non-users or alpha-blocker users. The pooled estimate showed no\nstatistically significant association (HR ~1.07, wide confidence interval) with\nsubstantial heterogeneity across studies. The authors conclude the evidence does not\nsupport a class-level risk increase but call for continued active surveillance and\nprospective studies given regulatory concern.\n", "relevance": "The first quantitative synthesis of the suicide/neuropsychiatric-safety literature for\n5-ARIs — the definitive summary estimate the corpus needs, including its null result\nand heterogeneity caveats.\n", "keywords": [ "meta-analysis", "suicide", "neuropsychiatric", "5-alpha-reductase inhibitor", "PRISMA", "observational" ], "verification_status": "verified-crossref-openalex", "study_type": "meta-analysis (of observational studies)", "sample_size": "11 studies in systematic review; 9 in meta-analysis", "quality_notes": "Peer-reviewed Frontiers journal; null pooled result with I²=59% heterogeneity — population mix (BPH vs AGA) limits PFS-specific inference.", "fulltext_url": "https://www.frontiersin.org/journals/urology/articles/10.3389/fruro.2026.1881635/pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "also_listed_in": [ "literature-sweep-2026-10" ], "note": "Merged in v1.14 with LIT-018 (same title, journal and year (Frontiers in Urology 2026)); LIT-018 is now a tombstone pointing here. PFS-012's placeholder author entry is replaced by LIT-018's author list." }, { "type": "peer-reviewed methods", "title": "Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence", "authors": [ "Healy, David", "Mangin, Dee" ], "journal": "Epidemiology and Psychiatric Sciences", "year": 2024, "doi": "10.1017/S2045796024000441", "url": "https://doi.org/10.1017/S2045796024000441", "citation": "Healy D, Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol Psychiatr Sci. 2024.", "tags": [ "PSSD", "epidemiology", "incidence", "prevalence", "methods", "pharmacovigilance", "coding" ], "_source_file": "peer_reviewed", "item_id": "PSSD-013", "collection_tag": "core" }, { "item_id": "DWP-001", "source_type": "reddit_post (reposted to forum; original on r/asktransgender)", "author": "u/drwillpowers (attributed — reposted by propeciahelp user as \"a comment from Dr. Will Powers on reddit\"; linked in TransWiki HRT wiki as authored by Drwillpowers)", "subreddit": "r/asktransgender", "date": "circa 2020–2021 (exact date not verified)", "url": "https://www.reddit.com/r/asktransgender/comments/enf843/has_anyone_here_taken_finasteride_or_dutasteride/", "repost_url": "https://forum.propeciahelp.com/t/dr-will-powers-theory-on-pfs/44137/1", "title": "Has anyone here taken finasteride or dutasteride and gotten post finasteride syndrome (PFS) from them? I have a theory as to why this seems to happen in transgender women more than cis men", "_source_file": "reddit", "collection_tag": "core" }, { "item_id": "DWP-002", "source_type": "reddit_post", "author": "u/drwillpowers (first-person clinical account on his personal subreddit; mirror of r/DrWillPowers)", "subreddit": "r/DrWillPowers", "date": "2026-09-14 (per author's own \"state of my research as of Sept 14 2026\" TLDR)", "url": "https://r.genit.al/r/DrWillPowers/hot?sort=hot&t=&after=t3_1iimy6k", "title": "Untitled long-form research update — new model of PFS/PSSD/post-drug syndromes (Sept 2026)", "_source_file": "reddit", "collection_tag": "core" }, { "item_id": "DWP-003", "source_type": "reddit_post (full text recovered via r.genit.al mirror, Oct 2026)", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "date": "circa May 2026 (archived 2026-05-08; Jan 2026 edit noted in post)", "url": "https://www.reddit.com/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "mirror_url": "https://r.genit.al/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "title": "I think I have figured out at least one specific phenotype of PFS, and it is different from the \"allopregnanolone\" theory", "_source_file": "reddit", "collection_tag": "core" }, { "item_id": "DWP-004", "source_type": "youtube_video (community video summarizing Powers' Reddit post and associated testing protocol)", "author": "not u/drwillpowers (community/SIDEfxHUB upload referencing his post)", "date": "not verified (video page crawled ~199 days before 2026-10-07)", "url": "https://www.youtube.com/watch?v=7iyhq47npE8", "title": "Possible PFS Mechanism Identified — Help Us Gather Patient Data", "_source_file": "reddit", "collection_tag": "core" }, { "item_id": "DWP-005", "source_type": "reddit_post", "author": "u/drwillpowers (attributed — TransWiki HRT wiki links it as his post)", "subreddit": "r/DrWillPowers", "date": "2021 (per wiki citation)", "url": "https://www.reddit.com/r/DrWillPowers/comments/qs1vqm/how_many_pfs_patients_has_dr_powers_helped/", "title": "How many PFS patients has Dr Powers helped?", "_source_file": "reddit", "collection_tag": "core" }, { "item_id": "DWP-006", "source_type": "reddit_post", "author": "u/drwillpowers (attributed via rdrama summary linking his posts)", "subreddit": "r/DrWillPowers", "date": "circa 2023 (post IDs 12g4rop / wybnef era)", "url": "https://old.reddit.com/r/DrWillPowers/comments/12g4rop/have_gender_dysphoria_hypermobile_adhd_or_autism", "title": "Have gender dysphoria, hypermobile, ADHD or autism… / The non-AD of trans…", "_source_file": "reddit", "collection_tag": "core" }, { "item_id": "DWP-007", "source_type": "community_discussion (patient-authored; documents reception of Powers' theory — NOT authored by u/drwillpowers)", "author": "u/various (r/DrWillPowers members)", "subreddit": "r/DrWillPowers", "date": "not verified (mirror crawled ~161 days before 2026-10-07)", "url": "https://r.genit.al/r/DrWillPowers/hot?sort=hot&t=&after=t3_1iimy6k", "title": "PFS/PSSD: I'm going to try something interesting…", "_source_file": "reddit", "collection_tag": "core" }, { "item_id": "DWP-008", "source_type": "community_discussion (patient-authored — NOT by u/drwillpowers)", "author": "u/various (r/DrWillPowers members)", "subreddit": "r/DrWillPowers", "date": "not verified (mirror crawled ~161 days before 2026-10-07)", "url": "https://r.genit.al/r/DrWillPowers/hot?sort=hot&t=&after=t3_1iimy6k", "title": "My HPTA Shutdown Experience PFS Journey (Powers Theory)", "_source_file": "reddit", "collection_tag": "core" }, { "item_id": "DWP-009", "source_type": "community_discussion (patient-authored — NOT by u/drwillpowers)", "author": "u/various (r/DrWillPowers members)", "subreddit": "r/DrWillPowers", "date": "not verified (mirror crawled ~168 days before 2026-10-07)", "url": "https://r.genit.al/r/DrWillPowers?sort=hot&t=&after=t3_1hrxcx2", "title": "Why does PFS cause numbness only in the penis? 2 years off fin, sensation at 5–10%", "_source_file": "reddit", "collection_tag": "core" }, { "title": "Dr. Will Powers Interview [PFS / PAS / PSSD Summit 2026]", "speaker": "Dr. Will Powers (interviewee); Robb, SIDEfxHUB (interviewer)", "channel": "SIDEfxHUB (attributed — description credits 'Rob at SIDEfxHUB')", "url": "https://www.youtube.com/watch?v=iWFDBRTgT3g", "upload_date": "circa May 2026 (approximate, inferred from index timestamp)", "duration": "unavailable via text fetch", "format": "interview", "transcript_available": false, "source_type": "youtube_interview", "relevance": "PFS, PAS, PSSD, post-drug syndrome mechanism theory", "keywords": [ "PFS", "PAS", "PSSD", "post-drug syndrome", "Will Powers", "SIDEfxHUB", "summit", "mechanism theory", "androgen metabolism" ], "_source_file": "youtube", "collection_tag": "core" }, { "title": "What's Happening to Androgen Metabolism in PFS? Dr. Will Powers #finasteride #podcast", "speaker": "Dr. Will Powers", "channel": "SIDEfxHUB (attributed — 'Full credit to Rob at SIDEfxHUB')", "url": "https://www.youtube.com/shorts/adfZxdlmPAk", "upload_date": "circa May 2026 (approximate)", "duration": "short (<60s)", "format": "youtube_short (clip from entry 1)", "transcript_available": false, "source_type": "youtube_short", "relevance": "PFS, androgen metabolism, hormonal pathways", "keywords": [ "PFS", "androgen metabolism", "finasteride", "hormonal pathways", "Will Powers", "5-alpha reductase" ], "_source_file": "youtube", "collection_tag": "core" }, { "title": "Could genetic differences explain why some individuals develop Post-Finasteride Syndrome (PFS)?", "speaker": "Dr. Will Powers", "channel": "SIDEfxHUB (attributed — 'Interview conducted by Rob at SIDEfxHUB')", "url": "https://www.youtube.com/shorts/LZoAudpbtQ0", "upload_date": "circa May 2026 (approximate)", "duration": "short (<60s)", "format": "youtube_short (clip from entry 1)", "transcript_available": false, "source_type": "youtube_short", "relevance": "PFS, genetics, individual susceptibility, whole genome sequencing", "keywords": [ "PFS", "genetics", "whole genome sequencing", "susceptibility", "pharmacogenomics", "Will Powers" ], "_source_file": "youtube", "collection_tag": "core" }, { "title": "Possible PFS Mechanism Identified — Help Us Gather Patient Data", "speaker": "SIDEfxHUB (presenting Dr. Powers' Reddit-post theory)", "channel": "SIDEfxHUB (attributed)", "url": "https://www.youtube.com/watch?v=7iyhq47npE8", "upload_date": "circa March 2026 (approximate, inferred from index timestamp)", "duration": "unavailable via text fetch", "format": "explainer / data-collection call", "transcript_available": false, "source_type": "youtube_explainer", "relevance": "PFS mechanism theory (Powers' Reddit post), patient data collection, hormone testing protocol", "keywords": [ "PFS", "mechanism", "androgen receptor", "mutation", "hormone panel", "androstanediol glucuronide", "DUTCH test", "patient data", "Will Powers", "reddit" ], "_source_file": "youtube", "collection_tag": "core" }, { "title": "Healthcare of the Transgender Patient (Powers Method)", "speaker": "William J. Powers, D.O., Powers Family Medicine", "channel": "reupload (original: 2019 Medical Education Week, Oakland University William Beaumont School of Medicine)", "url": "https://www.youtube.com/watch?v=3g52vlv5YWo", "upload_date": "original lecture 2019-05-13; this reupload circa 2024 (approximate)", "duration": "~1h 45m (per chapter list ending 1:45:27 Q&A)", "format": "medical lecture with chapters", "transcript_available": false, "source_type": "youtube_lecture", "relevance": "background pharmacology: estrone, progesterone, testosterone blockers, neurosteroid-relevant endocrinology underlying Powers' later PFS commentary", "keywords": [ "Powers Method", "HRT", "estrone", "progesterone", "testosterone", "bicalutamide", "neurosteroids", "endocrinology", "transgender medicine" ], "_source_file": "youtube", "collection_tag": "core" }, { "video_id": "iWFDBRTgT3g", "title": "Dr. Will Powers Interview [PFS / PAS / PSSD Summit 2026]", "speaker": "Dr. Will Powers (interviewee); Robb, SIDEfxHUB (interviewer)", "channel": "SIDEfxHUB - PFS & PSSD Patient Organisation", "url": "https://www.youtube.com/watch?v=iWFDBRTgT3g", "verified_live": "2026-10-07", "upload_date": "2026-04-29", "duration": "21:27 (1287s)", "views_at_collection": 9032, "format": "interview", "transcript_status": "full (YouTube auto-generated English captions, 350 cues)", "transcript_file": "transcripts/iWFDBRTgT3g.srt", "source_type": "youtube_interview", "relevance": "PFS, PAS, PSSD mechanism theory; Powers' unifying model; vulnerability screening", "keywords": [ "PFS", "PAS", "PSSD", "post-drug syndrome", "Will Powers", "SIDEfxHUB", "androgen metabolism", "glucuronidation", "UGT", "intracrine", "androgen receptor", "epigenetics", "ARID1A", "CHD8", "HDAC10", "neurosteroid phenotype", "androgenic silencing", "genome sequencing" ], "_source_file": "youtube_transcripts", "collection_tag": "core" }, { "video_id": "adfZxdlmPAk", "title": "What's Happening to Androgen Metabolism in PFS? Dr. Will Powers #finasteride #podcast", "speaker": "Dr. Will Powers", "channel": "Moral Medicine", "channel_note": "Clip from the SIDEfxHUB summit interview (iWFDBRTgT3g); published by Moral Medicine, credited to SIDEfxHUB", "url": "https://www.youtube.com/shorts/adfZxdlmPAk", "verified_live": "2026-10-07", "upload_date": "2026-05-08", "duration": "1:35 (95s)", "views_at_collection": 998, "format": "youtube_short", "transcript_status": "full (YouTube auto-generated English captions, 24 cues)", "transcript_file": "transcripts/adfZxdlmPAk.srt", "source_type": "youtube_short", "relevance": "PFS androgen metabolism; genetic redundancy model", "keywords": [ "PFS", "androgen metabolism", "finasteride", "glucuronidation", "5-alpha reductase", "genetics", "selection bias" ], "_source_file": "youtube_transcripts", "collection_tag": "core" }, { "video_id": "LZoAudpbtQ0", "title": "Could genetic differences explain why some individuals develop Post-Finasteride Syndrome (PFS)?", "speaker": "Dr. Will Powers", "channel": "Moral Medicine", "channel_note": "Clip from the SIDEfxHUB summit interview (iWFDBRTgT3g); published by Moral Medicine, interview by SIDEfxHUB", "url": "https://www.youtube.com/shorts/LZoAudpbtQ0", "verified_live": "2026-10-07", "upload_date": "2026-05-07", "duration": "1:04 (64s)", "views_at_collection": 753, "format": "youtube_short", "transcript_status": "full (YouTube auto-generated English captions, 17 cues)", "transcript_file": "transcripts/LZoAudpbtQ0.srt", "source_type": "youtube_short", "relevance": "PFS genetics; whole genome sequencing; susceptibility", "keywords": [ "PFS", "genetics", "whole genome sequencing", "susceptibility", "pharmacogenomics", "pattern recognition" ], "_source_file": "youtube_transcripts", "collection_tag": "core" }, { "video_id": "7iyhq47npE8", "title": "Possible PFS Mechanism Identified — Help Us Gather Patient Data", "speaker": "SIDEfxHUB presenter (Robb) summarizing Dr. Will Powers' Reddit-post theory", "channel": "SIDEfxHUB - PFS & PSSD Patient Organisation", "url": "https://www.youtube.com/watch?v=7iyhq47npE8", "verified_live": "2026-10-07", "upload_date": "2026-03-08", "duration": "6:42 (402s)", "views_at_collection": 2412, "format": "explainer / data-collection call", "transcript_status": "full (YouTube auto-generated English captions, 87 cues)", "transcript_file": "transcripts/7iyhq47npE8.srt", "source_type": "youtube_explainer", "relevance": "PFS mechanism theory; biomarker protocol; community data collection for summit", "keywords": [ "PFS", "mechanism", "glucuronidation", "intracellular androgens", "androstanediol glucuronide", "DUTCH test", "hormone panel", "patient data", "biomarkers" ], "_source_file": "youtube_transcripts", "collection_tag": "core" }, { "video_id": "3g52vlv5YWo", "title": "Healthcare of the Transgender Patient (Powers Method)", "speaker": "William J. Powers, D.O.", "channel": "Chen Merami", "channel_note": "Reupload; original lecture 2019-05-13, Oakland University William Beaumont School of Medicine Medical Education Week", "url": "https://www.youtube.com/watch?v=3g52vlv5YWo", "verified_live": "2026-10-07", "upload_date": "2024-04-22 (reupload; original 2019-05-13)", "duration": "2:03:27 (7407s)", "views_at_collection": 2396, "format": "medical lecture", "transcript_status": "full (YouTube auto-generated English captions, 1822 cues); PFS-relevant excerpts summarized below", "transcript_file": "transcripts/3g52vlv5YWo.srt", "source_type": "youtube_lecture", "relevance": "background pharmacology: 5ARI neurosteroid depletion, rectal progesterone protocol, androgen blockade", "keywords": [ "Powers Method", "finasteride", "allopregnanolone", "neurosteroids", "progesterone", "bicalutamide", "spironolactone", "5-alpha reductase", "postpartum depression", "brexanolone" ], "_source_file": "youtube_transcripts", "collection_tag": "core" }, { "video_id": "CZATt5AoQjw", "title": "PSSD and PFS: The Overlooked Syndromes No One Warns You About", "speaker": "Dr. Sanil Rege (consultant psychiatrist)", "channel": "Dr. Rege", "url": "https://www.youtube.com/watch?v=CZATt5AoQjw", "verified_live": "2026-10-07", "upload_date": "2024-07-03", "duration": "23:37 (1417s)", "views_at_collection": 16038, "format": "educational explainer", "transcript_status": "full (YouTube auto-generated English captions, 255 cues)", "transcript_file": "transcripts/CZATt5AoQjw.srt", "source_type": "youtube_educational", "relevance": "PFS/PSSD shared mechanisms; clinical overview; treatment avenues", "keywords": [ "PSSD", "PFS", "neuroactive steroids", "allopregnanolone", "androgen receptor", "epigenetics", "DNA methylation", "gut-brain axis", "dopamine", "serotonin", "PNMT", "noradrenaline" ], "_source_file": "youtube_transcripts", "collection_tag": "core" }, { "video_id": "17MNS2Z6kV0", "title": "Rethinking Reductase: The Case for Progesterone and DHT Balance in Men", "speaker": "unidentified presenter (Wellness By Design Project; not confirmed as Powers)", "channel": "The Wellness By Design Project", "url": "https://www.youtube.com/watch?v=17MNS2Z6kV0", "verified_live": "2026-10-07", "upload_date": "2026-02-16", "duration": "11:32 (692s)", "views_at_collection": 202, "format": "clinical presentation", "transcript_status": "full (YouTube auto-generated English captions, 122 cues)", "transcript_file": "transcripts/17MNS2Z6kV0.srt", "source_type": "youtube_presentation", "relevance": "5α/5β reductase biochemistry; allopregnanolone depletion in PFS; progesterone modulation", "keywords": [ "5-alpha reductase", "5-beta reductase", "DHT", "allopregnanolone", "progesterone", "neurosteroids", "GABA", "PFS", "bile", "DUTCH test" ], "verification_note": "Speaker not confirmed as Powers — topically aligned with his neurosteroid framing; label accordingly", "_source_file": "youtube_transcripts", "collection_tag": "core" }, { "video_id": "ARd9fyGRyQs", "title": "Post-Finasteride Syndrome - Cause & Effect! (TRT-clinic short)", "channel": "unidentified (TRT/HRT clinic channel)", "url": "https://www.youtube.com/watch?v=ARd9fyGRyQs", "verified_live": "2026-10-07", "availability": "UNAVAILABLE — video removed or made private (yt-dlp: 'This video is unavailable')", "transcript_status": "unavailable (video removed)", "source_type": "youtube_short", "relevance": "was: neurosteroid hypothesis of PFS (5α-reduced neurosteroids in CSF)", "keywords": [ "PFS", "neurosteroids", "cerebrospinal fluid", "5-alpha reductase" ], "gap_note": "Prior corpus described it as a TRT-clinic clip asserting CSF 5α-reductase produces local neurosteroids missing in PFS. Treat as lost source; do not cite without recovery (try Wayback Machine / alternate upload).", "_source_file": "youtube_transcripts", "collection_tag": "core" }, { "group_id": "ICD-SEX-01", "group_name": "Core sexual dysfunction (Healy 2022 necessary/additional criteria)", "maps_to": [ "CROSS-002 (Healy 2022): necessary criterion (2) enduring change in genital sensation; additional (3) loss of desire, (4) erectile dysfunction, (5) inability to orgasm / decreased orgasmic pleasure; PFS criteria (3)-(5)", "CROSS-001 (Healy 2018): genital numbness, pleasureless orgasm, loss of libido, impotence across all three drug classes", "PSSD-001 (Bala 2018): genital anesthesia, pleasureless orgasm, low libido, ED", "PFS-009 (Irwig 2011): 94% low libido, 92% ED/decreased arousal, 69% orgasm problems" ], "codes": [ { "icd10cm": "F52.0", "icd10cm_desc": "Hypoactive sexual desire disorder", "icd11": "HA00", "icd11_desc": "Hypoactive sexual desire dysfunction", "specificity": "Core match for loss-of-libido criterion. Note: F52.0's tabular header excludes substance-induced cases; use alongside T-codes for post-drug framing." }, { "icd10cm": "F52.21", "icd10cm_desc": "Male erectile disorder", "icd11": "HA01.1", "icd11_desc": "Male erectile dysfunction", "specificity": "Core match for ED criterion (males). Use HA01.12 (acquired, generalised) in ICD-11 when post-drug onset is documented." }, { "icd10cm": "N52.2", "icd10cm_desc": "Drug-induced erectile dysfunction", "icd11": "HA01.1 + NE60 (postcoordinated)", "icd11_desc": "Male erectile dysfunction + harmful effect of drug (cluster)", "specificity": "ICD-10-CM N52.2 explicitly captures drug-induced ED; pair with T-code for the agent. Useful for PFS cases where ED dominates." }, { "icd10cm": "F52.22", "icd10cm_desc": "Female sexual arousal disorder", "icd11": "HA01.0", "icd11_desc": "Female sexual arousal dysfunction", "specificity": "Female arousal/lubrication complaints (Healy 2022 ancillary: decreased vaginal lubrication)." }, { "icd10cm": "F52.31", "icd10cm_desc": "Female orgasmic disorder", "icd11": "HA02.0", "icd11_desc": "Anorgasmia", "specificity": "Female orgasmic dysfunction / pleasureless orgasm." }, { "icd10cm": "F52.32", "icd10cm_desc": "Male orgasmic disorder", "icd11": "HA02.0", "icd11_desc": "Anorgasmia", "specificity": "Male anorgasmia / markedly diminished orgasmic sensation. Tabular includes delayed ejaculation." }, { "icd10cm": "F52.32", "icd10cm_desc": "Male orgasmic disorder (delayed ejaculation inclusion term)", "icd11": "HA03.1", "icd11_desc": "Male delayed ejaculation", "specificity": "For reduced ejaculatory force / delayed ejaculation (Healy 2022 ancillary symptom in males)." }, { "icd10cm": "F52.4", "icd10cm_desc": "Premature ejaculation", "icd11": "HA03.0", "icd11_desc": "Male early ejaculation", "specificity": "Less central to PFS/PSSD; include for completeness of ejaculatory-dysfunction queries." }, { "icd10cm": "F52.8", "icd10cm_desc": "Other sexual dysfunction not due to a substance or known physiological condition", "icd11": "HA0Y", "icd11_desc": "Other specified sexual dysfunctions", "specificity": "Catch-all for atypical presentations (e.g., flaccid glans during erection, reduced nipple sensitivity)." }, { "icd10cm": "F52.9", "icd10cm_desc": "Unspecified sexual dysfunction not due to a substance or known physiological condition", "icd11": "HA0Z", "icd11_desc": "Sexual dysfunctions, unspecified", "specificity": "Last-resort code; Healy 2024 notes cases scatter under vague labels like this." } ], "_source_file": "icd_codes", "collection_tag": "core" }, { "group_id": "ICD-SENS-02", "group_name": "Genital sensory disturbance proxies (genital anesthesia / numbness)", "maps_to": [ "CROSS-002 (Healy 2022): necessary criterion (2) enduring change in somatic (tactile) or erogenous (sexual) genital sensation — the key differentiator from depressive relapse", "PSSD-006 (Ben-Sheetrit 2015): genital anesthesia independent of depression/anxiety", "DISC-013 (Melcangi 2017): abnormal pudendal somatosensory evoked potentials in 4 of 16 (objective neuropathy evidence)", "PSSD-001 (Bala 2018): genital anesthesia as hallmark PSSD symptom" ], "codes": [ { "icd10cm": "R20.0", "icd10cm_desc": "Anesthesia of skin", "icd11": "MB40.3", "icd11_desc": "Anaesthesia of skin", "specificity": "Best proxy for genital anesthesia/numbness. Symptom code; not a principal diagnosis once a definitive diagnosis is established." }, { "icd10cm": "R20.1", "icd10cm_desc": "Hypoesthesia of skin", "icd11": "ME65 (parent)", "icd11_desc": "Disturbances of skin sensation of unspecified aetiology", "specificity": "Reduced genital sensitivity (partial loss)." }, { "icd10cm": "R20.2", "icd10cm_desc": "Paresthesia of skin", "icd11": "ME65.4", "icd11_desc": "Tingling of skin", "specificity": "Tingling / pins-and-needles sensations; inclusion terms cover formication and tingling." }, { "icd10cm": "R20.8", "icd10cm_desc": "Other disturbances of skin sensation", "icd11": "ME65.Y", "icd11_desc": "Other specified disturbance of skin sensation", "specificity": "Atypical sensory complaints not fitting above (e.g., altered erogenous sensation quality)." }, { "icd10cm": "R20.9", "icd10cm_desc": "Unspecified disturbances of skin sensation", "icd11": "ME65.Z", "icd11_desc": "Disturbances of skin sensation of unspecified aetiology, unspecified", "specificity": "Unspecified sensory complaint; verify ME65.Z in the WHO ICD-11 browser before use." } ], "_source_file": "icd_codes", "collection_tag": "core" }, { "group_id": "ICD-PSYCH-03", "group_name": "Mood, anxiety, and emotional-numbing symptoms", "maps_to": [ "PFS-001 (Traish 2020): depressive symptoms, anxiety, suicidality as PFS domains", "DISC-013 (Melcangi 2017): 8 of 16 PFS patients met major depression criteria", "CROSS-002 (Healy 2022): ancillary non-sexual symptoms — emotional numbing, depersonalization", "PFS-012 (2026 meta-analysis): neuropsychiatric symptoms, suicidality signal" ], "codes": [ { "icd10cm": "F32.9", "icd10cm_desc": "Major depressive disorder, single episode, unspecified", "icd11": "6A70", "icd11_desc": "Single episode depressive disorder", "specificity": "Depressive presentations; specify severity (F32.0-F32.3) when documented." }, { "icd10cm": "F33.9", "icd10cm_desc": "Major depressive disorder, recurrent, unspecified", "icd11": "6A71", "icd11_desc": "Recurrent depressive disorder", "specificity": "Recurrent course; specify severity (F33.0-F33.2) when documented." }, { "icd10cm": "F32.A", "icd10cm_desc": "Depression, unspecified", "icd11": "6A70 / 6A71 (per course)", "icd11_desc": "Single episode / recurrent depressive disorder", "specificity": "Added FY2025 for depression below full MDD criteria; commonly used when severity is undocumented." }, { "icd10cm": "F41.1", "icd10cm_desc": "Generalized anxiety disorder", "icd11": "6B00", "icd11_desc": "Generalised anxiety disorder", "specificity": "Anxiety domain; #1 most-billed behavioral-health dx in the US." }, { "icd10cm": "R45.84", "icd10cm_desc": "Anhedonia", "icd11": "(no standalone code; capture under 6A70/6A71)", "icd11_desc": "n/a — anhedonia is a defining symptom of depressive disorders in ICD-11", "specificity": "Billable ICD-10-CM symptom code (FY2027 valid). Central to the anhedonia/low-libido PFS/PSSD subtype discussed in the corpus." }, { "icd10cm": "F48.1", "icd10cm_desc": "Depersonalization-derealization disorder", "icd11": "6B66", "icd11_desc": "Depersonalisation-derealisation disorder", "specificity": "Healy 2022 ancillary non-sexual symptom (depersonalization). Verify 6B66 in WHO browser." } ], "_source_file": "icd_codes", "collection_tag": "core" }, { "group_id": "ICD-NEURO-04", "group_name": "Cognitive dysfunction (\"brain fog\") and sleep disorders", "maps_to": [ "PFS-001 (Traish 2020): neurological/cognitive symptom domain of PFS", "CROSS-002 (Healy 2022): ancillary non-sexual symptoms — cognitive impairment", "PFS-003 (Giatti 2024): sleep disorders shared across PFS/PSSD", "PSSD-002 (Peleg 2022): sleep and neuroplasticity-related symptoms" ], "codes": [ { "icd10cm": "R41.84", "icd10cm_desc": "Other specified cognitive deficit", "icd11": "6D71", "icd11_desc": "Mild neurocognitive disorder", "specificity": "Best proxy for 'brain fog.' ICD-10-CM: code first the underlying condition if known. ICD-11 6D71 explicitly allows medication/substance-related etiology — highly relevant to post-drug framing." }, { "icd10cm": "R41.840", "icd10cm_desc": "Attention and concentration deficit", "icd11": "6D71", "icd11_desc": "Mild neurocognitive disorder", "specificity": "More specific sub-code when attention/concentration is the documented deficit." }, { "icd10cm": "G47.00", "icd10cm_desc": "Insomnia, unspecified", "icd11": "7A00", "icd11_desc": "Insomnia (chronic insomnia disorder grouping 7A00-7A0Z)", "specificity": "Sleep-disorder domain; use G47.0x subtypes when documented." } ], "_source_file": "icd_codes", "collection_tag": "core" }, { "group_id": "ICD-SAFE-05", "group_name": "Suicidality and safety screening", "maps_to": [ "PFS-001 (Traish 2020): suicidality as a PFS concern", "PFS-012 (2026 meta-analysis): 5alpha-reductase inhibitors and suicidality signal", "General pharmacovigilance need for post-drug syndrome registries" ], "codes": [ { "icd10cm": "R45.851", "icd10cm_desc": "Suicidal ideations", "icd11": "MB26.A", "icd11_desc": "Suicidal ideation", "specificity": "Billable symptom code in both systems. Secondary code; pair with mood-disorder code when applicable." }, { "icd10cm": "T14.91XA", "icd10cm_desc": "Suicide attempt, initial encounter", "icd11": "MB23.R", "icd11_desc": "Suicide attempt (exclusion reference of MB26.A)", "specificity": "For attempt events (distinct from ideation). Verify MB23.R in WHO browser." }, { "icd10cm": "Z13.31", "icd10cm_desc": "Encounter for screening for depression", "icd11": "QA45 (encounter for screening; verify)", "icd11_desc": "Screening encounter (verify exact QA code in WHO browser)", "specificity": "Screening code commonly used in research extracts to flag at-risk cohorts. Verify Z13.31/QA mapping against official tabulars before use." }, { "icd10cm": "Z91.5", "icd10cm_desc": "Personal history of self-harm", "icd11": "QC4B", "icd11_desc": "Personal history of self-harm (exclusion reference of MB26.A)", "specificity": "History flag for longitudinal registry datasets." } ], "_source_file": "icd_codes", "collection_tag": "core" }, { "group_id": "ICD-DRUG-06", "group_name": "Adverse-effect T-codes (ICD-10-CM) and drug-harm coding (ICD-11)", "maps_to": [ "CROSS-002 (Healy 2022): prior treatment with SRI / 5alpha-reductase inhibitor / isotretinoin as necessary diagnostic criteria", "CROSS-001 (Healy 2018): three drug classes — antidepressants, 5alpha-reductase inhibitors, isotretinoin", "General adverse-effect sequencing for post-drug persistence" ], "codes": [ { "icd10cm": "T43.225A / T43.225D / T43.225S", "icd10cm_desc": "Adverse effect of selective serotonin reuptake inhibitors (initial / subsequent / sequela)", "icd11": "NE60 + causative-agent postcoordination", "icd11_desc": "Harmful effects of drugs, medicaments or biological substances, NEC — cluster with the specific SRI", "specificity": "Direct T-code for SSRI adverse effects. The S (sequela) 7th character is the most appropriate for PSSD as a persistent post-discontinuation state." }, { "icd10cm": "T43.215A / T43.215D / T43.215S", "icd10cm_desc": "Adverse effect of selective serotonin and norepinephrine reuptake inhibitors", "icd11": "NE60 + causative-agent postcoordination", "icd11_desc": "Harmful effects of drugs, medicaments or biological substances, NEC", "specificity": "SNRI-triggered cases (Healy 2022: SRIs include SNRIs)." }, { "icd10cm": "T43.205A / T43.205D / T43.205S", "icd10cm_desc": "Adverse effect of unspecified antidepressants", "icd11": "NE60 + causative-agent postcoordination", "icd11_desc": "Harmful effects of drugs, medicaments or biological substances, NEC", "specificity": "Fallback when the antidepressant class is undocumented." }, { "icd10cm": "T50.995A / T50.995D / T50.995S", "icd10cm_desc": "Adverse effect of other drugs, medicaments and biological substances", "icd11": "NE60 + causative-agent postcoordination", "icd11_desc": "Harmful effects of drugs, medicaments or biological substances, NEC", "specificity": "Bucket for finasteride, dutasteride, and isotretinoin — none has a dedicated ICD-10-CM T-code (finasteride is not a hormone, so T38 does not apply). S (sequela) 7th character fits PFS/PRSD persistence." }, { "icd10cm": "T88.7XXA", "icd10cm_desc": "Unspecified adverse effect of drug or medicament, initial encounter", "icd11": "NE60", "icd11_desc": "Harmful effects of drugs, medicaments or biological substances, NEC", "specificity": "Only when the drug cannot be identified; prefer specific T-codes above." } ], "_source_file": "icd_codes", "collection_tag": "core" }, { "dataset": "PFS-PSSD-Post-Drug-Syndromes-Medication-Lists", "version": 1.0, "created": "2026-10-07", "source_corpus": "~/workspace/pfs_pssd_corpus/peer_reviewed_literature.md", "classes": [ { "id": "5ARI", "name": "5-alpha reductase inhibitors", "mechanism_class": "Block conversion of testosterone to dihydrotestosterone (DHT) and 5-alpha reduction of progesterone, corticosteroids and other steroids, depleting neurosteroids such as allopregnanolone.", "drugs": [ "finasteride", "dutasteride" ] }, { "id": "SSRI", "name": "Selective serotonin reuptake inhibitors", "mechanism_class": "Block the serotonin transporter (SERT), raising synaptic serotonin; downstream effects include 5-HT1A desensitization, dopamine inhibition, and (per Xie 2026) allopregnanolone depletion via 5-alpha-reductase inhibition.", "drugs": [ "citalopram", "escitalopram", "fluoxetine", "fluvoxamine", "paroxetine", "sertraline" ] }, { "id": "SNRI", "name": "Serotonin-norepinephrine reuptake inhibitors", "mechanism_class": "Block SERT and the norepinephrine transporter (NET); included in the 2019 EMA persistence warning alongside SSRIs.", "drugs": [ "desvenlafaxine", "duloxetine", "milnacipran", "venlafaxine" ] }, { "id": "RETINOID", "name": "Systemic retinoids", "mechanism_class": "Isotretinoin is a 13-cis-retinoic acid retinoid that shrinks sebaceous glands; proposed links to sexual dysfunction include testicular steroidogenesis effects and mood effects (Health Canada review).", "drugs": [ "isotretinoin" ] } ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-001", "generic": "finasteride", "brands": [ "Propecia (1 mg, androgenic alopecia)", "Proscar (5 mg, BPH)" ], "drug_class": "5-alpha reductase inhibitor (5-ARI)", "mechanism": "Inhibits type II (and at 5 mg also type I/III) 5-alpha-reductase, blocking testosterone-to-DHT conversion and 5-alpha reduction of progesterone, cortisol, aldosterone and other steroids; this depletes neurosteroids including allopregnanolone (Melcangi CSF studies).", "syndromes": [ "PFS" ], "corpus_citations": [ "PFS-001", "PFS-002", "PFS-004", "PFS-005", "PFS-006", "PFS-007", "PFS-009", "PFS-010", "PFS-011", "PFS-012", "CROSS-001", "CROSS-002" ], "label_notes": "FDA (April 2012): labels of finasteride 1 mg and 5 mg revised to indicate sexual side effects may persist after discontinuation. Propecia label notes 'sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, libido disorders, ejaculation disorders, and orgasm disorders.'", "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-002", "generic": "dutasteride", "brands": [ "Avodart (0.5 mg, BPH)", "Jalyn (dutasteride + tamsulosin)" ], "drug_class": "5-alpha reductase inhibitor (5-ARI)", "mechanism": "Dual inhibitor of 5-alpha-reductase types I and II; same downstream neurosteroid depletion as finasteride, with longer half-life.", "syndromes": [ "PFS" ], "corpus_citations": [ "PFS-001", "PFS-012" ], "label_notes": "Included in the 5-ARI class warnings on persistent sexual dysfunction (see finasteride); Belknap PeerJ analysis covered finasteride and dutasteride together.", "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-CLASS-SSRI", "label_notes_ema_2019": "EMA PRAC (May 2019): product information for SSRIs/SNRIs amended with the sentence 'There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.' Ten substances named: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran, venlafaxine. UK updated the same year; Australia TGA aligned 2024; Health Canada followed; US FDA had not added an equivalent persistence warning as of the sources found. Fluoxetine label warned since 2011 that 'symptoms of sexual dysfunction occasionally persist after discontinuation.'", "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-003", "generic": "citalopram", "brands": [ "Celexa" ], "drug_class": "SSRI", "mechanism": "SERT blockade; see class note.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "PSSD-002", "PSSD-006", "CROSS-001", "CROSS-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-004", "generic": "escitalopram", "brands": [ "Lexapro" ], "drug_class": "SSRI", "mechanism": "S-enantiomer of citalopram; SERT blockade; see class note.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "PSSD-002", "CROSS-001", "CROSS-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-005", "generic": "fluoxetine", "brands": [ "Prozac" ], "drug_class": "SSRI", "mechanism": "SERT blockade; long half-life; see class note.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "PSSD-002", "CROSS-001", "CROSS-002" ], "label_notes": "US label since 2011 warned that 'symptoms of sexual dysfunction occasionally persist after discontinuation' (per Drug Safety review, 2025).", "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-006", "generic": "fluvoxamine", "brands": [ "Luvox" ], "drug_class": "SSRI", "mechanism": "SERT blockade with sigma-1 activity; see class note.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "CROSS-001", "CROSS-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-007", "generic": "paroxetine", "brands": [ "Paxil" ], "drug_class": "SSRI", "mechanism": "SERT blockade; most-studied SSRI in the corpus preclinical series — shown to perturb neurosteroidogenesis in rat brain (PSSD-009), bind a novel off-target protein (PSSD-010), alter colonic steroidogenesis and microbiota (PSSD-011), and produce persistent transcriptomic changes in hypothalamus/nucleus accumbens after withdrawal (PSSD-012).", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-009", "PSSD-010", "PSSD-011", "PSSD-012", "PSSD-001", "PSSD-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-008", "generic": "sertraline", "brands": [ "Zoloft" ], "drug_class": "SSRI", "mechanism": "SERT blockade with mild dopamine transporter activity; see class note.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "PSSD-002", "PSSD-006", "CROSS-001", "CROSS-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-009", "generic": "desvenlafaxine", "brands": [ "Pristiq" ], "drug_class": "SNRI", "mechanism": "SERT + NET blockade; included in 2019 EMA persistence warning.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "CROSS-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-010", "generic": "duloxetine", "brands": [ "Cymbalta" ], "drug_class": "SNRI", "mechanism": "SERT + NET blockade; included in 2019 EMA persistence warning.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "CROSS-001", "CROSS-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-011", "generic": "milnacipran", "brands": [ "Savella" ], "drug_class": "SNRI", "mechanism": "SERT + NET blockade (relatively more noradrenergic); included in 2019 EMA persistence warning.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "CROSS-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-012", "generic": "venlafaxine", "brands": [ "Effexor" ], "drug_class": "SNRI", "mechanism": "SERT + NET blockade (dose-dependent); included in 2019 EMA persistence warning; cited in Csoka 2008 case reports.", "syndromes": [ "PSSD" ], "corpus_citations": [ "PSSD-001", "PSSD-004", "CROSS-001", "CROSS-002" ], "_source_file": "medications", "collection_tag": "core" }, { "item_id": "MED-013", "generic": "isotretinoin", "brands": [ "Accutane (original brand, discontinued)", "Absorica", "Absorica LD", "Claravis", "Amnesteem", "Myorisan", "Zenatane", "Roaccutane (UK)", "Epuris (Canada)" ], "drug_class": "Retinoid (13-cis-retinoic acid)", "mechanism": "Shrinks sebaceous glands and alters keratinization for severe acne; proposed sexual-dysfunction links include effects on testicular steroidogenesis/testosterone and mood (Health Canada safety review); mechanism of persistent post-retinoid dysfunction not established.", "syndromes": [ "PRSD" ], "corpus_citations": [ "CROSS-001", "CROSS-002" ], "label_notes": "FDA label centers on teratogenicity under the iPLEDGE REMS. Erectile dysfunction is mentioned in the product information for Epuris (isotretinoin, Canada) and Soriatane (acitretin). Health Canada (2015) safety review assessed impotence reports with oral retinoids. UK MHRA tightened prescribing controls with monitoring of sexual side effects. No EU-style 'persists after discontinuation' sentence found for isotretinoin in the sources reviewed.", "_source_file": "medications", "collection_tag": "core" }, { "item_id": "DS-001", "name": "PFS Network", "url": "https://www.pfsnetwork.org", "maintainer": "PFS Network (charity launched on Rare Disease Day 2021 by propeciahelp.com organizers)", "data_type": "patient advocacy org; research funder; science-summaries hub", "access": "public website; research updates via mailing list", "established": 2021, "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-002", "name": "propeciahelp.com — forum, Post-Drug Syndrome Survey, Therapeutic Outcomes reporting", "url": "http://propeciahelp.com/", "forum_url": "https://forum.propeciahelp.com/latest", "maintainer": "propeciahelp community administrators", "data_type": "patient registry (survey); discussion forum; therapeutic-outcomes tracker", "access": "public forum; survey and outcomes data accessible to members who complete the survey", "established": "forum 2006 (origins in Yahoo Groups 2003)", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-003", "name": "PSSD Network", "url": "https://www.pssdnetwork.org/patient-spotlight", "maintainer": "PSSD Network (patient advocacy)", "data_type": "patient story repository; advocacy hub", "access": "public", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-004", "name": "RxISK — adverse-event reporting and research (Dr David Healy group)", "url": "https://rxisk.org", "pssd_page": "https://rxisk.org/post-ssri-sexual-dysfunction-pssd/", "maintainer": "RxISK (David Healy and colleagues)", "data_type": "independent adverse-event reporting tool; published case-series research", "access": "public reporting tool; published papers open access", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-005", "name": "SIDEfxHUB — patient biomarker data collection", "url": "https://sidefxhub.com/articles/pfs-bloodwork-what-tests-to-consider-and-why/", "contact": "robb@sidefxhub.com", "maintainer": "SIDEfxHUB (patient-led)", "data_type": "community biomarker collection (hormone/metabolite panels)", "access": "participation by email submission; protocol published publicly", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-006", "name": "FDA Adverse Event Reporting System (FAERS)", "maintainer": "U.S. Food and Drug Administration (CDER/CBER)", "data_type": "spontaneous adverse-event reports (post-marketing surveillance)", "access": "public — interactive dashboard (reports 1968–present); quarterly raw data files (ASCII/SGML); openFDA API at https://api.fda.gov/drug/event.json; individual reports via FOIA", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-007", "name": "EudraVigilance — European database of suspected adverse drug reactions", "maintainer": "European Medicines Agency (EMA)", "data_type": "spontaneous adverse-event reports (EEA)", "access": "public aggregated data via the adrreports.eu portal (search by product or active substance); EMA user manual for the portal is published; full ICSR access restricted", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-008", "name": "VigiBase / VigiAccess — WHO global adverse-event database", "maintainer": "Uppsala Monitoring Centre (UMC), Sweden, on behalf of WHO", "data_type": "global individual case safety reports (ICSRs); 20M+ reports from 130+ countries (est. 1968–present)", "access": "VigiAccess — public web app with aggregate statistics; full VigiBase/VigiLyze access restricted to national pharmacovigilance centres and authorized users", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-009", "name": "MHRA Yellow Card scheme (UK)", "url": "https://yellowcard.mhra.gov.uk", "maintainer": "UK Medicines and Healthcare products Regulatory Agency (MHRA)", "data_type": "spontaneous suspected-ADR reports (UK)", "access": "public reporting (patients and clinicians); aggregate data via MHRA", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-010", "name": "Published genetic/molecular datasets — AR polymorphisms, SRD5A2 methylation, gene expression", "data_type": "published study data (not public biobanks)", "access": "via papers; raw data availability varies — contact authors", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-011", "name": "ClinicalTrials.gov", "url": "https://clinicaltrials.gov", "maintainer": "U.S. National Library of Medicine", "data_type": "trial registry", "access": "public search", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-012", "name": "Reusable datasets embedded in published studies", "data_type": "study-level datasets extractable from papers/supplements", "access": "via journals; some with supplementary files", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-013", "name": "Standardized codes for PFS/PSSD", "data_type": "controlled vocabularies", "access": "public references", "_source_file": "datasets", "collection_tag": "core" }, { "item_id": "DS-014", "name": "Implicated agents across post-drug syndromes (from corpus papers)", "data_type": "reference list derived from Healy 2018 (CROSS-001), RxISK, and corpus reviews", "access": "n/a — synthesis", "_source_file": "datasets", "collection_tag": "core" }, { "term": "Allopregnanolone", "category": "neurosteroid", "definition": "A progesterone-derived neurosteroid (made via 5-alpha-reductase and 3-alpha-HSD) that positively modulates GABA-A receptors, producing calming, anti-anxiety and antidepressant effects. The corpus uses it in two conflicting ways: Melcangi's CSF studies (PFS-004, PFS-005) and Powers' early theory (DWP-001) frame PFS as allopregnanolone DEFICIENCY, while Powers' 2026 revision (DWP-002) frames the anhedonic PFS/PSSD subtype as neurosteroid EXCESS — track which model a source means.", "used_in": [ "PFS-004", "PFS-005", "PFS-011", "PFS-012", "PSSD-003", "DWP-001", "DWP-002", "MED-001", "MED-002" ], "related_terms": [ "THDOC", "Androsterone", "Dihydroprogesterone", "GABA-A receptor", "Brexanolone" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "THDOC (tetrahydrodeoxycorticosterone)", "category": "neurosteroid", "definition": "A GABA-A-active neurosteroid derived from deoxycorticosterone. In Powers' 2026 model it is one of the neurosteroids pathologically OVERPRODUCED in the anhedonia/low-libido PFS/PSSD subtype, driving downstream neural network remodeling analogous to chronic benzodiazepine exposure.", "used_in": [ "DWP-002" ], "related_terms": [ "Allopregnanolone", "Androsterone", "GABA-A receptor" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Androsterone", "category": "neurosteroid", "definition": "A 5-alpha-reduced androgen metabolite that also modulates GABA-A receptors. Named alongside THDOC in Powers' neurosteroid-excess model of the anhedonic PFS/PSSD subtype.", "used_in": [ "DWP-002" ], "related_terms": [ "THDOC", "Allopregnanolone", "GABA-A receptor" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Dihydroprogesterone (DHP / 5-alpha-DHP)", "category": "neurosteroid", "definition": "The direct 5-alpha-reductase product of progesterone and the obligatory precursor of allopregnanolone. Found decreased in PFS patient plasma after finasteride discontinuation (PFS-004, PFS-005), showing the whole downstream neurosteroid chain is disrupted.", "used_in": [ "PFS-004", "PFS-005", "DWP-001" ], "related_terms": [ "Allopregnanolone", "Progesterone", "5-alpha-reductase" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Isopregnanolone", "category": "neurosteroid", "definition": "A progesterone-derived neurosteroid found decreased in the cerebrospinal fluid of PFS patients versus controls, part of the broad neurosteroid disruption signature.", "used_in": [ "PFS-004" ], "related_terms": [ "Allopregnanolone", "Tetrahydroprogesterone" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Pregnanolone", "category": "neurosteroid", "definition": "A neurosteroid in the progesterone metabolic pathway, discussed in corpus reviews of neurosteroidogenesis and its disruption by 5-alpha-reductase inhibitors and SSRIs.", "used_in": [ "PFS-011", "PSSD-003" ], "related_terms": [ "Allopregnanolone", "Dihydroprogesterone" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Tetrahydroprogesterone", "category": "neurosteroid", "definition": "A progesterone metabolite found decreased in PFS cerebrospinal fluid, indicating impaired downstream neurosteroid synthesis persisting after finasteride is stopped.", "used_in": [ "PFS-004", "PFS-005" ], "related_terms": [ "Allopregnanolone", "Isopregnanolone" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "3-alpha-androstanediol (3-alpha-diol)", "category": "neurosteroid", "definition": "A DHT metabolite that was ELEVATED in PFS plasma while downstream calming neurosteroids stayed low — interpreted in the corpus as a metabolic 'backlog' signal consistent with blocked or rerouted androgen metabolism.", "used_in": [ "PFS-004" ], "related_terms": [ "Dihydrotestosterone", "Androstanediol glucuronide" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Brexanolone", "category": "neurosteroid", "definition": "An intravenous synthetic formulation of allopregnanolone approved for postpartum depression. Powers (DWP-001) cited the close resemblance between PFS symptoms and severe postpartum depression — which responds to brexanolone — as support for his early allopregnanolone-deficiency theory.", "used_in": [ "DWP-001" ], "related_terms": [ "Allopregnanolone" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "5-alpha-reductase (5AR)", "category": "enzyme", "definition": "The enzyme family converting testosterone to dihydrotestosterone (DHT) and progesterone to dihydroprogesterone; it is also required for neurosteroid synthesis in the brain. Finasteride and dutasteride inhibit it, which is why the corpus treats 5AR blockade as the pharmacological starting point of PFS.", "used_in": [ "PFS-001", "PFS-002", "PFS-011", "PFS-012", "PSSD-003", "DWP-001", "DWP-009", "MED-001", "MED-002" ], "related_terms": [ "SRD5A2", "Finasteride (5ARI class)", "Allopregnanolone", "5-beta-reductase" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "SRD5A1", "category": "enzyme", "definition": "Gene encoding 5-alpha-reductase type 1, the isoenzyme expressed broadly including brain and liver. Covered in the systematic review of 5-alpha-reductase isoenzyme biology (PFS-011).", "used_in": [ "PFS-011" ], "related_terms": [ "SRD5A2", "SRD5A3", "5-alpha-reductase" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "SRD5A2", "category": "enzyme", "definition": "Gene encoding 5-alpha-reductase type 2, dominant in prostate and genital skin. A pilot study found differential SRD5A2 methylation in PFS cerebrospinal fluid versus controls, linking the drug's target gene itself to epigenetic changes.", "used_in": [ "PFS-011", "DS-010" ], "related_terms": [ "SRD5A1", "DNA methylation", "5-alpha-reductase" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "SRD5A3", "category": "enzyme", "definition": "Gene encoding the third 5-alpha-reductase isoenzyme, less characterized than types 1 and 2 but included in the corpus's systematic review of reductase biology.", "used_in": [ "PFS-011" ], "related_terms": [ "SRD5A1", "SRD5A2" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "3-alpha-HSD (3-alpha-hydroxysteroid dehydrogenase)", "category": "enzyme", "definition": "Enzyme family interconverting DHT with androstanediol and DHP with allopregnanolone — the on/off switch for GABA-active neurosteroids. Powers implicates UPREGULATED 3-alpha-HSD in his 2026 neurosteroid-excess model (DWP-002).", "used_in": [ "DWP-002" ], "related_terms": [ "AKR1C family", "Allopregnanolone", "Androstanediol glucuronide" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "AKR1C family", "category": "enzyme", "definition": "Aldo-keto reductase enzymes that include 3-alpha-HSD isoforms and act downstream of 5-alpha-reductase in neurosteroid synthesis. Powers' original PFS theory (DWP-001): only people carrying decreased-function AKR1C variants develop PFS when 5AR is blocked, which would explain the syndrome's rarity.", "used_in": [ "DWP-001" ], "related_terms": [ "3-alpha-HSD", "Allopregnanolone", "Pharmacoepigenetics" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "UGT (UDP-glucuronosyltransferase)", "category": "enzyme", "definition": "Enzymes that attach glucuronic acid to androgens and other steroids so they can be excreted. Powers reports disrupted glucuronidation/excretion — with UGT and ABCC transporter gene findings — as a core defect in his PFS model, leaving weak androgen metabolites to accumulate.", "used_in": [ "DWP-002", "iWFDBRTgT3g" ], "related_terms": [ "Glucuronidation", "Androstanediol glucuronide", "Beta-glucuronidase" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Glucuronidation", "category": "enzyme", "definition": "The conjugation pathway that tags androgens for urinary/biliary excretion — one of the 'lanes' in Powers' '15-lane highway' analogy for testosterone exit pathways. He reports glucuronidation defects as the most common finding in PFS patient genomes.", "used_in": [ "DWP-002", "iWFDBRTgT3g", "DS-005" ], "related_terms": [ "UGT", "Androstanediol glucuronide", "DUTCH test" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "5-beta-reductase", "category": "enzyme", "definition": "A parallel reductase pathway that tones hormones down for excretion and is essential for bile acid production. Discussed in the 'Rethinking Reductase' video as the overlooked counterpart to 5-alpha-reductase in hormone clearance.", "used_in": [ "DWP-009" ], "related_terms": [ "5-alpha-reductase", "DUTCH test" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Aromatase", "category": "enzyme", "definition": "Enzyme converting testosterone to estradiol. Relevant because PFS cerebrospinal fluid showed increased estradiol alongside decreased DHT, indicating the steroid pathway is rerouted — not just blocked — after finasteride.", "used_in": [ "PFS-004" ], "related_terms": [ "5-alpha-reductase", "Dihydrotestosterone" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Beta-glucuronidase", "category": "enzyme", "definition": "A gut bacterial enzyme that removes glucuronic acid tags, recycling androgens back into circulation instead of letting them be excreted. Powers implicates gut beta-glucuronidase activity in the disrupted androgen excretion of PFS and describes targeting it (e.g., with calcium D-glucarate).", "used_in": [ "DWP-002" ], "related_terms": [ "UGT", "Glucuronidation", "Calcium D-glucarate" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "PNMT (phenylethanolamine N-methyltransferase)", "category": "enzyme", "definition": "Enzyme converting noradrenaline to adrenaline. Giatti et al. (2024) propose PFS and PSSD mechanisms converge here, and the Dr. Rege video notes both finasteride and paroxetine may inhibit it — a candidate shared pharmacological node.", "used_in": [ "PFS-003" ], "related_terms": [ "Dopamine", "Serotonin" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Androgen receptor (AR)", "category": "receptor", "definition": "The nuclear receptor through which testosterone and DHT drive gene expression. The corpus reports it as OVEREXPRESSED in PFS penile skin (SIDE-009) and links AR gene CAG/GGN repeat variants to symptom patterns (PFS-007) — a compensatory upregulation that may paradoxically silence signaling when weak metabolites crowd the receptor.", "used_in": [ "PFS-007", "SIDE-009", "DWP-009", "iWFDBRTgT3g", "DS-010" ], "related_terms": [ "AR overexpression", "CAG repeat", "Dihydrotestosterone", "Intracrine signaling" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "GABA-A receptor", "category": "receptor", "definition": "The brain's main inhibitory receptor, positively modulated (activated) by allopregnanolone, THDOC and androsterone. It sits at the center of both corpus models: neurosteroid DEPLETION (early Powers, Melcangi) and neurosteroid EXCESS causing network remodeling like chronic benzodiazepine exposure (Powers 2026).", "used_in": [ "DWP-002" ], "related_terms": [ "Allopregnanolone", "THDOC", "Anhedonia" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "5-HT1A receptor", "category": "receptor", "definition": "A serotonin autoreceptor whose desensitization/downregulation is a leading mechanistic hypothesis for PSSD, alongside epigenetic changes and hormonal shifts.", "used_in": [ "PSSD-001", "PSSD-003" ], "related_terms": [ "Serotonin", "Dopamine" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Dopamine", "category": "receptor", "definition": "Neurotransmitter governing reward and motivation; the corpus proposes serotonergic drugs inhibit dopamine signaling in reward circuits (nucleus accumbens), contributing to anhedonia and sexual dysfunction in PSSD.", "used_in": [ "PSSD-001", "PSSD-002", "PSSD-003", "PSSD-012" ], "related_terms": [ "Nucleus accumbens", "Anhedonia", "Serotonin" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Nucleus accumbens", "category": "receptor", "definition": "The brain's reward center. Rat studies found persistent paroxetine-induced gene-expression changes here after withdrawal — the strongest preclinical evidence for lasting SSRI effects on sexual-reward circuitry.", "used_in": [ "PSSD-012" ], "related_terms": [ "Dopamine", "Epigenetics" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Serotonin", "category": "receptor", "definition": "Neurotransmitter targeted by SSRIs/SNRIs; beyond mood, the corpus implicates serotonergic disruption of dopamine, neurosteroid synthesis and gut signaling in persistent post-SSRI dysfunction.", "used_in": [ "PFS-003", "PSSD-001", "PSSD-002" ], "related_terms": [ "5-HT1A receptor", "Dopamine" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "DNA methylation", "category": "epigenetic", "definition": "An epigenetic mark that silences genes without changing DNA sequence. Central to Traish's 'drug-induced epigenetics' model: finasteride is proposed to trigger lasting methylation changes (e.g., at SRD5A2) that persist after the drug is gone.", "used_in": [ "PFS-001", "PFS-002", "PSSD-005" ], "related_terms": [ "Histone modification", "Pharmacoepigenetics", "SRD5A2" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Histone modification", "category": "epigenetic", "definition": "Chemical changes to the histone proteins around which DNA is wound, altering how accessible genes are. Listed alongside DNA methylation as a lasting epigenetic consequence of endocrine disruption in the PFS model.", "used_in": [ "PFS-001", "PFS-002" ], "related_terms": [ "DNA methylation", "HDAC" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "HDAC (histone deacetylase)", "category": "epigenetic", "definition": "Enzymes that remove acetyl groups from histones, typically silencing genes. The corpus mentions HDACs two ways: fasting-induced beta-hydroxybutyrate acts as an HDAC inhibitor (patient experiment, DWP-007), and HDAC10 recurs among genes Powers reports in PFS patient genomes.", "used_in": [ "DWP-007", "DWP-008", "iWFDBRTgT3g" ], "related_terms": [ "Histone modification", "ARID1A/CHD8/HDAC10" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "AR overexpression", "category": "epigenetic", "definition": "Abnormally high androgen-receptor levels found in PFS penile-skin tissue versus controls (1,446 genes over-expressed overall). Interpreted as a compensatory — and possibly epigenetically locked — response to impaired androgen signaling.", "used_in": [ "PFS-008" ], "related_terms": [ "Androgen receptor", "DNA methylation" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "CAG repeat", "category": "epigenetic", "definition": "A polymorphic glutamine-encoding tract in the androgen receptor gene; repeat length tunes receptor activity. In 66 PFS patients, CAG (and GGN) length variants were associated with different symptom patterns — a genetic-susceptibility finding.", "used_in": [ "PFS-007" ], "related_terms": [ "GGN repeat", "Androgen receptor" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "GGN repeat", "category": "epigenetic", "definition": "A polymorphic glycine-encoding tract in the androgen receptor gene, studied alongside CAG repeats for association with PFS symptom variation.", "used_in": [ "PFS-007" ], "related_terms": [ "CAG repeat", "Androgen receptor" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Pharmacoepigenetics", "category": "epigenetic", "definition": "The proposed field — introduced by Csoka & Szyf (2009) — studying lasting drug-induced epigenetic modifications as a general class of pharmaceutical side effects; the conceptual umbrella under which the corpus groups PFS and PSSD.", "used_in": [ "PSSD-005" ], "related_terms": [ "DNA methylation", "Post-drug syndrome" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "ARID1A / CHD8 / HDAC10", "category": "epigenetic", "definition": "Chromatin-remodeling/epigenetic-regulator genes that Powers reports recurring across PFS patient genomes in his summit interview — offered as candidate genetic-susceptibility loci for post-drug syndromes, pending formal publication.", "used_in": [ "iWFDBRTgT3g" ], "related_terms": [ "HDAC", "DNA methylation" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "DUTCH test", "category": "biomarker", "definition": "Dried Urine Test for Comprehensive Hormones: a urine panel mapping steroid metabolites and their excretion. Powers reports near-zero urinary androgens on DUTCH in over half his PFS patients — his key evidence for broken androgen excretion — and includes it in his three-test biomarker protocol.", "used_in": [ "DWP-002", "DWP-003", "DWP-004" ], "related_terms": [ "Androstanediol glucuronide", "Glucuronidation" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Androstanediol glucuronide (3-alpha-ADG)", "category": "biomarker", "definition": "A glucuronic-acid-conjugated DHT metabolite measurable in blood, used as a marker of androgen metabolism and excretion. One of the three tests in Powers' PFS biomarker battery (with morning hormone panel and DUTCH).", "used_in": [ "DWP-002", "DWP-004", "DS-005" ], "related_terms": [ "DUTCH test", "Glucuronidation", "UGT" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "CSF analysis", "category": "biomarker", "definition": "Cerebrospinal fluid sampling (via lumbar puncture) to measure brain neurosteroid levels directly. Melcangi's CSF studies provided the first biochemical evidence of persistent neurosteroid disruption in PFS; Powers has requested CSF mass-spectrometry collaboration to identify overproduced molecules.", "used_in": [ "PFS-004", "PFS-005", "DWP-002" ], "related_terms": [ "Mass spectrometry", "Allopregnanolone" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Mass spectrometry (LC-MS/MS)", "category": "biomarker", "definition": "Liquid chromatography-tandem mass spectrometry: the precise analytical method used to quantify neurosteroids in cerebrospinal fluid and plasma in the Melcangi PFS studies.", "used_in": [ "PFS-004", "DWP-002" ], "related_terms": [ "CSF analysis" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "ASEX", "category": "biomarker", "definition": "Arizona Sexual Experience Scale: a validated questionnaire measuring sexual dysfunction. Used in Irwig's finasteride follow-up (89% of men met dysfunction criteria) and in PSSD clinical characterization — one of the corpus's standard outcome instruments.", "used_in": [ "PFS-010", "DS-012" ], "related_terms": [ "Genital anesthesia", "Anhedonia" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Anhedonia", "category": "clinical", "definition": "The inability to feel pleasure. In Powers' 2026 model it defines one of two PFS/PSSD subtypes — the neurosteroid-excess, low-libido/anhedonic subtype — as distinct from the androgenic-signal-loss subtype.", "used_in": [ "DWP-002" ], "related_terms": [ "GABA-A receptor", "Dopamine", "Nucleus accumbens" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Genital anesthesia", "category": "clinical", "definition": "Loss or severe reduction of genital sensation; a hallmark PSSD symptom also reported in PFS (including a case of isolated penile numbness with normal systemic hormones, DWP-009). Healy's diagnostic criteria treat enduring genital sensory change as a necessary criterion.", "used_in": [ "PSSD-001", "PSSD-006", "DWP-009", "CROSS-002" ], "related_terms": [ "Pudendal neuropathy", "ASEX" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "HPG axis", "category": "clinical", "definition": "Hypothalamic-pituitary-gonadal axis: the hormonal control loop governing sex-hormone production. Discussed in the corpus regarding how drugs (and proposed interventions like fasting or HPTA shutdown) modulate or suppress it.", "used_in": [ "DWP-007" ], "related_terms": [ "HPTA axis" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "HPTA axis / HPTA shutdown", "category": "clinical", "definition": "Hypothalamic-pituitary-testicular/adrenal axis. Patients in the corpus report experiments with extended HPTA shutdown (suppressing endogenous hormone production); one reported a transient full-remission 'window' on testosterone reintroduction followed by a crash.", "used_in": [ "DWP-008" ], "related_terms": [ "HPG axis", "Castration trial", "Window and crash" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Castration trial", "category": "clinical", "definition": "CORPUS-SPECIFIC USAGE (Powers): a temporary period of chemical androgen deprivation used as a DIAGNOSTIC probe — 'unplug the router... do they reboot?' — to distinguish PFS subtypes. Powers reports it reliably restores androgenic signaling in the androgen-signal-loss subtype but not the anhedonic subtype. Not a standard medical term in this sense.", "used_in": [ "DWP-002" ], "related_terms": [ "HPTA shutdown", "Anhedonia" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Post-drug syndrome", "category": "clinical", "definition": "Umbrella term for persistent symptom syndromes that continue after a drug is discontinued — covering PFS, PSSD, post-SSRI syndromes and post-retinoid sexual dysfunction (PRSD). Healy's cross-drug case series (300 cases across drug classes) is the empirical basis for grouping them.", "used_in": [ "CROSS-001", "CROSS-002", "DWP-002" ], "related_terms": [ "Pharmacoepigenetics", "Genital anesthesia" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Intracrine signaling", "category": "clinical", "definition": "Hormone action that occurs locally within the cell where the hormone is made or metabolized, invisible to blood tests. Powers uses it distinctively: weak androgen metabolites crowd the androgen receptor INSIDE cells ('musical chairs with Helen Keller'), silencing signaling while serum labs look normal — his explanation for why standard blood work misses PFS.", "used_in": [ "iWFDBRTgT3g" ], "related_terms": [ "Androgen receptor", "Glucuronidation" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Window and crash", "category": "clinical", "definition": "CORPUS-SPECIFIC patient jargon: a transient period of full symptom remission (the 'window' — e.g., ~2 weeks after testosterone reintroduction) followed by relapse (the 'crash'). Powers' 2026 model reinterprets crashes as withdrawal-like effects from shifting potent-to-weak androgen ratios.", "used_in": [ "DWP-002", "DWP-008" ], "related_terms": [ "Castration trial", "HPTA shutdown" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Pudendal neuropathy", "category": "clinical", "definition": "Dysfunction of the pudendal nerve supplying the genitals. Melcangi's 2017 study found abnormal pudendal nerve potentials in 4 of 16 PFS patients (DISC-013), the first objective evidence of peripheral neuropathy in the syndrome; at Queen Square the same tests were normal in 8 of 9 PSSD patients with genital sensory loss (CUR-003).", "used_in": [ "DISC-013", "CUR-003" ], "related_terms": [ "Genital anesthesia", "Small fiber neuropathy (SFN)" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Calcium D-glucarate", "category": "clinical", "definition": "A supplement Powers reports using (with indomethacin) to support glucuronidation and lower neurosteroid load in his PFS protocol; patient 'crashes' on it are reinterpreted in his model as withdrawal-like effects rather than treatment failure.", "used_in": [ "DWP-002" ], "related_terms": [ "Beta-glucuronidase", "Glucuronidation", "Indomethacin" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Indomethacin", "category": "clinical", "definition": "An NSAID that Powers combines with calcium D-glucarate in his PFS protocol aimed at lowering neurosteroid load; mentioned as part of the intervention arm of his 2026 model.", "used_in": [ "DWP-002" ], "related_terms": [ "Calcium D-glucarate" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "Doxycycline", "category": "clinical", "definition": "A tetracycline antibiotic that Powers implicates as a possible gut-flora trigger route in his PFS model — an example of how non-hormonal drugs enter the post-drug-syndrome story via the gut-steroid axis.", "used_in": [ "DWP-002" ], "related_terms": [ "Beta-glucuronidase", "Post-drug syndrome" ], "_source_file": "glossary", "collection_tag": "core" }, { "term": "5-alpha-reductase inhibitor (5ARI)", "category": "clinical", "definition": "Drug class comprising finasteride and dutasteride, which block 5-alpha-reductase. The corpus's PFS literature concerns persistent effects after 5ARI discontinuation; FDA labeling (2012) notes sexual side effects may persist.", "used_in": [ "PFS-001", "MED-001", "MED-002" ], "related_terms": [ "5-alpha-reductase", "Finasteride" ], "_source_file": "glossary", "collection_tag": "core" }, { "date": "1982-05", "date_precision": "month", "event": "Isotretinoin (Accutane) approved by FDA", "category": "drug_approval", "significance": "Retinoid whose enduring sexual dysfunction cases later joined the cross-drug syndrome literature, suggesting a shared downstream pathway with finasteride and SSRIs.", "corpus_refs": [ "CROSS-001", "CROSS-002", "medication-lists.md (retinoids)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "1987-12", "date_precision": "month", "event": "Fluoxetine (Prozac) approved by FDA — first SSRI on the US market", "category": "drug_approval", "significance": "Opens the SSRI era; the drug class whose persistent post-discontinuation sexual effects became known as PSSD.", "corpus_refs": [ "PSSD-003", "medication-lists.md (SSRIs)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "1991-12", "date_precision": "month", "event": "Sertraline (Zoloft) approved by FDA", "category": "drug_approval", "significance": "Second major SSRI; later among the most-reported drugs in persistent-dysfunction case series.", "corpus_refs": [ "CROSS-001", "medication-lists.md (SSRIs)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "1992", "date_precision": "year", "event": "Finasteride 5 mg (Proscar) approved by FDA for benign prostatic hyperplasia", "category": "drug_approval", "significance": "First 5-alpha-reductase inhibitor on the market; persistent sexual effects in this population were later documented alongside the hair-loss cohort.", "corpus_refs": [ "PFS-001", "medication-lists.md (5-ARIs)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "1992-12", "date_precision": "month", "event": "Paroxetine (Paxil) approved by FDA", "category": "drug_approval", "significance": "Became the most deeply characterized SSRI in the corpus — four preclinical papers probe its neurosteroid, gut-microbiota, and transcriptomic effects.", "corpus_refs": [ "PSSD-009", "PSSD-010", "PSSD-011", "PSSD-012", "medication-lists.md (SSRIs)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "1997", "date_precision": "year", "event": "Finasteride 1 mg (Propecia) approved by FDA for male-pattern hair loss", "category": "drug_approval", "significance": "Moved finasteride into a young, healthy population — the cohort in which persistent post-discontinuation symptoms (PFS) were first systematically described.", "corpus_refs": [ "PFS-009", "PFS-010", "medication-lists.md (5-ARIs)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2001-11", "date_precision": "month", "event": "Dutasteride (Avodart) approved by FDA for BPH", "category": "drug_approval", "significance": "Dual 5-alpha-reductase inhibitor (types 1 and 2); included in PFS literature as a second 5-ARI trigger.", "corpus_refs": [ "PFS-001", "medication-lists.md (5-ARIs)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2008", "date_precision": "year", "event": "Csoka, Bahrick & Mehtonen publish first PSSD case series (J Sex Med)", "category": "paper", "significance": "Early cases of sexual dysfunction persisting years after SSRI/SNRI discontinuation; first proposal of medication-induced gene-expression changes as the mechanism.", "corpus_refs": [ "PSSD-004" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2009", "date_precision": "year", "event": "Csoka & Szyf propose 'epigenetic side-effects of common pharmaceuticals' (Med Hypotheses)", "category": "paper", "significance": "Conceptual umbrella for the entire corpus: lasting drug-induced epigenetic modifications as a general side-effect class, covering PFS and PSSD alike.", "corpus_refs": [ "PSSD-005" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2011-03", "date_precision": "month", "event": "FDA teleconference with Merck; label gains 'erectile dysfunction that continued after discontinuation of treatment'", "category": "regulatory", "significance": "First regulatory acknowledgment that finasteride sexual effects can outlast treatment — a precursor to the broader 2012 label revision.", "corpus_refs": [ "medication-lists.md (5-ARIs)", "https://www.bernsteinmedical.com/research/summary-of-finasteride-label-changes/" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2011-06", "date_precision": "month", "event": "Irwig & Kolukula publish landmark finasteride case series (J Sex Med)", "category": "paper", "significance": "71 healthy young men; 94% low libido, 92% erectile dysfunction persisting ~40 months after stopping — established persistence, not just on-treatment effects, as the issue.", "corpus_refs": [ "PFS-009" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2012-04-11", "date_precision": "exact", "event": "FDA announces label changes for Propecia and Proscar: sexual adverse events may persist after discontinuation", "category": "regulatory", "significance": "Propecia label adds persistent libido, ejaculation, and orgasm disorders; Proscar adds persistent decreased libido. The first major regulatory validation of PFS.", "corpus_refs": [ "medication-lists.md (5-ARIs)", "https://www.bernsteinmedical.com/research/summary-of-finasteride-label-changes/" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2012-07", "date_precision": "month", "event": "Post-Finasteride Syndrome Foundation (PFSF) established as 501(c)(3)", "category": "community", "significance": "Patient-founded organization that funded the first clinical PFS studies (Brigham and Women's Hospital; Baylor College of Medicine), seeding the research literature.", "corpus_refs": [ "related-datasets.md", "https://www.lawyersandsettlements.com/legal-news/propecia/propecia-lawsuit-finasteride-side-20-20131.html" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2012-11", "date_precision": "month", "event": "Irwig follow-up: 'could they be permanent?' (J Sex Med)", "category": "paper", "significance": "54 men reassessed ~14 months later: 96% still symptomatic. Duration of use did not predict recovery — evidence for individual susceptibility over dose-response.", "corpus_refs": [ "PFS-010" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2013-10", "date_precision": "month", "event": "Melcangi et al. measure neuroactive steroids in CSF of PFS patients (J Sex Med)", "category": "paper", "significance": "First direct biochemical evidence: persistent neurosteroid disruption in cerebrospinal fluid after finasteride discontinuation — the pharmacological mechanism at the heart of the corpus.", "corpus_refs": [ "PFS-004" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2014", "date_precision": "year", "event": "Hogan, Le Noury, Healy & Mangin publish 120 cases of enduring sexual dysfunction (Int J Risk Saf Med)", "category": "paper", "significance": "Early pharmacovigilance case series establishing the enduring-dysfunction signal across drug classes, before formal diagnostic criteria existed.", "corpus_refs": [ "CROSS-003" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2015", "date_precision": "year", "event": "Caruso et al. extend CSF/plasma neurosteroid findings (J Steroid Biochem Mol Biol)", "category": "paper", "significance": "Replication in 7 patients: broad steroid-pathway disruption — precursors pile up while downstream calming neurosteroids stay depleted.", "corpus_refs": [ "PFS-005" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2015", "date_precision": "year", "event": "Ben-Sheetrit et al. characterize PSSD clinically (J Clin Psychopharmacol)", "category": "paper", "significance": "532 surveyed, 183 possible cases; genital anesthesia independent of depression; no dose-response — the best clinical characterization of PSSD to date.", "corpus_refs": [ "PSSD-006" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2017", "date_precision": "year", "event": "Cauci et al. link androgen-receptor repeat polymorphisms to PFS symptom patterns (Sex Med)", "category": "paper", "significance": "Core genetic-susceptibility paper: AR (CAG)n/(GGN)n variants associated with different PFS symptom profiles — a precision-medicine angle for the corpus.", "corpus_refs": [ "PFS-007" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2017", "date_precision": "year", "event": "Melcangi et al. ask 'PFS and PSSD: two sides of the same coin?' (Endocrine)", "category": "paper", "significance": "Melcangi's group reports pudendal nerve testing and CSF neurosteroids in 16 PFS patients (DISC-013, 2017) — the first objective peripheral-nerve evidence, abnormal in 4 of 16 — and in 2018 reviews PFS and PSSD together as possibly 'two sides of the same coin' (PFS-006).", "corpus_refs": [ "DISC-013", "PFS-006" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2018-01", "date_precision": "month", "event": "Bala, Nguyen & Hellstrom publish PSSD literature review (Sex Med Rev)", "category": "paper", "significance": "Standard definitional review of PSSD — genital anesthesia, pleasureless orgasm, persistent low libido — with epigenetic and 5-HT1A theories.", "corpus_refs": [ "PSSD-001" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2018", "date_precision": "year", "event": "Traish introduces 'drug-induced epigenetics' model of PFS (Curr Sex Health Rep)", "category": "paper", "significance": "Argues finasteride reprograms gene regulation (DNA methylation, histone modification, AR upregulation) — the theoretical origin of the epigenetic model.", "corpus_refs": [ "PFS-002" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2018", "date_precision": "year", "event": "Healy, Le Noury & Mangin publish 300 cross-drug cases (Int J Risk Saf Med)", "category": "paper", "significance": "300 cases across 37 countries spanning antidepressants, 5-alpha-reductase inhibitors, and isotretinoin with shared genital-numbness/anorgasmia phenotype — empirical basis for grouping the syndromes.", "corpus_refs": [ "CROSS-001" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2019", "date_precision": "approximate", "event": "Dr Will Powers begins treating PFS patients (self-reported in 2026 interview)", "category": "powers", "significance": "Start of the clinical experience that produced his evolving PFS/PSSD theories; he reports ~100 PFS patients treated by 2026.", "corpus_refs": [ "youtube-transcripts.md (iWFDBRTgT3g [1:40-2:18])", "DWP-005" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2019-05-13", "date_precision": "exact", "event": "Powers delivers 'Healthcare of the Transgender Patient' lecture (Oakland University)", "category": "powers", "significance": "Foundational on-camera record of his endocrine reasoning — estrone, progesterone, androgen blockade — underlying his later neurosteroid commentary on post-drug syndromes.", "corpus_refs": [ "youtube-transcripts.md (3g52vlv5YWo)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2019-05-16", "date_precision": "exact", "event": "EMA PRAC concludes SSRI/SNRI sexual dysfunction can be long-lasting after discontinuation; public statement 2019-06-10", "category": "regulatory", "significance": "Label sentence added for 10 substances (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran, venlafaxine): 'There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation.' First regulator-level recognition of PSSD.", "corpus_refs": [ "medication-lists.md (SSRIs/SNRIs)", "https://www.madinamerica.com/2019/06/ema-acknowledges-persistent-sexual-dysfunction-ssris-snris/" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2019", "date_precision": "approximate", "event": "propeciahelp.com launches Post-Drug Syndrome Survey", "category": "community", "significance": "Patient-reported dataset (~3,000 data points; 265+ PFS, 100+ post-SSRI, 50+ post-retinoid submissions) — one of the largest structured post-drug syndrome datasets available to researchers.", "corpus_refs": [ "related-datasets.md (DS patient registries)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2020", "date_precision": "approximate", "event": "PFS Network founded as research charity (pfsnetwork.org)", "category": "community", "significance": "Patient-led charity organizing scientific research, including the Institute of Human Genetics (Germany) study — a key funder of PFS genetics work. Exact founding date unverified; flag before citing.", "corpus_refs": [ "related-datasets.md (DS-001 PFS Network)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2020-01", "date_precision": "month", "event": "Traish publishes 'PFS: a surmountable challenge for clinicians' (Fertil Steril)", "category": "paper", "significance": "250+ article review concluding PFS is a real persistent syndrome in a susceptible subset, framing finasteride as an endocrine disruptor — the foundational PFS review.", "corpus_refs": [ "PFS-001" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2020-2021", "date_precision": "approximate", "event": "DWP-001: Powers posts original PFS theory on r/asktransgender — allopregnanolone deficiency + AKR1C gene variants", "category": "powers", "significance": "Foundational statement of his early model: a gene-drug interaction theory in which only carriers of decreased-function AKR1C variants develop PFS when 5AR is blocked; noted postpartum-depression parallels and reported 2 patients improving on rectal progesterone (N=2, self-flagged as weak).", "corpus_refs": [ "DWP-001", "https://forum.propeciahelp.com/t/dr-will-powers-theory-on-pfs/44137/1" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2021-01", "date_precision": "month", "event": "Health Canada publishes safety review of persistent sexual dysfunction with SSRIs/SNRIs", "category": "regulatory", "significance": "Concluded it could neither confirm nor rule out causality but committed to updated warning language — the second major regulator to act after EMA.", "corpus_refs": [ "medication-lists.md (SSRIs/SNRIs)", "https://scienceblog.com/n-pssd-antidepressant-fda-warning-gap/" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2021", "date_precision": "year", "event": "DWP-005: 'How many PFS patients has Dr Powers helped?' thread on r/DrWillPowers", "category": "powers", "significance": "Early-stage clinical-experience anchor: patients describing decade-long symptoms; captures his PFS work before the later model revisions.", "corpus_refs": [ "DWP-005" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2021-10", "date_precision": "month", "event": "Diviccaro et al. show paroxetine perturbs neurosteroidogenesis with non-reversing withdrawal effects in rats (Psychoneuroendocrinology)", "category": "paper", "significance": "Preclinical proof that SSRIs disrupt neurosteroid synthesis — a direct pharmacological bridge between PSSD and the PFS neurosteroid mechanism.", "corpus_refs": [ "PSSD-009" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2022-02", "date_precision": "month", "event": "MHRA Yellow Card implements dedicated PSSD MedDRA code (10086208)", "category": "regulatory", "significance": "First pharmacovigilance coding specific to PSSD — earlier reports were scattered under generic terms and not recoded, which had blocked database studies.", "corpus_refs": [ "related-datasets.md (pharmacovigilance)", "icd-codes.md" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2022", "date_precision": "year", "event": "Healy et al. publish consensus diagnostic criteria for enduring sexual dysfunction (Int J Risk Saf Med)", "category": "paper", "significance": "Operational definitions for PSSD, PGAD, PFS, and post-retinoid dysfunction: prior drug exposure, ≥3 months persistence, exclusion of other causes — the criteria the corpus's ICD mappings are built on.", "corpus_refs": [ "CROSS-002", "icd-codes.md" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2022", "date_precision": "year", "event": "Peleg et al. review PSSD biological plausibility and risk factors (Sex Med Rev)", "category": "paper", "significance": "Directly addresses genetic predisposition and cross-drug vulnerability as PSSD risk factors, with a symptom-by-symptom mechanism proposal.", "corpus_refs": [ "PSSD-002" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2024-02", "date_precision": "month", "event": "Giatti et al. publish PFS/PSSD bridge review (Front Neuroendocrinol)", "category": "paper", "significance": "Argues PFS and PSSD share clinical features and likely common mechanisms — neuroactive steroids, neurotransmitter signaling, gut microbiota — justifying the single-corpus approach.", "corpus_refs": [ "PFS-003" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2024-05-24", "date_precision": "exact", "event": "Australia TGA aligns Product Information for all SSRIs/SNRIs: dysfunction 'can persist for weeks to years' after stopping", "category": "regulatory", "significance": "Latest major regulator action; six products needed updated warnings (citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine). The US FDA still has no equivalent warning.", "corpus_refs": [ "medication-lists.md (SSRIs/SNRIs)", "https://www.tga.gov.au/news/safety-updates/updated-warnings-about-persistent-sexual-dysfunction-antidepressants" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2024-12", "date_precision": "month", "event": "Giatti/Diviccaro transcriptomic study: persistent gene-expression changes in rat reward circuits after paroxetine withdrawal (Mol Neurobiol)", "category": "paper", "significance": "Strongest preclinical evidence for lasting SSRI-induced transcriptional changes in nucleus accumbens — persistent molecular footprint after the drug is gone.", "corpus_refs": [ "PSSD-012" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2026-03-08", "date_precision": "exact", "event": "SIDEfxHUB publishes 'Possible PFS Mechanism Identified' video built on Powers' Reddit mutation post", "category": "powers", "significance": "Translates Powers' theorizing into a community biomarker protocol: morning hormone panel + androstanediol glucuronide blood test + DUTCH urine test, with strict collection rules — the operational side of his research.", "corpus_refs": [ "youtube-transcripts.md (7iyhq47npE8)", "DWP-003", "DWP-004" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2026", "date_precision": "approximate", "event": "DWP-003: Powers reports 'at least one specific [mutation]' in a PFS patient fitting his model (r/DrWillPowers)", "category": "powers", "significance": "Potentially the key genetics-first post in his PFS work; full text not retrievable during collection — highest-priority gap. Exact date unverified; cited by secondary sources and the March 2026 SIDEfxHUB video.", "corpus_refs": [ "DWP-003" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2026-04-29", "date_precision": "exact", "event": "Powers summit interview uploaded (recorded at 2026 PFS/PAS/PSSD Summit)", "category": "powers", "significance": "Richest primary source on his mature model: androgen-metabolism genomes 'broken at baseline,' glucuronidation-defect selection bias, three phenotypes (neurosteroid vs androgenic-silencing), window/crash dynamics, chemical-castration trials, epigenetic genes (ARID1A/CHD8/HDAC10), and a planned consensus paper for the Journal of Sexual Medicine.", "corpus_refs": [ "youtube-transcripts.md (iWFDBRTgT3g)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2026-05-07", "date_precision": "exact", "event": "Moral Medicine publishes Shorts clipped from the summit interview (androgen metabolism; genetics/WGS)", "category": "powers", "significance": "Condensed public statements of the highway/selection-bias model and the whole-genome-sequencing approach (~100 PFS patients) — the most shareable artifacts of his 2026 model.", "corpus_refs": [ "youtube-transcripts.md (adfZxdlmPAk, LZoAudpbtQ0)" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2026-09-14", "date_precision": "exact", "event": "DWP-002: Powers posts revised 'new model' — anhedonic PFS/PSSD driven by neurosteroid EXCESS, not deficiency", "category": "powers", "significance": "Major self-revision: the anhedonia/low-libido subtype is driven by pathological excess of GABA-A-modulating neurosteroids (THDOC, androsterone) causing network remodeling (benzodiazepine analogy). Splits PFS into androgenic-signal-loss vs neurosteroid-excess subtypes; implicates upregulated 3α-HSD, broken glucuronidation (UGT enzymes, gut beta-glucuronidase), and proposes CSF mass spectrometry to identify the overproduced molecule(s).", "corpus_refs": [ "DWP-002" ], "_source_file": "timeline", "collection_tag": "core" }, { "date": "2026", "date_precision": "year", "event": "Xie et al. publish comprehensive PSSD review identifying 5-alpha-reductase-mediated allopregnanolone depletion in PSSD", "category": "paper", "significance": "Newest comprehensive review; implicates SSRIs in the same 5α-reductase/neurosteroid pathway as finasteride — the strongest pharmacological bridge between PSSD and PFS to date.", "corpus_refs": [ "PSSD-003" ], "_source_file": "timeline", "collection_tag": "core" }, { "mechanism_id": "MECH-01", "mechanism": "Neurosteroid depletion (allopregnanolone and related 5α-reduced neurosteroids)", "pfs_status": "supported", "pfs_evidence": "CSF LC-MS/MS in PFS patients shows persistently decreased tetrahydroprogesterone, isopregnanolone, DHT and related neurosteroids with elevated testosterone/estradiol after discontinuation.", "pssd_status": "suggested", "pssd_evidence": "Xie 2026 review identifies allopregnanolone depletion via 5α-reductase inhibition as a PSSD mechanism; paroxetine disrupts neurosteroidogenesis in rats with incomplete reversal on withdrawal — no human CSF studies in corpus.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence on isotretinoin and neurosteroids.", "corpus_refs": [ "PFS-004", "PFS-005", "DISC-013", "PFS-011", "PSSD-003", "PSSD-009", "DWP-001", "YT-iWFDBRTgT3g" ], "evidence_notes": "The single best-evidenced PFS mechanism (three independent CSF cohorts). The PSSD link rests on one 2026 review plus preclinical data — plausible but thinner.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-02", "mechanism": "Neurosteroid excess / GABA-A overactivation (Powers 2026 revision)", "pfs_status": "conflicting", "pfs_evidence": "Powers 2026 proposes the anhedonia/low-libido subtype is driven by EXCESS of GABA-A-active neurosteroids (THDOC, androsterone) causing network remodeling — directly contradicting his 2020 deficiency model and Melcangi depletion data; he reconciles via subtypes.", "pssd_status": "conflicting", "pssd_evidence": "Powers extends the excess model to an anhedonic PSSD subtype via a shared GABAergic mechanism, while Xie 2026 maintains the depletion model for PSSD.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "DWP-001", "DWP-002", "PFS-004", "PFS-005", "PSSD-003", "YT-iWFDBRTgT3g" ], "evidence_notes": "Single-investigator hypothesis (Reddit post + interview); unpublished, untested. Flagged as speculation — but it is Powers' current model and must be represented.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-03", "mechanism": "Androgen receptor upregulation / altered sensitivity", "pfs_status": "supported", "pfs_evidence": "Baylor penile-skin microarray found significant AR overexpression among 3,700+ differentially expressed genes (preliminary, conference-level); Traish 2020 proposes AR upregulation as part of the epigenetic model; Powers' intracrine model centers on upregulated AR crowded by weak metabolites.", "pssd_status": "suggested", "pssd_evidence": "Included in Rege's shared-mechanism framing and the Giatti 2024 bridge; no PSSD-specific AR expression data in corpus.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "PFS-001", "PFS-008", "PFS-003", "YT-iWFDBRTgT3g", "YT-CZATt5AoQjw" ], "evidence_notes": "PFS evidence converges from three independent angles (transcriptomics, review model, clinical theorizing) but the key primary study is preliminary.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-04", "mechanism": "AR gene polymorphisms (CAG/GGN repeat lengths)", "pfs_status": "supported", "pfs_evidence": "Cauci 2017 (n=66 PFS patients): (CAG)n and (GGN)n repeat lengths associated with different symptom patterns (libido, genital sensitivity, muscle, skin), U-shaped for some symptoms.", "pssd_status": "suggested", "pssd_evidence": "Peleg 2022 lists genetic predisposition as a PSSD risk factor; Rege cites glutamatergic (not AR) polymorphisms — no AR-specific PSSD data in corpus.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "PFS-007", "SIDE-011", "SIDE-010", "PSSD-002", "YT-CZATt5AoQjw" ], "evidence_notes": "The strongest human genetic-susceptibility finding in the corpus, from two studies by one Trieste group whose PFS cohorts (69 and 66) may overlap (SIDE-011, PFS-007); a US study of 25 men found no explanatory AR or SRD5A variants (SIDE-010). PFS-only; needs independent replication.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-05", "mechanism": "Epigenetic changes (DNA methylation, histone modification, HDAC)", "pfs_status": "supported", "pfs_evidence": "Traish 2018/2020 drug-induced epigenetics model; Melcangi-team CSF gene-promoter methylation finding (via Rege); Powers reports recurrent ARID1A/CHD8/HDAC10 glitches in PFS genomes.", "pssd_status": "supported", "pssd_evidence": "Csoka/Szyf 2009 pharmacoepigenetics hypothesis; Xie 2026 epigenetic silencing of dopaminergic reward circuits; persistent transcriptomic changes after paroxetine withdrawal in rats (PSSD-012); Rege mechanism 4.", "prsd_status": "unstudied", "prsd_evidence": "No PRSD-specific epigenetic data in corpus; Healy cross-drug grouping hypothesizes a shared downstream pathway but provides no retinoid epigenetic evidence.", "corpus_refs": [ "PFS-001", "PFS-002", "PSSD-003", "PSSD-005", "PSSD-012", "YT-iWFDBRTgT3g", "YT-CZATt5AoQjw" ], "evidence_notes": "The best-supported SHARED mechanism — the leading candidate for why effects outlast drug exposure across syndromes.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-06", "mechanism": "Persistent gene-expression changes (transcriptomics)", "pfs_status": "supported", "pfs_evidence": "Baylor 2021 microarray: 1,446 genes over-expressed / 2,318 under-expressed in PFS penile skin vs controls — flagged preliminary (conference report, journal publication unconfirmed).", "pssd_status": "suggested", "pssd_evidence": "Giatti 2024: whole-transcriptome changes in rat hypothalamus/nucleus accumbens after paroxetine, some persisting after withdrawal — preclinical only.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "PFS-008", "PSSD-012" ], "evidence_notes": "Human PFS data is preliminary; PSSD data is preclinical. Both point the same direction but neither is definitive.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-07", "mechanism": "5-HT1A desensitization / serotonergic–dopaminergic imbalance", "pfs_status": "suggested", "pfs_evidence": "Giatti 2024 bridge includes serotonin/dopamine/catecholamine signaling; Rege shared mechanisms 1–2 (testosterone→dopamine via nitric oxide synthase; serotonergic inhibition of dopamine) — no PFS-primary data.", "pssd_status": "supported", "pssd_evidence": "Bala 2018 and Xie 2026 reviews: 5-HT1A desensitization and serotonergic inhibition of nucleus accumbens dopamine as core PSSD pathophysiology (emotional blunting + sexual dysfunction).", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "PSSD-001", "PSSD-003", "PFS-003", "YT-CZATt5AoQjw" ], "evidence_notes": "The most PSSD-specific mechanism in the matrix — the one place PSSD evidence outruns PFS evidence.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-08", "mechanism": "Gut microbiota / gut-brain-steroid axis", "pfs_status": "suggested", "pfs_evidence": "Giatti 2024 bridge lists gut microbiota; Rege PFS mechanism 5: finasteride reduces gut microbiome diversity — review/video level.", "pssd_status": "suggested", "pssd_evidence": "Diviccaro 2022 (PSSD-011): paroxetine altered colonic steroidogenesis and microbiota in rats — preclinical; Rege PSSD mechanism 6.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "PFS-003", "PSSD-011", "YT-CZATt5AoQjw" ], "evidence_notes": "Convergent but early: a review-level claim for PFS, one preclinical study for PSSD. Powers separately implicates gut beta-glucuronidase in androgen excretion (DWP-002).", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-09", "mechanism": "Pudendal / peripheral neuropathy (genital sensory changes)", "pfs_status": "supported", "pfs_evidence": "Melcangi 2017 (DISC-013, n=16): abnormal pudendal somatosensory evoked potentials in 4 of 16, the men with severe erectile dysfunction — the first objective neuropathy evidence in PFS.", "pssd_status": "suggested", "pssd_evidence": "Genital anesthesia is the hallmark PSSD symptom, independent of depression (Ben-Sheetrit 2015; Healy 2022 criteria). Objective testing now exists: at Queen Square all 9 PSSD patients had genital sensory loss on examination, but pelvic neurophysiology (pudendal, dermatomal and tibial SEPs) was normal in 8, which the authors read as a central mechanism (CUR-003); a 43-patient chart review used quantitative sensory testing (LIT-033); corneal confocal microscopy in small mixed post-drug series suggests small-fibre involvement (LIT-040, SIDE-002).", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "DISC-013", "PSSD-006", "CROSS-002", "CUR-003", "LIT-033", "LIT-040", "SIDE-002" ], "evidence_notes": "Symptom-level evidence is strong for both. Large-fibre nerve tests were abnormal in a minority of PFS patients (DISC-013) and normal in most PSSD patients tested (CUR-003); small fibres have been looked at only by corneal microscopy in tiny mixed series, and no skin-biopsy study exists.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-10", "mechanism": "HPG-axis disruption (gonadotropins, testosterone, prolactin)", "pfs_status": "suggested", "pfs_evidence": "Powers clinical observations: rectal-progesterone suppression of LH/FSH (2019 lecture), HPTA-shutdown 'window then crash' patient reports — no formal HPG study in corpus.", "pssd_status": "suggested", "pssd_evidence": "Rege PSSD mechanism 3: decreased gonadotropins/testosterone with elevated prolactin (dopamine–prolactin inverse relationship) — review/video level.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "DWP-002", "YT-3g52vlv5YWo", "YT-CZATt5AoQjw" ], "evidence_notes": "Thin on both sides; mostly clinical observation and review-level claims. Notably, routine HPG labs are often normal in these patients — which is itself informative.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-11", "mechanism": "Glucuronidation / excretion defects (UGT enzymes, DUTCH findings)", "pfs_status": "suggested", "pfs_evidence": "Powers 2026 only: WGS implicates UGT/ABCC variants; >50% of his PFS patients show near-zero urinary androgens on DUTCH; 3α-androstanediol glucuronide assays 'maxing out' — unpublished, single-investigator.", "pssd_status": "unstudied", "pssd_evidence": "Powers describes PSSD as 'same but different... just which metabolite problem, which gene' — no PSSD-specific data.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "DWP-002", "YT-iWFDBRTgT3g", "YT-7iyhq47npE8" ], "evidence_notes": "The newest and least-tested mechanism in the matrix — Powers' signature contribution. Testable via the SIDEfxHUB three-test battery; treat as hypothesis.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "mechanism_id": "MECH-12", "mechanism": "PNMT inhibition (noradrenaline/adrenaline balance in erectile physiology)", "pfs_status": "suggested", "pfs_evidence": "Rege video only: finasteride inhibits phenylethanolamine N-methyltransferase (noradrenaline→adrenaline); excess noradrenaline favors flaccid state. Single video source.", "pssd_status": "suggested", "pssd_evidence": "Rege video only: paroxetine likewise inhibits PNMT — presented as a shared mechanism. Single video source.", "prsd_status": "unstudied", "prsd_evidence": "No corpus evidence.", "corpus_refs": [ "YT-CZATt5AoQjw", "PFS-003" ], "evidence_notes": "Intriguing because it is one of very few mechanisms attributed to BOTH drug classes by the same source — but it appears only in a YouTube explainer, not in the peer-reviewed corpus. Verify before citing.", "_source_file": "mechanism_matrix", "collection_tag": "core" }, { "question_id": "OQ-001", "question": "Are persistent symptoms driven by neurosteroid DEFICIENCY or neurosteroid EXCESS?", "side_a": "Deficiency model", "side_b": "Excess model", "status": "Unresolved — the same researcher's model flipped between 2020 and 2026", "corpus_refs": [ "DWP-001", "DWP-002", "PFS-004", "PFS-005", "DISC-013", "PSSD-003" ], "speculation_flag": true, "evidence_needed": "Direct measurement of neurosteroid concentrations in CSF of symptomatic vs recovered vs never-affected individuals (Powers' requested CSF mass-spec study); longitudinal sampling before, during, and after drug exposure", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-002", "question": "Do these drugs cause persistent syndromes, or are reports explained by nocebo, ascertainment bias, or the underlying condition?", "side_a": "Drug-caused persistent injury", "side_b": "Bias / confounding explanations", "status": "Contested — persistent-syndrome literature vs mainstream skepticism", "corpus_refs": [ "PFS-001", "PFS-009", "PFS-010", "PSSD-004", "PSSD-006", "CROSS-001", "PSSD-007" ], "speculation_flag": false, "evidence_needed": "Prospective cohorts with pre-drug baselines and blinded outcome assessment; active-comparator studies distinguishing drug effect from depression/hair-loss distress", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-003", "question": "Is there human in-vivo proof of lasting epigenetic changes, or is the epigenetic model still hypothesis?", "side_a": "Epigenetic reprogramming is the mechanism", "side_b": "Hypothesis awaiting human proof", "status": "Hypothesis with suggestive but incomplete human evidence", "corpus_refs": [ "PFS-001", "PFS-002", "PFS-008", "PSSD-004", "PSSD-005", "PSSD-012", "PFS-007" ], "speculation_flag": true, "evidence_needed": "Longitudinal human studies measuring DNA methylation / histone marks before, during, and after drug exposure, with correlation to symptom persistence vs recovery", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-004", "question": "Do PFS, PSSD, and post-retinoid dysfunction share one downstream pathway, or are they distinct drug-specific pathologies?", "side_a": "Single shared pathway", "side_b": "Distinct pathologies", "status": "Actively debated; bridge papers argue shared, but direct comparative data are thin", "corpus_refs": [ "CROSS-001", "CROSS-002", "PFS-003", "PSSD-003", "PFS-006" ], "speculation_flag": true, "evidence_needed": "Head-to-head biomarker studies (CSF neurosteroids, DUTCH panels, nerve testing) across all three syndromes in the same lab with the same assays", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-005", "question": "Is temporary androgen deprivation ('castration trial') a legitimate mechanistic probe, or an unacceptably risky intervention?", "side_a": "Legitimate probe of the backlog/clearance model", "side_b": "Risky and unproven; mainstream caution warranted", "status": "Single-clinician observational claim; no controlled data", "corpus_refs": [ "DWP-002" ], "speculation_flag": true, "evidence_needed": "Controlled, ethically overseen studies with pre-registered endpoints and safety monitoring; independent replication of the 'restorative' effect", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-006", "question": "Is progesterone / allopregnanolone supplementation rational for PFS, given the absence of RCTs?", "side_a": "Rational targeted intervention", "side_b": "Unproven; theoretical risk of harm in some subtypes", "status": "Mechanistic rationale only; no RCTs; N=2 case evidence", "corpus_refs": [ "DWP-001", "DWP-002", "PFS-004", "PFS-005" ], "speculation_flag": true, "evidence_needed": "Randomized controlled trials stratified by subtype (androgenic-loss vs anhedonic); biomarker-stratified enrollment", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-007", "question": "How common are these syndromes?", "side_a": "Under-recognized and undercounted", "side_b": "Rare; apparent frequency inflated by selection bias", "status": "Unquantified — methods papers explain why estimates don't exist", "corpus_refs": [ "PSSD-013", "PFS-009", "PSSD-006", "PSSD-003" ], "speculation_flag": false, "evidence_needed": "Population-based prospective studies with systematic ascertainment; validated coding enabling EHR database studies", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-008", "question": "Are Healy et al.'s 2022 diagnostic criteria valid given the lack of DSM/ICD recognition?", "side_a": "Criteria are a valid operational foundation", "side_b": "Without DSM/ICD recognition, validity is unestablished", "status": "Consensus criteria exist; official nosology has not adopted them", "corpus_refs": [ "CROSS-002", "PSSD-013", "PSSD-007" ], "speculation_flag": false, "evidence_needed": "Field trials of inter-rater reliability; validation against biomarkers; eventual DSM/ICD deliberation", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-009", "question": "Is gut microbiota disruption a causal driver of these syndromes or an epiphenomenon?", "side_a": "Causal contributor via the gut-brain-steroid axis", "side_b": "Epiphenomenon or confounded association", "status": "Early-stage; preclinical signals, no causal human data", "corpus_refs": [ "PFS-003", "PSSD-011", "DWP-002" ], "speculation_flag": true, "evidence_needed": "Human studies linking specific microbial/steroid-metabolite changes to symptoms; interventional trials (e.g., targeted probiotics, beta-glucuronidase modulation) with pre-registered endpoints", "_source_file": "open_questions", "collection_tag": "core" }, { "question_id": "OQ-010", "question": "Do PFS and PSSD genital anesthesia share one mechanism?", "side_a": "Shared peripheral-nerve mechanism", "side_b": "Different mechanisms producing similar symptoms", "status": "Pudendal nerve tests were abnormal in a minority of PFS patients (DISC-013) but normal in 8 of 9 PSSD patients (CUR-003), whose authors propose a central mechanism; small-fibre involvement has not been tested by skin biopsy", "corpus_refs": [ "DISC-013", "CUR-003", "PSSD-004", "CROSS-001", "PFS-003", "LIT-040" ], "speculation_flag": true, "evidence_needed": "Small-fibre testing (skin biopsy, corneal confocal microscopy) in defined PSSD and PFS cohorts against controls; the full Queen Square paper; pudendal SEPs in post-retinoid cohorts", "_source_file": "open_questions", "collection_tag": "core" }, { "gene_symbol": "AKR1C1", "full_name": "aldo-keto reductase family 1 member C1", "location": "10p15-p14 (AKR1C gene cluster, chromosome 10)", "function_summary": "Cytosolic NAD(P)H-dependent oxidoreductase with mainly 20-alpha-hydroxysteroid dehydrogenase activity; converts progesterone to the inactive 20-alpha-hydroxyprogesterone and also reduces a range of aldehydes, ketones, and xenobiotics. One of four closely related AKR1C enzymes clustered together on chromosome 10 with overlapping but distinct substrate preferences.", "corpus_relevance": "Member of the AKR1C family at the center of Powers' original PFS theory (DWP-001), which proposed that decreased-function variants in AKR1C enzymes impair downstream neurosteroid synthesis when 5-alpha-reductase is blocked, explaining why only a susceptible subset develops PFS. AKR1C1's 20-alpha-HSD activity sits on the progesterone/allopregnanolone axis Powers discusses. Attribution: theoretical-per-Powers (unpublished Reddit theorizing); no PFS patient variant data in corpus.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "DWP-001" ], "related_genes": [ "AKR1C2", "AKR1C3", "AKR1C4", "SRD5A1", "SRD5A2" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "AKR1C2", "full_name": "aldo-keto reductase family 1 member C2", "location": "10p15-p14 (AKR1C gene cluster, chromosome 10)", "function_summary": "3-alpha-hydroxysteroid dehydrogenase type 3; interconverts DHT and the much weaker 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol), effectively switching DHT's androgenic signal off, and participates in synthesis of neurosteroids such as allopregnanolone and tetrahydrodeoxycorticosterone. Human AKR1C2 variants are linked to differences of sex development, underscoring its role in androgen handling.", "corpus_relevance": "The most mechanistically pivotal AKR1C member for the corpus: its DHT-to-3-alpha-diol reaction is the enzymatic 'off switch' Powers invokes in both his 2020 deficiency model (DWP-001, where impaired AKR1C function starves neurosteroid synthesis) and his 2026 revision (DWP-002, where upregulated 3-alpha-HSD activity drives neurosteroid excess). Powers' reported patient mutations (DWP-003) are framed against this pathway. Attribution: theoretical-per-Powers; the gene's androgen-metabolism role is established biology, its PFS link is not.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "DWP-001", "DWP-002", "DWP-003" ], "related_genes": [ "AKR1C1", "AKR1C3", "AKR1C4", "AR", "SRD5A2" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "AKR1C3", "full_name": "aldo-keto reductase family 1 member C3", "location": "10p15-p14 (AKR1C gene cluster, chromosome 10)", "function_summary": "3-alpha-hydroxysteroid dehydrogenase type 2 (also 17-beta-hydroxysteroid dehydrogenase type 5); metabolizes prostaglandins, estrogens, and progesterone in addition to androgens, and is overexpressed in prostate cancer. Broadest substrate range of the four AKR1C isoforms.", "corpus_relevance": "Included as part of the AKR1C cluster Powers implicates in his susceptibility model (DWP-001); its prostaglandin and estrogen/progesterone activity widens the candidate pathways beyond pure androgen metabolism. Less specifically discussed than AKR1C2 in Powers' posts. Attribution: theoretical-per-Powers.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "DWP-001" ], "related_genes": [ "AKR1C1", "AKR1C2", "AKR1C4", "CYP19A1" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "AKR1C4", "full_name": "aldo-keto reductase family 1 member C4", "location": "10p15-p14 (AKR1C gene cluster, chromosome 10)", "function_summary": "3-alpha-hydroxysteroid dehydrogenase type 1; liver-restricted isoform that reduces 3-keto-5-dihydrosteroids to tetrahydro products and participates in neurosteroid synthesis. Loss of AKR1C4 alone does not cause developmental phenotypes but can worsen the effects of AKR1C2 variants.", "corpus_relevance": "Completes the AKR1C cluster in Powers' DWP-001 susceptibility model; its liver-restricted expression is relevant because systemic steroid clearance runs through the liver. Attribution: theoretical-per-Powers.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "DWP-001" ], "related_genes": [ "AKR1C1", "AKR1C2", "AKR1C3", "UGT1A1", "UGT2B7" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "AR", "full_name": "androgen receptor", "location": "Xq12", "function_summary": "Steroid-hormone-activated transcription factor (nuclear receptor subfamily 3, group C, member 4). On binding testosterone or DHT it sheds accessory proteins, moves to the nucleus, dimerizes, and switches on androgen-responsive genes. Its N-terminal domain carries two polymorphic trinucleotide repeats encoding polyglutamine (CAG) and polyglycine (GGN) tracts that modulate receptor activity.", "corpus_relevance": "Central to the corpus on two independent lines. Peer-reviewed: Cauci et al. 2017 (PFS-007) associated AR CAG/GGN repeat-length variants with different PFS symptom patterns in 66 patients, and the Baylor gene-expression report (PFS-008, preliminary) found AR overexpression in PFS penile skin. Powers: DWP-002 reframes the androgenic-signal-loss PFS subtype as intracellular weak-metabolite crowding at the AR (intracrine signaling), invisible to serum tests. Attribution: clinical-human (preliminary) plus theoretical-per-Powers.", "evidence_tier": "clinical-human", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene?LinkName=geoprofiles_gene&from_uid=131962649", "ncbi_gene_id": null, "uniprot_id": "ANDR_HUMAN", "corpus_refs": [ "PFS-007", "PFS-008", "DWP-002", "iWFDBRTgT3g" ], "related_genes": [ "SRD5A2", "AKR1C2", "HSD3B2", "CYP17A1" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "SRD5A1", "full_name": "steroid 5 alpha-reductase 1", "location": "5p15", "function_summary": "3-oxo-5-alpha-steroid 4-dehydrogenase 1; converts testosterone to the more potent DHT and reduces progesterone, corticosterone, and other steroids via 5-alpha-reduction (hydride transfer from NADPH to carbon 5). Also active in bile-acid biosynthesis; broadly expressed including skin and liver.", "corpus_relevance": "One of three 5-alpha-reductase isoenzymes reviewed in PFS-011 (Rodriguez-Cerdeira systematic review of 83 articles on SRD5A neurosteroid biology). Finasteride inhibits type 2 (and type 1 at higher doses); dutasteride blocks types 1 and 2 - so SRD5A1 is the isoenzyme left partially active under finasteride, relevant to differential drug effects. The 5AR enzymes are the direct drug targets whose blockade initiates every downstream PFS mechanism in the corpus. Attribution: peer-reviewed (drug-target biology).", "evidence_tier": "clinical-human", "ncbi_url": null, "ncbi_gene_id": 6715, "uniprot_id": "P18405", "corpus_refs": [ "PFS-001", "PFS-011", "PFS-012" ], "related_genes": [ "SRD5A2", "SRD5A3", "AKR1C2", "HSD3B1" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "SRD5A2", "full_name": "steroid 5 alpha-reductase 2", "location": "2p23", "function_summary": "3-oxo-5-alpha-steroid 4-dehydrogenase 2; the dominant isoenzyme in prostate and genital skin, converting testosterone to DHT. Loss-of-function variants cause 5-alpha-reductase-2 deficiency, a 46,XY difference of sex development - direct human proof of what impaired SRD5A2 does to androgen signaling.", "corpus_relevance": "The primary finasteride target and the most genetically studied gene in the corpus: a pilot study found differential SRD5A2 methylation in PFS cerebrospinal fluid versus controls (PFS-011; also DS-010 in the datasets guide), tying the drug's own target gene to epigenetic change - the core of Traish's drug-induced-epigenetics model (PFS-001, PFS-002). Powers' entire framework (DWP-001, DWP-002) starts from 5AR blockade. Attribution: peer-reviewed (pilot human data, preliminary).", "evidence_tier": "clinical-human", "ncbi_url": null, "ncbi_gene_id": 6716, "uniprot_id": "P31213", "corpus_refs": [ "PFS-001", "PFS-002", "PFS-004", "PFS-005", "PFS-011", "DWP-001", "DWP-002", "DS-010" ], "related_genes": [ "SRD5A1", "SRD5A3", "AR", "AKR1C2" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "SRD5A3", "full_name": "steroid 5 alpha-reductase 3", "location": "4q12", "function_summary": "Third 5-alpha-reductase isoenzyme (318 amino acids; about 20 percent homology with types 1 and 2); less characterized than types 1 and 2, with roles in protein N-glycosylation as well as steroid reduction.", "corpus_relevance": "Included in the PFS-011 systematic review of reductase biology; not a finasteride/dutasteride target of note, but completes the isoenzyme family for the corpus's pharmacology layer. Attribution: peer-reviewed (background pathway).", "evidence_tier": "background-pathway", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "PFS-011" ], "related_genes": [ "SRD5A1", "SRD5A2" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "ARID1A", "full_name": "AT-rich interaction domain 1A", "location": "1p36.11", "function_summary": "Core DNA-binding subunit of the mammalian SWI/SNF (BAF) chromatin-remodeling complex; uses an ARID domain to bind AT-rich DNA and targets the remodeling complex to chromatin, regulating transcription, DNA repair, and differentiation. Frequently mutated in cancers; germline variants cause Coffin-Siris syndrome.", "corpus_relevance": "One of three epigenetic-regulator genes Powers reports recurring across PFS patient genomes in his 2026 summit interview (iWFDBRTgT3g), offered as candidate genetic-susceptibility loci for post-drug syndromes. If validated, it would connect PFS susceptibility to chromatin-remodeling machinery - consistent with the corpus's epigenetic theme (Traish PFS-002, HDAC findings). Attribution: theoretical-per-Powers (unpublished interview claim, pending formal publication).", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "iWFDBRTgT3g", "PFS-002" ], "related_genes": [ "CHD8", "HDAC10", "AR" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "CHD8", "full_name": "chromodomain helicase DNA binding protein 8", "location": "14q11.2", "function_summary": "ATP-dependent chromatin-remodeling enzyme of the CHD family (SNF2-like ATPase plus chromodomains); regulates transcription both up and down depending on recruited cofactors, interacting with beta-catenin/Wnt signaling, p53, CTCF, and histone-methylation complexes. A high-confidence autism risk gene; variants cause a neurodevelopmental syndrome.", "corpus_relevance": "Second of Powers' three recurring patient-genome hits (iWFDBRTgT3g), proposed as a PFS susceptibility locus. Notably, CHD8 is an established neurodevelopmental chromatin regulator - its appearance in Powers' patient genomes, if real, would parallel the corpus's neurosteroid/neurodevelopmental threads. Attribution: theoretical-per-Powers (unpublished interview claim).", "evidence_tier": "theoretical-per-Powers", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene/57680", "ncbi_gene_id": 57680, "uniprot_id": null, "corpus_refs": [ "iWFDBRTgT3g" ], "related_genes": [ "ARID1A", "HDAC10" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "HDAC10", "full_name": "histone deacetylase 10", "location": "22q13.33", "function_summary": "Class IIb histone deacetylase that removes acetyl groups from lysine residues on core histones (and polyamines such as N8-acetylspermidine), producing a tag for epigenetic repression; acts in large multiprotein complexes to regulate transcription, cell-cycle progression, and development.", "corpus_relevance": "Third of Powers' recurring genome hits (iWFDBRTgT3g). A histone deacetylase is a natural fit for the corpus's epigenetic models - Traish's drug-induced epigenetics (PFS-002), patient fasting/HDAC experiments discussed on r/DrWillPowers (DWP-007), and Powers' own castration-trial framing all orbit histone-modification biology. Attribution: theoretical-per-Powers (unpublished interview claim).", "evidence_tier": "theoretical-per-Powers", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene/83933", "ncbi_gene_id": 83933, "uniprot_id": "HDA10_HUMAN", "corpus_refs": [ "iWFDBRTgT3g", "PFS-002", "DWP-002", "DWP-007" ], "related_genes": [ "ARID1A", "CHD8", "AR" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "UGT1A1", "full_name": "UDP glucuronosyltransferase family 1 member A1", "location": "chromosome 2 (2q37 region; 233.76-233.77 Mb GRCh38)", "function_summary": "UDP-glucuronosyltransferase that conjugates glucuronic acid onto lipophilic molecules - steroids, bilirubin, hormones, drugs - converting them to water-soluble, excretable metabolites. Over 100 described variants alter its activity (for example, Gilbert syndrome variants).", "corpus_relevance": "Powers' DWP-002 model centers on broken glucuronidation/excretion: more than half of his PFS patients showed near-zero urinary androgens on DUTCH testing, implicating defective UGT-mediated clearance, and he trialed calcium D-glucarate (a beta-glucuronidase inhibitor) to lower neurosteroid load. UGT1A1 represents the glucuronidation pathway in the library; the androgen-specific clearance work falls mainly to the UGT2B cluster. Attribution: theoretical-per-Powers for the PFS link; the enzyme's clearance role is established.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": 54658, "uniprot_id": "P22309", "corpus_refs": [ "DWP-002", "iWFDBRTgT3g" ], "related_genes": [ "UGT2B7", "UGT2B15", "UGT2B17", "ABCC2", "ABCC3" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "UGT2B7", "full_name": "UDP glucuronosyltransferase family 2 member B7", "location": "chromosome 4 (UGT2B gene cluster, 4q13 region)", "function_summary": "Broad-specificity glucuronosyltransferase of the UGT2B cluster that conjugates steroid hormones and many drugs for excretion; handles a wide substrate range including opioids and NSAIDs alongside endogenous steroids.", "corpus_relevance": "Part of the UGT2B androgen-clearance cluster Powers implicates via the DUTCH-test findings (DWP-002): if glucuronidation of androgen metabolites fails, active and weak androgens accumulate intracellularly - the metabolite backlog his model describes. Attribution: theoretical-per-Powers.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "DWP-002" ], "related_genes": [ "UGT1A1", "UGT2B15", "UGT2B17", "ABCC2" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "UGT2B15", "full_name": "UDP glucuronosyltransferase family 2 member B15", "location": "chromosome 4 (UGT2B gene cluster, 4q13 region)", "function_summary": "Androgen-conjugating UGT expressed in liver, prostate, adipose, skin, and other tissues; glucuronidates DHT, androsterone, and androstane-3-alpha,17-beta-diol, directly terminating their activity and marking them for urinary excretion.", "corpus_relevance": "The most directly relevant UGT for Powers' model: it clears exactly the androgens at issue (DHT, androsterone, 3-alpha-diol), and defective UGT2B15 activity would produce the near-zero urinary androgen pattern he reports on DUTCH testing (DWP-002). Attribution: theoretical-per-Powers.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "DWP-002" ], "related_genes": [ "UGT2B7", "UGT2B17", "UGT1A1", "AKR1C2", "AR" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "UGT2B17", "full_name": "UDP glucuronosyltransferase family 2 member B17", "location": "4q13.2", "function_summary": "Steroid-glucuronidating enzyme of extrahepatic tissues (notably prostate) that conjugates C19 steroids including DHT, androsterone, and 3-alpha-diol; notable for common copy-number variation (whole-gene deletion is frequent) associated in the literature with osteoporosis susceptibility.", "corpus_relevance": "Powers' DWP-002 excretion-defect model needs a genetic explanation for why clearance fails in some patients; UGT2B17's common deletion polymorphism makes it a natural candidate susceptibility locus of exactly the type Powers hunts (see DWP-003 mutation post). Copy-number variation here is established; any PFS link is Powers-theorizing. Attribution: theoretical-per-Powers.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene?LinkName=geoprofiles_gene&from_uid=132100191", "ncbi_gene_id": 7367, "uniprot_id": null, "corpus_refs": [ "DWP-002", "DWP-003" ], "related_genes": [ "UGT2B15", "UGT2B7", "UGT1A1", "ABCC3" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "ABCC2", "full_name": "ATP binding cassette subfamily C member 2", "location": "10q24", "function_summary": "Apical membrane efflux pump (MRP2) of liver, kidney, and intestine that exports organic anions - including bilirubin glucuronides and drug conjugates - out of cells for elimination. Loss causes Dubin-Johnson syndrome; polymorphisms alter drug pharmacokinetics.", "corpus_relevance": "Named among the transporter genes in Powers' DWP-002 model: after UGTs conjugate androgen metabolites, ABCC-family pumps must export them; a defect anywhere in the conjugate-then-export chain backs metabolites up intracellularly. Attribution: theoretical-per-Powers.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "DWP-002", "iWFDBRTgT3g" ], "related_genes": [ "ABCC3", "UGT2B15", "UGT2B17", "UGT1A1" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "ABCC3", "full_name": "ATP binding cassette subfamily C member 3", "location": "17q21.33", "function_summary": "Basolateral membrane efflux pump (MRP3) of liver, intestine, kidney, adrenals, and pancreas that exports organic anions - bile constituents, bilirubin glucuronides, steroid conjugates - into blood for renal elimination; upregulated when ABCC2 fails, showing the two pumps compensate for each other.", "corpus_relevance": "The second transporter in Powers' DWP-002 export chain; its basolateral position makes it the backup route for conjugated androgens when apical export is impaired. Attribution: theoretical-per-Powers.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene/8714", "ncbi_gene_id": 8714, "uniprot_id": null, "corpus_refs": [ "DWP-002", "iWFDBRTgT3g" ], "related_genes": [ "ABCC2", "UGT2B17", "UGT2B15" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "MTHFR", "full_name": "methylenetetrahydrofolate reductase", "location": "1p36.3", "function_summary": "Rate-limiting enzyme of folate metabolism that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the methyl donor for remethylating homocysteine to methionine and ultimately producing S-adenosylmethionine - the universal methyl donor for DNA, RNA, and protein methylation. The common C677T variant (A222V) substantially reduces enzyme activity.", "corpus_relevance": "Powers described mining patient genomes for shared variants and trialing methylated B vitamins (L-methylfolate, methylcobalamin) with self-reported benefit (DWP-006) - MTHFR is the canonical gene behind that methylation-support rationale. It connects the corpus's epigenetic theme (DNA methylation in PFS-002, PFS-011) to one-carbon metabolism. Attribution: Powers' clinical anecdote (unpublished); MTHFR biochemistry is established, its PFS relevance is not.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "DWP-006", "PFS-002", "PFS-011" ], "related_genes": [ "ARID1A", "CHD8", "HDAC10" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "HSD3B1", "full_name": "hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1", "location": "1p13.1", "function_summary": "Bifunctional enzyme oxidizing delta-5-3-beta-hydroxysteroids and isomerizing them to delta-4-ketosteroids - an essential step in making all classes of active steroid hormones. HSD3B1 is expressed in placenta and peripheral tissues (critical for placental progesterone production).", "corpus_relevance": "Background-pathway gene: sits upstream of progesterone/allopregnanolone synthesis, the neurosteroid axis at the heart of both Powers' models and the Melcangi CSF studies (PFS-004, PFS-005). Included to complete the steroidogenic pathway map; not directly implicated in any corpus PFS/PSSD finding.", "evidence_tier": "background-pathway", "ncbi_url": null, "ncbi_gene_id": 3283, "uniprot_id": "P14060", "corpus_refs": [ "PFS-004", "PFS-005", "PFS-011" ], "related_genes": [ "HSD3B2", "CYP17A1", "SRD5A1", "AKR1C1" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "HSD3B2", "full_name": "hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2", "location": "1p13.1", "function_summary": "The adrenal/gonadal isoform of 3-beta-HSD, predominantly expressed in adrenals, ovaries, and testes; catalyzes the same essential delta-5-to-delta-4 steroid conversion. Deficiency causes a rare congenital adrenal hyperplasia.", "corpus_relevance": "Background-pathway gene completing the steroidogenic map alongside HSD3B1; adrenal/gonadal expression places it at the source of the androgen and neurosteroid precursors whose downstream handling is disputed in the corpus. Not directly implicated in PFS/PSSD findings.", "evidence_tier": "background-pathway", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene?LinkName=medgen_gene_diseases&from_uid=452446", "ncbi_gene_id": 3284, "uniprot_id": "P26439", "corpus_refs": [ "PFS-011" ], "related_genes": [ "HSD3B1", "CYP17A1", "CYP19A1", "SRD5A2" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "CYP17A1", "full_name": "cytochrome P450 family 17 subfamily A member 1", "location": "10q24.32", "function_summary": "Dual-function P450 enzyme with 17-alpha-hydroxylase and 17,20-lyase activities - the key branch point of steroidogenesis that diverts pregnenolone/progesterone toward glucocorticoids versus DHEA and androstenedione (androgen precursors). Expressed in adrenals, gonads, and other tissues; deficiency causes 17-hydroxylase deficiency with pseudohermaphroditism and adrenal hyperplasia.", "corpus_relevance": "Background-pathway gene: the gatekeeper deciding how much steroid flux becomes androgen versus glucocorticoid, hence upstream of every androgen/neurosteroid balance the corpus debates. Included to complete the pathway; no direct PFS/PSSD implication in the corpus.", "evidence_tier": "background-pathway", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene/1586", "ncbi_gene_id": 1586, "uniprot_id": null, "corpus_refs": [ "PFS-011" ], "related_genes": [ "HSD3B2", "CYP19A1", "SRD5A1", "AR" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "CYP19A1", "full_name": "cytochrome P450 family 19 subfamily A member 1", "location": "15q21.2", "function_summary": "Aromatase - the P450 enzyme catalyzing the final steps of estrogen biosynthesis, converting androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). Tissue-specific promoters drive expression in placenta, gonads, adipose, and brain; variants alter aromatase activity with broad endocrine effects.", "corpus_relevance": "Background-pathway gene: aromatization is the alternative fate of testosterone besides 5-alpha-reduction to DHT, so CYP19A1 activity shapes the androgen/estrogen balance Powers and the papers discuss (for example, elevated estradiol in PFS CSF, PFS-004; estradiol management in Powers' clinical commentary). No direct PFS/PSSD implication in the corpus.", "evidence_tier": "background-pathway", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=1588", "ncbi_gene_id": 1588, "uniprot_id": null, "corpus_refs": [ "PFS-004", "PFS-011" ], "related_genes": [ "CYP17A1", "HSD3B2", "AR", "AKR1C3" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "SULT2A1", "full_name": "sulfotransferase family 2A member 1", "location": "19q13.33", "function_summary": "Cytosolic sulfotransferase expressed in liver and adrenal glands that catalyzes the sulfation of steroids and bile acids, converting them into water-soluble sulfate conjugates for excretion; variants are studied for effects on circulating DHEA-sulfate levels.", "corpus_relevance": "Powers named SULT2A1 in his DWP-003 post (circa May 2026, direct retrieval): weakening mutations impair the sulfation exit route for testosterone, amplifying the core UGT2B17 glucuronidation defect. In his multi-exit model, testosterone must leave the cell via glucuronidation (UGT2B15/2B17), sulfation (SULT2A1), or metabolic conversion - losing both primary exits deepens intracellular androgen trapping, which he proposes leads to receptor downregulation and eventual epigenetic silencing of androgen signaling. SULT2A1 therefore sits in the same defective-exit-routes phenotype as the UGT cluster. Attribution: theoretical-per-Powers (unpublished Reddit theorizing); no PFS patient variant data in corpus.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene/6822", "ncbi_gene_id": 6822, "uniprot_id": "Q06520", "corpus_refs": [ "DWP-003" ], "related_genes": [ "UGT2B17", "UGT2B15", "UGT2B7", "HSD17B2", "SLCO1B1" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "HSD17B2", "full_name": "hydroxysteroid 17-beta dehydrogenase 2", "location": "16q23.3", "function_summary": "Short-chain dehydrogenase/reductase (17-beta-HSD type 2) that inactivates sex steroids, oxidizing testosterone to androstenedione, estradiol to estrone, and androstenediol to DHEA; described as the key 17-beta-HSD isozyme in androgen and estrogen inactivation, and also shows 20-alpha-HSD activity.", "corpus_relevance": "Powers named HSD17B2 in his DWP-003 post: a defective enzyme impairs testosterone-to-androstenedione conversion, worsening the androgen backup. Because androstenedione remains androgenic and still requires glucuronidation, sulfation, or aromatization for exit, losing this escape route compounds the UGT2B17 core defect after finasteride closes the DHT exit. The enzyme's normal role is antiandrogenic (it inactivates testosterone), so its defect removes an inactivation pathway. Attribution: theoretical-per-Powers (unpublished Reddit theorizing); no PFS patient variant data in corpus.", "evidence_tier": "theoretical-per-Powers", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene/3294", "ncbi_gene_id": 3294, "uniprot_id": "P37059", "corpus_refs": [ "DWP-003" ], "related_genes": [ "SRD5A2", "CYP17A1", "CYP19A1", "AKR1C2", "UGT2B17" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "SLCO1B1", "full_name": "solute carrier organic anion transporter family member 1B1", "location": "12p12.1", "function_summary": "Encodes OATP1B1, the sodium-independent organic-anion transporter on liver cell membranes that moves bilirubin, hormones, toxins, and many drugs from blood into the liver for clearance; biallelic loss together with SLCO1B3 causes Rotor syndrome (conjugated hyperbilirubinemia).", "corpus_relevance": "From Powers' January 2026 edit to DWP-003 (direct retrieval): a PFS patient's whole-genome sequencing revealed rs200994482 (c.1865+1G>A, heterozygous), which he described as likely pathogenic and a Rotor-syndrome carrier variant. He proposed this produces the same PFS phenotype through a different mutation - defective OATP1B1-mediated recycling/recovery/accrual of glucuronidated steroids, rather than defective conjugation. This extends his glucuronidation-excretion model from UGT conjugation defects to re-uptake/recycling defects. Variant details are as Powers reported; verify in ClinVar/dbSNP before research use. Attribution: theoretical-per-Powers (unpublished Reddit theorizing).", "evidence_tier": "theoretical-per-Powers", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene/10599", "ncbi_gene_id": 10599, "uniprot_id": "Q9Y6L6", "corpus_refs": [ "DWP-003", "DWP-002", "iWFDBRTgT3g" ], "related_genes": [ "UGT2B17", "UGT2B15", "UGT1A1", "ABCC2", "ABCC3" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "CYP21A2", "full_name": "cytochrome P450 family 21 subfamily A member 2", "location": "6p21.3", "function_summary": "Adrenal endoplasmic-reticulum P450 (steroid 21-hydroxylase) required for cortisol and aldosterone synthesis, converting progesterone and 17-hydroxyprogesterone toward their 21-hydroxylated products; mutations are the cause of congenital adrenal hyperplasia.", "corpus_relevance": "Adjacent gene (not PFS-specific): from Powers' MTF subtype post (r/DrWillPowers/comments/1ctrlyu, circa 2016, direct retrieval), where he hypothesized that patients carrying fewer than two fully functional CYP21A2 copies (one normal plus one weak, two weak, or a single weak copy) develop a subclinical adrenal-insufficiency picture - poor stress tolerance with paradoxical stress-induced androgen byproducts, including elevated 11-oxo-androgens on Labcorp panels. Low-dose hydrocortisone reportedly helped selected patients. Included as adjacent methodology context for Powers' gene-hunting approach; flagged as not a PFS claim. Attribution: theoretical-per-Powers (adjacent, trans-HRT context).", "evidence_tier": "theoretical-per-Powers", "ncbi_url": "https://www.ncbi.nlm.nih.gov/gene/1589", "ncbi_gene_id": 1589, "uniprot_id": "P08686", "corpus_refs": [ "powers-gene-list" ], "related_genes": [ "CYP21A2P", "CYP11A1", "CYP17A1", "HSD3B2" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "CYP21A2P", "full_name": "cytochrome P450 family 21 subfamily A member 2, pseudogene (HGNC: CYP21A1P)", "location": "6p21.3 (approx. 30 kb from CYP21A2)", "function_summary": "Nonfunctional pseudogene sharing about 98 percent exon sequence identity with CYP21A2, carrying deteriorating mutations (frameshifts, premature stop codons); it acts as the reservoir for gene-conversion events that create most pathogenic CYP21A2 alleles.", "corpus_relevance": "Adjacent pseudogene (not PFS-specific): Powers discussed the CYP21A2 pseudogene in his MTF adrenal post, hypothesizing that extra transcribed pseudogene copies could double cortisol output. The highly homologous locus (CYP21A1P per HGNC convention) underpins the gene-conversion mechanism behind most 21-hydroxylase-deficiency alleles. Included as adjacent context; flagged as not a PFS claim. Attribution: theoretical-per-Powers (adjacent).", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "powers-gene-list" ], "related_genes": [ "CYP21A2", "CYP11A1" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene_symbol": "CYP11A1", "full_name": "cytochrome P450 family 11 subfamily A member 1", "location": "15q24.1", "function_summary": "Mitochondrial P450 (P450scc, cholesterol side-chain cleavage enzyme) catalyzing the first, rate-limiting step of steroidogenesis - three sequential reactions converting cholesterol to pregnenolone; severe loss disrupts all adrenal and gonadal steroid synthesis.", "corpus_relevance": "Adjacent gene (not PFS-specific): a patient edit Powers discussed on his MTF adrenal post carried a CYP11A1 frameshift (DEL chr15:74343131 T A->T, heterozygous, rs757299093, allele frequency about 1 in 15,000), which he described as ClinVar-pathogenic for CYP11A1-related congenital adrenal insufficiency. He framed it as a non-21-hydroxylase route to the same adrenal phenotype - anything disrupting adrenal/cortisol synthesis can produce similar output. Variant details are as Powers reported; verify in ClinVar/dbSNP before research use. Attribution: theoretical-per-Powers (adjacent).", "evidence_tier": "theoretical-per-Powers", "ncbi_url": null, "ncbi_gene_id": null, "uniprot_id": null, "corpus_refs": [ "powers-gene-list" ], "related_genes": [ "CYP21A2", "CYP17A1", "HSD3B2" ], "_source_file": "gene_library", "collection_tag": "core" }, { "gene": "UGT2B17", "variant": "defective (major)", "source_post": "I think I have figured out at least one specific phenotype of PFS, and it is different from the \"allopregnanolone\" theory (r/DrWillPowers/comments/1poj0ky)", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "mirror_url": "https://r.genit.al/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "date": "circa May 2026 (archived 2026-05-08)", "confidence": "direct", "tags": [ "PFS", "UGT2B17", "glucuronidation", "pharmacogenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "UGT2B15; UGT2B7", "variant": "defective (minor)", "source_post": "r/DrWillPowers/comments/1poj0ky", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "date": "circa May 2026", "confidence": "direct", "tags": [ "PFS", "glucuronidation", "pharmacogenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "SULT2A1", "variant": "weakening mutations", "source_post": "r/DrWillPowers/comments/1poj0ky", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "date": "circa May 2026", "confidence": "direct", "tags": [ "PFS", "sulfation", "pharmacogenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "HSD17B2", "variant": "defective", "source_post": "r/DrWillPowers/comments/1poj0ky", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "date": "circa May 2026", "confidence": "direct", "tags": [ "PFS", "androgen-metabolism", "pharmacogenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "AKR1C1; AKR1C2; AKR1C3; AKR1C4", "variant": "defects (unspecified)", "source_post": "r/DrWillPowers/comments/1poj0ky", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "date": "circa May 2026", "confidence": "direct", "tags": [ "PFS", "AKR1C", "androgen-metabolism", "epigenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "SRD5A1", "variant": "epigenetic silencing (acquired, not germline)", "source_post": "r/DrWillPowers/comments/1poj0ky", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "date": "circa May 2026", "confidence": "direct", "tags": [ "PFS", "SRD5A1", "epigenetics", "HDAC" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "SLCO1B1", "variant": "rs200994482, ENST00000256958.3:c.1865+1G>A, heterozygous, likely pathogenic; allele frequency 0.000132", "source_post": "r/DrWillPowers/comments/1poj0ky (January 2026 edit)", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1poj0ky/i_think_i_have_figured_out_at_least_one_specific/", "date": "2026-01 (edit to May 2026 post)", "confidence": "direct", "tags": [ "PFS", "SLCO1B1", "Rotor-syndrome", "pharmacogenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "AKR1C (family)", "variant": "decreased-function variants", "source_post": "Has anyone here taken finasteride or dutasteride and gotten post finasteride syndrome (PFS) from them? (r/asktransgender)", "source_url": "https://www.reddit.com/r/asktransgender/comments/enf843/has_anyone_here_taken_finasteride_or_dutasteride/", "repost_url": "https://forum.propeciahelp.com/t/dr-will-powers-theory-on-pfs/44137/1", "date": "circa 2020-2021", "confidence": "secondary", "tags": [ "PFS", "AKR1C", "allopregnanolone", "neurosteroids", "pharmacogenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "3α-HSD (3α-hydroxysteroid oxidoreductase/dehydrogenase; encoded by AKR1C2/AKR1C4)", "variant": "upregulated (acquired)", "source_post": "Untitled long-form research update — new model of PFS/PSSD/post-drug syndromes (r/DrWillPowers, Sept 2026)", "mirror_url": "https://r.genit.al/r/DrWillPowers/hot?sort=hot&t=&after=t3_1iimy6k", "date": "2026-09-14", "confidence": "direct", "tags": [ "PFS", "PSSD", "3a-HSD", "THDOC", "neurosteroid-excess", "GABA-A" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "UGTs (glucuronosyltransferase enzymes, general)", "variant": "defects (unspecified)", "source_post": "r/DrWillPowers long-form update, Sept 2026", "mirror_url": "https://r.genit.al/r/DrWillPowers/hot?sort=hot&t=&after=t3_1iimy6k", "date": "2026-09-14", "confidence": "direct", "tags": [ "PFS", "PSSD", "UGT", "glucuronidation", "DUTCH-test" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "ARID1A; CHD8; HDAC10", "variant": "recurring \"glitches\" (unspecified)", "source": "Dr. Will Powers Interview [PFS / PAS / PSSD Summit 2026], SIDEfxHUB", "source_url": "https://www.youtube.com/watch?v=iWFDBRTgT3g", "date": "2026-04-29", "confidence": "interview", "tags": [ "PFS", "epigenetics", "ARID1A", "CHD8", "HDAC10", "whole-genome-sequencing" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "ABCC (family)", "variant": "unspecified", "source": "Dr. Will Powers Interview [PFS / PAS / PSSD Summit 2026], SIDEfxHUB", "source_url": "https://www.youtube.com/watch?v=iWFDBRTgT3g", "date": "2026-04-29", "confidence": "interview", "tags": [ "PFS", "ABCC", "transporters", "pharmacogenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "AR", "variant": "upregulated expression (~1.7x, citing Khera); theorized epigenetic silencing in his phenotype", "source": "Summit interview 2026; r/DrWillPowers/comments/1poj0ky", "source_url": "https://www.youtube.com/watch?v=iWFDBRTgT3g", "date": "2026-04-29; circa May 2026", "confidence": "interview/direct", "tags": [ "PFS", "androgen-receptor", "epigenetics" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "CYP21A2; CYP21A2P", "variant": "hypothesized reduced functional copies (one normal + one weak, two weak, single weak) or extra transcribed pseudogene copies", "source_post": "There is a subtype of MTF patient who has chronic anxiety... (r/DrWillPowers/comments/1ctrlyu)", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1ctrlyu/there_is_a_subtype_of_mtf_patient_who_has_chronic/", "mirror_url": "https://r.genit.al/r/DrWillPowers/comments/1ctrlyu/there_is_a_subtype_of_mtf_patient_who_has_chronic/", "date": "circa 2016 (post age ~3566 days at retrieval)", "confidence": "direct (adjacent)", "tags": [ "CYP21A2", "adrenal", "cortisol", "11-oxo-androgens" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "CYP11A1", "variant": "frameshift DEL chr15:74343131 T A->T, heterozygous, rs757299093, allele frequency 1 in 15,000, ClinVar pathogenic (CYP11A1-related condition / congenital adrenal insufficiency with 46,XY sex reversal or 46,XY DSD-adrenal insufficiency)", "source_post": "r/DrWillPowers/comments/1ctrlyu (edit)", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/1ctrlyu/there_is_a_subtype_of_mtf_patient_who_has_chronic/", "date": "edit, date unverified", "confidence": "direct (adjacent)", "tags": [ "CYP11A1", "adrenal", "cortisol" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "MTHFR", "variant": "\"two bad copies\" (self-reported); common MTHFR SNPs (e.g., rs1801131, rs1801133) in patients", "source_post": "Have Gender Dysphoria? Hypermobile? ADHD or Autism? POTS? IBS? Hashimotos? Give methylated B vitamins a try! (r/DrWillPowers/comments/12g4rop)", "source_url": "https://www.reddit.com/r/DrWillPowers/comments/12g4rop/have_gender_dysphoria_hypermobile_adhd_or_autism", "mirror_url": "https://r.genit.al/r/DrWillPowers/comments/12g4rop/have_gender_dysphoria_hypermobile_adhd_or_autism/", "date": "circa 2023", "confidence": "direct (adjacent)", "tags": [ "MTHFR", "methylation", "homocysteine" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "gene": "6p21 locus (MHC region)", "variant": "unspecified (\"6p21 syndrome\" comorbidity cluster)", "source_post": "pinned post concept on r/DrWillPowers (\"Meyer-Powers Syndrome FAQ\", r/DrWillPowers/comments/15328em — deleted)", "date": "circa 2023", "confidence": "secondary (adjacent)", "tags": [ "6p21", "comorbidity", "MHC" ], "_source_file": "powers_gene_list", "collection_tag": "core" }, { "item_id": "DISC-002", "source_type": "peer-reviewed paper", "title": "Forty Years Searching for Neurosteroid Binding Sites on GABAA Receptors", "authors": "Mortensen M, Bright DP, Fagotti J, Dorovykh V, Cerna B, Smart TG", "journal_or_site": "Neuroscience", "year_or_date": "2025 (epub 2024 Jun 7)", "url": "https://doi.org/10.1016/j.neuroscience.2024.06.002", "doi": "10.1016/j.neuroscience.2024.06.002", "type": "peer-reviewed paper", "abstract_or_summary": "Review summarizing four decades of research locating where neurosteroids act on GABA-A receptors. It walks through mutagenesis, chimeric receptors, and electrophysiology work that mapped potentiation and direct-activation pockets within the receptor's transmembrane domains, and how endogenous neurosteroids like allopregnanolone tune inhibitory signaling. It also weighs remaining open questions about site conservation across receptor isoforms.", "keywords": [ "neurosteroids", "GABA-A receptor", "allopregnanolone", "binding site", "inhibitory neurotransmission", "review" ], "relevance": "Allopregnanolone depletion and GABA-A dysregulation are core mechanistic hypotheses in PFS/PSSD; this review gives a rigorous structural basis for claims about neurosteroid action and therapeutic targeting.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "note": "Direct DOI page failed to load (transport timeouts); metadata confirmed via independent PubMed search record (PMID 38852898, free full text).", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "fulltext_url": "https://doi.org/10.1016/j.neuroscience.2024.06.002", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "38852898" }, { "item_id": "DISC-003", "source_type": "peer-reviewed paper", "title": "Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution", "authors": "Gauthier-Landry L, Bélanger A, Barbier O", "journal_or_site": "Journal of Steroid Biochemistry and Molecular Biology", "year_or_date": "2015 (epub 2014)", "url": "https://doi.org/10.1016/j.jsbmb.2014.05.009", "doi": "10.1016/j.jsbmb.2014.05.009", "type": "peer-reviewed paper", "abstract_or_summary": "Review of two glucuronidation enzymes, UGT2B15 and UGT2B17, that convert DHT metabolites (3α-diol and androsterone) into inactive, easily excreted glucuronide conjugates. It describes how these enzymes control local androgen availability and androgen-receptor signaling in prostate tissue, shape responses to anti-androgen drugs, and how AR and its splice variants regulate the enzymes' expression. It closes by asking whether the AR–UGT axis could serve as a prognostic marker or drug target.", "keywords": [ "UGT2B17", "UGT2B15", "glucuronidation", "androgen metabolism", "dihydrotestosterone", "androgen receptor", "pharmacogenetics" ], "relevance": "UGT2B17 is Dr Will Powers' theorized core defect in PFS (corpus DWP-003); this review details exactly how UGT2B17 clears androgenic steroids, grounding post-drug androgen-signaling and pharmacogenetic hypotheses.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "note": "Direct DOI page failed to load (transport timeouts); metadata confirmed via multiple independent citation records (PMID 24861263; J Steroid Biochem Mol Biol. 2015;145:187-92).", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "pmid": "24861263" }, { "item_id": "DISC-004", "source_type": "peer-reviewed paper", "title": "Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity", "authors": "Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y", "journal_or_site": "Prostate", "year_or_date": "2010", "url": "https://pubmed.ncbi.nlm.nih.gov/20058237/", "doi": "10.1002/pros.21107", "type": "peer-reviewed paper", "abstract_or_summary": "Preclinical prostate-cancer study in which prolonged bicalutamide exposure produced a resistant cell subline that overexpressed androgen receptor protein and phosphorylated AR, proliferating at tenfold lower androgen concentrations than parent cells — without AR gene mutation or amplification. Bicalutamide even stimulated proliferation of the resistant cells, showing the receptor itself had become the hypersensitivity driver.", "keywords": [ "bicalutamide", "androgen receptor overexpression", "androgen hypersensitivity", "drug resistance", "antiandrogen" ], "relevance": "Demonstrates that chronic anti-androgen exposure can leave behind persistent AR upregulation and hypersensitivity to low androgens — a receptor-adaptation paradigm directly analogous to post-antiandrogen persistent syndromes such as PFS.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "pmid": "20058237" }, { "item_id": "DISC-005", "source_type": "peer-reviewed paper", "title": "Potential role of CYP2D6 in the central nervous system", "authors": "Cheng J, Zhen Y, Miksys S, Beyoğlu D, Krausz KW, Tyndale RF, Yu A, Idle JR, Gonzalez FJ", "journal_or_site": "Xenobiotica", "year_or_date": "2013", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3750078/", "type": "peer-reviewed paper", "abstract_or_summary": "Mouse study using a transgenic human-CYP2D6 model, finding that human CYP2D6 is expressed not only in liver but also in brain, where it altered serotonin and metabolite levels plus broader brain metabolomic profiles, and shifted anxiety-related behavior. The authors conclude CYP2D6 plays neurophysiological roles beyond hepatic drug metabolism and propose the transgenic mouse as a tool for studying them.", "keywords": [ "CYP2D6", "brain", "serotonin", "anxiety", "transgenic mouse", "pharmacogenetics", "neurophysiology" ], "relevance": "CYP2D6 metabolizes many SSRIs and shows brain activity linked to serotonin turnover and anxiety — relevant to pharmacogenetic differences in SSRI exposure/withdrawal and PSSD susceptibility hypotheses.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "note": "Discord context label 'Alterations of gut microbiota…' does NOT match this link; PMC3750078 (PMID 23614566) is the CYP2D6-in-brain paper. The gut-microbiota paper is item 8 (PMID 32951160) — contexts appear swapped.", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-006", "source_type": "foundation news", "title": "Biotech Firm with Promising Treatment for Peripheral Nerve Damage Solicits Input from PFS Patients", "authors": "PFS Foundation", "journal_or_site": "The Post-Finasteride Syndrome Foundation", "year_or_date": "2024-09-16", "url": "https://www.pfsfoundation.org/news/biotech-firm-with-promising-treatment-for-peripheral-nerve-damage-soliciting-input-from-pfs-patients/", "type": "foundation news", "abstract_or_summary": "Foundation news report on San Diego biotech WinSanTor, which launched a survey of PFS and PSSD patients with sexual sensory disorders as it explores expanding its topical nerve-regenerating drug pirenzepine 4% (WST-057) — developed for diabetic peripheral neuropathy — toward genital numbness. The company notes the drug could reach patients via the FDA's Expanded Access (compassionate use) pathway under its Fast Track designation. The post also cites the Milano Project's investigation of peripheral-nerve morphology in a PFS model.", "keywords": [ "PFS Foundation", "WinSanTor", "pirenzepine", "peripheral neuropathy", "genital numbness", "compassionate use", "treatment pipeline" ], "relevance": "Genital anesthesia is a hallmark PFS/PSSD symptom framed here as peripheral nerve damage; tracks a potential repurposed therapy, a patient survey data source, and overlaps with Powers-community discussion of numbness mechanisms.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-007", "source_type": "foundation news", "title": "Quitting Finasteride Leads to Persistent Behavioral Alterations Including Increased Anxiety-like Conduct and Marked Avoidance of New Experiences, According to New Preclinical Research", "authors": "PFS Foundation", "journal_or_site": "The Post-Finasteride Syndrome Foundation", "year_or_date": "2026-03-09", "url": "https://www.pfsfoundation.org/news/quitting-finasteride-leads-to-persistent-behavioral-alterations-including-increased-anxiety-like-conduct-and-marked-avoidance-of-new-experiences-according-to-new-preclinical-research/", "type": "foundation news", "abstract_or_summary": "Foundation news post covering Milano Project study No. 2 (Cioffi & Diviccaro, Journal of Neuroendocrinology): in rats treated with finasteride for 20 days, little behavioral change appeared during dosing, but 30 days after withdrawal the animals showed increased locomotion, anxiety-like behavior, and marked avoidance of novel stimuli in open-field and elevated-plus-maze tests. The post also previews Milano Project investigations 3–4 (genital numbness/PIEZO2, synaptogenesis).", "keywords": [ "PFS Foundation", "Milano Project", "finasteride withdrawal", "anxiety", "novelty avoidance", "animal model", "Melcangi" ], "relevance": "Preclinical support for the withdrawal-phase onset pattern defining PFS, and a marker for ongoing Milano Project molecular work the corpus should track.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-008", "source_type": "peer-reviewed paper", "title": "Alterations of gut microbiota composition in post-finasteride patients: a pilot study", "authors": "Borgo F, Macandog AD, Diviccaro S, Falvo E, Giatti S, Cavaletti G, Melcangi RC", "journal_or_site": "Journal of Endocrinological Investigation", "year_or_date": "2021", "url": "https://pubmed.ncbi.nlm.nih.gov/32951160/", "doi": "10.1007/s40618-020-01424-0", "type": "peer-reviewed paper", "abstract_or_summary": "Pilot study comparing fecal microbiota of 21 PFS patients (23 recruited, 2 excluded for low sequencing depth) with 10 healthy men whose sequences came from an earlier study, using 16S rRNA sequencing. Two richness measures (Chao1 and Faith's phylogenetic diversity) were lower in the PFS group, while Shannon diversity, observed OTUs and evenness did not differ. A patient subset showed lower levels of Faecalibacterium and Ruminococcaceae and higher Alloprevotella and Odoribacter. The authors proposed gut dysbiosis as a possible diagnostic marker and therapeutic target for the syndrome.", "keywords": [ "PFS", "gut microbiota", "gut-brain axis", "dysbiosis", "16S rRNA", "Faecalibacterium", "pilot study", "Melcangi" ], "relevance": "Pilot evidence of an association between PFS and altered gut bacteria (21 patients vs 10 older healthy controls from an earlier study), with no significant link found between the bacteria and clinical characteristics; it connects to the growing body of Melcangi-group work on finasteride, microbiota, and neuroinflammation (see also DISC-009, DISC-010).", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "note": "Discord context label 'CYP2D in the brain' does NOT match this link; PMID 32951160 is the gut-microbiota PFS paper. Contexts for items 5 and 8 appear swapped.", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "sidefxhub_curated": true, "sidefxhub_article_title": "Gut Microbiota Alterations in PFS Patients", "fulltext_url": "https://link.springer.com/content/pdf/10.1007/s40618-020-01424-0.pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "32951160", "plain": { "summary": "Researchers compared the bacteria in stool samples from 21 men with lasting symptoms after finasteride with stored results from 10 healthy men studied earlier. On some measures the men with symptoms had a less varied mix of gut bacteria, and several kinds of bacteria were more or less common than in the healthy men. The men with symptoms fell into two groups with different bacteria, and one of these groups stood further apart from the healthy men than the other.", "caveat": "It can't show whether these differences cause symptoms, result from them or come from something else: the study was small, the healthy men came from an earlier study and were on average about 12 years older, and each man gave only one sample." }, "evidence": { "design": "Pilot case-control comparison at a single time point of stool bacteria (16S rRNA gene sequencing) in men with PFS vs healthy men whose sequences came from an earlier study", "design_class": "case-control", "setting": "Patients from the Italian finasteride side effects network; Milan, Italy; ethics approval 2018 (protocol 434/2018); dates not stated", "population": "Men aged 25–51 with persistent sexual and mental-health symptoms after finasteride 1–1.25 mg/day for hair loss, stopped at least 3 months earlier, with no psychiatric disorder or sexual dysfunction before finasteride and no drugs known to interfere with microbiome analysis. All white (Caucasian), on a Mediterranean diet, with no comorbidities, no prebiotics, probiotics or antibiotics after finasteride, and no constipation or irritable bowel syndrome. Controls: 10 healthy men from an earlier study, described as matched for ethnicity, sex, diet and BMI.", "n": 31, "n_note": "21 patients analysed (2 of 23 excluded for too few sequencing reads) and 10 healthy men", "exposure": "Finasteride 1–1.25 mg/day for hair loss; mean treatment 1,176 days; 433–7,111 days since stopping (median 2,465)", "comparator": "10 healthy men whose raw sequences came from an earlier study (Borgo et al. 2018); their finasteride history is not stated", "outcome": "Within-sample diversity of gut bacteria (Chao1, Faith's phylogenetic diversity, observed OTUs, Shannon, evenness), between-sample diversity (UniFrac, Bray–Curtis), and the relative abundance of bacterial groups.", "follow_up": "None; a single home-collected stool sample per person", "results": [ { "text": "Within-sample diversity: lower richness in PFS by Chao1 (p = 0.047) and Faith's PD (p = 0.047); no difference by observed OTUs (p = 0.40), Shannon (p = 0.75) or Simpson/evenness (p = 0.89)", "where": "p. 1266; Fig. 1, p. 1267" }, { "text": "Between-sample diversity separated PFS from healthy (unweighted UniFrac p = 0.001, Bray–Curtis p = 0.001, weighted UniFrac p = 0.05). Patients formed two sub-clusters; sub-cluster B did not separate from healthy on weighted UniFrac (p = 0.37). Sub-cluster sizes are not stated", "where": "p. 1266; Fig. 2, p. 1268" }, { "text": "Phyla (mean relative abundance, healthy vs PFS): lower Proteobacteria (10.2% vs 4.5%, p = 0.009) and Actinobacteria (22.6% vs 4.5%, p = 0.0003); Firmicutes 45.4% vs 57.6% (p = 0.09). Genera lower in PFS include Subdoligranulum (3.8% vs 0.9%), Phascolarctobacterium, Ruminococcaceae UCG-002 (4.2% vs 0.12%) and Escherichia–Shigella", "where": "pp. 1266–1267; Fig. 3, p. 1268" }, { "text": "In sub-cluster A only, vs healthy: lower Faecalibacterium (p = 0.02) and Ruminococcaceae UCG-005 (p = 0.02), higher Alloprevotella (p = 0.03) and Odoribacter (p = 0.02)", "where": "p. 1267; Fig. 4" }, { "text": "No significant association between the bacteria and participant or clinical characteristics; time since stopping finasteride leaned towards sub-cluster A (p = 0.06). The sub-clusters did not differ in age, BMI, treatment period, time since stopping or reported symptoms", "where": "pp. 1266, 1269" } ], "limitations_stated": [ "A small cohort, for an emerging and rare syndrome", "The symptom questionnaire is not validated", "Patients and controls differed in age (p = 0.002); the authors consider adult gut bacteria stable with age", "Two samples had too few sequencing reads and were excluded" ], "design_notes": [ "Controls were 10 men from an earlier study whose stored sequences were reused; the paper does not say whether their samples were collected, extracted and sequenced in the same way or run as the patients', which can by itself produce differences", "Controls were older; from Table 1, mean age 48.7 vs 36.9 in the 21 patients analysed", "Shallow sequencing (rarefied to 1,336 reads per sample), many diversity measures and many bacterial groups tested, with no correction for multiple testing stated; the two diversity differences are at p = 0.047", "Some reported abundances do not add up: the healthy group's phylum means sum to 118.6% (45.4 + 40.4 + 10.2 + 22.6), and in PFS the Bifidobacteriaceae family (12.3%) exceeds its own phylum, Actinobacteria (4.5%)", "The Discussion calls the Firmicutes increase significant (p. 1268); the Results give p = 0.09 (p. 1266)", "Recalled before finasteride, 16 of 23 (69.6%) reported irritability and 15 of 23 (65.2%) anxiety sometimes or often" ], "funding": "Università degli Studi di Milano (open access, CRUI-CARE agreement); MIUR \"Progetto Eccellenza\"; Post-Finasteride Foundation to R.C. Melcangi", "interests": "None declared", "supports": "Differences in gut bacteria between a small group of men with PFS and a smaller, older group of healthy men from an earlier study. It cannot show that finasteride caused the differences or that they cause symptoms, and it does not establish a diagnostic marker.", "extracted_from": "fulltexts/DISC-008-Alterations-of-gut-microbiota-composition-in-post.pdf (publisher PDF, CC BY 4.0, 11 pp.; page refs are the journal's printed page numbers, 1263–1273)", "extracted": "2026-10-10" } }, { "item_id": "DISC-009", "source_type": "peer-reviewed paper", "title": "Gut Inflammation Induced by Finasteride Withdrawal: Therapeutic Effect of Allopregnanolone in Adult Male Rats", "authors": "Diviccaro S, Giatti S, Cioffi L, Falvo E, Herian M, Caruso D, Melcangi RC", "journal_or_site": "Biomolecules", "year_or_date": "2022", "url": "https://pubmed.ncbi.nlm.nih.gov/36358917/", "doi": "10.3390/biom12111567", "type": "peer-reviewed paper", "abstract_or_summary": "Rat study of 20-day finasteride treatment followed by one-month withdrawal, measuring steroids, neurotransmitters, cytokines, and gut-permeability markers in the colon. Both treatment and withdrawal lowered allopregnanolone, and post-withdrawal this coincided with rises in IL-1β, TNF-α and serotonin and a drop in dopamine — changes that allopregnanolone treatment partly reversed. The authors point to allopregnanolone's links with GABA-A receptors and its precursor pregnenolone as key to its action.", "keywords": [ "finasteride withdrawal", "allopregnanolone", "gut inflammation", "cytokines", "serotonin", "dopamine", "GABA-A receptor", "rat model" ], "relevance": "Ties neurosteroid depletion to gut inflammation and neurotransmitter shifts in a PFS model, and directly tests allopregnanolone as a candidate therapy — a central thread for post-drug neurosteroid hypotheses.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "note": "Discord context label 'CYP2D6 study' does NOT match this link; PMID 36358917 is the finasteride-withdrawal/allopregnanolone paper.", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "fulltext_url": "https://www.mdpi.com/2218-273X/12/11/1567/pdf?version=1666786464", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "36358917" }, { "item_id": "DISC-010", "source_type": "peer-reviewed paper", "title": "Exploration of the Possible Relationships Between Gut and Hypothalamic Inflammation and Allopregnanolone: Preclinical Findings in a Post-Finasteride Rat Model", "authors": "Diviccaro S, Oleari R, Amoruso F, Fontana F, Cioffi L, Chrostek G, Abenante V, Troisi J, Cariboni A, Giatti S, Melcangi RC", "journal_or_site": "Biomolecules", "year_or_date": "2025", "url": "https://pubmed.ncbi.nlm.nih.gov/40723915/", "doi": "10.3390/biom15071044", "type": "peer-reviewed paper", "abstract_or_summary": "2025 follow-up preclinical study in rats treated with finasteride for 20 days then withdrawn for a month, with allopregnanolone given to a subgroup during withdrawal. Withdrawal produced colonic inflammation (elevated M1 macrophages, reduced butyrate) alongside hypothalamic neuroinflammation (GFAP, Iba-1) and blood–brain-barrier integrity changes; allopregnanolone treatment rescued many of these markers, though only partially restoring mucosal and BBB structure and the NF-κB/PPARγ pathway.", "keywords": [ "finasteride withdrawal", "allopregnanolone", "hypothalamic inflammation", "neuroinflammation", "gut-brain axis", "blood-brain barrier", "butyrate", "NF-κB", "rat model" ], "relevance": "Extends the PFS gut–brain inflammation model from the colon to the hypothalamus with metabolomic and BBB readouts, strengthening the mechanistic case for neurosteroid-based intervention strategies.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "note": "Discord context label 'CYP2D6 gene variants' does NOT match this link; PMID 40723915 is the finasteride/allopregnanolone gut–hypothalamus paper.", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "fulltext_url": "https://www.mdpi.com/2218-273X/15/7/1044/pdf?version=1752821279", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "40723915" }, { "item_id": "DISC-011", "source_type": "news article", "title": "SSRI e disfunzione sessuale, PSSD: mancano gli studi ma non i segni clinici", "authors": "AboutPharma (redazione)", "journal_or_site": "AboutPharma", "year_or_date": "2024", "url": "https://www.aboutpharma.com/scienza-ricerca/ssri-e-disfunzione-sessuale-pssd-mancano-gli-studi-ma-non-i-segni-clinici/", "type": "news article", "abstract_or_summary": "Italian trade-press article on SSRIs and sexual dysfunction / PSSD, arguing that dedicated studies are still lacking while clinical signs of persistent sexual dysfunction after SSRI treatment are well known. Page fetch timed out and the article could not be located via web search, so article content is unverified beyond the URL slug and the discord listing.", "keywords": [ "PSSD", "SSRI", "sexual dysfunction", "Italy", "news coverage" ], "relevance": "Provides a journalism-side record of PSSD recognition in the Italian medical press (2024), useful for the corpus's media/coverage layer, not as scientific evidence.", "starred": true, "curated_source": "PSSD discord", "verification_status": "metadata-tentative", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-012", "source_type": "peer-reviewed paper", "title": "Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level", "authors": "S Giatti, L Cioffi, S Diviccaro, R Piazza, R C Melcangi", "journal_or_site": "Journal of Endocrinological Investigation", "year_or_date": "2024", "url": "https://pubmed.ncbi.nlm.nih.gov/38493246/", "doi": "10.1007/s40618-024-02345-y", "type": "peer-reviewed paper", "abstract_or_summary": "Whole-transcriptome (RNA-seq) analysis of hypothalamus and hippocampus in adult male rats treated with finasteride for 20 days and examined 24 h after last dose and 1 month after withdrawal. Treatment altered 186 genes in hypothalamus and 19 in hippocampus; differential expression was no longer detectable at withdrawal, though gene-set enrichment signals persisted at both time points. Dysregulated genes (TTR, DIO2, CLDN1/2, SLC4A5, KCNE2, CROT, HCRT, MARCKSL1, VGF, IRF2BPL) were mapped onto clinical side effects such as depression, anxiety, memory/attention disturbance, and sleep disruption.", "keywords": [ "finasteride", "PFS", "transcriptomics", "hypothalamus", "hippocampus", "neurosteroids", "gene expression", "withdrawal" ], "relevance": "Core PFS mechanistic paper: genome-wide brain transcriptome after finasteride and its withdrawal, directly feeding the corpus's gene-expression and neurosteroid-dysregulation tracks. NOTE: discord label 'CYP2D and drug metabolism' is incorrect; PMID 38493246 is this Melcangi-group finasteride study.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "fulltext_url": "https://link.springer.com/content/pdf/10.1007/s40618-024-02345-y.pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "38493246" }, { "item_id": "DISC-013", "source_type": "peer-reviewed paper", "title": "Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients", "authors": "Roberto Cosimo Melcangi, Daniele Santi, Roberto Spezzano, Maria Grimoldi, Tommaso Tabacchi, Maria Letizia Fusco, Silvia Diviccaro, Silvia Giatti, Giuseppe Carrà, Donatella Caruso, Manuela Simoni, Guido Cavaletti", "journal_or_site": "The Journal of Steroid Biochemistry and Molecular Biology", "year_or_date": "2017", "url": "https://pubmed.ncbi.nlm.nih.gov/28408350/", "doi": "10.1016/j.jsbmb.2017.04.003", "type": "peer-reviewed paper", "abstract_or_summary": "Multicenter case-control study of 16 men with post-finasteride syndrome, combining psychiatric/andrological phenotyping with cerebrospinal fluid and plasma neuroactive-steroid measurements in 14 of them (2 declined CSF sampling), compared against 25 surgical controls. Eight of sixteen patients met criteria for major depressive disorder and all showed erectile dysfunction; pudendal-nerve somatosensory evoked potentials were abnormal in 4 of 16 (25%), which the authors linked to severe erectile dysfunction and took to suggest peripheral neuropathy. CSF showed decreased pregnenolone, progesterone/DHP, DHT, and 17beta-estradiol with increased DHEA, testosterone, and 5alpha-androstane-3alpha,17beta-diol relative to controls. The authors interpreted this as finasteride broadly perturbing neuroactive-steroid pathways beyond simple 5alpha-reduction blockade, but there were no before-treatment measurements or finasteride-exposed controls, and they called for asymptomatic former users as comparators in future studies.", "keywords": [ "PFS", "neuroactive steroids", "CSF", "depression", "erectile dysfunction", "finasteride", "neurosteroids" ], "relevance": "Foundational clinical PFS paper pairing psychiatric/andrological phenotyping with CSF neurosteroid profiling; anchors the neurosteroid-dysregulation hypothesis of PFS. NOTE: discord label 'CYP2D pharmacogenomics' is incorrect; PMID 28408350 is this Melcangi neuroactive-steroid study.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "sidefxhub_curated": true, "sidefxhub_article_title": "Neuroactive Steroid Levels in PFS Patients", "fulltext_url": "https://iris.unimore.it/bitstream/11380/1131597/4/POST_PRINTj.jsbmb.2017.04.003.pdf", "fulltext_source": "repository", "oa_status": "green", "oa_license": "", "pmid": "28408350", "plain": { "summary": "Researchers in Italy examined 16 men, aged 22 to 44, who still had sexual and mental-health symptoms at least three months after stopping finasteride for hair loss. All 16 had some degree of erection problems (10 of them severe), half met the criteria for major depression, and a test of the nerve that carries feeling from the penis was abnormal in 4 of them. In the 14 who gave a sample of spinal fluid (the fluid around the brain and spinal cord), levels of several steroid hormones that act on the brain differed from those of 25 people having planned leg surgery. Some were lower, including DHT (a stronger form of testosterone), and some were higher, including testosterone itself.", "caveat": "It can't show that finasteride caused any of this: the study was small, there were no measurements from before treatment, the mood, sexual and nerve tests had no comparison group at all, and the paper doesn't say whether the surgery patients had ever taken finasteride." }, "evidence": { "design": "Case-control study at a single time point: clinical assessment of men with post-finasteride syndrome (no comparison group), plus cerebrospinal fluid (CSF) and plasma neuroactive steroid levels compared with surgical controls", "design_class": "case-control", "setting": "Patients recruited through the Italian network on finasteride side effects; controls at San Gerardo Hospital, Monza, Italy; study dates not stated", "population": "Men aged 22–44 with persistent sexual and mental-health symptoms after finasteride 1–1.25 mg/day for hair loss, stopped at least 3 months earlier, with no reported depression or sexual dysfunction before finasteride and no drugs known to affect neuroactive steroids. Controls: 25 otherwise healthy people having spinal anaesthesia for planned lower-limb orthopaedic surgery, screened for neurological and psychiatric disorders; mean age 33, not significantly different from patients (p = 0.791).", "n": 41, "n_note": "16 men with PFS assessed clinically (mean age 32), of whom 14 gave paired CSF and plasma (2 declined CSF sampling); 25 controls for steroid levels only", "exposure": "Finasteride 1–1.25 mg/day for hair loss; mean treatment 1,037 days; 451–4,697 days since stopping (median 1,970)", "comparator": "Steroid levels only, against 25 surgical controls whose sex and finasteride history are not stated; no comparison group for the psychiatric, sexual-function, testicular or nerve tests", "outcome": "Major depressive disorder (K-10 screen, then the MINI diagnostic interview for those screening positive); Beck Depression and Anxiety Inventories; erectile dysfunction by IIEF-15 (erectile function score of 25 or less); testicular ultrasound; pudendal nerve somatosensory evoked potentials (PN-SEPs); 11 neuroactive steroids in CSF and plasma by LC-MS/MS.", "follow_up": "None; a single assessment, a median of 1,970 days after stopping finasteride", "results": [ { "text": "Major depressive disorder in 8 of 16 (50%); 9 of 16 screened positive on the K-10. Men with MDD vs without had higher Beck Depression (20.87 ± 11.62 vs 7.62 ± 6.48) and Beck Anxiety (21.50 ± 10.76 vs 7.50 ± 5.55) scores", "where": "p. 16; Table 2, p. 34" }, { "text": "All 16 had erectile dysfunction (mean erectile function score 10.31 ± 9.48): 10 severe (62.5%), 6 mild-moderate (37.5%). MDD and ED were not associated (p = 0.296). Testicular volume was normal (right 17.77 ± 5.06 mL, left 17.13 ± 4.69 mL)", "where": "p. 16; Table 3, p. 35" }, { "text": "PN-SEPs abnormal in 4 of 16 (25%): no reproducible response in 3, delayed P1 wave in 1. The paper reports abnormal results were linked to severe ED (p = 0.032) but does not give the split; even if all 4 were among the 10 men with severe ED, Fisher's exact test (the paper's stated test for categorical data, p. 15) gives p = 0.23 two-sided (0.12 one-sided), so the reported p-value cannot be reproduced from the counts given", "where": "p. 17" }, { "text": "CSF, 14 patients vs 25 controls (pg/µL, mean): lower pregnenolone (0.12 vs 0.31), progesterone (undetectable vs 0.19), dihydroprogesterone (0.56 vs 2.83), DHT (0.06 vs 0.25, about a quarter) and 17β-estradiol (undetectable vs 0.07); higher DHEA (0.33 vs 0.20), testosterone (1.97 vs 0.13, about 15-fold) and 3α-diol (0.20 vs undetectable)", "where": "p. 17; Table 4, p. 36" }, { "text": "Plasma: higher pregnenolone (2.48 vs 0.96), DHEA (8.79 vs 1.86, about 4.7-fold) and testosterone (12.3 vs 5.70, about 2.2-fold); lower dihydroprogesterone (0.26 vs 0.73) and tetrahydroprogesterone (undetectable vs 0.29); DHT not different (0.49 vs 0.42). The plasma pattern did not mirror CSF", "where": "pp. 17–18; Table 4, p. 36" }, { "text": "At assessment, all 16 reported loss of libido, difficulty getting an erection and a felt loss of connection between brain and penis at least sometimes (10, 9 and 10 \"always\"); 14 reported genital numbness, 13 depression or hopelessness and 9 suicidal thoughts at least sometimes", "where": "Table 1, p. 33" } ], "limitations_stated": [ "The symptom questionnaire is not validated", "Nerve testing was limited to PN-SEPs, to limit patient discomfort", "A link between neuroactive steroids and ED has not been demonstrated", "Larger studies are needed on CSF progesterone and depression", "Steroid changes differ from the group's earlier, smaller studies and remain heterogeneous; future studies need more patients, an age-matched control group and asymptomatic former users of similar doses", "The mechanism of PFS is still not demonstrated" ], "design_notes": [ "Described as prospective and longitudinal, but results come from one assessment, with no measurements from before or during finasteride", "The diagnostic interview for depression was given only to the 9 men who screened positive on the K-10, so MDD could only be found among those 9", "Table 1 records symptoms before finasteride, recalled at assessment, despite the entry criteria: 6 of 16 reported depression or hopelessness and 2 of 16 erection difficulty at least sometimes, and 11 of 16 anxiety", "Table 3 lists left varicocele in 8 of 16 (50%) and right in 1; the text does not discuss it", "Sampling conditions (such as time of day or fasting) are not described for either group, which matters for hormones such as testosterone", "Eleven steroids in two fluids were compared, with no correction for multiple testing stated", "The same 16 patients were re-analysed in DISC-025 (2019), which reports CSF results for all 16 and a patient mean age of 34.5; this paper says 2 declined CSF sampling and gives a mean age of 32", "Accepted manuscript; the published version may differ in detail" ], "funding": "Post-Finasteride Foundation, financial support to R.C. Melcangi; the funder's role is not stated", "interests": "Not stated (no declaration in the accepted manuscript)", "supports": "That some men with persistent symptoms after finasteride have erection problems, depression in about half, abnormal penile nerve tests in a quarter, and spinal-fluid steroid levels that differ from those of surgical controls. It does not establish that finasteride caused these differences, nor how common they are among former users.", "extracted_from": "fulltexts/DISC-013-Neuroactive-steroid-levels-and-psychiatric-and-and.pdf (accepted manuscript, IRIS UNIMORE repository copy, 36 pp.; page refs are PDF page indices)", "extracted": "2026-10-10" } }, { "item_id": "DISC-014", "collection_tag": "pssd-discord", "title": "Transcriptomic Profile of the Male Rat Hypothalamus and Nucleus Accumbens After Paroxetine Treatment and Withdrawal: Possible Causes of Sexual Dysfunction", "doi": "10.1007/s12035-024-04592-9", "url": "https://pubmed.ncbi.nlm.nih.gov/39495228/", "status": "duplicate-tombstone", "duplicate_of": "PSSD-012", "tombstone_note": "Deduplicated in corpus v1.14: this record described the same paper as PSSD-012 (same DOI 10.1007/s12035-024-04592-9 and title). PSSD-012 is the canonical record; this record's pmid, abstract_or_summary, relevance, keywords, verification_status, starred, curated_source moved there, and its listing in pssd-discord is now PSSD-012's also_listed_in. Kept as a tombstone per the no-silent-deletions policy; do not count as a separate paper." }, { "item_id": "DISC-015", "source_type": "conference abstract", "title": "Paroxetine-induced dopamine dysregulation: insights into the pathogenesis of post-SSRI sexual dysfunction (PSSD)", "authors": "S Giatti, G Chrostek, L Cioffi, S Diviccaro, F Sanna, R C Melcangi", "journal_or_site": "The Journal of Sexual Medicine", "year_or_date": "2025", "url": "https://academic.oup.com/jsm/article/22/Supplement_2/qdaf077.001/8127441", "doi": "10.1093/jsxmed/qdaf077.001", "type": "conference abstract", "abstract_or_summary": "Congress abstract (J Sex Med Vol 22, Suppl 2, May 2025) extending the Melcangi group's paroxetine work into dopamine signaling: adult male rats treated with paroxetine for 14 days showed significantly reduced dopamine in nucleus accumbens both 24 h after dosing and after 1 month of suspension. qPCR showed elevated MAO-A during treatment and altered TH, VMAT2, DRD1, and DRD2 expression during suspension, suggesting lasting dopaminergic remodeling in a motivation/sexual-behavior circuit.", "keywords": [ "PSSD", "paroxetine", "dopamine", "nucleus accumbens", "MAO-A", "DRD1/DRD2", "conference abstract" ], "relevance": "PSSD-relevant conference abstract-only report (peer-reviewed venue, abstract only — not a full paper) linking paroxetine withdrawal to persistent dopamine dysregulation in the nucleus accumbens, a sexual-motivation hub.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-016", "source_type": "conference abstract", "title": "(166) Paroxetine-induced alterations in neurosteroidogenic gene expression in the female nucleus accumbens: insights into post-SSRI sexual dysfunction", "authors": "G Chrostek, S Diviccaro, L Cioffi, R C Melcangi, S Giatti", "journal_or_site": "The Journal of Sexual Medicine", "year_or_date": "2026", "url": "https://academic.oup.com/jsm/article/23/Supplement_4/qdag118.150/8701903", "doi": "10.1093/jsxmed/qdag118.150", "type": "conference abstract", "abstract_or_summary": "Congress abstract (J Sex Med Vol 23, Suppl 4, June 2026; article page 403'd, metadata recovered via Crossref) reporting paroxetine effects on neurosteroid-synthesis genes in female rats, a neglected sex in PSSD research. qPCR of the nucleus accumbens after 14 days of paroxetine showed increased StAR and decreased TSPO and 3alpha-HSOR at treatment end, with StAR, TSPO, 3beta-HSD, and 3alpha-HSOR all reduced one month after withdrawal, pointing to persistent disruption of neurosteroidogenesis after SSRI withdrawal in females.", "keywords": [ "PSSD", "paroxetine", "neurosteroidogenesis", "StAR", "TSPO", "nucleus accumbens", "female", "conference abstract" ], "relevance": "Rare female-sex PSSD mechanistic abstract (abstract only, not a full paper): SSRI withdrawal persistently disrupts neurosteroid-synthesis gene expression in a sexual-motivation circuit, supporting a shared neurosteroid mechanism across PFS and PSSD.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-017", "source_type": "forum case report", "title": "80% PFS recovery (PropeciaHelp member story)", "authors": "PropeciaHelp forum member (Russia/Israel, 45 y.o.)", "journal_or_site": "forum.propeciahelp.com", "year_or_date": "date not captured from thread page", "url": "https://forum.propeciahelp.com/t/80-pfs-recovery/61196", "type": "forum case report", "abstract_or_summary": "Anecdotal member story: after ~6 months of finasteride (1 mg/day) the poster developed complete loss of libido, severe insomnia, restless leg syndrome, and depression that persisted about 10 years; a 13-day Ayurveda/Panchakarma fast with castor oil gave transient full remission, and a supervised 6-day dry fast then produced what he describes as ~80% recovery of libido, mood, energy, sleep, and restless legs. He speculates — without evidence — that a finasteride-related substance persisted in the body and was cleared by fasting; he later re-crashed after a short course of topical dutasteride.", "keywords": [ "PFS", "recovery", "anecdotal", "fasting", "finasteride", "dutasteride", "case report" ], "relevance": "Anecdotal patient recovery narrative — illustrates heterogeneity of PFS courses and self-experimentation in the patient community, but it is a single unverified forum post, not evidence of efficacy. Include as patient-voice material only; do not overstate.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-018", "source_type": "peer-reviewed paper", "title": "Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2", "authors": "Hiroyuki Hirai, Kazuya Tanaka, Shoichi Takano, Michiko Ichimasa, Masataka Nakamura, Kinya Nagata", "journal_or_site": "The Journal of Immunology", "year_or_date": "2002", "url": "https://pubmed.ncbi.nlm.nih.gov/11801628/", "doi": "10.4049/jimmunol.168.3.981", "type": "peer-reviewed paper", "abstract_or_summary": "Found that indomethacin — normally known as a COX inhibitor — acts as a functional agonist of the PGD2 receptor CRTH2 (now DP2) at submicromolar concentrations, driving calcium mobilization and chemotaxis of Th2 cells, eosinophils, and basophils, while other NSAIDs (aspirin, sulindac, diclofenac, acemetacin) showed no such effect. The results implicate CRTH2 in mediating some indomethacin-specific therapeutic or adverse effects independent of cyclooxygenases and PPARs.", "keywords": [ "indomethacin", "CRTH2", "DP2", "prostaglandin D2", "chemotaxis", "NSAID", "immunology" ], "relevance": "Mechanistic pharmacology context: indomethacin has off-target receptor activity beyond COX inhibition, relevant to PSSD/PFS discussions where indomethacin appears (e.g., 3alpha-HSOR inhibition in neurosteroid studies) — cautions against assuming simple COX-mediated mechanisms. NOTE: discord label 'Stress & neurosteroids' is incorrect; PMID 11801628 is this CRTH2 immunology paper.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "pmid": "11801628", "fulltext_note": "No free full text: paywalled at the publisher (checked 2026-10-09)" }, { "item_id": "DISC-019", "source_type": "peer-reviewed paper", "title": "Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions", "authors": "R S Kahn, M Davidson, P Kanof, R T McQueeney, R R Singh, K L Davis", "journal_or_site": "Psychopharmacology (Berl)", "year_or_date": "1991", "url": "https://pubmed.ncbi.nlm.nih.gov/2006246/", "doi": "10.1007/BF02244081", "type": "peer-reviewed paper", "abstract_or_summary": "Controlled clinical trial in eight normal subjects showing that a single 150 mg oral dose of indomethacin significantly raised plasma homovanillic acid (pHVA, a dopamine metabolite) versus placebo. The authors interpreted this as evidence that prostaglandin synthesis inhibition increases central dopamine turnover in humans, paralleling animal findings.", "keywords": [ "indomethacin", "dopamine", "homovanillic acid", "prostaglandins", "human trial" ], "relevance": "Human pharmacology data on a prostaglandin–dopamine interaction: relevant to dopamine-centered PSSD hypotheses (cf. DISC-015) and to indomethacin's neuropharmacological profile. NOTE: discord label 'Gene variants' is incorrect; PMID 2006246 is this indomethacin–dopamine study.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "pmid": "2006246" }, { "item_id": "DISC-020", "source_type": "peer-reviewed paper", "title": "Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA_A receptor function and seizure susceptibility", "authors": "Doodipala S Reddy, Michael A Rogawski", "journal_or_site": "The Journal of Neuroscience", "year_or_date": "2002", "url": "https://www.jneurosci.org/content/22/9/3795", "doi": "10.1523/JNEUROSCI.22-09-03795.2002", "type": "peer-reviewed paper", "abstract_or_summary": "Demonstrated that acute swim stress raises plasma THDOC (allotetrahydrodeoxycorticosterone) in rats and increases the seizure threshold, and that the 5alpha-reductase inhibitor finasteride reverses this stress-induced anticonvulsant effect by blocking conversion of deoxycorticosterone to DHDOC/THDOC. In hippocampal neurons, DHDOC and THDOC potentiated and directly activated GABA_A receptor chloride currents, establishing stress-derived neurosteroids as endogenous GABA_A modulators whose synthesis depends on 5alpha-reductase.", "keywords": [ "neurosteroids", "THDOC", "GABA_A", "finasteride", "5alpha-reductase", "stress", "indomethacin", "3alpha-HSOR" ], "relevance": "Classic paper showing finasteride blocks stress-induced neurosteroid synthesis via 5alpha-reductase inhibition — direct mechanistic support for the hypothesis that 5alpha-reductase blockade disrupts endogenous GABAergic neurosteroid tone, a proposed mechanism in both PFS and PSSD.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "fulltext_url": "https://www.jneurosci.org/content/jneuro/22/9/3795.full.pdf", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "", "pmid": "11978855" }, { "item_id": "DISC-021", "source_type": "reddit post", "title": "r/microbiomenews post (Reddit share link GBv7vIM60O — post content unverifiable)", "authors": "unknown", "journal_or_site": "reddit.com/r/microbiomenews", "year_or_date": "unknown", "url": "https://www.reddit.com/r/microbiomenews/s/GBv7vIM60O", "type": "reddit post", "abstract_or_summary": "UNVERIFIABLE: reddit.com is blocked from this environment (policy-level block), so the share link could not be opened. The 's/GBv7vIM60O' token is an opaque Reddit share short-link that only Reddit's servers can resolve to a post ID, so it could not be mapped to a post via web search either. A targeted search for the token returned no results. The link was labeled in the Discord list as 'Microbiome news' from r/microbiomenews, but the specific post's title, author, date, and content are unknown.", "keywords": [ "reddit", "microbiome", "r/microbiomenews", "unverifiable", "share link" ], "relevance": "Cannot be assessed — the post's subject is unknown. Candidate PFS/PSSD angles (e.g., gut-brain axis, probiotic discussion) are speculation only.", "starred": true, "curated_source": "PSSD discord", "verification_status": "link-dead", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-022", "source_type": "peer-reviewed paper", "title": "Indomethacin-associated sexual dysfunction", "authors": "L G Miller, J C Rogers, D E Swee", "journal_or_site": "Journal of Family Practice", "year_or_date": "1989", "url": "https://pubmed.ncbi.nlm.nih.gov/2526860/", "type": "peer-reviewed paper", "abstract_or_summary": "A brief 1989 case report from Baylor College of Medicine's Department of Family Medicine describing a case of sexual dysfunction associated with indomethacin, an NSAID prescribed for back pain. The PubMed record lists no abstract; the MeSH indexing classifies it as chemically induced erectile dysfunction in a middle-aged male (Case Reports). NOTE: the Discord list labeled this link 'Aryl-sulfatase activity' — that label is wrong; PMID 2526860 is this indomethacin case report.", "keywords": [ "indomethacin", "NSAID", "erectile dysfunction", "case report", "drug-induced sexual dysfunction", 1989 ], "relevance": "Directly relevant as an early example of drug-induced sexual dysfunction being reported in the literature — the same phenomenon class that PFS/PSSD describe, here with an NSAID rather than finasteride or an SSRI, supporting the corpus's 'related post-drug syndromes' scope.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-023", "source_type": "peer-reviewed paper", "title": "CYP2D in the brain", "authors": "Yoshihiko Funae, Wataru Kishimoto, Toshio Cho, Toshiro Niwa, Toyoko Hiroi", "journal_or_site": "Drug Metabolism and Pharmacokinetics", "year_or_date": "2003", "url": "https://pubmed.ncbi.nlm.nih.gov/15618754/", "doi": "10.2133/dmpk.18.337", "type": "peer-reviewed paper", "abstract_or_summary": "This review surveys CYP2D isoforms in the brain: in rats CYP2D4 mRNA is most abundant in cerebellum, striatum, pons and medulla, while in humans only CYP2D6 is expressed, highest in cerebellum. It reports that CYP2D enzymes metabolize both xenobiotics (antidepressants, beta-blockers, antiarrhythmics) and endogenous substrates, that CYP2D6 alone among 11 tested human P450s efficiently converts tyramine to dopamine, and that CYP2D4/CYP2D6 carry steroid 21-hydroxylase activity for progesterone and allopregnanolone in the brain. The authors conclude brain CYP2D participates in neuronal amine/steroid metabolism and CNS regulation.", "keywords": [ "CYP2D6", "CYP2D4", "brain", "neurosteroids", "dopamine", "tyramine", "allopregnanolone", "progesterone", "drug metabolism" ], "relevance": "Highly relevant pharmacogenetic context: CYP2D6 metabolizes many SSRIs/SNRIs and converts tyramine to dopamine, and it hydroxylates neurosteroids like allopregnanolone — implicating CYP2D in both the dopamine signaling deficits and neurosteroid disruption discussed in PSSD/PFS theories.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "pmid": "15618754" }, { "item_id": "DISC-024", "source_type": "peer-reviewed paper", "title": "CYP2D6 Is Inducible by Endogenous and Exogenous Corticosteroids", "authors": "Muhammad Farooq, Edward J Kelly, Jashvant D Unadkat", "journal_or_site": "Drug Metabolism and Disposition", "year_or_date": "2016", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4851303/", "doi": "10.1124/dmd.115.069229", "type": "peer-reviewed paper", "abstract_or_summary": "The authors challenged the dogma that CYP2D6 is non-inducible, showing that in sandwich-cultured human hepatocytes CYP2D6 mRNA, protein, and activity were robustly (>10-fold) induced by endogenous (cortisol, corticosterone) and exogenous (dexamethasone, prednisolone) corticosteroids — but that this induction was masked when culture medium contained routine supplemental dexamethasone. They linked the cortisol data to the observed ~2-3-fold CYP2D6 induction in late pregnancy. CRITICAL: this paper has been RETRACTED (retraction notice: Drug Metab Dispos. 2018 Sep;46(9):1360), shown on the PMC page. NOTE: the Discord list labeled this 'Urinary steroid profile (2013)' — that label is wrong; PMC4851303 is this 2016 CYP2D6 induction paper.", "keywords": [ "CYP2D6", "corticosteroids", "cortisol", "enzyme induction", "dexamethasone", "hepatocytes", "retracted" ], "relevance": "Relevant to SSRI/SNRI metabolism (CYP2D6 clears many antidepressants) and to steroid-hormone interplay with drug-metabolizing enzymes — but it is RETRACTED, so its findings must not be treated as reliable evidence in the corpus.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "retraction": "RETRACTED — Drug Metab Dispos. 2018 Sep;46(9):1360. Do not cite as evidence.", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/4851303", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "26965986", "pmcid": "PMC4851303" }, { "item_id": "DISC-025", "source_type": "peer-reviewed paper", "title": "Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study", "authors": "Roberto Cosimo Melcangi, Livio Casarini, Marco Marino, Daniele Santi, Samantha Sperduti, Silvia Giatti, Silvia Diviccaro, Maria Grimoldi, Donatella Caruso, Guido Cavaletti, Manuela Simoni", "journal_or_site": "Endocrine Connections", "year_or_date": "2019", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6652249", "doi": "10.1530/EC-19-0199", "type": "peer-reviewed paper", "abstract_or_summary": "In this pilot case-control study, 16 PFS patients were compared with 36 controls who had never used finasteride: 18 surgical patients giving cerebrospinal fluid (2 of whom also gave blood) and 18 blood-only donors; controls' mean age was 40.8 years vs 34.5 in patients. The SRD5A2 gene promoter was methylated in cerebrospinal fluid-derived DNA of 56.3% of PFS patients (9 of 16) versus 7.7% of the 13 controls with enough CSF DNA (1 of 13), while no methylation appeared in blood samples of either group (16 patients, 20 controls) and the SRD5A1 promoter was unmethylated everywhere. The authors proposed this tissue-specific epigenetic silencing of the 5α-reductase type 2 gene as a candidate mechanism for the neuroactive-steroid disturbances and behavioral symptoms previously documented in PFS. They cautioned it is unknown whether the methylation pattern is pre-existing or induced by finasteride treatment.", "keywords": [ "SRD5A2", "5-alpha-reductase", "methylation", "epigenetics", "cerebrospinal fluid", "neuroactive steroids", "post-finasteride syndrome", "pilot study", "Melcangi" ], "relevance": "Pilot evidence (16 vs 13) of SRD5A2 promoter methylation in CSF-derived DNA, but not blood, of men with PFS, relevant to epigenetic hypotheses of persistent post-drug syndromes. The degree of methylation did not correlate with CSF steroid levels and methylation status was unrelated to clinical scores; specificity to PFS is untested without asymptomatic finasteride-exposed controls, and any relevance to PSSD is by analogy, as only PFS was studied.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord", "sidefxhub_curated": true, "sidefxhub_article_title": "Altered SRD5A2 Gene Methylation in PFS Patients", "fulltext_url": "https://doi.org/10.1530/ec-19-0199", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "31272082", "plain": { "summary": "Researchers looked for a chemical tag on DNA (called methylation) that can turn down the gene for the enzyme finasteride blocks. They tested DNA from the spinal fluid (the fluid around the brain and spinal cord) and blood of 16 men with lasting symptoms after finasteride, and of people who had never taken it. In spinal fluid the tag was found in 9 of the 16 men and in 1 of 13 comparison people; it was not found in anyone's blood. Men with and without the tag had similar scores for erection problems, depression and anxiety.", "caveat": "It can't tell whether the tag was caused by finasteride or was there from birth, as the authors say themselves; the groups were very small, and no one who took finasteride without problems was tested." }, "evidence": { "design": "Secondary analysis of the DISC-013 case-control study: methylation of the SRD5A1 and SRD5A2 gene promoters in DNA from CSF and blood, men with PFS vs controls, with CSF steroid levels and clinical scores compared by methylation status (pilot)", "design_class": "case-control", "setting": "Patients from the Italian network of finasteride side effects; controls at San Gerardo Hospital, Monza, plus blood donors; laboratory work in Modena, Italy; dates not stated", "population": "16 men aged 22–44 with persistent sexual and mental-health symptoms after finasteride 1–1.25 mg/day for hair loss, stopped at least 3 months earlier; the same patients as DISC-013. Controls had never used finasteride: 18 otherwise healthy people having spinal anaesthesia for planned lower-limb orthopaedic surgery (CSF; 2 also gave blood) and 18 healthy blood donors. Mean age 40.8 ± 17.9 in controls vs 34.5 ± 8.8 in patients (P = 0.192).", "n": 29, "n_note": "29 in the main CSF comparison (16 patients, 13 controls; CSF DNA was insufficient in 5 of 18 control samples). Blood DNA from 16 patients and 20 controls. 36 controls recruited in all; the overlap between CSF and blood controls is not fully stated, so the total analysed across both tissues is 47–49", "exposure": "Finasteride 1–1.25 mg/day for hair loss, stopped at least 3 months earlier; duration not reported in this paper", "comparator": "Controls who never used finasteride; within patients, methylated vs unmethylated", "outcome": "Promoter methylation of SRD5A1 and SRD5A2 by quantitative methylation-specific PCR, \"methylated\" meaning 10% or more methylated DNA. Secondary: CSF levels of 11 neuroactive steroids (taken from DISC-013), and erectile function, depression and anxiety scores, by methylation status.", "follow_up": "None; a single sample per person", "results": [ { "text": "SRD5A2 promoter methylated in CSF DNA of 9 of 16 patients (56.3%) vs 1 of 13 controls (7.7%); P = 0.006 by Pearson's chi-square, which recomputes correctly (chi-square 7.49). Two expected cell counts are below 5; Fisher's exact test gives P = 0.008", "where": "p. 1121, Table 1" }, { "text": "In the 9 methylated patients, methylation ranged from 15.4% to 100% (mean 40.3%, median 31.8%); the one methylated control (58.0%) was a man with normotensive hydrocephalus", "where": "p. 1121" }, { "text": "SRD5A2 unmethylated in every blood sample (16 patients, 20 controls); SRD5A1 unmethylated in every sample, blood or CSF", "where": "p. 1121" }, { "text": "CSF steroids (pg/µL, mean) in 12 unmethylated controls, 7 unmethylated and 9 methylated patients: unmethylated patients had lower pregnenolone (0.09 vs 0.39), DHT (0.05 vs 0.15) and dihydroprogesterone (0.25, the detection limit, vs 3.07) and higher testosterone (2.53 vs 0.23) than controls; methylated patients differed from controls only in dihydroprogesterone (1.00 vs 3.07). Steroid levels did not correlate with the percentage of methylation (P > 0.05)", "where": "pp. 1121–1122, Table 2" }, { "text": "Methylated and unmethylated patients did not differ in degree of ED (P = 0.362), any IIEF-15 domain (P = 0.456 to 0.805), K-10 (P = 0.890), Beck Depression (P = 0.475) or Beck Anxiety (P = 0.485) scores", "where": "p. 1121" } ], "limitations_stated": [ "The low number of subjects; the steroid results \"must be interpreted with extreme caution\"", "It cannot be established whether the methylation was set before birth or caused by finasteride", "Whether the sexual and psychiatric symptoms relate to methylation cannot be concluded", "DNA extraction was insufficient in five CSF samples", "The LC-MS/MS method's sensitivity was limited for some steroids", "The proposed mechanism (finasteride altering DNA methylation in the nervous system) is \"highly speculative\"" ], "design_notes": [ "No finasteride users without symptoms were tested, so the study cannot separate an association with PFS from one with finasteride exposure itself", "The method assumes the few cells in CSF are nervous-system (ependymal) cells representative of the brain; which cells the DNA came from was not checked", "Controls were different people for each tissue: CSF from surgical patients, blood mostly from separate donors. The abstract's \"20 age-matched healthy men\" are the blood controls; the 13 CSF controls' age is not given separately", "Inconsistent with the source study: DISC-013 says 2 of these 16 men declined CSF sampling and reports CSF steroids for 14, whereas this paper gives CSF DNA and CSF steroid results for all 16 (7 + 9); mean patient age is 34.5 here vs 32 in DISC-013", "Some Table 2 entries look inconsistent: controls' 17β-estradiol is 0.4 ± 0.06 pg/µL against 0.02 in unmethylated patients, yet P = 0.676; controls' testosterone is 0.23 ± 0.85. DISC-013 gave control CSF values of 0.07 ± 0.05 and 0.13 ± 0.11. These may be typographical; the paper does not allow a check", "Three-way comparisons of 11 steroids in groups of 7 to 12, with no correction for multiple testing stated" ], "funding": "Post-Finasteride Foundation", "interests": "None declared", "supports": "A difference, in a pilot study, in a DNA tag on the SRD5A2 gene in spinal-fluid cells between 16 men with PFS and 13 controls. It cannot show whether finasteride caused the tag, whether it explains symptoms (it did not track them here), or that it is specific to PFS.", "extracted_from": "fulltexts/DISC-025-Altered-methylation-pattern-of-the-SRD5A2-gene-in.pdf (publisher PDF, CC BY 4.0, 8 pp.; page refs are the journal's printed page numbers, 1118–1125)", "extracted": "2026-10-10" } }, { "item_id": "DISC-026", "source_type": "peer-reviewed paper", "title": "Genome-wide Copy-Number-Variation Study Identified a Susceptibility Gene, UGT2B17, for Osteoporosis", "authors": "Tie-Lin Yang, Xiang-Ding Chen, Yan Guo, Shu-Feng Lei, Jin-Tang Wang, Qi Zhou, Feng Pan, Yuan Chen, Zhi-Xin Zhu, Teng Chen, Meng Li, Hong Zhang, Liang Zhang, Betty M Drees, James J Hamilton, Christopher J Papasian, Robert R Recker, Xiao-Ping Song, Jing Cheng, Hong-Wen Deng", "journal_or_site": "American Journal of Human Genetics", "year_or_date": "2008", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2667994/", "type": "peer-reviewed paper", "abstract_or_summary": "A genome-wide copy-number-variation (CNV) analysis in 700 elderly Chinese subjects (350 hip-fracture cases, 350 controls) found that CNV at 4q13.2, encompassing the UGT2B17 gene, was significantly associated with osteoporotic fracture, replicated in an independent Chinese sample and associated with hip bone-mineral density in Chinese and white cohorts. Because UGT2B17 encodes an enzyme that catabolizes steroid hormones, the authors measured serum testosterone and estradiol in 236 young Chinese males and found that men lacking UGT2B17 copies had significantly higher testosterone and estradiol levels, tying the CNV to sex-steroid exposure.", "keywords": [ "UGT2B17", "copy number variation", "osteoporosis", "testosterone", "estradiol", "steroid glucuronidation", "pharmacogenetics", "4q13.2" ], "relevance": "Directly on point for the corpus: UGT2B17 is the gene Dr Will Powers theorizes as the 'base, core defect' in PFS (DWP-003), and this paper demonstrates that UGT2B17 copy-number variation alters systemic testosterone/estradiol levels — the same steroid-hormone clearance mechanism implicated in post-drug syndrome pathophysiology.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-027", "source_type": "news article", "title": "Vagus Nerve Required for Normal Dopamine Reward Signals", "authors": "Technology Networks", "journal_or_site": "Technology Networks (neuroscience news)", "year_or_date": "date not shown on fetched page; covers a Science Advances 2026 paper (doi:10.1126/sciadv.adz0828); Discord list labeled it 2024", "url": "https://www.technologynetworks.com/neuroscience/news/the-vagus-nerve-shapes-dopamine-responses-to-food-and-drugs-409184", "type": "news article", "abstract_or_summary": "This science-news piece summarizes a mouse study (Onimus et al., Sci Adv) finding that gut-to-brain signals carried by the vagus nerve are required for normal mesolimbic dopamine reward responses. Mice with the vagus nerve cut below the diaphragm showed blunted dopamine responses in the nucleus accumbens during food anticipation, eating, and drug (cocaine, morphine, amphetamine) exposure, plus impaired reinforcement learning — while movement-related dopamine signaling stayed intact. The authors frame the gut as a central coordinator of the 'body-brain tango' in reward, with caveats that vagotomy is a blunt intervention and translation to humans is limited.", "keywords": [ "vagus nerve", "dopamine", "gut-brain axis", "nucleus accumbens", "reward", "reinforcement learning", "cocaine", "morphine", "microbiome" ], "relevance": "Relevant to PSSD/PFS through two converging axes: dopamine reward/motivation deficits (anhedonia, sexual reward dysfunction) and the gut-brain/microbiome axis — it provides a mechanistic bridge between peripheral nerve/microbiome disruption and central dopamine dysfunction.", "starred": true, "curated_source": "PSSD discord", "verification_status": "verified", "_source_file": "pssd_discord_papers", "collection_tag": "pssd-discord" }, { "item_id": "DISC-V01", "source_type": "youtube_video", "title": "Game Over Post Finasteride Syndrome - How I Recovered Part 1 of 2 | BrongFogBoy", "channel": "BrongFogBoy", "url": "https://www.youtube.com/watch?v=mQAnwC6dTkE", "upload_date": "2023-02-20", "duration": "14:02", "view_count": 8086, "transcript_status": "full", "transcript_files": [ "transcripts/mQAnwC6dTkE.srt", "transcripts/mQAnwC6dTkE.txt" ], "starred": true, "curated_source": "PSSD discord", "discord_list_ref": "#17 — listed as 'Game Over Post Finasteride Syndrome' (2024); actual upload 2023-02-20", "summary": "BrongFogBoy, a decade-long propeciahelp forum member, recounts ten years on 5-alpha-reductase inhibitors (finasteride, then Proscar, then dutasteride/Avodart) ending in a severe crash after stopping: anhedonia, brain fog, depression, insomnia, and post-exertional malaise that cost him his job and relationship. His self-described recovery came from an extreme self-experiment — one gram of iodine daily for seven days (as a biofilm disruptor) followed by a self-administered fecal microbiota transplant from a healthy donor. He is explicit that this is his personal account, that it could be dangerous, and that he is not recommending it; he defines 'recovery' strictly as full return to pre-drug function rather than managed symptoms.", "key_points": [ "[00:00:00] Opens with a disclaimer: not a doctor, not medical advice — consult a physician.", "[00:00:12] Defines 'recovery' strictly: a full return to the pre-finasteride state, rejecting looser forum usages (symptom control, temporary remission).", "[00:01:18] Reports restored exercise tolerance, diet freedom, sexual function, and — his worst symptom — complete resolution of brain fog (the source of his username) and anhedonia ('like a zombie').", "[00:02:31] Establishes credibility: 10+ years and hundreds of posts on propeciahelp under the same username, distinguishing himself from drive-by 'cure' claims.", "[00:03:31] Drug history: finasteride from ~18 for ~7 years with subtle unnoticed effects ('frog in boiling water'), Proscar ~2 years, then Avodart (dutasteride) ~1 year with 'gigantic' side effects — ~10 straight years on 5-ARIs total.", "[00:04:55] On stopping: a 3–6 day rush of energy/vitality, brief re-exposure confirming the drug link, then after ~2 weeks feeling better than he had in a decade — a complete crash: anhedonia, depression, no creativity, insomnia, feeling bad after workouts, horrible brain fog.", "[00:07:49] Anti-nocebo argument: he fully believed stopping would restore him, so placebo expectation should have made him fine — the opposite happened.", "[00:09:06] Recovery method: 1 gram/day of pure iodine for 7 days (~500x a typical supplement dose) followed by DIY fecal transplant; explicitly warns it could be dangerous and is not a recommendation.", "[00:10:07] 'Smoking gun' stool test: near-total absence of lactobacillus and bifidobacterium, which his doctor called unprecedented; says ~95% of forum members who posted tests showed the same depletion.", "[00:11:12] Medical-grade probiotics (VSL#3) did nothing — in his view probiotics will not fix PFS.", "[00:12:14] First FMT worked for one day then failed; repeats and a second donor also failed — until he added iodine on the theory that biofilms/fungus were blocking colonization, after which the transplant held." ], "keywords": [ "PFS", "patient recovery account", "gut microbiome", "fecal microbiota transplant", "FMT", "iodine", "biofilms", "lactobacillus", "bifidobacterium", "brain fog", "anhedonia", "dutasteride", "crash", "post-exertional malaise" ], "relevance": "Patient-reported PFS recovery via a gut-axis intervention (high-dose iodine + DIY fecal transplant), motivated by stool tests showing near-absent lactobacillus/bifidobacterium — a pattern the speaker says ~95% of forum testers shared. Directly feeds the corpus's gut-microbiome thread (cf. Giatti 2024 PFS-003, PSSD-011). N=1, uncontrolled, author-flagged as potentially dangerous; include with caveats, not as guidance.", "_source_file": "pssd_discord_videos", "collection_tag": "pssd-discord" }, { "item_id": "DISC-V02", "source_type": "youtube_video", "title": "The unlikely duo raising awareness about cancer treatment side effects | Australian Story", "channel": "ABC News In-depth", "url": "https://www.youtube.com/watch?v=qPHfIKwyyj0", "upload_date": "2025-07-16", "duration": "29:28", "view_count": 15392, "transcript_status": "full", "transcript_files": [ "transcripts/qPHfIKwyyj0.srt", "transcripts/qPHfIKwyyj0.txt" ], "starred": true, "curated_source": "PSSD discord", "discord_list_ref": "#22 — listed as 'Castration side-effects' (2024); actual title/channel/date differ (see above). The label is a reasonable shorthand: the video is about ADT, i.e., chemical castration, for prostate cancer.", "summary": "This ABC Australian Story episode (July 2025) follows two Australians — Tim, a writer living with metastatic prostate cancer on ten years of androgen deprivation therapy, and Liz, widow of Craig — campaigning for awareness of ADT's devastating side effects. Both describe the same cluster: zero libido, erectile dysfunction, genital shrinkage, breast swelling, emotional blunting, and depression, alongside starkly inadequate informed consent ('I've only had one patient have an adverse reaction'). They frame ADT plainly as the chemical castration of millions of men without support tools, while Tim closes by calling it a 'necessary evil' that saved his life.", "key_points": [ "[00:01:22] Framing: ADT 'does save lives but it can also have life wrecking consequences for some patients.'", "[00:10:24] ADT explained: therapy to block testosterone 'because prostate cancer actually feeds off testosterone.'", "[00:10:39] Informed-consent gap: when Craig's wife asked about mental-health impact, the oncologist said he'd 'only had one patient have an adverse reaction' — so she 'parked it.'", "[00:11:20] Craig's onset within ~2 months: irritability, poor sleep, fatigue, visibly rapid aging.", "[00:11:56] 'Zero libido whatsoever' — described as the key troubling symptom.", "[00:13:31] Tim on learning the frontline treatment for the most common cancer in men 'amounted to chemical castration': loss of libido, erectile function, bone density, muscle mass — with no mention of suicide risk in the consent discussion.", "[00:14:24] 'It absolutely feels like your masculinity is being taken from you... I consider myself entirely asexual' — plus breast swelling, genital shrinkage, and deep emotional vulnerability.", "[00:19:08] Convinced ADT caused his darkest periods; calls the warnings 'entirely inadequate' and prescribing ADT without support 'medically negligent.'", "[00:19:50] 'We're chemically castrating millions of men all the time and not giving them any tools to manage' — the advocacy thesis.", "[00:26:32] Balanced close: 'If I hadn't done ADT hormone treatment, I don't think I'd still be here... it was a necessary evil.'" ], "keywords": [ "ADT", "androgen deprivation therapy", "chemical castration", "prostate cancer", "libido loss", "erectile dysfunction", "informed consent", "patient advocacy", "asexuality", "depression" ], "relevance": "Mainstream documentary on prolonged androgen deprivation producing persistent sexual and psychological effects — the clinical real-world parallel to Powers' 'castration trial' concept (DWP-002) and the corpus's androgenic-silencing phenotype. The informed-consent/recognition-gap theme mirrors the PFS/PSSD clinician-dismissal literature (PSSD-008). Useful comparator: androgen-signaling loss with known cause and no expectation of nocebo.", "_source_file": "pssd_discord_videos", "collection_tag": "pssd-discord" }, { "item_id": "PRH-0117", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wkblxb/the_problems_with_the_theory_of_impaired_androgen/pb0p54t/", "date_raw": "2026-09-20T19:15:54Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"The Problems with the Theory of Impaired Androgen Signaling caused by Metabolite Accumulation: A Peaceful Challenge to Dr. Powers’ Thesis\" by [username removed]:\n\n> Yesterday, while commenting on [username removed] post (a very good post, btw), I ended up starting a discussion about the thesis proposed there and some of the problems I have with both it and Dr. Powers' original thesis more broadly. I spent some time thinking about whether I should make a post about this, mainly because I am aware of the multitude of things the doctor has had to deal with lately. However, since he himself seems to encourage people to challenge his theories (and I personally think that this only contributes to refining them), I decided to write this.\n>\n> I anticipate that this will probably be a long post, and that my goal here is not to attack him or anyone else here. I simply want to peacefully reflect on some aspects of his ideas that seem flawed (or not very plausible) to me.\n>\n> 1. The UGT2B17 deletion problem\n>\n> I think the vast majority of people here are already quite familiar with the theory developed by Dr. Powers in this subreddit over the past few months. Therefore, I will not bother describing it again in all its details, and will only revisit some of its main points so that I can discuss them throughout this post.\n>\n> In short, we know that Dr. Powers' propositions are based on the idea that PFS patients tend to have, at baseline, glucuronidation problems that make them susceptible to “metabolic catastrophes” when exposed to finasteride. The best example of this, although it does not seem to be limited to it and apparently depends on a number of other […]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0127", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wkblxb/the_problems_with_the_theory_of_impaired_androgen/pasp33r/", "date_raw": "2026-09-19T16:47:22Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"The Problems with the Theory of Impaired Androgen Signaling caused by Metabolite Accumulation: A Peaceful Challenge to Dr. Powers’ Thesis\" by [username removed]:\n\n> Yesterday, while commenting on [username removed] post (a very good post, btw), I ended up starting a discussion about the thesis proposed there and some of the problems I have with both it and Dr. Powers' original thesis more broadly. I spent some time thinking about whether I should make a post about this, mainly because I am aware of the multitude of things the doctor has had to deal with lately. However, since he himself seems to encourage people to challenge his theories (and I personally think that this only contributes to refining them), I decided to write this.\n>\n> I anticipate that this will probably be a long post, and that my goal here is not to attack him or anyone else here. I simply want to peacefully reflect on some aspects of his ideas that seem flawed (or not very plausible) to me.\n>\n> 1. The UGT2B17 deletion problem\n>\n> I think the vast majority of people here are already quite familiar with the theory developed by Dr. Powers in this subreddit over the past few months. Therefore, I will not bother describing it again in all its details, and will only revisit some of its main points so that I can discuss them throughout this post.\n>\n> In short, we know that Dr. Powers' propositions are based on the idea that PFS patients tend to have, at baseline, glucuronidation problems that make them susceptible to “metabolic catastrophes” when exposed to finasteride. The best example of this, although it does not seem to be limited to it and apparently depends on a number of other […]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0124", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wkblxb/the_problems_with_the_theory_of_impaired_androgen/patbew9/", "date_raw": "2026-09-19T18:28:23Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> There can certainly be debate about the group selected for the study and whether it captures all PFS phenotypes. I don’t disagree with that.\n>\n> However, my point was more specific: there is a widespread idea, both here and on other forums, that people with PFS have sexual problems because they lack adequate androgenic signaling. That idea is also part of the argument made in your post.\n>\n> The Basaria study, however, challenges that interpretation. The fact that the PFS group had significant sexual symptoms while showing no evidence of impaired androgenic signaling makes it difficult to attribute those symptoms to reduced peripheral androgenicity, even if such abnormalities may exist in some individuals.\n>\n> I have some other observations as well, but I’ll wait until you’ve had a chance to comment more thoroughly on the points I raised in the post. In any case, I appreciate your initial comments.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0126", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wkblxb/the_problems_with_the_theory_of_impaired_androgen/pasp6eq/", "date_raw": "2026-09-19T16:47:47Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to u/Drwillpowers:\n\n> I\"ll try and comment on this more in detail later, but I'll say this much. \n>\n> Many of the men that I have with PFS actually have had regeneration of their hair while on it. \n>\n> I now have multiple that have osteopenia or osteoporosis. Indicating that they have had a failure of their normal androgenic signaling or estrogenic signaling. \n>\n> Ugt2b17 was just one of the first things that I noticed was statistically anomalously common. But, what I've noticed collectively is that there's just disruption in a multitude of different pathways. The amount of different ways that I have seen it be disrupted is crazy. Everything ranging from abcc Gene class stop codons to the inability to make the glucuronide molecule from a deficiency in that specific gene. \n>\n> Effectively, it is a combination of a multitude of different inborn deficiencies that results in the susceptibility and you're not going to find a statistically significant difference or it would have been found on the gwas studies. \n>\n> Imagine that you have a thousand people that all have a medical condition. In that group, there are a hundred different ways via 100 different genes to cause the exact same phenotype. A good example of something like this is eye color. There's a lot of different ways to make certain colored eyes. \n>\n> If you then take 10,000 people, and you look at that group and you trying to determine what the cause is of blue or pink or whatever colored eyes, you're going to struggle, because you're not going to find a statistically significant difference among all of them that stands out unless you happen to land on the most common specific gene. This is what is happening to the hEDS studies. \n>\n> They continue to do these gwas studies on heds, and they don't find shit. Or they find some really really obscure new version of EDS that only was picked up because they had a ridiculously large sample size but it still doesn't explain the overwhelming majority of that phenotype. (I have a consistent theory on hEDS and […]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0490", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1ux9f7a/massive_mental_benefits_from_fin_and_prog/oxpnj04/", "date_raw": "2026-07-15T16:45:23Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"Massive mental benefits from fin and prog\" by [username removed]:\n\n> [removed]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0134", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1whds5k/why_does_calcium_d_glucarate_cause_anxiety/pa7001a/", "date_raw": "2026-09-16T16:41:07Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> I don’t think all PSSD symptoms can be attributed to this accumulation. If that were the case, why would some of us experience anxiety in the first place? It seems that only severe PSSD cases experience excessive calming and a reduced responsiveness to stimuli. I think the 5-HT2A and 5-HT1A receptors may play a role in this.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0647", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1skv97m/repost_dutch_test_results/ot9nudx/", "date_raw": "2026-06-23T04:58:34Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Yeah sorry about that didn’t mean to throw you off. Just jumpy about supplements. Afraid to crash. Def a boon for the ugt2b17 deleted pssd case\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0451", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1v04hi4/how_does_progesterone_therapy_work_within_the_new/oydat5q/", "date_raw": "2026-07-18T22:04:12Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"How does progesterone therapy work within the new PFS model of the disease?\" by [username removed]:\n\n> Many people report improvements -though not complete remission- from high-dose oral or rectal progesterone combined with pregnenolone and DHEA.\n>\n> If the current model involves a buildup of metabolites inside cells, why would increasing progesterone help?\n>\n> I wonder if this is similar to why a subset of people improve with TRT or DHT interventions, even though, according to the model, they should theoretically get worse.\n>\n> Also, if progesterone somehow increases the clearance of these metabolites, why doesn't it lead to full remission? Why does it seem to produce only a partial recovery?\n>\n> Just trying to make sense of all this. ;)\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1191", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sogz8p/anhedonic_substance_blockage_with_pfspssdpas/ohcag18/", "date_raw": "2026-04-20T22:15:56Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"Anhedonic Substance Blockage with PFS/PSSD/PAS\" by [username removed]:\n\n> [removed]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0880", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1tez1i7/broken_gradient_concentration_theory_camp_for_pssd/omcplci/", "date_raw": "2026-05-17T18:55:08Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"broken gradient concentration theory cAMP ( for PSSD )\" by [username removed]:\n\n> firstly, let me say thank you DrPowers for all the work you are doing for PFS and PSSD community. As a PSSD sufferer i appreciate it. This thing has ruined my life, but i am fighting. \n>\n> I've spent recent few days studying your posts on PFS and PSSD mechanisms you are proposing or thinking of.\n>\n> my background is mathematics, not biology/medicine so maybe im connecting the dots, maybe not but please hear me out everyone.\n>\n> here is a wild guess : \n>\n> SSRI use - > cellurar transporter ABCC5 is blocked -> gradient is damaged ( but we dont know how, maybe cAMP lvl is flatlined, maybe cell is oversaturated with metabolic waste ) -> no signal -> system stuck in bad equilibirum -> numbness, anhedonia, genital anasthesia \n>\n> so i read that you have some initial success with roflumilast ( pde4 inhibitor ) but you are unsure if thats a window or permanent improvement \n>\n> so what do you think about this strategy ?\n>\n> perhaps this signalling mechanism is stuck in a scenario optimized for high stimulus, which is no longer there, after stopping SSRI use, or just from adaptation\n>\n> instead of shocking a system with surge ( like giving PDE4 ) , lets starve it with use of sertonin and dopamine receptor antagonists , we block signals, we trick cells to thinking there is sensory deprivation, mechanism has to upregulate\n>\n> how to do it ? 5ht1a receptor antagonist. i think it worked with rats, but assumed mechanism of action was different. https://pubmed.ncbi.nlm.nih.gov/19435548/\n>\n> kind regards and all the best […]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1269", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1shdmvr/why_do_people_feel_better_on_anti_androgens_in_pfs/ofm7m2z/", "date_raw": "2026-04-11T18:45:09Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> En mi caso con 41 años y SPF, homocisteína alta, hierro bajo, tibc bajo, vpm bajo. También he sufrido de acné desde siempre, lo cual como indica parece estar ligado con algunas personas que desarrollamos SPF. Muchas gracias por todo su trabajo doctor, ojalá consigamos una cura.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1398", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1s8132u/had_another_random_pssdpfs_thought_about_the/odpk7sz/", "date_raw": "2026-04-01T15:22:34Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Interesting post. I came here from the PSSD subreddit. \n>\n> Wondering. What's your opinion on Ashwagandha causing a condition that is very similar to PSSD/PFS? There is a whole sub for that as well. r/AshwagandhaSyndrome\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1330", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sdp93j/any_chance_someone_could_help_me_make_sense_of_a/oeq07l6/", "date_raw": "2026-04-07T01:29:40Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Your line about how it's a cruel trick of nature has me worried, I won't lie. Is it straight up possible that I just won't be able to actually transition with this unfortunate set of genes?\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0915", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1svrsrz/im_back_from_the_pfs_congress_i_know_everyone/olli3ad/", "date_raw": "2026-05-13T16:42:59Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Thank you very much Dr!\n> It's relieving to know that altough there's 1000's of genes over/under expressed & DNA methylation, all because of Fin, this disease would not be directly transferred to the child. It would be an extremely tough pill to swallow for me.\n>\n> You've explained that PFS patients already have androgen metabolism broken at baseline, before taking Finasteride. (Hope I got that right) \n> I assume you were somewhat referring to this with homo-& heterozygous reference.\n> I understand that these specific features can be inherited, as they've been a part of me for years before getting this disease.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0774", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1tw4lis/very_scared_pfs/oqkx7oi/", "date_raw": "2026-06-09T04:23:34Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> I'm sure testosterone made your sexuality so fricken manly dood!! \n>\n> Sexual orientation doesn't change sweetheart, its not possible. People just get more comfortable with themselves after transition. No one becomes gay afterward, those people were always gay and just repressing it because it conflicted with their views of themselves.\n>\n> Perpetuating this rhetoric is harmful because people tried to change the sexualities of gay people for centuries.\n>\n> Its also misogynistic because its almost always something like \"estrogen turned me into a straight submissive bottom!\" Like, that's not what estrogen does, or lesbians wouldn't exist.\n>\n> But judging from your post history girlie, I'm guessing you don't care about misogyny because you think being an incel makes you such a heccin valid boi!!\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0736", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1u3f83t/im_starting_to_see_trends_in_pssd_genomes_this_is/or9ppeh/", "date_raw": "2026-06-12T17:40:28Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Good day, Doctor. I hope you can read my comment. I'm almost certain that our PSSD is due to something very similar or the same as PFS. I'm taking testosterone (it was below the normal range), my testosterone level has doubled, and the free testosterone is now five times higher, but my libido and desire aren't increasing. A healthy friend is taking testosterone for gym training and is erect all day long with a sky-high libido. Our bodies have testosterone, but our systems don't process it. SSRIs, while we're taking them, make ejaculation difficult due to the increase in serotonin, and they also damage our androgen receptors. When I stopped taking the SSRIs, I was able to ejaculate again, but the rest didn't return (libido, visual arousal, etc.). PS: Now that I'm taking testosterone, when I have a window, it's stronger than before I started. I think it's because with more testosterone in my system, when the door opens, more testosterone enters, and my libido skyrockets. I don't know why the genital numbness occurs. My nerves are fine. Right after ejaculating, my penis experiences the hypersensitivity that occurs after orgasm. But during intercourse, it's numb.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1344", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sbm8xq/i_collect_more_and_more_labsgenomedutch_tests/oeh09ou/", "date_raw": "2026-04-05T17:54:43Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> A lot of the science kind of went over my head here but I have a general understanding of what you're saying. I'm curious if there's any way I can test myself and send you the results for your data? I'm a one-pill case with every. single. symptom. so probably about as purely PFS as you can get. What test would one do to get this info?\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1380", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sbm8xq/i_collect_more_and_more_labsgenomedutch_tests/oe4ylg9/", "date_raw": "2026-04-03T20:27:42Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> [removed] — view removed comment\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0235", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1vc13m7/castration_trial_on_post_anastrazole_syndrome/p2f0c4r/", "date_raw": "2 months ago", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"Castration trial on Post anastrazole syndrome\" by [username removed]:\n\n> Disclaimer: this is not medical advice, I got my doctor to try the castration method with me. 6 weeks of relugolix with 2weeks of hydrocortisone (same time starting after 2weeks of relugolix).\n> I used AI to write the summary about me below but I entered all the data myself.\n> I will update you guys every two weeks.\n> Now I got only sexual symptoms like PFS but first 6 month was so many symptoms I don’t have the patience to write them out.\n> —————- Summary starts:\n> Patient: 26-year-old male\n> Crash: 5 years ago — anastrozole + exogenous testosterone (anabolic steroids), alongside ketoconazole shampoo and minoxidil. Not finasteride-triggered. Supraphysiological T converted to DHT via fully intact 5-alpha reductase; anastrozole blocked the aromatase escape valve; genetically impaired clearance system overwhelmed by the substrate load. Result: zero libido for 5 years, diffuse frontal hairline thinning (crown/mid-scalp/sides preserved, non-Norwood pattern, follicles present but miniaturized), watery/reduced semen quality, standard hormone panels reported as normal.\n> Genetics (consumer SNP array):\n> SLCO1B1 — homozygous *5 (rs4149056 TT) — most severe finding, clinically validated\n> UGT2B17 — likely heterozygous deletion (rs4440295 no-call)\n> UGT2B15 — multiple indels\n> UGT2B7 — deletion indels\n> ABCC2 — rs717620 CC, reduced expression (Powers flags this as a top-tier PFS gene independently)\n> SLCO1B3 — heterozygous, partial backup capacity\n> COMT — homozygous Met/Met (rs4680 AA) — slow, clinically […]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1393", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1s8132u/had_another_random_pssdpfs_thought_about_the/oe0pep7/", "date_raw": "2026-04-03T05:14:02Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Following up from an earlier comment – would these imbalances/anomalies be present in someone before they developed PFS? I assume yes, as they originate from inborn errors of metabolism.\n>\n> If so, getting comprehensive hormone testing would probably be a good way to \"guess\" if there is something wrong with one's endocrine system and thus whether they should take the risk with finasteride.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0051", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wqfz31/theory_as_to_why_some_people_so_sensitive_to/pce5jz4/", "thread_title": "Theory as to why some people so sensitive to Calcium-D-Glucarate", "thread_author": "[username removed]", "date_raw": "2026-09-27T16:23:12Z", "score": 32, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> does this mean clearing out the androgen clog with relugolix is not necessary? or you have to do that first before ungabaing yourself?\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0039", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wvi4g0/castration_trial_outcome_poll/pdg55rd/", "thread_title": "Castration trial outcome poll", "thread_author": "(deleted)", "date_raw": "2026-10-02T17:09:19Z", "score": 18, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"Castration trial outcome poll\" by [username removed]:\n\n> [deleted]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0159", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1ulvt5c/my_suppression_trial_results_and_experience/p9e8nab/", "thread_title": "Why \"X treatment crashed me bro\" is counterintuitive to the reality of these conditions, and that which makes you feel a little bad may be in reality, what you need to recover. I think I have figured out the true nature of the low libido/anhedonia/substance resistance in PFS/PSSD and how to fix it.", "thread_author": "Drwillpowers", "date_raw": "2026-09-12T18:10:57Z", "score": 32, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Hi dr., are you basing your conclusion that it fixes androgen signaling on the results from that single first patient (mile high guy), or are you seeing this in other patients undergoing castration under your supervision as well?\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0052", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wqfz31/theory_as_to_why_some_people_so_sensitive_to/pce3pap/", "thread_title": "Theory as to why some people so sensitive to Calcium-D-Glucarate", "thread_author": "[username removed]", "date_raw": "2026-09-27T16:15:22Z", "score": 16, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> What if we appear to be one of those who do not respond to CDG at all? I tried up to 5 grams for a couple of days without any effect. I've been doing things to improve gut health and I am retrying it, but could it be that CDG is not effective enough for some of us?\n>\n> Also, I posted this somewhere else, but what do you make of the recoveries from cycling androsterone products? there was a high who posted a lot in the past \"cdnuts\" who recovered by cycling androsterone and some people were able to replicate it.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0560", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1ulvt5c/my_suppression_trial_results_and_experience/owssppm/", "thread_title": "CDG Theory", "thread_author": "[username removed]", "date_raw": "2 months ago (circa 2026-08-07; export dated 2026-10-07)", "score": 7, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"My Suppression Trial results and experience\" by [username removed]:\n\n> DO NOT DM ME I WILL INGORE YOU. I WILL ONLY LOOK AT COMMENTS \n>\n> So I was the patient that did the \"castration\" trial. I would say suppression because it was temporary and the word castration scares people. I used Orgovyx and Leuprolide which are used to treat prostate cancer. The testosterone comes back folks!\n>\n> TL;DR the trial wasn't that bad and now my testosterone is higher, I have stronger nocturnal erections and morning wood. I sleep much better. I still have blunted emotions/ anhedonia and sexual numbness/ low libido.\n>\n> We did this trial because I had an elevated 3adg/ 3a-Androstanediol Glucuronide reading on my blood test. It was over 5000, above the highest range. For those who don't know, Dr Powers gives you hcg to see how you respond. It didn't help me right away but that's when we noticed this reading. \n>\n> I also had an array of androgen metabolism mutations in my genome including but definitely not limited to a UGT2B17 deletion which showed 0 testosterone in my DUTCH test which means I can't glucoronidate testosterone. I REPEAT, THIS ALONE DOES NOT MAKE YOU VULNERABLE TO PFS. I had many more mutations, like ABCC, some others which are listed in an old email from the doctor now that I can't find.\n>\n> Edit: this comment lists my relevant genome findings: https://www.reddit.com/r/DrWillPowers/s/sViR9IjK3g\n>\n> 3adg is a proxy for intracellular androgen buildup caused by finasteride which is the cornerstone of Dr Powers Theory on how PFS happens. I'm not going to repeat it to […]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0007", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wy05fo/is_progesterone_therapy_still_used_for_some_pfs/pe2h2t1/", "thread_title": "Is progesterone therapy still used for some PFS patients?", "thread_author": "[username removed]", "date_raw": "2026-10-05T18:43:55Z", "score": 14, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"Is progesterone therapy still used for some PFS patients?\" by [username removed]:\n\n> (Im post AI) I personally never crash and just have sexual side effects, my only bad reactions to any intervention is slightly lower libido that is already super low let’s say from 5% to 1%. HCG (all my libido,random erections, pleasure all symptoms resolved within 3h post injection but stoped working after 4months)worked perfect and 2years later my erections are still improved from it. steroids or supplements don’t do shit so my guess is that I’m neurosteroid deficient since no other stuff even changes how I feel. (except cdg which I used for 80days at 3g a day but it only gave me a bit better libido for 2 weeks). My question is, is progesterone therapy worth trying with Sommer or is it out of the window with the new model?\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1077", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1t034l8/anyone_want_to_analyse_my_test_results/ojcidja/", "thread_title": "Cure for PFS", "thread_author": "[username removed]", "date_raw": "2026-05-01T16:37:12Z", "score": 5, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> So if i have issues metabolizing antidepressants, and its difficult for me to eliminate them, you think there would be a huge build up. Which would then cause massive down regulation? So a couple thoughts, now that i am off zoloft for 10 months, would be: I'm just down regulated like crazy and am low on dopamine and seratonin. Or since i can't eliminate the drug, its still piled up like crazy? And perhaps the level of disfunction in the gene determines the amount of time it takes to eliminate it? Like how one guy heals from pssd in 2yrs and one in 20yrs. Maybe 20yr guy is heavily dysfunctional in the gene. \n>\n> Just brain storming here. I dont really know shit about how this works. But how could we test those theories to get an answer?\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1081", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1t0rpzb/cure_for_pfs/ojbmf2y/", "thread_title": "Cure for PFS", "thread_author": "[username removed]", "date_raw": "2026-05-01T14:09:08Z", "score": 51, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"Cure for PFS\" by [username removed]:\n\n> I want you to be honest with me. I recently developed this, and it's a real mess. I can't imagine living with this. It's a little-known disease that's often overlooked. I've seen that Dr. Will Powers is one of the few people who knows the most about this and is one of the most dedicated. Do you think there will be a cure for this? If so, how many years do you think it will take? Above all, I want honesty, no false hopes.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1363", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1s7freh/any_advice_feeling_desperate_for_sleep/oe9vndv/", "thread_title": "I collect more and more labs/genome/dutch tests that support my theory on PFS. I really think I have it nailed down. I d...", "thread_author": "Drwillpowers", "date_raw": "2026-04-04T15:55:18Z", "score": 4, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Thank you so much. There is already an enormous improvement. I did wake at the usual time (2:30-3, which may be habit rather than physiology, but then slept from 3 to 7:30. Incredible. This is life changing. I appreciate you so very much!\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0330", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1v66poo/can_you_stop_hairloss_effectively_without_risking/p0lswb7/", "thread_title": "Can you stop Hairloss effectively without risking PFS?", "thread_author": "[username removed]", "date_raw": "2026-07-30T04:02:01Z", "score": 17, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Fair, and I take the point that you're filtering on rare high REVEL variants, not the common ones. That answers part of what I wrote.\n>\n> What I still can't get past is the denominator. You said somewhere else the population frequency of that ABCC2 stop codon is known. So the other number is the one that decides whether the test is worth running: how often does it show up in your patients who took a 5ARI and were fine? You've got genomes on half your DPC panel and plenty of them are on dut.\n>\n> If it's 40% in crash cases and 1% in everyone else, that's a real screen and I'd pay for sequencing tomorrow. If it's 40% and 15%, it isn't. Do you have any sense of that second number?\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0853", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1tizv4b/3a_results/oncxb7m/", "thread_title": "Help me understand what Dr Powers' model for PFS says about risk profile of quitting finasteride.", "thread_author": "[username removed]", "date_raw": "2026-05-23T02:14:50Z", "score": 6, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> Knock on wood it’s the same. It’d be a much quicker cure for pssd\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-1255", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/PSSD (export metadata; permalink resolves to r/DrWillPowers thread — likely crossposted)", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sks05w/deleted_by_user/og1d629/", "thread_title": "My doctor, William Powers, is looking for data from PSSD patients", "thread_author": "[username removed]", "date_raw": "2026-04-13T23:48:22Z", "score": 16, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"[deleted by user]\" by [username removed]:\n\n> [removed]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0231", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1vi4e56/if_you_have_pfs_pssd_your_genetics_do_you_have/p2h1vsi/", "thread_title": "Dr. Powers' opinion on FMT?", "thread_author": "[username removed]", "date_raw": "2026-08-08T15:11:58Z", "score": 8, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to a community member:\n\n> I’m a woman with PSSD. I don’t believe I have NCAH, but I just got my WGS back and one of the initial reports says I’m a carrier for a gene related to 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia.\n>\n> Variant Identifier: rs6471 , RCV000012934\n>\n> Your Data: GT\n>\n> Risk Status: Likely Carrier\n>\n> Gene: CYP21A2\n>\n> The variant rs6471 in CYP21A2 is often associated with non-classic forms of CAH, which tend to have milder symptoms that may present later in life.\n>\n> Ran it through GENE.IOBIO:\n>\n> Gene: CYP21A2\n>\n> Variant: c.844G>T\n>\n> Protein: p.Val282Leu\n>\n> rsID: rs6471\n>\n> Zygosity: Het\n>\n> Ref Allele: G\n>\n> Alt Allele: T\n>\n> Freq: 1.09% (gnomAD genomes v4, 0.0109 allele frequency)\n>\n> REVEL: 0.311\n>\n> I have some salt craving and low blood pressure, but not really any of the other developmental symptoms of NCAH. It says #1 Phenolyzer in Gene.iobio for Congenital Adrenal Hyperplasia and that it’s listed as pathogenic/likely pathogenic. But REVEL score isn’t very high. Not sure if this is helpful.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0252", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1vg8u4y/question_to_dr_powers_what_is_the_significance_of/p1w4bo3/", "thread_title": "Question to Dr Powers: What is the significance of 17-hydroxyprogesterone to progesterone ratio for PFS patients?", "thread_author": "[username removed]", "date_raw": "2026-08-05T17:07:58Z", "score": 10, "verification_status": "parent context recovered via r.genit.al mirror 2026-10-07; comment text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Powers' comment replies to the original post \"Question to Dr Powers: What is the significance of 17-hydroxyprogesterone to progesterone ratio for PFS patients?\" by [username removed]:\n\n> 25M mild to moderate PFS for 6 years now. This is my bloodwork from a few months ago. Planning to repeat this with the DUTCH test next week. Genome results to come in 2 months. Symptoms (all started during PFS): ED, reduced genital sensitivity, slight genital shrinkage, dry mouth and joints, poor sleep, fatigue, overall poor gut health, migraines\n>\n> Test Name\n> Results\n> Units\n> Bio. Ref. Interval\n>\n> STEROID PANEL 3,13 STEROIDS (LC-MS/MS)\n>\n> Aldosterone\n> 14.00\n> ng/L\n> <25 – 229 (Seated) / 29 – 145 (Supine)\n>\n> Androstenedione\n> 1460.00\n> ng/L\n> 500 – 2500 (Adult Male)\n>\n> Cortisol\n> 202.00\n> μg/L\n> 50 – 250 (8 AM) / 30 – 160 (4 PM)\n>\n> Cortisone\n> 18.00\n> μg/L\n> 6.00 – 27.00\n>\n> Corticosterone\n> 9.03\n> μg/L\n> 1.00 – 20.00\n>\n> 11-Deoxycortisol\n> 0.85\n> μg/L\n> 0.50 – 3.00\n>\n> 21-Deoxycortisol\n> <0.027\n> μg/L\n> 0.02 – 0.15\n>\n> DHEA\n> 6.30\n> μg/L\n> 1.8 – 12.5 (Adult Male)\n>\n> DHEAS\n> 1770.00\n> μg/L\n> 99.00 – 6154.00\n>\n> 11-Deoxycorticosterone\n> 0.13\n> μg/L\n> 0.02 – 0.15\n>\n> 17-α-Hydroxyprogesterone\n> 2.02\n> μg/L\n> 0.20 – 2.20\n>\n> Progesterone\n> 0.24\n> μg/L\n> 0.19 – 1.40\n>\n> Testosterone, Total Ultrasensitive\n> 10.50\n> μg/L\n> 2.50 – 10.00\n>\n> I read in Dr Powers' personal observations document that high 17-ohp may reflect slower downstream disposal or reduced metabolite appearance. What does this mean for PFS?\n>\n> I have always had high T after quitting finasteride and a normal e2 and DHT but the ratio of them to test is very low. Also I read that DHEA-DHEAS ratio needs to be 1:1000 although I have no idea how important this is for PFS. I have always had high bilirubin and prolactin which Dr Powers […]\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-07; Powers' comment text itself is from John's user-provided export.)" }, { "item_id": "PRH-0787", "source_type": "reddit-post", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1tyv1hw/pfs_metabolite_theory_and_initial_chemical/", "title": "PFS metabolite theory, and initial chemical castration cure trial patient update. Also research update.", "date_raw": "2026-06-06T22:40:19Z", "score": "(not in export)", "verification_status": "post body verified via r.genit.al mirror 2026-10-07; post text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Original post by Powers — self-text as served by the r.genit.al mirror on 2026-10-07 (consistent with the text captured in John's export):\n\nI keep being asked this all over reddit so I'm making a brief update. \n\nOn the GNRH drugs, it took this patient approximately 2 weeks to reach a level of T and DHT that could be considered \"chemically castrated\". Effectively, what could be considered an adrenal level of production. \n\nPatient zero's weirdest baseline metabolite value was a 3A-ADG that was astronomical. So high it could not be measured. Just, something over 5000ng/dl could have been 5001, could have been 100,000ng/dl. no idea. Assay got maxed out. \n\nDespite T and DHT being wiped, that value hung out in the average male range for weeks after that point. \n\nIts now been almost 6 weeks since we started this journey, and his 3A-ADG has finally dropped below 100ng/dl, which means as far as I know, he's clean of androgenic metabolite build up. \n\nDuring this time, we also did a brief course of daily hydrocortisone replacement at slightly supraphysiological dosing in order to wipe out a potential middle glucocorticoid metabolite build up. In most \"melty\" patients, this is 11DOC, but it can vary in my experience. Disable ACTH and CRH, and the body stops making these precursors to cortisol, and they can wash out. This was done just to make sure there was no occult metabolite pile up there. \n\nAt this point, we're just waiting for his system to wash out the GNRH drug and reboot. I expect he will start to come online by the end of June and produce his own natural hormones again. I imagine it will take him a few weeks from that point to decide if he feels normal and cured or partially so or not at all, and based on that, there are plans of what to do next. But I do hope this is all that's required for most patients of the \"androgenic signal loss\" Post Finasteride Syndrome phenotype due to metabolite buildup. \n\nnon-seq, I did meet with people from corewell about them funding and starting a research study, and we have more meetings to do about this as well, but it does seem like the plan is to put my theory of exactly how PFS works and what genetic mutations cause someone to be vulnerable to it to the test with formal and funded academic research. \n\nThis is a glacially slow process sort of thing, as academia always is, so I will continue to do my own thing with my own patients while that process is underway, but I figured I should mention that it will be happening. \n\nThat's all for now, please stop asking on unrelated threads every time I comment on literally anything. PFS cure project test #1, \"have you tried unplugging it and plugging it back in again?\" is still underway. This is all the information I have until he reboots naturally, and even then, I expect a few weeks of time from that point for him to really know if he feels right or not. If you ask in a comment thread, I will be linking this post until I have more information to offer. \n\n-Dr. P" }, { "item_id": "PRH-0745", "source_type": "reddit-post", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1u3f83t/im_starting_to_see_trends_in_pssd_genomes_this_is/", "title": "I'm starting to see trends in PSSD genomes, this is one. DBH", "date_raw": "2026-06-11T23:41:29Z", "score": "(not in export)", "verification_status": "post body recovered via r.genit.al mirror 2026-10-07 (was empty in John's user-provided export)", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Original post by Powers — full self-text recovered from the r.genit.al mirror on 2026-10-07 (the export captured the title only):\n\nBasically I've got a lot of PSSD dutch tests now. The one factor that seems to be common among them is a low dopamine metabolite, Homovanillate. \n\n\n\nThis is a breakdown product of dopamine. The general consensus of course among everyone is that this means that the dopamine levels are too low. Low HVA must mean low dopamine right? \n\n\n\nI've been suspicious of this narrative for a while as PSSD behaves a lot like PFS, and it is my suspicion in one of my many theories that could potentially explain the mechanistic behavior of PSSD that there is a buildup of an intracellular transmitter, or the erasure of a concentration gradient. \n\n\n\nFor signaling to occur, there has to be a difference. If there is no difference, there is no signal. Biological systems are tuned to operate within a particular parameter of concentrations of things, and if that were deranged too much, I could imagine erasure of signaling occurring. This is what happens with PFS with intracellular metabolite accumulation. \n\n\n\nI suspect that the reason that this value is often low is not because dopamine levels are low but rather dopamine metabolism is poor. Dopamine levels might actually be astronomical.\n\n\n\nSlow COMT seems to be relatively common among PSSD patients, but there's a mutation now that I've seen show up in genomes too much. \n\n\n\nBasically, I keep finding rare, high revel score glitches in Dopamine Beta Hydroxylase. \n\n\n\nhttps://en.wikipedia.org/wiki/Dopamine_beta-hydroxylase\n\n\n\nI do not think that this is the magic gene for PSSD, but it has now shown up a statistically anomalous amount to the point where I'm suspicious that it is at least one of the possible glitches that form the family of things that make someone susceptible to PSSD. \n\n\n\nFor PFS I've isolated these two things like glucuronidation or transport or so on. ABCCs, UGTs, SLCOs etc. \n\n\n\nI'm still working on that for PSSD, but if you have a genome and you are a PSSD patient, take a look at this specific gene. I'm curious to see if this is a statistical glitch or a real signal. \n\n\n\nI plan on probing this in my own patients by utilizing high dose apomorphine as it is a dopamine receptor agonist without actually being dopamine. Adding more dopamine to the situation likely would make things worse if this theory is the correct one. Apomorphine may \"window\" someone with this problem. It in no way would be a cure, but simply a probe to give information. But if it does temporarily restore some functionality that would be intriguing. If it does absolutely nothing, that would be useful information as well. \n\n\n\nAgain I have many mechanistic theories that make sense on paper, but only one of them (maybe) is correct at this time. This was the same for PFS, and it took me quite a while to narrow down which was the mechanistically sound and genetically coherent one. But I do plan on attacking this problem systematically the same way.\n\n\n\nThank you if you are willing to offer this personal information here anonymously.\n\n\n\n-Dr. Powers" }, { "item_id": "PRH-1493", "source_type": "reddit-post", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1rwnt0l/you_know_pssd_and_pfs_may_actually_be_the_same/", "title": "You know, PSSD and PFS may actually be the same thing. Anyone got any data for me?", "date_raw": "2026-03-17T23:49:38Z", "score": "(not in export)", "verification_status": "post body recovered via r.genit.al mirror 2026-10-07 (was empty in John's user-provided export)", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Original post by Powers — full self-text recovered from the r.genit.al mirror on 2026-10-07 (the export captured the title only):\n\nI was thinking about PSSD the other night when talking to some sufferers about it. They asked me if there was any point in ordering the labs i'm currently looking into for PFS that seem to be abnormal a stupidly high amount of times in my PFS people. Those are:\n\nA normal testosterone blood value\n\nAND\n\nA stupidly high, or stupidly low 3A-ADG or 11-Oxo-Androgen panel, or any other oddball androgen metabolism product (something on the chain on the way from T-synthesis to its excretion that is wildly out of place, indicating an inborn error of metabolism\n\nOR\n\nA stupidly high, or stupidly low urinary testosterone value. \n\nAND FOR A TREAT AND BONUS POINTS:\n\nmajor disruptive genetic mutations or stop codons or flat out deletions of any of the following (this is not an exhaustive list but seems to be the most common ones)\n\nABCC2, ABCC3, ABCC4, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1, UGT2B17, UGT2B15, UGT2B7, UGDH, AKR1D1, H6PD, HSD11B1/2, STS\n\nBut this person wanted to know, would these be relevant for someone with PSSD. Initially, my gut response was like \"nah\" but then I actually put some thought into it, and I realized, PSSD may actually just be functioning exactly the same as PFS, just some slightly different inborn errors of metabolism + fuckery caused by various SSRIs. \n\nThis is my exact response to that person: \n\n\" But....\n\n if you want me to go full tinfoil hat on this and will let me just randomly prognosticate? Fuck I love doing that shit, so here you go: \n\nSSRIs are known to inhibit some of the critical big 4 for androgen metabolism. Those are UGT2B15 and UGT2B17, UGT2B7, and UGT1A4. \n\nFluoxetine inhibits UGT2B7 and UGT1A4, Sertraline inhibits UGT2B7, and Paroxetine inhibits UGT1A4. \n\nThen, gluc'd steroids have to be exported from cells using MRP transporters, the relevant ones for my theory are ABCC2, 3 and 4. \n\nSetraline inhibits ABCC2 (MRP2) and Fluoxetine does that to MRP 2 and 4. \n\nTHEN \n\nThere is another exit path, which is sulfation. \n\nSSRIs can mess up sulfation, specifically SULT2A1, which could compound an inborn error as well. \n\nAnd then fluox messes with CYP2d6, and CYP3A4, and parox 2d6, and sertraline 2c19 and I think maybe 3a4 as well but dont hold me to that one. \n\nThose are the backup pathways, hydroxylation, and so if you're already fucked in another way, yeah that could worsen it.\n\nSo it is plausible that someone with an inborn error like the ones that finasteride fucks people up with (UGT2B17 in particular), could suffer from taking a SSRI by knocking out some of the other pathways that are not defective in that patient, creating a similar outcome. \n\nhowever this is \"on paper\" and I have ZERO evidence to support that theory. But I only have zero because I don't treat much PSSD, and so data is limited.   \n\nIn short, yeah, its possible, it works theoretically, but unlike the PFS guys, I have no data for this, and so you'd be the first if you did, which I would welcome. \n\n- Will \n\nAny explanation for PFS or PSSD has to explain why there are \"windows\" to the disease, and why some treatments initially cause improvement followed by yet another \"Crash\". I suspect the simplest answer here is that a \"window\" is when someone's metabolite 100 car pileup finally gets cleared out, and the androgen/estrogen/etc receptors can finally hear something again instead of just weak metabolites piled to the ceiling in terms of receptor noise. However, administering a powerful androgen can in theory briefly upregulate some of those clearance enzymes, but ultimately, that same molecule (like DHB or others people use) will get glucuronidated or otherwise \"metabolite'd\" and then stack in the corner like any other thing. \n\nIt also has to explain why males are disproportionately affected beyond just \"exposed to fin more\". The more severe cases I've seen are people who are male, and also have a non-stoppable testosterone source. Doing weekly injections or worse, testosterone pellets (which give no shits what your LH/FSH are, they just keep releasing T into a massively overcrowded system). \n\nMostly all of the female PFS cases I have seen aren't true PFS, they are masculinization after exposure to finasteride, or some sort of skin damage situation with stretch marks/striae and I suspect in most of those, the problem revolves around excretion of glucocorticoids and effectively the same thing as the guys with PFS, but instead of testosterone metabolites, they build up astronomical amounts of glucocorticoids in the skin cells, while maintaining normal serum levels. Another \"the molecule checks in but doesn't check out\" situation. \n\nSome treatments at first are beneficial, and later harmful (what people report). \n\nThis is i suspect why HCG can improve someone, but simultaneously crash them. This is also why sometimes restoring the trigger of the crash can un-crash someone. It alters the enzyme dynamics and metabolite flow temporarily. This paradoxical behavior makes sense in the context of the buildup of ungodly amounts of intermediary molecules that are shifted around with enzyme modification/induction/inhibition, all caused by various other molecules these people are putting into their bodies seeking a cure. \n\nThis is also why a cure for one person crashes another. They have different enzyme deletions/failures at baseline. \n\nI am absolutely certain that this situation that I am witnessing in clinical practice and in lab work and with matching genomic findings (like a UGT2B17 deletion) is absolutely ONE of the possible ways to get a PFS like syndrome. But I'm starting to wonder, is PSSD just the same pathophysiology, just reached via other molecules and enzyme knockouts? \n\nSo yeah, if anyone with PSSD has the above labs, and or glitches in the above genes. Comment below, because I'm starting to wonder if the thing that quacks like a duck is also a duck and not its own separate disorder, but the same pathophysiology of inborn error of metabolism + novel drug = failure to clear metabolites = crash. \n\nReally though, if you've got PSSD and say have no urinary androgen metabolites on dutch testing, really really let me know that. I dont have enough PSSD cases yet to have enough data to begin my usual autistic pattern recognition machine rituals. That would help. \n\n- Dr P" }, { "item_id": "PRH-1153", "source_type": "reddit-post", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sxj2wa/as_promised_this_post_contains_the_document_ive/", "title": "As promised, this post contains the document I've made that summarizes the lab findings I personally suspect a...", "date_raw": "2026-04-27T22:35:13Z", "score": "(not in export)", "verification_status": "post body recovered via r.genit.al mirror 2026-10-07 (was empty in John's user-provided export)", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Original post by Powers — full self-text recovered from the r.genit.al mirror on 2026-10-07 (the export captured the title only):\n\nA follow up to my earlier post: \n\nAs part of the First World Congress on PSSD, PFS, and PAS hosted by Corewell Health on April 24, 2026, I shared a set of personal, exploratory observations based on a small number of individuals who voluntarily shared de‑identified laboratory information with me.\n\nI’ve put together a written summary for anyone who wants to review the patterns we discussed at the First World Congress.\n\nThis document is strictly informational and educational. It reflects my own observations and interpretations and is not medical advice, not diagnostic, not predictive, and not intended to guide treatment or clinical decision‑making. Full disclaimers are included in the document.\n\nYou can read the summary and download the PDF file here:\n\nSummary of Personal Observations: Steroid-Related Laboratory Risk Patterns Prior to 5ARI Exposure\n\nI’m happy to discuss general concepts here, but I can’t answer personal medical questions, interpret labs, or give individualized guidance in this forum. Please keep that in mind.\n\nThanks to everyone who has been contributing thoughtful questions and ideas. I am looking forward to seeing where this goes.\n\n— Will\n\nPS: Adding the labcorp \"Androsterone\" value to this for PSSD as well (it seems to show up absurdly commonly as either slightly to severely elevated in both male and female PSSD patients)." }, { "item_id": "PRH-1405", "source_type": "reddit-post", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1s8132u/had_another_random_pssdpfs_thought_about_the/", "title": "Had another random PSSD/PFS thought about the glucuronidation theory. Do any of you with PFS have elevated sul...", "date_raw": "2026-03-30T19:44:12Z", "score": "(not in export)", "verification_status": "post body recovered via r.genit.al mirror 2026-10-07 (was empty in John's user-provided export)", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Original post by Powers — full self-text recovered from the r.genit.al mirror on 2026-10-07 (the export captured the title only):\n\nHaving looked at a bunch of these genomes, it is glaringly obvious to me that there are 1000 roads to rome when it comes to PFS. Yeah, the UGT2B17 defect is the most common and slam dunk one, but I'm finding varied mutations all over the body's glucuronidation pathways, and thus it seems different drug combos can produce different outcomes with different metabolite build up outcomes. \n\nSure, the textbook labs right now are a dutch test with some absurd result (high or low), a 3a-Androstanediol Glucuronide blood test (super high or low). \n\nBut I noticed the bilirubin glitch running labs the other day (looks like gilberts on testing, you can see a slightly off panel on a fractionated bilirubin test or just a plain elevated bilirubin (like 1.4 or something) on a CMP. Shows overall strain on the \"glucuronidation\" systemic process, but its slight. \n\nBut I haven't been considering the idea that if glucuronidation is down, perhaps sulfation will be utilized by the body as an alternative highway to crank up to compensate(like how people with these glucuronidation defects seek out finasteride because they had a high DHT at baseline BECAUSE of their inborn glitch in glucuronidation genes makes DHT high at baseline). \n\nAnybody out there have some weird lab result in say Estrone or Estradiol Sulfate? Or Dhea vs DHEA sulfate? I would imagine very high sulfation labs in someone with a glucuronidation defect bad enough to force the shunt down that pathway. \n\nI also can plausibly imagine really odd SHBG values, either quite high or quite low, again. \n\nBasically the theme here is \"this lab makes no sense in ratio to this other one\". \n\nFor example, the first ones I noticed:\n\nDude has totally normal T value in the dead middle of the band. His T is say 650ng/dl\n\nBut then, dude has a urinary T of 2. Like barely detectable. \n\nThat makes no sense, so it begs the question, why? Then we identify what gene is down that does that (UGT2B17) and then you have your answer. \n\nI'm trying to think of any other \"Screening\" labs that would be weird in PFS and possibly PSSD patients if my theory is truly correct, so let me know if you already have any oddball results in these. This is not a call to go get them done, I have no idea if they are relevant or not, its just a an early theory. \n\nE1S, E2S, DHEA : DHEAS \n\n- Dr P" }, { "item_id": "PRH-0336", "source_type": "reddit-post", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1va42ar/pssd_question_for_the_peanut_gallery_how_many_of/", "title": "PSSD question for the peanut gallery. How many of you were on hormone replacement at the time of developing it...", "date_raw": "2026-07-29T18:08:15Z", "score": "(not in export)", "verification_status": "post body recovered via r.genit.al mirror 2026-10-07 (was empty in John's user-provided export)", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Original post by Powers — full self-text recovered from the r.genit.al mirror on 2026-10-07 (the export captured the title only):\n\nLabs are coming back on the theory that I had a few weeks ago on PSSD patients i've seen. \n\nSome of my PSSD patients are reporting improvement from taking CDG (though some not or are worsened by it). In theory, at least for this phenotype of PSSD, it could help. \n\nIf you're not enlightened on this more recent theory of mine, here's some recent posts related to it:\n\nhttps://www.reddit.com/r/DrWillPowers/comments/1v6nodd/definitive_phenotype_overlap_pfs_and_pssd_normal/\n\nhttps://www.reddit.com/r/DrWillPowers/comments/1uu1arm/pssd_an_odd_signal_can_pssd_people_keep_an_eye/\n\nIf you've ever been to my practice, you know I'm a bit eccentric. I am assuredly a bit of a kook, but I've come to peace with it. I was hanging up some new aperture science art in the \"portal\" room yesterday after patients. This is not typical doctor behavior, but I've never been good at \"typical\" so I just keep doing my own thing. \n\nI've got a bunch of schizophrenic relatives, and I assuredly have toed that line at certain points in my life. Part of schizophrenia is basically erroneous pattern recognition. Seeing things where there isn't really a pattern there. That being said, people like that can sometimes literally see things other people can't see, but they really are there. Its cranked up pattern recognition, and crank it up to 11 and it glitches out. \n\nPattern recognition is basically the thing my brain does best above all other cognitive abilities. One of the oddities I noticed about PFS dudes was that before PFS, a large amount of them were basically GI-Joe clones. They were hypermasculine men compared to your average men when it was a male patient. This was very curious to me, and was one heavily weighted datapoint in the training data for my brain of trying to solve \"how does PFS work?\". \n\nI have noticed some different patterns in my PSSD patients, but I'm going to hold those cards for now until I'm more confident in them as I know a lot of what I say gets parroted elsewhere. I have learned my lesson on airing my \"hrm I wonder\" thoughts, as 95% of those are wrong. I'm keeping it now to \"hrm, I'm pretty sure this might be\".\n\nThat being said, I am starting to find consistent lab pattern anomalies in PSSD patients. \n\nA lot (but not all) poisonous chemicals taste bad. For starving humans that thought hemlock didn't taste extremely bitter, they tended to not exist to have more kids. This is called selective pressure. Humans have many redundant pathways as evolution encouraged this to allow for both glitches to be tolerated as well as for them to sometimes be beneficial. Even ones not always directly beneficial for the person's own reproductive capacity can be beneficial for their family or village, so they are selected for anyway and carried on recessively. \n\nThis is how you get people who are \"fine\" but lack a redundancy pathway, but once challenged with a foreign substance, boom, catastrophe. \n\nIn the above linked posts, you can see how hormone synthesis and metabolism intersects with neurosteroid synthesis and metabolism. A glitch on one highway can result in traffic buildup on another. Not gridlock, but traffic. But add \"an accident\" and now no cars are moving. \n\nTheoretically, if my idea on this is correct, an additional risk factor for the development of PSSD would be the same as PFS, overburdening a metabolism system. \n\nHow do you do that? Well, you use exogenous molecules. That molecule could be an SSRI that majorly upregulates neurosteroid synthesis until it hits a point of metabolite accumulation and lockout, in the same way that you inject a bunch of androgens (even if they give you a \"window\") that ends up increased metabolite load over what would normally be physiologically possible. Then the body's feedback loop mechanisms preserve the dysfunctional state, as they keep trying to correct for a problem that evolution never accounted for as it wasn't possible for it to exist without exogenous drugs/hormones. \n\nPair that problem with an inborn error of metabolism/excretion or transport, and you suddenly get a situation where the rate of neurosteroid/hormone/etc coming in exceeds the rate that it leaves. Once the concentration gets high enough, you get lock out. Signaling ceases. You've turned it up to 11 and the speakers blow out. \n\nI don't think they blow out permanently, but, they will remain silenced until signaling is restored. If signaling is down for a prolonged timeframe, you'll start to see atrophy of the most distal and weak aspects of that system. Just like the collapse of rome, the most distant colonies go down first, and you get small fiber neuropathy, atrophy, and other more persistent symptoms. This could explain why some people \"recover\" but have some lasting damage that has to be dealt with medically in other means. \n\nThe osteoporosis cases with PFS highlight this pretty well. Even if I cure the PFS overnight with a magic wand that wipes out all metabolite build up and restores signaling to normal, the osteoporosis remains. \n\nAlright, before this turns into a rambling rant that sounds more schizo than usual, simple question for the PSSD people here. \n\nWere you using birth control, injectable T? Anything that would boost your overall hormone load at the time of the development of PSSD? If you were not, would you consider yourself pre-PSSD to be a particularly overly libidinous person compared to peers at baseline? Do you look like you have a \"lot of hormones\" for your gender? \n\nThanks to everyone who continues to work on this problem, including members like [username removed] for making tools to help the community look at their own genomes to save me time and help find patterns. For users like [username removed] who did something incredibly brave and shared their experience in detail with the community. And For really anyone who is helping with this project. I really deeply believe this is a solvable problem, but that the solution is going to be truly something counterintuitive and will require some outside the box thinking. If the solution was easy, it would have been found ages ago, but nothing good ever comes easy, so lets keep working hard at it okay? \n\nYes, I know I am supposed to be taking a break but I got this lab result this morning and was like holy fuck its real, so forgive my excited rant. \n\n- Dr P" }, { "item_id": "PRH-0178", "source_type": "reddit-post", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1vwekwb/a_request_for_pfs_and_pssd_patients_taking_cdg_to/", "title": "A request for PFS and PSSD patients taking CDG to help symptoms. Can you do something for me?", "date_raw": "2026-08-23T18:16:29Z", "score": "(not in export)", "verification_status": "post body recovered via r.genit.al mirror 2026-10-07 (was empty in John's user-provided export)", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Original post by Powers — full self-text recovered from the r.genit.al mirror on 2026-10-07 (the export captured the title only):\n\nI think I may have solved something recently with some various posts and comments by people on the subreddit. \n\nThe persistent forms of PFS and PSSD are the same condition, just caused via different mechanisms, and the slightly different phenotypes relate to which specific neurosteroid pile up is the case in that specific human. . \n\nHere is what I think is happening for those with mental symptoms, anhedonia, genital numbness, etc. I suspect that each sub phenotype is related to whatever inborn error of metabolism/enzymes they have, that results in one specific neurosteroid being their primary pile up, and thereby affecting different neurons/brain regions slightly differently. \n\nCalcium d glucarate is reducing the recycling of various 3A reduced androgen metabolites:\n\n3a-androstanediol\n\nAndrosterone\n\nEtiocholanolone\n\nPossibly other 3a-hydroxysteroids\n\nAllopregnanolone and pregnanolone\n\n(Other phenotypes probably exist with neurosteroids like THDOC related to 11BHSD glitches)\n\nThe free 3a-hydroxysteroids can positively modulate GABA-A. Their glucuronides, (what I'm clocking on labs rather often above the measurable limit) such as 3A-ADG are much more polar and probably function mostly as transport/excretion products rather than strong central GABA-A modulators. They however reveal the truth, inside the brain, the 3A-AD and related molecules are at absurd levels. Why did they get like this? Finasteride caused the pileup via 5ari or an SSRI drove up their synthesis, creating the feedback loop. The mic gets too close to the speaker, and we get trapped in a loop. \n\nWith the GABA-A channels propped open all the time, substances like alcohol just....don't do anything. As they are like pissing into an ocean of GABA-A, but on the other side, the system adjusts to this constant GABA-A activity, and networks reconfigure around it. More semi-permanent neurological rewiring as a result. \n\nSo whats up with the CDG? \n\nEarly phase (slight neurosteroid level drop): CDG reduces pathological steroid deconjugation/recycling and lowers excessive tissue exposure. Sexual sensation, cognition, anhedonia or other PFS/PSSD symptoms briefly improve.\n\nLater phase (significant drop): continued blockade depletes the recyclable pool enough that inhibitory 3a-neurosteroid tone suddenly becomes inadequate. GABA-A no longer is propped wide open due to the drop off in neurosteroids. People start to feel anxious, not great. Some negative symptoms they dislike. \n\nCollapse: The GABA-A receptor population, already extremely over adapted to abnormal steroid levels propping it open almost permanently for many years prior to this, becomes functionally very under-modulated, producing panic and neuromuscular hyperexcitability. (Aka, the palpitations, anxiety, and \"stiffness\" of the muscles) that people are reporting in comments after taking high dose CDG for a while. \n\nThe subjective “cliff” does not require CDG pharmacokinetics to suddenly change. A slowly falling neurosteroid concentration can cross a nonlinear receptor/network threshold and then BAM, panic, anxiety, stiffness, and if bad enough, seizure. \n\nThese negative symptoms feel bad. People are not having a good time. This drug that helped them at first now feels like something that's going to cause them to literally die. They stop taking it, and call it a failure. \n\nMany of you got these disorders from a single pill, and have spent years chasing windows. Lets change the plan a little bit here. You've spent years in a state with massive fuckery happening with GABA-A, this isn't going to be fixed instantly. I've been taking a stimulant medication for the past 26 years, if I quit tomorrow, I would take probably 3-6 months to return to some sort of \"Baseline\" and in some ways, I might take even longer than that to truly \"normalize\". \n\nIf you are taking CDG, and you start to get these symptoms, back off. The goal is to do this slowly, to allow the system time to adjust to these changes, and to gradually get back to normal functional levels of GABA-A signaling. That will not be accomplished overnight with 1 pill. \n\nIf you get into a car accident, it takes only a single second of not paying attention to wreck your car. One little mistake. But it takes much longer than that for the repair shop to fix it. There is no \"accident reversal\" button. Things are messed up, they will need time to be repaired. Stop chasing windows. Think about the situation as slowly changing the steroid environment such that your brain can gradually return to baseline. \n\n(Valproate does this as well, separately from its HDAC abilities, which is something I realized could be an explanation for why people have recovered from using it, among many other things that tinker with this process). \n\nMy brain is great at pattern recognition and zooming out and seeing the big picture. Let me worry about figuring out what are the BEST treatment strategies to do this in the most efficient and safe way. \n\nBut CDG is OTC, so if you elect to take it and it \"crashes\" you, consider microdosing it right up to this \"I feel anxious\" threshold. Ideally, you will just faintly feel something, and that \"faint effect\" over months is what we're looking to do. \n\nCastration was the solution for androgenic signal loss, as that system can adapt vastly faster than the brain can. Will it also help for the neurosteroid pile up? Possibly, but it may take much much longer in that state for things to normalize, and that's what I'm trying to figure out. If I can do that without having to castrate someone for months, that seems like a safer and better option. But treatment isn't going to be a one pill solution. I am certain of this. \n\nIf you want to help me figure this out, and you personally have chosen to try CDG, do me this solid. \n\nTake it, and if you reach a point where you're getting anxiety/palpitations/muscle spasm, back off. Go back to a dose where maybe you just barely feel that a bit. But not anything severe. Do that for a while, and then when you feel settled out there, you can try pushing it harder until you reach the edge of the chasm again, then again, back off. The goal is to look over the edge without falling in. That slight pressure will cause the system to modulate around it. \n\nThis is not a normal staircase, this is a staircase with many very long landings, allowing your system time to gradually adapt and return to how it was before all this started. \n\nAs is always the case, this is not medical advice, please check with your own doctor about the safety of anything for your own medical care. But if you ARE going to take this supplement and do this anyway, let me know if this information works out the way I think it's going to. \n\n- Dr P" }, { "item_id": "PRH-0402", "source_type": "reddit-post", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1v3m1gi/anyone_out_there_with_pfspssdpostdrug_who_has/", "title": "Anyone out there with PFS/PSSD/Post-drug who has developed osteoporosis or hypermobility since the incident?", "date_raw": "2026-07-22T16:59:32Z", "score": "(not in export)", "verification_status": "post body recovered via r.genit.al mirror 2026-10-07 (was empty in John's user-provided export)", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "_source_file": "powers_history_curated", "collection_tag": "powers-reddit-history", "parent_context": "Original post by Powers — full self-text recovered from the r.genit.al mirror on 2026-10-07 (the export captured the title only):\n\nI have lately been horrified to discover some of my PFS/PSSD patients are to their own surprise, hypermobile, and one recently had an absurdly bad DEXA. while i await dexa results on some other patients, I'm wondering if anyone else has had issues with:\n\nOsteopenia/osteoporosis, or \"you know, I've had a lot of fractures since getting PFS/PSSD\"\nHypermobility : Everyone says \"I\"m not hypermobile\" until I bend their thumb to their wrist or extend their elbow past 180 degrees and then they go \"oh shit\". So check all the things:\n\nhttps://www.ehlers-danlos.com/assessing-joint-hypermobility/\n\nIf my mechanistic theory is correct, a subset of PFS/PSSD/Post-Druggies (Someone please give me a better generic name for this, as I can't keep writing Accutane/LionsMane/etc), should have these problems, and I just haven't perhaps been looking for it directly like I am now. I'd like to not have to wait 8 weeks to get my answer to this, so if this is you, let me know below (or if not!)\n\nAlso, the longer you've had it, the more likely this should be, FYI. \n\n- Dr Powers" }, { "item_id": "LIT-001", "source_type": "peer-reviewed paper", "title": "Post-finasteride syndrome: An emerging clinical problem", "authors": "Silvia Diviccaro, Roberto Cosimo Melcangi, Silvia Giatti", "journal_or_site": "Neurobiology of Stress", "year_or_date": 2019, "doi": "10.1016/j.ynstr.2019.100209", "url": "https://doi.org/10.1016/j.ynstr.2019.100209", "abstract_or_summary": "This review, authored by the Milan neurosteroid group, frames persistent adverse effects\nof 5-alpha-reductase inhibitors as an emerging clinical problem. It surveys reports of\nsexual dysfunction and mood disturbance during finasteride/dutasteride treatment and the\nsmaller literature on symptoms that persist after discontinuation, defining the PFS phenotype\n(sexual symptoms plus depression, anxiety, cognitive complaints). The authors note that\nmost evidence at the time rested on patient self-report, that clinical studies were few,\nand that molecular and genetic mechanisms had barely been explored in either patients or\nanimal models, concluding that dedicated mechanistic work was urgently needed.\n", "study_type": "review", "sample_size": "n/a (narrative review)", "keywords": [ "post-finasteride syndrome", "5-alpha-reductase inhibitor", "neurosteroid", "sexual dysfunction", "mood", "Melcangi", "Diviccaro" ], "relevance": "The keystone neurosteroid-group review that names PFS an emerging clinical problem and\nexplicitly calls for mechanistic/genetic investigation — a direct framing document for\nthe corpus's neurosteroid axis, surprisingly absent from v1.4.\n", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Elsevier journal; authors are the core PFS neurosteroid research group.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-001", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.sciencedirect.com/science/article/pii/S235228951930061X/pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by-nc-nd", "pmid": "32435662" }, { "item_id": "LIT-002", "source_type": "peer-reviewed paper", "title": "Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride", "authors": "Tina Kiguradze, William H. Temps, Paul R. Yarnold, John Cashy, Robert E. Brannigan, Beatrice Nardone, Giuseppe Micali, Dennis Paul West, Steven M. Belknap", "journal_or_site": "PeerJ", "year_or_date": 2017, "doi": "10.7717/peerj.3020", "url": "https://doi.org/10.7717/peerj.3020", "abstract_or_summary": "Using electronic medical records from Northwestern Medicine, the authors tested whether longer 5-alpha-reductase inhibitor exposure raises the risk of persistent erectile dysfunction (PED, lasting at least 90 days after stopping the drug). Among 11,909 exposed men, 167 (1.4%) developed PED with a median persistence of about 1,348 days after discontinuation; roughly a third of men with new erectile dysfunction had the persistent form. Classification-tree modelling identified exposure duration, prostate disease, age, and NSAID use as predictors. In men aged 16–42 on the hair-loss dose, PED occurred in 1.16% of those with more than 205 days of exposure vs 0.24% with less (about 4.9-fold); the paper also reports a 4.8-fold risk for men without prostate disease taking NSAIDs with more than ~208 days of exposure, a figure that by its own counts compares them with men not taking NSAIDs (against shorter exposure in the same group it is about 2.5-fold). The authors conclude that the findings contradict label claims that longer exposure does not increase risk and that sexual effects resolve on discontinuation.", "study_type": "retrospective cohort (electronic medical records)", "sample_size": "11,909 men exposed to finasteride/dutasteride (167 with PED); young-men subgroup analysis included", "keywords": [ "persistent erectile dysfunction", "5-alpha-reductase inhibitor", "finasteride", "dutasteride", "cohort", "duration-response", "NNH" ], "relevance": "The largest exposure-outcome study of persistent ED after 5-ARI use, providing\nduration-response evidence and number-needed-to-harm estimates — the core\npharmacoepidemiologic anchor for PFS persistence claims.\n", "verification_status": "verified-crossref-openalex-pubmed", "quality_notes": "Peer-reviewed open-access journal (PMID 28289563); retrospective EMR design with manual chart review of outcomes.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-002", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://doi.org/10.7717/peerj.3020", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "28289563", "plain": { "summary": "Researchers went through the medical records of about 12,000 men at one Chicago health system who had been prescribed finasteride or dutasteride. About 1 in 70 developed erection problems that were still being recorded at least three months after they stopped the drug, and for half of them the problems were still noted more than three and a half years later. The longer men had taken the drug, the more likely this was: among men under 43 on the hair-loss dose, about 1 in 86 who took it for more than about seven months had lasting erection problems, compared with about 1 in 424 who took it for less.", "caveat": "It can't prove the drug caused the problems: it used existing records, not a trial, and it only counted erection problems that a doctor wrote down and treated with an erection drug, so it says nothing about other reported symptoms such as low mood or genital numbness." }, "evidence": { "design": "Retrospective cohort study of electronic medical records, comparing longer with shorter exposure within exposed men (classification tree analysis)", "design_class": "observational-cohort", "setting": "Northwestern Medicine Enterprise Data Warehouse (Chicago, USA), records 1992–2015", "population": "Men aged 16–89 prescribed finasteride or dutasteride, with no recorded erectile dysfunction, low libido or PDE5 inhibitor use before their first prescription. Subgroup: men aged 16–42 taking only finasteride at 1.25 mg/day or less (the hair-loss dose; 5 mg tablets were often split).", "n": 11909, "n_note": "11,909 men evaluated for persistent ED, from 17,475 exposed among 691,268 men in the records; subgroup 4,284", "exposure": "Finasteride (≤1.25 mg/day or higher doses) or dutasteride; duration counted from first prescription", "comparator": "Men in the same cohort with shorter exposure (no unexposed group in the main analysis)", "outcome": "Persistent erectile dysfunction: a new ED diagnosis with a PDE5 inhibitor prescription, and a physician's note of ED lasting at least 90 days after stopping the drug (the FDA's criterion), confirmed by two reviewers. Secondary: new ED, new low libido.", "follow_up": "Persistent ED assessed in records from January 1992 to September 2013", "results": [ { "text": "Persistent ED in 167 of 11,909 men (1.4%); median persistence 1,348 days after stopping (IQR 631.5–2,320.5)", "where": "p. 12" }, { "text": "167 of the 530 men with new ED (31.5%) had the persistent form", "where": "p. 12" }, { "text": "Men without prostate disease who also took NSAIDs: persistent ED in 2.1% (26 of 1,231) with more than 208.5 days of exposure vs 0.83% (19 of 2,294) with shorter exposure. The paper reports a 4.8-fold risk (NNH 59.8; p < 0.002); those figures match a comparison with men without prostate disease who took no NSAIDs (0.44%, 19 of 4,331), not with the shorter-exposure NSAID group (about 2.5-fold)", "where": "pp. 17–18, Fig. 2A" }, { "text": "Men aged 16–42 on finasteride ≤1.25 mg/day: persistent ED in 34 of 4,284 (0.79%), median 1,534 days; more than 205 days of exposure 1.16% (30 of 2,587) vs 0.24% (4 of 1,697) with shorter exposure, 4.9-fold (NNH 108.2; p < 0.004)", "where": "p. 18, Fig. 2B" }, { "text": "Exposure duration predicted persistent ED better than age, hypertension, diabetes, smoking, alcohol misuse, obesity and depression; only prostate disease and prostate surgery predicted it better", "where": "pp. 17, 19" } ], "limitations_stated": [ "Possible confounding by factors linked to 5-ARI use; NSAID use may reflect why NSAIDs were prescribed rather than an effect of them", "Detection depended on what clinicians recorded; no validated questionnaire such as the IIEF was available", "With no unexposed group in the main analysis, the NNH is an upper bound; the authors expect a placebo-controlled trial would show a higher risk", "The exposure cutpoints (about 205–208 days) are not safe thresholds", "Other reported effects (cognitive, psychological, genital numbness, other sexual effects) were not studied", "Older men probably under-report sexual problems" ], "design_notes": [ "One US health system; results may not generalise", "Persistent ED required a PDE5 inhibitor prescription, so untreated cases were not counted", "Exposure is measured from prescriptions, not from whether the drug was taken", "The analysis method (optimal discriminant / classification tree analysis) is uncommon, and its cutpoints are derived from the data" ], "funding": "US National Institutes of Health grants, and a gift from the Post-Finasteride Syndrome Foundation; the authors state the funders had no role in the study.", "interests": "One author (Yarnold) is an employee of Optimal Data Analysis, LLC", "supports": "An association between longer finasteride or dutasteride use and erectile dysfunction that persists after stopping, in routine care. It does not establish causation, and its rates are not population-wide frequencies.", "extracted_from": "fulltexts/LIT-002-Persistent-erectile-dysfunction-in-men-exposed-to.pdf (publisher PDF, CC BY 4.0, 31 pp.)", "extracted": "2026-10-10" } }, { "item_id": "LIT-003", "source_type": "peer-reviewed paper", "title": "How routine pharmacovigilance failed to identify finasteride's persistent sexual side effects", "authors": "Michael S. Irwig", "journal_or_site": "Andrology", "year_or_date": 2022, "doi": "10.1111/andr.13122", "url": "https://doi.org/10.1111/andr.13122", "abstract_or_summary": "This opinion article examined how Merck and the US FDA handled signals of persistent sexual adverse effects of finasteride, noting the first regulatory warnings in Sweden (2008) and the UK (2009) and two independent groups' peer-reviewed reports of persistent effects in 2011. Drawing on Merck documents unsealed in 2021, it described a 2009 Risk Management Plan that identified 278 cases of erectile dysfunction that had not recovered, after which Merck's safety team planned routine pharmacovigilance for another two years rather than further prospective studies. The FDA approved a label warning of erectile dysfunction continuing after discontinuation in 2011, effective 2012, but the author held it partly responsible for not requiring further safety studies. He argued that the original trials could not properly assess sexual adverse effects, as they used no validated sexual-function instruments, were not powered to detect adverse effects rarer than 1%, and usually did not disclose details of participants who had adverse effects or withdrew. He noted that the incidence of persistent effects was unknown and that adverse events were heavily under-reported.", "study_type": "opinion article", "sample_size": "n/a (regulatory and literature analysis)", "keywords": [ "pharmacovigilance", "finasteride", "persistent sexual dysfunction", "regulatory", "signal detection", "Irwig" ], "relevance": "Argues that Merck had a signal of persistent erectile dysfunction by 2009 but chose routine pharmacovigilance over further studies, and that the FDA did not require them. Essential context for the corpus on how post-drug syndromes can go unaddressed by standard safety surveillance.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Wiley journal; single-author analysis by a leading PFS clinical researcher.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-003", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/andr.13122", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "", "pmid": "34713622", "volume": "10", "pages": "207-208", "plain": { "summary": "This short opinion article, by a US hormone specialist, looks at how the maker of finasteride and the US drug regulator handled early signs that the drug's sexual side effects could last after people stopped taking it. Company documents made public in 2021 show that by 2009 the maker knew of 278 reports of erection problems that had not gone away, but chose to keep relying on routine side-effect reporting for two more years instead of running new studies. The author argues this was a missed chance, and that the original trials were not set up to pick up rare sexual side effects.", "caveat": "It can't tell us how often these lasting problems happen or whether the drug causes them: it is one doctor's opinion, based on company documents and earlier reports, and it adds no new patient data." }, "evidence": { "design": "Opinion article; single-author commentary on unsealed Merck documents, FDA labelling history and published literature", "design_class": "commentary", "setting": "Merck and the US FDA, with reference to earlier Swedish and UK warnings; Merck documents unsealed in January 2021", "population": "Not applicable; concerns men who used finasteride, mainly 1 mg/day for male pattern hair loss (Propecia)", "n": null, "n_note": "Not applicable (opinion article, no new data). Figures cited: 278 unrecovered erectile dysfunction reports in Merck's safety database; 3,210 patients in Merck's phase III trials of 1 mg/day; about 4.6 million men given finasteride 1 mg from 1998 to 2008; 10,295 serious adverse event reports for finasteride in FAERS as of June 2021", "exposure": "Finasteride (Propecia 1 mg; Proscar also mentioned)", "comparator": "None", "outcome": "How persistent sexual side effects were detected, assessed and acted on by Merck and the FDA", "follow_up": "Not applicable; covers events from 1998 to June 2021", "results": [ { "text": "The first regulatory warnings of persistent sexual effects came from Sweden (2008) and the UK (2009); two independent groups published peer-reviewed reports of persistent effects in 2011", "where": "p. 207" }, { "text": "Merck's Risk Management Plan (version 1.0, February 2009), discussed by its Risk Management Safety Team in June 2009, listed three potential risks (persistent erectile dysfunction, male infertility, depressive disorders) and identified 278 cases of erectile dysfunction that had not recovered; the plan noted that critical data were missing in most of them, while also describing several representative cases without apparent confounders", "where": "p. 207" }, { "text": "In March 2011 the FDA held a teleconference with Merck and approved adding erectile dysfunction continuing after discontinuation to the label; the labelling changes to Propecia and Proscar took effect in April 2012", "where": "p. 207" }, { "text": "Merck's phase III trials of 1 mg/day included 3,210 patients with a mean exposure of 749 days; citing a meta-analysis, the author notes the trials used no validated sexual-function instruments, were not powered to detect adverse effects rarer than 1%, and usually did not disclose details of participants who had adverse effects or withdrew", "where": "pp. 207–208" }, { "text": "About 4.6 million men received finasteride 1 mg from 1998 to 2008 (Merck's estimate); the FDA's FAERS dashboard listed 10,295 serious adverse events for finasteride as of June 2021, and three of the four most common reaction types were sexual (erectile dysfunction, sexual dysfunction, decreased libido)", "where": "p. 208" }, { "text": "Merck's team planned routine pharmacovigilance for another two years rather than prospective studies with validated instruments; the author argues the FDA also bears some responsibility for not requiring further safety studies", "where": "p. 208" } ], "limitations_stated": [ "Most of Merck's 278 cases lacked critical data (time from stopping to report, other medicines, medical history), as Merck's own report said", "Much of the controversy comes from the inherent limitations of post-marketing data", "The incidence of persistent sexual effects is unknown, and adverse drug events are grossly under-reported" ], "design_notes": [ "A two-page opinion piece by one author, with no methods section and no systematic search of sources", "Its main source is litigation documents cited as a Merck supplementary file (ref. 5); the article quotes and summarises them, so their full context cannot be judged from the article alone", "The author co-wrote one of the two 2011 studies it cites as the first reports of persistent effects (ref. 2)", "FAERS figures are counts of reports, not rates; the author himself says the incidence is unknown" ], "funding": "None declared", "interests": "None declared", "supports": "An account of what Merck's 2009 risk management plan recorded about unrecovered erectile dysfunction and how Merck and the FDA responded. It provides no new data on how often persistent effects occur or whether finasteride causes them.", "extracted_from": "fulltexts/LIT-003-How-routine-pharmacovigilance-failed-to-identify-f.pdf (publisher PDF, no open licence stated, 2 pp.; page refs are the printed page numbers 207–208)", "extracted": "2026-10-10" } }, { "item_id": "LIT-004", "source_type": "peer-reviewed paper", "title": "An observational retrospective evaluation of 79 young men with long‐term adverse effects after use of finasteride against androgenetic alopecia", "authors": "Giorgio Chiriacò, Sabina Cauci, Giorgio Mazzon, Carlo Simone Trombetta", "journal_or_site": "Andrology", "year_or_date": 2016, "doi": "10.1111/andr.12147", "url": "https://doi.org/10.1111/andr.12147", "abstract_or_summary": "Seventy-nine men (mean age ~33) reporting long-term adverse effects after finasteride for\nhair loss were surveyed with a 100-item questionnaire plus validated sexual and aging-male\nsymptom scales. Mean time since discontinuation was about 44 months, documenting\nmulti-year persistence. The most common sexual complaints were loss of penile sensitivity\n(87%), reduced ejaculatory force (82%), and low penile temperature (79%) — genital\nsensory loss outranked severe erectile dysfunction in frequency. Non-sexual symptoms were\ndominated by anhedonia (76%), impaired concentration (72%), and loss of muscle tone or\nmass (52%), supporting a multisystem syndrome rather than isolated sexual dysfunction.\n", "study_type": "retrospective observational (questionnaire)", "sample_size": "79 men with long-term adverse effects (mean 44 months post-discontinuation)", "keywords": [ "post-finasteride syndrome", "case series", "penile sensitivity", "anhedonia", "cognitive symptoms", "muscle loss" ], "relevance": "A foundational PFS phenotyping case series: a one-time questionnaire survey of 79 selected men with persistent symptoms, describing their sexual, neuropsychiatric and physical symptoms a mean of 44 months after discontinuation; its percentages apply to this group, not to PFS in general. The clinical counterpart to the corpus's mechanistic entries.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Wiley journal; 62 of 79 men (78%) were recruited from Propeciahelp.com, an internet forum for PFS, and 66 had been in the group's earlier studies (selection-bias caveat).", "sweep_date": "2026-10-07", "axis_id": "LIT-A-004", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/andr.12147", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "", "pmid": "26763726", "plain": { "summary": "Researchers in Italy asked 79 young men who still had problems after stopping the hair-loss drug finasteride to fill in detailed questionnaires, on average almost four years after they had stopped. Nearly 9 in 10 reported less feeling in the penis, and about 8 in 10 reported weaker ejaculation and a penis that felt colder. About 3 in 4 said they felt less pleasure or emotion in life, about 7 in 10 had trouble concentrating, and about half reported losing muscle. About 6 in 10 said their symptoms had got worse after they stopped the drug.", "caveat": "It can't show how common these problems are among men who take finasteride, or prove the drug caused them: every man in it already had lasting symptoms, most were found through an online forum for affected men, there was no comparison group, and how they were before the drug was based on memory." }, "evidence": { "design": "Retrospective observational study (authors' term); one-time questionnaire survey of men with persistent symptoms after finasteride, with recalled pre-treatment sexual function and no comparison group", "design_class": "case-series", "setting": "Urology Unit, Trieste University Hospital (Italy); participants from several countries (Italy 34.2%, Canada and USA 20.2% each, UK 12.7%); study dates not stated", "population": "Men over 18 and under 50 who took finasteride for hair loss and had side effects lasting at least 6 months after stopping, and who had seen a doctor at least once, including a blood test. Required ASEX scores in the dysfunction range or an AMS score of 27 or more. Excluded: documented sexual dysfunction or mental illness before finasteride, BMI over 30, chronic disease, earlier hormone-altering drugs, and anyone involved in finasteride litigation.", "n": 79, "n_note": "79 men, 17 from the clinic and 62 from Propeciahelp.com (an internet forum for PFS); 66 had been in the group's earlier studies; AMS data for 78", "exposure": "Finasteride for hair loss at 1 mg/day (57, 72.2%), 1.25 mg/day (18, 22.8%) or 0.5 mg/day (4, 5.1%); mean use 27.3 months (range 1–120)", "comparator": "None; current ASEX compared with the same men's recalled pre-finasteride ASEX", "outcome": "Symptom type and frequency from an ad hoc 100-item questionnaire; sexual function on the Arizona Sexual Experience Scale (ASEX, 5–30, higher is worse; dysfunction defined as 19 or more, any item 5 or more, or any three items 4 or more); androgen-deficiency symptoms on the Aging Male Symptom scale (AMS, 17–85; severe 50 or more).", "follow_up": "None; single assessment a mean 44.1 months (180–5,057 days) after stopping finasteride", "results": [ { "text": "Symptoms began during finasteride use in 71 of 79 (89.9%) and after stopping in 8 (10.1%); since stopping, symptoms had worsened in 49 (62.0%), were unchanged in 19 (24.1%) and improved in 11 (13.9%)", "where": "p. 247, Table 1" }, { "text": "Sexual symptoms on the ad hoc questionnaire: loss of penile sensitivity 69 (87.3%), decreased ejaculatory force 65 (82.3%), decreased penile temperature 62 (78.5%), reduced ejaculate volume 58 (73.4%), loss of scrotal sensitivity 49 (62.0%)", "where": "p. 247, Table 1" }, { "text": "Non-sexual symptoms: reduced pleasure or emotions (anhedonia) 60 (75.9%), lack of concentration 57 (72.2%), loss of muscle tone or mass 41 (51.9%), anxiety 20 (25.3%), gynecomastia 8 (10.1%)", "where": "p. 247, Table 1" }, { "text": "ASEX total 21.0 ± 2.67 now vs 7.7 ± 2.52 recalled before finasteride (p < 0.001); 78.5% scored 19 or more. Scores of 5–6 (severe): sex drive 55 of 79 (69.6%), getting or keeping an erection 35 (44.3%), reaching orgasm 15 (19.0%), orgasm satisfaction 16 (20.3%)", "where": "pp. 247–248, Table 2" }, { "text": "Sexual arousal: the paper reports 13.9% with scores of 5–6 and a mean of 4.4 ± 0.87, but Table 2's post-finasteride arousal row does not add up. Its counts (1, 11, 30, 31, 5, 6) sum to 84 (106.3%), not 79, and give a mean of about 3.5 (SD about 1.1). Every other row in Table 2 matches its stated mean and SD, and the total of 21.0 is consistent with 4.4, so the 13.9% figure (repeated in the text and conclusion) cannot be confirmed", "where": "pp. 247–249, Table 2" }, { "text": "AMS (78 men): mean 52.3 ± 10.47; severe (50 or more) 47 (60.3%), moderate 27 (34.6%), slight 4 (5.1%)", "where": "p. 247" } ], "limitations_stated": [ "Retrospective design, with no baseline information from before finasteride use", "Participants were recalled by phone after taking part via a dedicated website, so several biases cannot be excluded; incomplete clinical assessment from the records provided; missing or non-spontaneous information", "No objective testing of penile sensitivity", "Relatively small number of men, partly because of strict selection" ], "design_notes": [ "All men already had persistent symptoms and were selected partly on dysfunction scores, so the percentages describe this group, not how often symptoms occur in finasteride users", "62 of 79 were recruited from a PFS internet forum, and 66 of 79 had taken part in the group's earlier studies", "Pre-finasteride function was rated from memory, years later", "The headline comparison (87.3% loss of penile sensitivity vs 44.3% severe erection difficulty) sets a yes/no item from the ad hoc questionnaire against severe scores on a different scale", "The ad hoc 100-item questionnaire is not a validated instrument, and the paper says medical visits took place \"when done\", without saying how many men were examined", "Inclusion says under 50 years old, while results give an age range of 22–50" ], "funding": "University of Udine and University of Trieste grants, 2012–2014", "interests": "None declared", "supports": "A description of the symptoms reported by a selected group of men with lasting problems after finasteride for hair loss, notably genital sensory changes and non-sexual symptoms. It cannot give frequencies for finasteride users in general or establish causation.", "extracted_from": "fulltexts/LIT-004-An-observational-retrospective-evaluation-of-79-yo.pdf (publisher PDF, no open licence stated, 6 pp.; page refs are the printed page numbers 245–250)", "extracted": "2026-10-10" } }, { "item_id": "LIT-005", "source_type": "peer-reviewed paper", "title": "Immunohistochemical Evaluation of Androgen Receptor and Nerve Structure Density in Human Prepuce from Patients with Persistent Sexual Side Effects after Finasteride Use for Androgenetic Alopecia", "authors": "Carla Di Loreto, Francesco La Marra, Giorgio Mazzon, Emanuele Belgrano, Carlo Simone Trombetta, Sabina Cauci", "journal_or_site": "PLoS ONE", "year_or_date": 2014, "doi": "10.1371/journal.pone.0100237", "url": "https://doi.org/10.1371/journal.pone.0100237", "abstract_or_summary": "In a retrospective case-control design, foreskin tissue from 8 men with persistent sexual\nside effects (including genital sensitivity loss) more than 6 months after stopping\nfinasteride was compared with tissue from 11 healthy circumcision controls never exposed\nto the drug. Immunohistochemistry showed significantly higher nuclear androgen-receptor\ndensity in stromal and epithelial cells of cases versus controls, while nerve density and\nvessel smooth-muscle AR positivity did not differ. The authors interpret receptor\nupregulation as a possible compensatory response to prior androgen deprivation, offering\none of the first tissue-level molecular correlates of persistent genital symptoms.\n", "study_type": "retrospective case-control (tissue immunohistochemistry)", "sample_size": "8 cases / 11 controls", "keywords": [ "androgen receptor", "foreskin", "immunohistochemistry", "genital sensitivity", "case-control", "AR upregulation" ], "relevance": "Rare human tissue evidence in PFS: reports a higher percentage of stromal and epithelial cells with androgen-receptor-stained nuclei (semi-quantitative immunohistochemistry) in foreskin from 8 affected men than from 11 unexposed controls, relevant to the corpus's androgen-signaling mechanism thread. It did not measure AR gene expression or receptor function, which the authors say their design cannot determine.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed; small sample (n=8 cases) but invasive-tissue design; findings are hypothesis-generating.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-005", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "Finasteride: The Molecular Links to Side Effects", "fulltext_url": "https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0100237&type=printable", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "24959691", "plain": { "summary": "Researchers in Italy took a small skin sample from the foreskin of 8 men who had lasting sexual problems, including loss of feeling in the penis, more than 6 months after stopping finasteride for hair loss. They compared it with foreskin removed during circumcision from 11 men who had never taken the drug. In two of the three tissue types checked, more cells in the finasteride group showed the androgen receptor, the part of a cell that male hormones such as testosterone act through. The number of nerves looked about the same in both groups.", "caveat": "It can't show that finasteride caused the difference or what it means for how the tissue works, because the groups were very small, the tissue was collected in different ways, and there were no samples from before the men took the drug." }, "evidence": { "design": "Retrospective case-control study comparing immunohistochemistry of foreskin tissue from men with persistent sexual side effects after finasteride with finasteride-naive men undergoing circumcision", "design_class": "case-control", "setting": "Urological Unit, University Hospital of Trieste (enrolment, visits) and University Hospital of Udine (laboratory analyses), Italy; study dates not stated", "population": "Cases, 8 white men aged 29–43 who took finasteride for hair loss and had sexual side effects, including self-reported loss of genital sensitivity, lasting 6 months or more after stopping; 5 enrolled after a clinical consultation and 3 through the Propeciahelp.com forum. Controls, 11 otherwise healthy white men aged 23–49 with hair loss (Norwood grade 2 or more), never exposed to finasteride or other anti-androgenic drugs, undergoing circumcision for phimosis. Both groups excluded obesity (BMI over 30) and chronic disease.", "n": 19, "n_note": "8 cases and 11 controls", "exposure": "Finasteride for hair loss, 4 men at 1 mg/day and 4 at 1.25 mg/day (quartered 5 mg tablets); mean duration 956 ± 1,130 days (range 49–3,100).", "comparator": "Finasteride-naive men with hair loss, circumcised for phimosis", "outcome": "Percentage of epithelial, stromal and vessel smooth-muscle cells with androgen receptor (AR) positive nuclei (semi-quantitative immunohistochemistry, AR441 antibody); nerve density on H&E slides (average of 25 fields); serum total and calculated free testosterone. In cases only, the ASEX sexual-function score now and as recalled for before finasteride. Assessors blinded to subject characteristics.", "follow_up": "None (single visit and tissue sample), a mean 1,672 ± 862 days after stopping finasteride (range 240–3,010)", "results": [ { "text": "Stromal cells with AR-positive nuclei 40.0 ± 15.1% in cases vs 23.4 ± 8.68% in controls (p = 0.023), about 1.7-fold by the paper's means (described as \"almost 2-fold\")", "where": "p. 4, Table 2" }, { "text": "Epithelial cells 80.6 ± 8.63% vs 65.0 ± 19.1% (p = 0.043); vessel smooth-muscle cells 3.13 ± 3.04% vs 3.41 ± 2.61% (p = 0.331); average of the three 41.2 ± 4.46% vs 30.6 ± 8.75% (p = 0.007)", "where": "p. 4, Table 2" }, { "text": "No difference in nerve density (2.22 ± 0.653 vs 1.91 ± 0.952, p = 0.215), total testosterone (11.6 ± 2.96 vs 13.6 ± 3.45 nmol/L, p = 0.290) or calculated free testosterone (218 ± 52.2 vs 270 ± 80.2 pmol/L, p = 0.413)", "where": "pp. 4–5, Table 2" }, { "text": "Ratio of AR-positive stromal cells (%) to total testosterone 3.47 ± 1.25 vs 1.86 ± 0.372 (p = 0.001), about 1.9-fold (described as 2-fold); to free testosterone 0.192 ± 0.095 vs 0.096 ± 0.027 (p = 0.005), 2.0-fold", "where": "p. 5, Table 2" }, { "text": "Within the 8 cases, worse current sexual function went with fewer AR-positive stromal cells (rho −0.722, p = 0.043), more strongly for the change from recalled pre-finasteride ASEX (rho −0.913, p = 0.002)", "where": "p. 5" }, { "text": "All 8 cases reported loss of penile sensitivity and of pleasurable response to touch; 7 of 8 loss of scrotal or testicular sensitivity, erectile dysfunction, hardened or rubbery tissue, and flaccidity or retraction into the scrotum. ASEX 22.5 ± 2.78 now vs 7.6 ± 1.92 recalled for before finasteride", "where": "pp. 3–4, Table 1" } ], "limitations_stated": [ "Small number of subjects, partly due to strict selection", "DHT, especially local tissue DHT, could not be measured", "No testing for androgen receptor gene polymorphisms, partly offset by hair-loss-matched controls", "Retrospective design, with no tissue from before or during finasteride use", "The design cannot show whether the nuclear AR in cases works normally as a transcription factor", "The apparent AR increase might reflect low local androgen levels" ], "design_notes": [ "Tissue was obtained differently (5 mm punch biopsy, 2–4 mm deep, in cases vs circumcision tissue in controls), and controls had phimosis, a foreskin condition; the paper does not discuss whether either affects AR staining or nerve counts", "Scoring was semi-quantitative by light microscopy; the number of assessors and their agreement are not reported", "Very small groups, several outcomes and no correction for multiple comparisons; the correlations are within 8 men", "Pre-finasteride ASEX scores were recalled at interview, and the before/after comparison used an unpaired test (Mann–Whitney) on the same men", "Among cases, 3 had used testosterone after finasteride (stopped over a year before entry) and 5 had used tadalafil", "The matching method is not described beyond age and hair-loss grade; no case was married or partnered vs 5 of 11 controls (p = 0.045)" ], "funding": "University of Udine funds; the funders had no role in the study", "interests": "None declared", "supports": "A difference in the proportion of androgen-receptor-positive cells in foreskin tissue between 8 men with persistent sexual symptoms after finasteride and 11 unexposed men, with no difference in nerve density. It cannot establish that finasteride caused the difference, or what it means for receptor function.", "extracted_from": "fulltexts/LIT-005-Immunohistochemical-Evaluation-of-Androgen-Recepto.pdf (publisher PDF, CC BY, 7 pp.; page refs are the printed page numbers 1–7, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-006", "source_type": "peer-reviewed paper", "title": "Persistent Sexual and Psychological Symptoms After Finasteride Discontinuation: A Cross-Sectional Observational Study", "authors": "Paweł Jędrzejczyk, Tomasz Ząbkowski, Jarosław Ratajski, Kamil Ciechan, Tomasz Waldemar Kaminski, Patryk Uciechowski, Tomasz Syryło", "journal_or_site": "Journal of Clinical Medicine", "year_or_date": 2026, "doi": "10.3390/jcm15082947", "url": "https://doi.org/10.3390/jcm15082947", "abstract_or_summary": "This 2026 cross-sectional study enrolled 129 men with prior finasteride exposure for hair loss or prostate enlargement and measured sexual function, depression, and anxiety with validated instruments (IIEF, PHQ-9, GAD-7). Erectile function remained impaired at follow-up while depressive and anxiety scores improved only partially without normalizing in most participants. The authors reported that greater cumulative finasteride exposure and older age were independently associated with worse sexual and psychological symptom severity in multivariable modelling, but the paper did not present the regression estimates (no odds ratios, confidence intervals or p-values). The authors called for prospective studies to define risk factors and long-term trajectories.", "study_type": "cross-sectional observational", "sample_size": "129 men with prior finasteride exposure", "keywords": [ "post-finasteride syndrome", "cross-sectional", "IIEF", "PHQ-9", "GAD-7", "cumulative exposure", "dose-response" ], "relevance": "A recent clinical cohort of 129 men reporting symptoms after stopping finasteride (no minimum duration; 70 took the 5 mg prostate dose) in which the authors link greater cumulative exposure and older age to symptom severity, relevant to the corpus's clinical axis. It reports no dose-response estimates, and cumulative dose is strongly correlated with age.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed MDPI journal; cross-sectional design limits causal inference.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-006", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.mdpi.com/2077-0383/15/8/2947/pdf?version=1776071176", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "42074750", "plain": { "summary": "Doctors in Poland assessed 129 men who had stopped finasteride, taken for hair loss or an enlarged prostate, and still had symptoms, using standard questionnaires about erections, low mood and anxiety. Erection scores barely changed over the six months after stopping. Low-mood scores improved somewhat and anxiety scores, which started low, improved slightly, but the authors say most men did not return to normal. Men who were older, or who had taken more of the drug in total, tended to have worse scores.", "caveat": "It can't show how common these problems are or that the drug caused them: it included only men who already had symptoms, had no comparison group, and does not report the figures behind its main finding about age and total dose." }, "evidence": { "design": "Cross-sectional study (the authors' label) of men reporting symptoms after stopping finasteride, with retrospectively collected exposure data, questionnaire scores reported at baseline and 1, 3 and 6 months, median-split comparisons and regression", "design_class": "cross-sectional", "setting": "Not described. The authors are from clinics and hospitals in Warsaw, Poland; the study was approved by the review board of the Military Institute of Medicine (National Research Institute) on 25 June 2025. Recruitment route and dates are not stated.", "population": "Adult men who had taken finasteride at any dose for male pattern hair loss or benign prostatic hyperplasia, had stopped, and reported symptoms at evaluation (no minimum duration). Mean age 47.1 years (median 49, IQR 31.5–62); 59 took 1 mg/day and 70 took 5 mg/day. The number in each indication group is not reported.", "n": 129, "n_note": "129 men analysed; the number assessed at each follow-up time point is not reported", "exposure": "Finasteride 1 mg or 5 mg/day; median treatment 24 months (IQR 12.5–36); cumulative exposure (daily dose × months) median 44 (IQR 18.5–153); median 8 months (IQR 1–17) from stopping to evaluation.", "comparator": "None (no unexposed group); comparisons within the cohort by median splits of age, cumulative dose and testosterone, and across time points", "outcome": "Erectile function (IIEF; version not stated), depressive symptoms (PHQ-9) and anxiety (GAD-7), given in clinician-guided interviews; serum testosterone, DHT, LH, FSH, SHBG, oestradiol and prolactin; self-reported somatic symptoms.", "follow_up": "Scores reported at baseline and 1, 3 and 6 months after stopping; how and when these were collected is not described", "results": [ { "text": "Erection scores (IIEF) did not change: mean 15.2 ± 0.46 (SEM) at baseline, 15.3 at 1 and 3 months, and 15.4 ± 0.47 at 6 months", "where": "p. 5, Fig. 1A" }, { "text": "PHQ-9 fell from 12.4 ± 0.41 to 10.7 (1 month), 10.1 (3 months) and 9.1 ± 0.41 (6 months), a drop of 3.3 points. The paper says mean scores stayed in the moderate range throughout; it does not state its cut-offs, and on the instrument's widely used bands a mean of 9.1 falls in the mild band", "where": "p. 5, Fig. 1B" }, { "text": "GAD-7 fell from 3.29 ± 0.23 to 2.54 ± 0.20 at 6 months. The conclusions describe anxiety as elevated (p. 11), but on the GAD-7's widely used bands both means fall in the minimal range", "where": "p. 6, Fig. 1C; p. 11" }, { "text": "Symptoms began during therapy or immediately after stopping in 83 of 129 men (64%); sleep disturbance in 75 (58%); fatigue in 86 (67%)", "where": "p. 4; Table 1, p. 5" }, { "text": "Treatment duration, cumulative dose and age are reported as \"the strongest predictors of symptom severity\". The methods say results are given as odds ratios with 95% confidence intervals, but no estimates, intervals, p-values or regression table appear in the paper", "where": "pp. 4, 8" }, { "text": "Median splits: men with higher cumulative exposure were older, with lower testosterone, higher LH, poorer baseline IIEF and worse mental-status scores. Men with higher testosterone were younger, with higher DHT and better baseline erectile function, yet the text also states that testosterone did not differentiate sexual or psychiatric symptom severity", "where": "pp. 6, 8, 10; Figs 3–4" } ], "limitations_stated": [ "Modest sample size, with limited power for subgroup and indication-specific analyses", "Possible selection and recall bias from the observational design", "Only men reporting persistent symptoms were included, so prevalence, incidence and relative risk cannot be estimated, and more severe cases are over-represented", "No standard definition of persistent symptoms; persistence meant symptoms present at the evaluation", "No data on sexual function before finasteride, or on comorbidities such as diabetes and hypertension or on other medicines; unmeasured confounding cannot be excluded", "Men under 30 were under-represented", "Reasons for stopping finasteride were not collected" ], "design_notes": [ "Described as cross-sectional, yet it reports scores at baseline and 1, 3 and 6 months after stopping; baseline is not defined, and a median of 8 months (IQR 1–17) from stopping to evaluation is hard to reconcile with that schedule", "Cumulative dose is mg/day × months, so the 70 men on 5 mg accrue five times the monthly exposure of those on 1 mg; age correlated strongly with cumulative dose, and the hair-loss vs prostate split is not reported, so dose, indication and age are hard to separate", "Persistence had no minimum duration, and the lower IQR bound of time since stopping is 1 month, so at least a quarter of men were evaluated about a month or less after stopping", "No setting, recruitment route or study dates are described, and the IIEF version and score range are not stated", "Some statements conflict, e.g. ethics approval is described as not required (p. 4) but also as granted under protocol 40/25 (p. 11), and Table 1 has a \"Currently on medication\" row coded 1 for 29 men, unexplained given that all had stopped (p. 3)" ], "funding": "No external funding", "interests": "None declared", "supports": "An association, within men who already report symptoms after stopping finasteride, between older age or greater total exposure and worse sexual and mood scores, as stated by the authors without reported estimates. It cannot estimate how often such symptoms occur, establish causation, or separate dose from age and indication.", "extracted_from": "fulltexts/LIT-006-Persistent-Sexual-and-Psychological-Symptoms-After.pdf (publisher PDF, CC BY, 12 pp.; page refs are the printed \"N of 12\" page numbers, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-007", "source_type": "peer-reviewed paper", "title": "Post-finasteride syndrome - a true clinical entity?", "authors": "Simone Cilio, Georgios Tsampoukas, Afonso Morgado, Pedro Ramos, Suks Minhas", "journal_or_site": "International Journal of Impotence Research", "year_or_date": 2025, "doi": "10.1038/s41443-025-01025-6", "url": "https://doi.org/10.1038/s41443-025-01025-6", "abstract_or_summary": "This 2025 review critically appraises whether post-finasteride syndrome constitutes a\ngenuine clinical entity. The authors survey its reported sexual, neuropsychiatric, and\nphysical manifestations and the proposed mechanisms — neurobiological alterations and\ngenetic predisposition — while engaging the controversy over its existence and medical\nrecognition. They conclude that affected men can develop a substantial burden of physical\nand psychological symptoms, stressing patient education, pre-prescription risk\nassessment, and a multidisciplinary research and policy response.\n", "study_type": "review", "sample_size": "n/a (narrative review)", "keywords": [ "post-finasteride syndrome", "clinical entity", "controversy", "neuropsychiatric", "risk assessment" ], "relevance": "The most current high-profile synthesis of the PFS-existence debate in a Nature-portfolio\nurology journal — useful as the corpus's up-to-date framing of diagnostic controversy.\n", "verification_status": "verified-crossref-openalex-pubmed", "quality_notes": "Peer-reviewed (PMID 39953145); narrative review, reflects authorial synthesis rather than new data.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-007", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "39953145" }, { "item_id": "LIT-008", "source_type": "peer-reviewed paper", "title": "The post-finasteride syndrome: possible etiological mechanisms and symptoms", "authors": "Herman H. J. Leliefeld, Frans M.J. Debruyne, Yacov Reisman", "journal_or_site": "International Journal of Impotence Research", "year_or_date": 2023, "doi": "10.1038/s41443-023-00759-5", "url": "https://doi.org/10.1038/s41443-023-00759-5", "abstract_or_summary": "The authors review how 5-alpha-reductase inhibitors, though targeted at prostate and\nscalp, act on three reductase isoenzymes distributed across many organs including the\nbrain. They argue the lipophilic drugs cross the blood-brain barrier and can suppress a\nwide range of neurosteroids beyond dihydrotestosterone, altering neurochemistry and\nimpairing neurogenesis. The paper catalogs persistent sexual, neurological, psychiatric,\nendocrine, metabolic, and ophthalmological complaints and urges greater physician\nawareness and therapeutic research.\n", "study_type": "review", "sample_size": "n/a (narrative review)", "keywords": [ "post-finasteride syndrome", "etiology", "neurosteroid", "blood-brain barrier", "SRD5A isoenzymes", "neurogenesis" ], "relevance": "Mechanism-focused review tying PFS symptoms to central 5-AR inhibition, neurosteroid\ndepletion, and impaired neurogenesis — a concise statement of the neurosteroid\nhypothesis the corpus is built around.\n", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Nature-portfolio journal; narrative review.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-008", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "37697052", "fulltext_note": "No free full text: paywalled at the publisher despite an open-access listing (checked 2026-10-09)" }, { "item_id": "LIT-009", "source_type": "peer-reviewed paper", "title": "Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia", "authors": "Mohit Khera, Jeffrey K. Than, James E. Anaissie, Ali A. Antar, Weitao Song, Boriss Y. Losso, Alexander W. Pastuszak, Taylor P. Kohn, Jorge Rivera Mirabal", "journal_or_site": "Translational Andrology and Urology", "year_or_date": 2020, "doi": "10.21037/tau.2020.03.21", "url": "https://doi.org/10.21037/tau.2020.03.21", "abstract_or_summary": "In what the authors described as a prospective case-control study, 25 young men with persistent adverse effects after finasteride for hair loss were compared with 28 controls using validated questionnaires (IIEF, IPSS, PHQ-9, sleepiness scales, androgen-deficiency scales); only the finasteride group underwent penile duplex Doppler ultrasound. Of the 24 men scanned, 17 had some vascular abnormality: arterial insufficiency in 8, venous leak in 4 and a borderline result in 5. The finasteride group's total IIEF score was higher (better) than the controls' (median 35 vs 29), with no difference in the erectile function domain (9 vs 11, p = 0.378). The finasteride group reported more urinary symptoms (IPSS 10 vs 3) and depressive symptoms (PHQ-9 10 vs 1), and 2 of the 25 men died by suicide during or after the study.", "study_type": "prospective case-control", "sample_size": "25 cases / 28 controls (methods also state 25 controls; 14 and 15 controls completed the IIEF and IPSS)", "keywords": [ "penile vascular", "duplex Doppler", "case-control", "erectile dysfunction", "IIEF", "Khera" ], "relevance": "Penile duplex Doppler findings in men with persistent symptoms after finasteride for hair loss, a possible peripheral vascular correlate for the corpus's clinical axis alongside neuropathy findings. Only the finasteride group was scanned, and the 68% abnormal figure includes 5 borderline results.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed; modest sample. Described as prospective, but questionnaire and laboratory data were extracted from medical records, and the Doppler endpoint had no control group.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-009", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "Penile Vascular Abnormalities After Stopping 5ARIs | Persistent Side Effects of 5-alpha-Reductase Inhibitors (two articles, same paper)", "fulltext_url": "https://tau.amegroups.com/article/viewFile/39898/pdf", "fulltext_source": "publisher OA", "oa_status": "diamond", "oa_license": "cc-by-nc-nd", "pmid": "32676403", "plain": { "summary": "Doctors at one US clinic compared 25 men who had taken finasteride for hair loss and reported lasting side effects with 28 men who had not taken it, using standard questionnaires. The finasteride group reported more urinary symptoms and more low mood, but their overall sexual-function scores were not worse and their erection scores were similar. Of the 24 men in the finasteride group who had a blood-flow scan of the penis, 17 had an abnormal or borderline result; the comparison group was not scanned. Two men in the finasteride group died by suicide during or after the study.", "caveat": "It can't show that finasteride caused these differences, because the men were patients at a clinic for sexual problems, the comparison group was older and heavier and often skipped the questionnaires, and only the finasteride group had the scan." }, "evidence": { "design": "Single-centre comparison of men with persistent symptoms after finasteride for hair loss and men without 5-ARI exposure (the authors call it a prospective case-control study), with penile duplex Doppler ultrasound in the finasteride group only", "design_class": "case-control", "setting": "Urology clinic, Baylor College of Medicine Medical Center, Houston, Texas (USA), March 2013 to September 2018", "population": "Men over 18 seen for sexual dysfunction at the principal investigator's clinic. Cases, men who had taken finasteride for hair loss (one later took dutasteride for 24 months) and reported persistent effects; median age 38 (IQR 33–42), median BMI 24.5. Controls, men without 5-ARI exposure being evaluated for circumcision; median age 41 (IQR 35–62, p = 0.13), median BMI 30.6 (p < 0.001).", "n": 53, "n_note": "25 cases and 28 controls per the abstract and methods, though the methods also say \"Twenty-five control patients\" were included. Completed: IIEF 23 cases and 14 controls; IPSS 23 and 15. Doppler in 24 cases, no controls.", "exposure": "Finasteride for hair loss, median 18 months (IQR 4–96); 11 of 25 (44%) at about 1 mg (0.2–1.25 mg), dose for the others not reported. Time since stopping is not reported.", "comparator": "Men without 5-ARI exposure evaluated for circumcision (questionnaires only)", "outcome": "IIEF (total and domains), IPSS (urinary symptoms), PHQ-9 (depression), Epworth Sleepiness Scale and ADAM (androgen deficiency) questionnaires. Cases only, penile duplex Doppler after intracavernosal injection (arterial insufficiency, peak systolic velocity under 25 cm/s; \"gray zone\" 25–35 cm/s; venous leak, end diastolic velocity over 5 cm/s) and non-validated genital and musculoskeletal symptom surveys.", "follow_up": "None (single assessment); baseline, laboratory and questionnaire results extracted from medical records", "results": [ { "text": "Doppler (cases only, 24 scanned): 17 had \"some vascular abnormality\", reported as 17 of 25 (68%); of the 24 scanned it is 71%. Arterial insufficiency 8 (reported as 32%; 33% of 24), gray zone 5 of 25 (20%), venous leak 4 (reported as 16%; 17% of 24). The three categories sum to 17, so the total includes the 5 gray-zone men; arterial insufficiency or venous leak alone is 12 of 24 (50%)", "where": "p. 1204" }, { "text": "Total IIEF was higher (better) in the finasteride group, median 35 (IQR 29–43) vs 29 (27–32), p = 0.035. Erectile function domain 9 vs 11 (p = 0.378); sexual desire 9 vs 4 and overall satisfaction 10 vs 5 were higher in the finasteride group (both p < 0.001)", "where": "pp. 1203–1205, Table 2" }, { "text": "Total IPSS 10 (IQR 5–16) vs 3 (2–8), p = 0.009, worse for incomplete emptying, frequency, weak stream and urinary quality of life", "where": "p. 1204, Table 3" }, { "text": "PHQ-9 10 (IQR 6.5–16) vs 1 (0–2), p < 0.001, higher on 8 of 9 items, including thoughts of being better off dead or of self-harm (1 [0–1] vs 0 [0–0], p = 0.007). Sleepiness (ESS) did not differ, 5.5 vs 6 (p = 0.929)", "where": "pp. 1204–1205, Table 4" }, { "text": "18 of 25 cases (72%) had a chart-documented history of depression with or without anxiety; 2 of 25 (8%) died by suicide during or after the study, none of the controls", "where": "p. 1205" }, { "text": "Self-reported by cases: at least one genital complaint 18 of 25 (72%), genital pain or numbness 15 (60%), at least one musculoskeletal complaint 19 (76%). Fatigue is given as \"12 of 25 (45%)\", but 12 of 25 is 48%; muscle atrophy as \"5 of 25 (25%)\" on p. 1204 and 20% on p. 1206 (5 of 25 is 20%)", "where": "pp. 1204, 1206" } ], "limitations_stated": [ "Survey completion rates differed between groups", "Variable duration of 5-ARI therapy", "Selection bias", "No questionnaire data from before 5-ARI use", "No Doppler results in the control arm", "Depression and suicidality findings may be confounded by higher rates of suicidal ideation in men with hair loss", "The ADAM erection-strength item may reflect the age difference or baseline erections" ], "design_notes": [ "No control comparison exists for the vascular finding in the title, and all participants came from men seen for sexual dysfunction", "Cases scored higher than controls on IIEF sexual desire, yet on the ADAM questionnaire more often reported decreased libido (p = 0.006); the paper does not reconcile the two", "Controls were older and heavier, only half completed the IIEF, testosterone was available for 3 controls and DHT for none, and comparisons were unadjusted", "Described as prospective, but data were extracted from medical records; no definition of persistence or time since stopping is given", "Reported median DHT (366 ng/dL) lies below its own IQR (373–509), and a DHT this close to the testosterone median (450 ng/dL) would be unusual, so the figure or unit may be in error" ], "funding": "Unrestricted grant from the Post-Finasteride Foundation; one author (Pastuszak) supported by an NIH K08 award (K08DK115835-01) and a Urology Care Foundation Rising Stars award. The paper does not state the funders' role.", "interests": "Khera is a consultant for Endo, AbbVie and Boston Scientific; the other authors declare none", "supports": "That men seen at one clinic with persistent symptoms after finasteride for hair loss report more urinary and depressive symptoms than an unexposed clinic group, and that many had abnormal or borderline penile Doppler results. With no scans in controls and similar erectile-function scores, it cannot show that finasteride causes vascular changes or how common they are.", "extracted_from": "fulltexts/LIT-009-Penile-vascular-abnormalities-in-young-men-with-pe.pdf (publisher PDF, CC BY-NC-ND 4.0, 9 pp.; page refs are the printed journal pages 1201–1209; the first page carries no printed number and is p. 1201)", "extracted": "2026-10-10" } }, { "item_id": "LIT-010", "source_type": "peer-reviewed paper", "title": "Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study", "authors": "Moussa Laanani, Alain Weill, Fabrice Jollant, Mahmoud Zureik, Rosemary Dray‐Spira", "journal_or_site": "Scientific Reports", "year_or_date": 2023, "doi": "10.1038/s41598-023-32356-3", "url": "https://doi.org/10.1038/s41598-023-32356-3", "abstract_or_summary": "Using the French national health data system, investigators compared suicidal outcomes between 69,786 new finasteride users and 217,577 new dutasteride users aged 50+ treated for prostate enlargement (2012–2016), with inverse-probability weighting for psychiatric and medical confounders. Overall, finasteride was not associated with a statistically significant excess of suicide death or self-harm hospitalization versus dutasteride, although self-harm with intensive care admission was more frequent (13 vs 16 events; HR 2.60, 95% CI 1.25–5.38). In men with a history of mood disorders, finasteride was associated with more of the composite outcome (HR 1.64, 1.00–2.68), suicide death (HR 2.71, 1.07–6.91), violent self-harm (HR 3.11, 1.01–9.61) and self-harm with intensive care admission (HR 3.97, 1.26–12.5), each based on few events (25, 8, 6 and 7 on finasteride). Follow-up ended when men stopped or switched treatment (median treatment 66 vs 87 days), so the study did not address suicidal risk after discontinuation.", "study_type": "retrospective cohort (nationwide claims)", "sample_size": "69,786 finasteride vs 217,577 dutasteride new users", "keywords": [ "suicide", "self-harm", "finasteride", "dutasteride", "nationwide cohort", "pharmacoepidemiology", "SNDS" ], "relevance": "The largest comparative safety study of finasteride versus dutasteride on suicidal\noutcomes — critical quantitative context for the corpus's neuropsychiatric thread and\nfor the 2026 meta-analysis (LIT-A-018).\n", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Nature-portfolio journal; claims-data design; BPH population (older men), not the young AGA population most associated with PFS.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-010", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.nature.com/articles/s41598-023-32356-3.pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "37002313", "plain": { "summary": "Researchers used France's national health insurance records to follow nearly 290,000 men aged 50 or over who started finasteride, or a similar drug called dutasteride, for an enlarged prostate. While the men were taking the drug (usually for only a few months), suicide deaths and hospital stays for self-harm were rare with both: about 1 in 1,300 men on finasteride and 1 in 1,600 on dutasteride. After allowing for differences between the groups, finasteride did not show a clearly higher risk overall. In men with a past mood disorder such as depression, finasteride was linked with more suicide deaths and serious self-harm, but this rests on small numbers (8 suicide deaths among men on finasteride and 10 in the larger group on dutasteride).", "caveat": "It can't show whether either drug raises risk compared with taking neither, because it only compared the two drugs, and it stopped following men once they stopped or switched, so it says nothing about effects after stopping or about younger men taking the lower hair-loss dose." }, "evidence": { "design": "Nationwide retrospective cohort of new users in linked claims, hospital and death-registry data, comparing finasteride with dutasteride (active comparator); Cox models with inverse probability of treatment weighting (IPTW)", "design_class": "observational-cohort", "setting": "French National Health Data System (SNDS), linking outpatient claims, hospital discharges and the causes-of-death registry; restricted to the general health insurance scheme (76% of residents). Treatment starts 1 January 2012 to 30 June 2016, follow-up to 31 December 2016.", "population": "Men aged 50 or older newly starting finasteride 5 mg or dutasteride 0.5 mg (alone or with an alpha-blocker), with no dispensing of either drug in 2011. Men aged 49 or younger were excluded to limit hair-loss use of the reimbursed 5 mg tablet. Median age 72.0 (finasteride) vs 71.1 (dutasteride) in the abstract and on p. 4; Table 1 gives 71.7 for dutasteride. Prior psychiatric history 28.4% vs 25.6%; prior mood disorder 12.4% (8,638) vs 10.8% (23,503).", "n": 287363, "n_note": "69,786 finasteride and 217,577 dutasteride new users (31,344.9 and 110,329.4 person-years), from 279,332 and 554,773 men dispensed the drugs", "exposure": "Finasteride 5 mg (ATC G04CB01); exposure days from tablets dispensed plus a 15-day grace period", "comparator": "Dutasteride 0.5 mg new users (ATC G04CB02, G04CA52); no unexposed group", "outcome": "Primary, the first of suicide death (ICD-10 X60–X84 as underlying cause on the death certificate) or hospitalisation for self-harm (same codes). Secondary, each separately, and severe self-harm (violent means, X66–X83, or intensive care admission). Weighted for age, start year, prostatic and psychiatric history and treatments, and Charlson comorbidities; analyses repeated by psychiatric history and with follow-up cut at 90 days.", "follow_up": "On treatment only, from first dispensing to event, stopping or switching, death or 31 December 2016. Median treatment duration 66 days (IQR 29–182) for finasteride and 87 days (31–220) for dutasteride.", "results": [ { "text": "Whole cohort, suicide death or self-harm hospitalisation: 52 events (1.66 per 1,000 person-years) on finasteride vs 133 (1.21) on dutasteride; HR 1.21 (95% CI 0.87–1.67). Rates recompute from the counts and person-years", "where": "pp. 1, 4–5; Table 2, p. 7" }, { "text": "Separately: suicide death 18 (0.57) vs 47 (0.43), HR 1.25 (0.72–2.16); self-harm hospitalisation 34 (1.08) vs 87 (0.79), HR 1.17 (0.79–1.75)", "where": "Table 2, p. 7" }, { "text": "Self-harm with intensive care admission, whole cohort: 13 (0.41) vs 16 (0.15), HR 2.60 (1.25–5.38). Self-harm by violent means: 11 vs 21, HR 1.75 (0.84–3.64)", "where": "p. 5; Table 3, p. 8" }, { "text": "Men with a history of mood disorders: composite 25 vs 46 events, HR 1.64 (1.00–2.68; p = 0.049); suicide death 8 vs 10, HR 2.71 (1.07–6.91); violent self-harm 6 vs 6, HR 3.11 (1.01–9.61); self-harm with intensive care 7 vs 5, HR 3.97 (1.26–12.5)", "where": "pp. 1, 5; Tables 2–3, pp. 7–8" }, { "text": "Men with no psychiatric history or prior self-harm: composite 12 vs 49 events, HR 0.78 (0.41–1.47); suicide death 5 vs 21, HR 0.77 (0.29–2.05)", "where": "Table 2, p. 7" }, { "text": "First 90 days only: composite 32 vs 64 events, HR 1.46 (0.95–2.25). In men with prior mood disorders, suicide death 3 vs 5, HR 4.66 (1.10–19.7), and self-harm with intensive care 4 vs 1, HR 11.4 (1.29–100.1)", "where": "Tables 2–3, pp. 7–8" } ], "limitations_stated": [ "Few events in the psychiatric subgroups; those results need caution and confirmation", "Psychiatric disorders are hard to identify in SNDS, so residual confounding by their presence and severity cannot be excluded", "Possible residual confounding from missing sociodemographic data", "Self-harm codes cannot separate suicide attempts from non-suicidal self-injury; only hospitalised acts are captured", "Hair loss may be more common in the finasteride group and could not be adjusted for; this would overestimate the finasteride risk", "Cannot distinguish a raised risk with finasteride from a protective effect of dutasteride", "Restricted to the general insurance scheme (excluding, e.g., farmers), reducing power", "Results cannot be directly generalised to 1 mg finasteride for hair loss" ], "design_notes": [ "Active-comparator design, so it shows only whether finasteride differs from dutasteride; an effect shared by both drugs would not appear", "Follow-up stopped at discontinuation or switch and treatment episodes were short (mean on-treatment follow-up, from person-years / n, about 0.45 vs 0.51 years), so it addresses risk during treatment, not after stopping", "Indication is not recorded in the database; prostate enlargement is inferred from age 50 or over and the 5 mg / 0.5 mg doses", "Tables 2–3 report 45 subgroup-by-outcome rows (44 estimable) without adjustment for multiple comparisons; 10 have p < 0.05, and the significant subgroup estimates rest on 3 to 25 events in the finasteride arm", "Outcomes cover only deaths and hospital-treated self-harm, not suicidal thoughts, depression or self-harm without admission", "Exposure is inferred from pharmacy dispensing, not confirmed intake" ], "funding": "None (\"This research received no funding\"); the authors are from Epiphare (French medicines agency ANSM and national health insurance CNAM) and academic centres", "interests": "None declared", "supports": "That, during treatment for an enlarged prostate in men aged 50 or over, finasteride 5 mg was not associated with more suicide deaths or self-harm admissions overall than dutasteride, with a signal in men with prior mood disorders that rests on few events. It cannot address risk compared with no treatment, risk after stopping, or the 1 mg hair-loss dose in younger men.", "extracted_from": "fulltexts/LIT-010-Suicidal-risk-associated-with-finasteride-versus-d.pdf (publisher PDF, CC BY 4.0, 12 pp.; page refs are the printed article page numbers 1–12, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-011", "source_type": "peer-reviewed paper", "title": "Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride", "authors": "Qingpin Xiao, Lei Wang, Shreyas Supekar, Tao Shen, Heng Liu, Fei Ye, Junzhou Huang, Hao Fan, Zhiyi Wei, Cheng Zhang", "journal_or_site": "Nature Communications", "year_or_date": 2020, "doi": "10.1038/s41467-020-19249-z", "url": "https://doi.org/10.1038/s41467-020-19249-z", "abstract_or_summary": "The authors reported the first atomic structure of human steroid 5-alpha-reductase 2, the enzyme finasteride inhibits, resolved at 2.8 angstroms. It revealed an unusual seven-transmembrane topology. The bound ligand was not finasteride itself but an NADP–dihydrofinasteride adduct, an intermediate of the enzyme acting on finasteride, held in a largely enclosed cavity; this showed how finasteride blocks the enzyme. How the enzyme reduces testosterone to dihydrotestosterone was proposed from a computer-docked testosterone pose, supported by two mutants (E57Q and Y91F) that reduced or abolished activity. The work filled a long-standing gap in understanding this membrane-bound steroid enzyme and provided a template for studying related reductases and inhibitor design.", "study_type": "structural biology (protein crystallography)", "sample_size": "n/a (molecular structure)", "keywords": [ "SRD5A2", "crystal structure", "finasteride binding", "steroid metabolism", "enzyme mechanism" ], "relevance": "First atomic structure of a finasteride-derived adduct bound to its target enzyme (SRD5A2), showing how finasteride binds and blocks the enzyme at the molecular level — the mechanistic anchor for the corpus's gene/enzyme axis.", "verification_status": "verified-crossref-openalex", "quality_notes": "High-impact peer-reviewed journal; fundamental structural biology, no clinical component.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-011", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.nature.com/articles/s41467-020-19249-z.pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "32702725", "plain": { "summary": "Finasteride works by blocking an enzyme, 5-alpha-reductase type 2, that turns testosterone into a stronger hormone called DHT. This team produced the first detailed 3D map of the human enzyme, made by shining X-rays through tiny crystals of the protein with the drug inside. The map shows the drug fused to the enzyme's helper molecule and sealed inside a pocket in the enzyme, which fits with earlier lab measurements that an enzyme blocked this way stays blocked for weeks. It also shows which parts of the enzyme do the work, and why some inherited faults in its gene stop it working.", "caveat": "It can't show what the drug does in a person's body: it is a picture of one protein, made in insect cells and studied in the lab, so it says nothing about side effects or whether any effects last after stopping." }, "evidence": { "design": "Structural biology: X-ray crystal structure of human steroid 5α-reductase 2 (SRD5A2) with finasteride and NADPH, with computer docking, molecular dynamics simulations, two-residue mutagenesis with enzyme-activity assays, and mapping of disease-causing mutations", "design_class": "in-vitro", "setting": "Laboratory study (Southern University of Science and Technology, Shenzhen; University of Pittsburgh; A*STAR Bioinformatics Institute, Singapore; Tencent AI Lab); X-ray data collected at the Advanced Photon Source, Argonne", "population": "Recombinant full-length human SRD5A2 made in insect (Sf9) cells and purified in the presence of finasteride; no human or animal participants", "n": null, "n_note": "Not applicable; one structure (diffraction data merged from 5 crystals), enzyme assays repeated 3 to 5 times per condition, 4 simulations", "exposure": "Finasteride (0.5–1.0 µM throughout purification; 0.5 mM in the activity assay) with the cofactor NADPH", "comparator": "Wild-type enzyme vs E57Q and Y91F mutants, and with vs without finasteride, in the activity assay; comparison with published structures of steroid 5β-reductase (AKR1D1), a bacterial sterol reductase (MaSR1) and ICMT", "outcome": "Atomic structure and ligand binding mode; conversion of testosterone to DHT (DHT/testosterone ratio by mass spectrometry); protein flexibility in simulations; location of disease-causing mutations", "follow_up": "Not applicable (assay incubation 4 hours at 37 °C; simulations about 1.25 µs per system)", "results": [ { "text": "Structure solved at 2.8 Å; the enzyme has seven transmembrane helices (unlike the 10 of the bacterial MaSR1), with all 254 residues modelled except the first four and S39–A43; deposited as PDB 7BW1", "where": "pp. 1–3, 9, Table 1 (p. 3)" }, { "text": "The bound ligand is not finasteride itself but an NADP–dihydrofinasteride adduct, with the NADPH C-4 and finasteride C-2 atoms about 1.5 Å apart (a covalent bond), sealed in a cavity open only to the membrane; this matches earlier enzymology. Citing that work (Ki ≤ 3 × 10⁻¹³ M, koff = 2.74 × 10⁻⁷ s⁻¹), the paper gives a half-life of about 31 days for the enzyme–adduct complex; ln 2 / koff gives about 29 days", "where": "p. 3, Fig. 2 (p. 4)" }, { "text": "Proposed mechanism: residues E57 and Y91 hold the steroid's C-3 carbonyl so NADPH can transfer a hydride; the testosterone pose comes from computer docking (hydride about 2.5 Å from the Δ4,5 bond). Y91F essentially abolished DHT formation and E57Q reduced it (Fig. 3e, read from the chart, DHT/T about 2.2% wild type, 1.0% E57Q, near 0 Y91F, and about 0.5% wild type with 0.5 mM finasteride)", "where": "p. 4, Fig. 3 (p. 5)" }, { "text": "Selectivity: arginine R114 hydrogen-bonds finasteride's tert-butylacetamide tail; SRD5A1 has a methionine at this position, which may explain finasteride's preference for type 2", "where": "pp. 3–4" }, { "text": "Simulations showed the cytosolic loop L1 (and less so L5) to be highly flexible, opening the NADPH pocket; the authors propose L1 acts as a gate for cofactor exchange, consistent with its higher crystal B-factors", "where": "p. 5, Fig. 4 (p. 6)" }, { "text": "Over 100 SRD5A2 gene mutations cause 5α-reductase deficiency; most mapped missense sites line the ligand cavity (e.g. R227Q, R171S, likely disrupting NADP binding), while others such as C133G and R246 changes likely affect folding or stability", "where": "p. 6, Fig. 5 (p. 7)" } ], "limitations_stated": [ "The enzyme aggregated without a ligand, so it was purified and crystallised with finasteride throughout; there is no inhibitor-free structure", "Experimental (anomalous) phasing failed; the structure was solved by molecular replacement from a computer-predicted model", "The testosterone pose is from docking, not observed, and the catalytic and inhibition mechanisms are proposed", "Residues 1–4 and S39–A43 were not resolved and were modelled for the simulations", "The adduct probably formed from insect-cell NADPH during expression", "Structures of other membrane steroid reductases (SRD5A3, DHCR7) are still needed" ], "design_notes": [ "A lab structure of one protein made in insect cells; it carries no information on doses, tissue levels or effects in people", "Activity assays used insect-cell membranes with 0.5 mM testosterone and 0.5 mM finasteride at pH 5.0, conditions chosen for the assay rather than clinical exposures (p. 9)", "Mutagenesis covered two residues, each mutant tested in 3 experiments", "The Fig. 3 legend gives four independent experiments for wild type plus finasteride (p. 5); the Methods say five (p. 9)", "Simulations are described as about 1.25 µs for each of four systems but about 5.4 µs in total, 2.7 µs per state (p. 9); four times 1.25 is 5.0", "SRD5A1 and SRD5A3 were compared only by sequence, and gene regulation (expression, methylation) is outside the study's scope" ], "funding": "US National Institutes of Health grant R35GM128641 (to C.Z.); National Natural Science Foundation of China 31971131 and 31770791 and Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Fundamental Research Institutions 2019SHIBS0002 (to Z.W.); Biomedical Research Council of A*STAR (to S.S. and H.F.) (p. 10)", "interests": "None declared", "supports": "How finasteride binds and blocks human SRD5A2 at the molecular level, and why the block at the enzyme is long lasting. It cannot support any claim about clinical effects, side effects, persistence of symptoms in people, or regulation of the SRD5A2 gene.", "extracted_from": "fulltexts/LIT-011-Structure-of-human-steroid-5-reductase-2-with-the.pdf (publisher PDF, Nature Communications 11, 5430, CC BY 4.0, 11 pp.; pages cited are the journal's printed page numbers, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-012", "source_type": "peer-reviewed paper", "title": "Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target", "authors": "Silvia Giatti, Alessandro Di Domizio, Silvia Diviccaro, Eva Falvo, Donatella Caruso, Alessandro Contini, Roberto Cosimo Melcangi", "journal_or_site": "Journal of Medicinal Chemistry", "year_or_date": 2021, "doi": "10.1021/acs.jmedchem.0c02039", "url": "https://doi.org/10.1021/acs.jmedchem.0c02039", "abstract_or_summary": "Reasoning that finasteride's sexual, psychological, and physical complaints may involve\nactions beyond 5-alpha-reductase inhibition, the Melcangi group ran a proteome-wide\ncomputational screen for additional finasteride binding partners. The screen flagged\nphenylethanolamine N-methyltransferase (PNMT) — the rate-limiting enzyme in epinephrine\n(adrenaline) synthesis — as a plausible off-target, a prediction supported by molecular\ndocking. The finding opens a non-androgenic mechanistic route (stress-hormone\ndysregulation) for finasteride's systemic effects.\n", "study_type": "in-silico proteome-wide screening (computational)", "sample_size": "n/a (computational screen of human proteome structures)", "keywords": [ "off-target", "PNMT", "epinephrine", "proteome-wide screening", "docking", "Melcangi", "Giatti", "stress hormone" ], "relevance": "Identifies a novel non-5AR finasteride target in the adrenaline-synthesis pathway —\na genuinely new mechanistic hypothesis for systemic PFS symptoms, from the core\nneurosteroid group.\n", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed ACS journal; computational prediction — experimental validation status should be checked before treating PNMT as established.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-012", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c02039", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "33843213" }, { "item_id": "LIT-013", "source_type": "peer-reviewed paper", "title": "Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens", "authors": "Alessio Soggiù, Cristian Piras, Viviana Greco, Paola Devoto, Andrea Urbani, Luigino Calzetta, Marco Bortolato, Paola Roncada", "journal_or_site": "Psychoneuroendocrinology", "year_or_date": 2016, "doi": "10.1016/j.psyneuen.2016.10.001", "url": "https://doi.org/10.1016/j.psyneuen.2016.10.001", "abstract_or_summary": "Building on evidence that finasteride can blunt dopamine-receptor signalling in the\nnucleus accumbens — a hub of the reward circuit — the authors profiled protein expression\nin this region after acute and subchronic finasteride treatment in rats (n=5 per group)\nusing two-dimensional electrophoresis coupled with mass spectrometry. The study maps\nwhich protein networks shift when 5-alpha-reductase is blocked in a reward-related brain\nregion, aiming to explain both the drug's adverse psychological effects and its\nparadoxical therapeutic signals in dopamine-linked neuropsychiatric conditions.\n", "study_type": "animal (rat proteomics)", "sample_size": "n=5/group (acute and subchronic treatment arms)", "keywords": [ "proteomics", "nucleus accumbens", "dopamine", "reward circuit", "rat", "neurosteroid", "2D electrophoresis" ], "relevance": "Direct protein-expression evidence of finasteride's impact on reward-circuit\nneurochemistry — bridges the corpus's gene-expression/proteomics axis with the\nanhedonia and motivational symptoms reported in PFS.\n", "verification_status": "verified-crossref-openalex-pubmed", "quality_notes": "Peer-reviewed (PMID 27750143); small animal sample; acute/subchronic dosing rather than withdrawal model.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-013", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "27750143" }, { "item_id": "LIT-014", "source_type": "peer-reviewed paper", "title": "Finasteride Treatment Inhibits Adult Hippocampal Neurogenesis in Male Mice", "authors": "Benedikt Römer, Natascha Pfeiffer, Sabina Lewicka, Nadia Benabdallah, Miriam Annika Vogt, Michael Deuschle, Barbara Vollmayr, Peter Gass", "journal_or_site": "Pharmacopsychiatry", "year_or_date": 2010, "doi": "10.1055/s-0030-1249095", "url": "https://doi.org/10.1055/s-0030-1249095", "abstract_or_summary": "Because 5-alpha-reductase also generates neurosteroids implicated in depression, the\nauthors asked whether finasteride alters adult hippocampal neurogenesis in male mice.\nAfter 7 days of treatment, brain dihydrotestosterone fell and the number of newborn\ncells and young neurons in the hippocampus was significantly reduced; neurogenesis had\nrecovered by 35 days after the last dose. The authors propose that structural effects on\nneural plasticity could contribute to depressive episodes reported with finasteride.\n", "study_type": "animal (mouse)", "sample_size": "not stated in abstract (male C57BL/6N mice, vehicle-controlled)", "keywords": [ "hippocampal neurogenesis", "mouse", "neurosteroid", "depression", "neural plasticity", "DHT" ], "relevance": "Early demonstration that finasteride suppresses hippocampal neurogenesis via\nneurosteroid depletion — a foundational animal-mechanism paper for the corpus's\nneurosteroid/depression thread.\n", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed; effect was reversible within 35 days in this short-treatment model (contrast with human persistence claims).", "sweep_date": "2026-10-07", "axis_id": "LIT-A-014", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "20486040" }, { "item_id": "LIT-015", "source_type": "peer-reviewed paper", "title": "Finasteride withdrawal induces anxiety‐like behavior and novelty avoidance in adult male rats", "authors": "Lucia Cioffi, Silvia Diviccaro, Gabriela Chrostek, Francesco Paolo Ulloa Severino, Silvia Giatti, Diego Scheggia, Roberto Cosimo Melcangi", "journal_or_site": "Journal of Neuroendocrinology", "year_or_date": 2026, "doi": "10.1111/jne.70150", "url": "https://doi.org/10.1111/jne.70150", "abstract_or_summary": "Adult male rats received 20 days of finasteride and were then tested both on-drug and\none month after discontinuation using open-field, elevated-plus-maze, and novelty-seeking\nparadigms. Effects during treatment were mild, but a clear anxiety-like phenotype —\nhyperactivity, reduced centre exploration, and marked avoidance of novel stimuli —\nemerged at withdrawal. The authors present this as an animal analogue of\npost-discontinuation vulnerability in PFS and argue for monitoring patients after, not\njust during, finasteride therapy. The study used forty rats (finasteride or vehicle) and was funded by the Post-Finasteride Syndrome Foundation; it is open access under CC-BY.", "study_type": "animal (rat, withdrawal model)", "sample_size": "not stated in abstract (adult male rats, vehicle-controlled)", "keywords": [ "finasteride withdrawal", "anxiety", "novelty avoidance", "rat", "animal model", "PFS model", "Diviccaro", "Melcangi" ], "relevance": "The first dedicated finasteride-withdrawal animal model from the Melcangi group,\nshowing delayed anxiety-like effects emerging after discontinuation — the closest\nexperimental analogue of the post-drug persistence defining PFS.\n", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed; very recent (2026); behavioural model — translational relevance to human PFS requires caution.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-015", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12949371/", "fulltext_source": "PMC", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "41761643", "pmcid": "PMC12949371", "also_listed_in": [ "researcher-list-2026-10" ], "note": "Merged in v1.14 with RES-004 (same DOI 10.1111/jne.70150, PMID 41761643 and title); RES-004 is now a tombstone pointing here. The PMC full text replaces the Wiley DOI link as the free full-text source." }, { "item_id": "LIT-016", "source_type": "peer-reviewed paper", "title": "Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year", "authors": "Yu Ra Lee, Eunju Im, Haksoon Kim, Bark‐Lynn Lew, Woo‐Young Sim, Jeongae Lee, Han Bin Oh, Ki Jung Paeng", "journal_or_site": "Metabolites", "year_or_date": 2020, "doi": "10.3390/metabo10040131", "url": "https://doi.org/10.3390/metabo10040131", "abstract_or_summary": "Using LC-MS–based untargeted and targeted metabolomics, the authors compared urinary\nsteroid profiles of men treated with finasteride for one year for hair loss against\nhealthy controls. Beyond the expected DHT suppression (confirmed via the urinary DHT/T\nratio), they found broader shifts in steroid hormone biosynthesis, including altered\nurinary androgens and estrogens. The authors conclude that finasteride's systemic\nmetabolic footprint extends past androgen blockade and flag urinary estrogens as a\ncandidate biomarker axis for further PFS investigation.\n", "study_type": "human metabolomics (case-control)", "sample_size": "not stated in abstract (MPB patients on 1-year finasteride vs healthy controls)", "keywords": [ "metabolomics", "urine", "steroid signature", "estrogen", "DHT/T ratio", "LC-MS", "biomarker" ], "relevance": "Human in-vivo evidence that finasteride perturbs systemic steroid metabolism beyond DHT\n(including estrogens) — supports the corpus's broad-endocrine-disruption framing and\nsuggests urinary steroid biomarkers.\n", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed MDPI journal; on-treatment (not post-discontinuation) profiling; sample size not in abstract.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-016", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.mdpi.com/2218-1989/10/4/131/pdf?version=1585575064", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "32235609" }, { "item_id": "LIT-017", "source_type": "peer-reviewed paper", "title": "Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low‐Dose Finasteride: A Pharmacovigilance Study", "authors": "Ayad K. Ali, Balraj S Heran, Mahyar Etminan", "journal_or_site": "Pharmacotherapy", "year_or_date": 2015, "doi": "10.1002/phar.1612", "url": "https://doi.org/10.1002/phar.1612", "abstract_or_summary": "Mining US FDA adverse-event reports (1998–2013) for men aged 18–45 on low-dose (1 mg)\nfinasteride, the authors applied disproportionality analysis to detect signals for\npersistent sexual dysfunction and suicidal ideation. Of 4,910 reports, 577 described\npersistent sexual dysfunction and 39 described suicidal ideation; nearly 90% of the\nsuicidal-ideation cases also reported sexual dysfunction, and most events were rated\nserious (death, hospitalization, or disability). The study provided early quantitative\nbacking for the persistent-sexual-dysfunction signal specifically in young hair-loss\npatients.\n", "study_type": "pharmacovigilance disproportionality analysis (FAERS)", "sample_size": "4,910 adverse-event reports (577 persistent sexual dysfunction; 39 suicidal ideation)", "keywords": [ "pharmacovigilance", "FAERS", "suicidal ideation", "persistent sexual dysfunction", "low-dose finasteride", "young men", "disproportionality" ], "relevance": "Early quantitative signal for persistent sexual dysfunction and suicidality in young\nlow-dose finasteride users — the pharmacovigilance evidence base underlying later\nregulatory label changes.\n", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed; spontaneous-report data (reporting biases); disproportionality signals are hypothesis-generating, not causal.", "sweep_date": "2026-10-07", "axis_id": "LIT-A-017", "sweep_axis": "pfs", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "26133534" }, { "item_id": "LIT-018", "collection_tag": "literature-sweep-2026-10", "title": "5-α-reductase inhibitors and the risk of suicide and neuropsychiatric symptoms: a meta-analysis of observational studies", "doi": "10.3389/fruro.2026.1881635", "url": "https://www.frontiersin.org/journals/urology/articles/10.3389/fruro.2026.1881635/full", "status": "duplicate-tombstone", "duplicate_of": "PFS-012", "tombstone_note": "Deduplicated in corpus v1.14: this record described the same paper as PFS-012 (same title, journal and year (Frontiers in Urology 2026)). PFS-012 is the canonical record; this record's doi, abstract_or_summary, relevance, keywords, verification_status, study_type, sample_size, quality_notes, fulltext_url, fulltext_source, oa_status, oa_license, authors moved there, and its listing in literature-sweep-2026-10 is now PFS-012's also_listed_in. Kept as a tombstone per the no-silent-deletions policy; do not count as a separate paper." }, { "item_id": "LIT-019", "collection_tag": "literature-sweep-2026-10", "title": "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases", "doi": "10.3233/JRS-180744", "url": "https://doi.org/10.3233/JRS-180744", "status": "duplicate-tombstone", "duplicate_of": "CROSS-001", "tombstone_note": "Deduplicated in corpus v1.14: this record described the same paper as CROSS-001 (same DOI 10.3233/JRS-180744, PMID 29733030 and title). CROSS-001 is the canonical record; this record's abstract_or_summary, relevance, keywords, verification_status, study_type, sample_size, quality_notes, fulltext_url, fulltext_source, oa_status, oa_license moved there, and its listing in literature-sweep-2026-10 is now CROSS-001's also_listed_in. Kept as a tombstone per the no-silent-deletions policy; do not count as a separate paper." }, { "item_id": "LIT-020", "source_type": "peer-reviewed paper", "title": "Citizen petition: Sexual side effects of SSRIs and SNRIs", "authors": [ "David Healy" ], "journal_or_site": "International Journal of Risk & Safety in Medicine", "year_or_date": 2018, "doi": "10.3233/jrs-180745", "url": "https://doi.org/10.3233/jrs-180745", "abstract_or_summary": "This is the published text of a citizen petition asking the US FDA to require boxed warnings and label changes for all SSRI and SNRI products regarding persistent sexual dysfunction after discontinuation. The petition marshals the history of regulatory signals: a 1991 UK report of enduring dysfunction, Dutch pharmacovigilance (Lareb) case series, early case literature, the 2011 Prozac label amendment, and DSM-5's acknowledgment that SSRI-induced sexual dysfunction can persist. It documents how early trials undercounted sexual side effects and how post-marketing evidence forced regulators' attention. The same petition, filed in parallel in Europe, led the EMA to add a persistence warning to antidepressant labels in 2019.", "study_type": "regulatory petition", "sample_size": "n/a (document-based; cites case series and pharmacovigilance reports)", "keywords": [ "PSSD", "FDA", "EMA", "citizen petition", "drug labeling", "pharmacovigilance", "SSRI", "SNRI" ], "relevance": "The regulatory document behind the 2019 EMA label change on persistent post-SSRI sexual dysfunction. Essential for the corpus's regulatory/history axis; rich bibliography of early PSSD evidence. (Free full text on PubMed Central: PMC6004927.)", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed publication of an advocacy/regulatory document; argumentative rather than primary research, but historically pivotal.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-002", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://journals.sagepub.com/doi/pdf/10.3233/JRS-180745", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc", "pmid": "29733031", "fulltext_note": "Link updated 2026-10-09: IOS Press journals moved to SAGE" }, { "item_id": "LIT-021", "collection_tag": "literature-sweep-2026-10", "title": "Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin", "doi": "10.3233/jrs-210023", "url": "https://doi.org/10.3233/jrs-210023", "status": "duplicate-tombstone", "duplicate_of": "CROSS-002", "tombstone_note": "Deduplicated in corpus v1.14: this record described the same paper as CROSS-002 (same DOI 10.3233/JRS-210023 and title). CROSS-002 is the canonical record; this record's pmid, abstract_or_summary, relevance, keywords, verification_status, study_type, sample_size, quality_notes, fulltext_url, fulltext_source, oa_status, oa_license moved there, and its listing in literature-sweep-2026-10 is now CROSS-002's also_listed_in. Kept as a tombstone per the no-silent-deletions policy; do not count as a separate paper." }, { "item_id": "LIT-022", "source_type": "peer-reviewed paper", "title": "Post-SSRI sexual dysfunction & other enduring sexual dysfunctions", "authors": [ "David Healy" ], "journal_or_site": "Epidemiology and Psychiatric Sciences", "year_or_date": 2019, "doi": "10.1017/s2045796019000519", "url": "https://doi.org/10.1017/s2045796019000519", "abstract_or_summary": "Healy traces the history of enduring sexual dysfunction after antidepressants from 1991 regulator reports through the first formal PSSD descriptions in 2006, arguing the syndrome has major clinical, research, and regulatory implications that psychiatry has been slow to absorb. He discusses how trial design and reporting conventions kept sexual effects invisible, why persistent dysfunction challenges the assumption that drug effects end at discontinuation, and what the phenomenon implies for informed consent. The paper frames PSSD alongside other tardive drug-induced syndromes as a neglected area of pharmacoepidemiology.", "study_type": "review", "sample_size": "n/a", "keywords": [ "PSSD", "history of psychiatry", "pharmacoepidemiology", "informed consent", "tardive syndromes", "review" ], "relevance": "Concise historical/epidemiological framing of PSSD by the field's central researcher, in a Cambridge journal. Useful as the corpus's \"why this matters\" narrative citation.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Single-author perspective piece; interpretive rather than systematic.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-004", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.cambridge.org/core/services/aop-cambridge-core/content/view/8343798C6C29E850661020EF0CEA8968/S2045796019000519a.pdf/div-class-title-post-ssri-sexual-dysfunction-and-other-enduring-sexual-dysfunctions-div.pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc-sa", "pmid": "31543091" }, { "item_id": "LIT-023", "source_type": "peer-reviewed paper", "title": "Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants", "authors": [ "Joseph Ben-Sheetrit", "Yehonathan Hermon", "Shlomo Birkenfeld", "Yehiel Gutman", "Antonei Benjamin Csoka", "Paz Toren" ], "journal_or_site": "Annals of General Psychiatry", "year_or_date": 2023, "doi": "10.1186/s12991-023-00447-0", "url": "https://doi.org/10.1186/s12991-023-00447-0", "abstract_or_summary": "Using Israeli health-maintenance-organization (Clalit Health Services) records over a 19-year period, the authors compared 866 healthy, non-smoking men aged 21-49 who had used serotonergic antidepressants with 11,436 eligible men who had not (unmatched controls), using PDE-5 inhibitor prescriptions as the marker of erectile dysfunction (ED). Serotonergic antidepressant use was associated with roughly threefold higher odds of a PDE-5 inhibitor prescription at any time in the study period after adjustment, although only 24 of the 74 users with such a prescription had their first one after their first antidepressant. Four of 866 exposed men (0.46%, about 1 in 216) met full PSSD case criteria, which required ED treatment starting within 12 months of the antidepressant and continuing at least 1 month after stopping it. The authors reported a prevalence of 4.3 per 100,000 among male Clalit members aged 21-49 in its Tel-Aviv district (4 of 92,476), although cases were sought only among the 12,302 who met the inclusion criteria, and concluded the risk was small but real and consistent with prior PSSD literature.", "study_type": "retrospective cohort", "sample_size": "n=12,302 males (866 serotonergic-antidepressant users, 11,436 non-users); 4 users met full PSSD criteria", "keywords": [ "PSSD", "epidemiology", "risk estimate", "serotonergic antidepressants", "erectile dysfunction", "pharmacoepidemiology" ], "relevance": "One of the only quantitative PSSD estimates in the literature: 4 of 866 healthy, never-smoking men aged 21-49 with BMI under 25 (about 1 in 216), counting only erectile dysfunction treated with a PDE-5 inhibitor that began within 12 months of the antidepressant and continued at least 1 month after stopping it (3.6-14.8 months recorded). The denominator includes men who did not stop, there is no comparison with non-users and two of the four cases involved tricyclics, so it is a count under a narrow definition rather than a general PSSD risk; core epidemiology citation for the corpus.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. PSSD ascertained via ED-treatment prescriptions, so milder or non-ED phenotypes are missed; authors note this.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-005", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "Risk of Post-SSRI Sexual Dysfunction: A Retrospective Study", "fulltext_url": "https://annals-general-psychiatry.biomedcentral.com/counter/pdf/10.1186/s12991-023-00447-0", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "37085865", "plain": { "summary": "Researchers searched the health records of about 12,300 healthy, non-smoking men aged 21 to 49 at one Israeli health service. About 1 in 12 men who had taken an antidepressant that acts on serotonin (a brain chemical; most had taken an SSRI) had been prescribed an erection drug at some point, compared with 1 in 40 men who had not; for most, the records don't show the erection drug came after the antidepressant. Four of the 866 men on these antidepressants, about 1 in 216, started an erection drug within a year of the antidepressant and were still taking it at least a month after stopping the antidepressant. Their records showed about 4 to 15 months of erection-drug use by the end of the study.", "caveat": "It can't prove the antidepressants caused the problems or show that they were permanent: it used existing records, counted only erection problems treated with a prescribed erection drug in a hand-picked group of healthy men, followed the four men for months rather than years, and worked out the 1 in 216 from every man who took the drug, not only those who stopped it." }, "evidence": { "design": "Retrospective cohort study of health-maintenance-organisation records, comparing men who used serotonergic antidepressants with men who did not (logistic regression), plus a stepwise count of PSSD cases among the users", "design_class": "observational-cohort", "setting": "Clalit Health Services (CHS) database, Tel-Aviv district, Israel; a 19-year retrospective period (calendar years not stated)", "population": "Men aged 21–49 with a last recorded BMI under 25, who had never smoked, with no recorded medical or psychiatric condition or medication associated with ED (other than a history of depression or anxiety and the antidepressants themselves), no 5α-reductase inhibitor use (finasteride, dutasteride) and no alcohol or substance use disorder.", "n": 12302, "n_note": "12,302 men (866 antidepressant users, 11,436 non-users), selected from 92,476 male CHS members aged 21–49 among 309,417 members in the district", "exposure": "Any serotonergic antidepressant during the study period. Among users, SSRIs 79.9%, tricyclics 15.6%, SNRIs 8.1%, Hypericum (St John's wort) 6.1%, and smaller numbers of mirtazapine, mianserin, trazodone, vortioxetine, maprotiline and phenelzine; 76.4% used only one antidepressant.", "comparator": "Men meeting the same criteria with no serotonergic antidepressant in the study period (not matched; the groups differed slightly in age, socioeconomic status and BMI)", "outcome": "ED, defined as one or more prescriptions of a PDE-5 inhibitor (erection drug) at any time in the study period. PSSD, counted among users only: no ED treatment before the antidepressant, first PDE-5 inhibitor within 12 months of starting the antidepressant, antidepressant stopped (not through non-compliance), no active depression or anxiety diagnosis, and PDE-5 inhibitor use continuing at least 1 month after stopping.", "follow_up": "Records over a 19-year period (dates not given); the 4 PSSD cases had 3.6–14.8 months of PDE-5 inhibitor treatment by the end of the study period", "results": [ { "text": "PDE-5 inhibitor use in 74 of 866 users (8.5%) vs 286 of 11,436 non-users (2.5%); crude odds ratio 3.6 (95% CI 2.8–4.8). Recomputed from these counts, the odds ratio is 3.64 and the risk ratio about 3.4", "where": "p. 4; Tables 3–4, p. 6" }, { "text": "Adjusted for age, socioeconomic status, BMI, depression and anxiety, odds ratio 3.2 (95% CI 2.3–4.4); depression and anxiety had no significant effect beyond antidepressant use, age, BMI and socioeconomic status", "where": "pp. 4–5; Table 4, p. 6" }, { "text": "Case-finding among the 866 users: 74 had a PDE-5 inhibitor; 24 had no earlier ED treatment and a first antidepressant prescription before their first PDE-5 inhibitor; 9 started the PDE-5 inhibitor within 12 months of the antidepressant; 7 had stopped the antidepressant; 5 had not stopped through non-compliance and had no active depression or anxiety diagnosis; 4 kept using PDE-5 inhibitors for at least 1 month after stopping", "where": "Fig. 1B, p. 5" }, { "text": "PSSD in 4 of 866 users (0.46%; 866 ÷ 4 = 216.5, reported as \"1 in 216\"). The four were aged 32–42, had taken escitalopram, paroxetine, imipramine or nortriptyline for 4–8 months before starting a PDE-5 inhibitor, and had 3.6–14.8 months of PDE-5 inhibitor treatment by the end of the study period. The denominator is all 866 users; the paper does not report how many of them stopped their antidepressant", "where": "pp. 6–7; Fig. 1B, p. 5" }, { "text": "Reported prevalence 4.3 per 100,000 (4 of 92,476; recomputed 4.33). The denominator is all male CHS members aged 21–49 in the district, but cases were sought only among the 12,302 (13.3%) who met the inclusion criteria", "where": "p. 7; Fig. 1A, p. 5" } ], "limitations_stated": [ "Retrospective design, men only, and reliance on physician-diagnosed conditions for medical history (which they argue is reduced by excluding on both diagnoses and related medications)", "Counting only ED, rather than other forms of sexual dysfunction, may underestimate the true prevalence of PSSD", "The estimate reflects otherwise healthy men and may underestimate prevalence in the general population", "Requiring PDE-5 inhibitor treatment sets a high threshold for detection; many men may not seek help because of shame or unawareness" ], "design_notes": [ "The odds ratios count PDE-5 inhibitor use at any time in the study period. In Fig. 1B, 50 of the 74 users with a PDE-5 inhibitor did not have a first antidepressant prescription before their first PDE-5 inhibitor (with no earlier ED treatment), so the threefold association does not show that ED treatment followed the antidepressant", "The Methods' exclusions for PDE-5 inhibitor use before the antidepressant, non-compliance, and active depression or anxiety appear as steps in the PSSD case count (Fig. 1B), not in the cohort flow used for the odds ratios (Fig. 1A)", "The 0.46% (1 in 216) divides 4 cases by all 866 users, including men who may not have stopped (only 7 of the 9 with early ED treatment had stopped). No comparable count of persisting PDE-5 inhibitor use is given for the 11,436 non-users, so it is not an excess over background; no confidence interval is given, and it rests on 4 cases", "The 12-month window from antidepressant to first PDE-5 inhibitor (chosen to limit misattribution; the authors cite a mean delay of about 30 months in seeking ED treatment) removed 15 of the 24 users whose ED treatment began after the antidepressant", "Persistence required at least 1 month of PDE-5 inhibitor use after stopping, and the cases had 3.6–14.8 months recorded; this follow-up does not show the \"irreversible\" course named in the title", "Serotonergic antidepressants here include tricyclics, mirtazapine, mianserin, trazodone and St John's wort; two of the four case drugs named are tricyclics (imipramine, nortriptyline), so the figure is not SSRI-specific", "Highly selected sample, 12,302 of 92,476 male members aged 21–49 (13.3%); one health-service district; results may not generalise", "Table 2 has internal inconsistencies. \"Four or more\" antidepressants is given as 26 (0.9%), but the counts then sum to 884, not 866, and 26 of 866 is 3.0%; 8 men would give both 0.9% and a total of 866. SSRIs are given as 892 (79.9%), more than the 866 users; 692 would give 79.9%. The main results do not depend on these figures" ], "funding": "No specific grant from any funding agency in the public, commercial or not-for-profit sectors", "interests": "None declared", "supports": "An association, in healthy Israeli men aged 21–49, between serotonergic antidepressant use and having a PDE-5 inhibitor prescription at some point, and a count of 4 users (of 866) whose erection-drug treatment began within a year of the antidepressant and continued at least a month after stopping it. It does not establish causation, that ED treatment followed the antidepressant in most cases, or a general risk of PSSD.", "extracted_from": "fulltexts/LIT-023-Estimating-the-risk-of-irreversible-post-SSRI-sexu.pdf (publisher PDF, CC BY 4.0, 9 pp.; page refs are the printed \"Page N of 9\" numbers, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-024", "source_type": "peer-reviewed paper", "title": "Characterizing post-SSRI sexual dysfunction and its impact on quality of life through an international online survey", "authors": [ "Alaina Studt", "Margaret K. Gannon", "Joanna A. Orzel", "Ashley Vaughan", "Amy Marcia Pearlman" ], "journal_or_site": "International Journal of Risk & Safety in Medicine", "year_or_date": 2021, "doi": "10.3233/jrs-210039", "url": "https://doi.org/10.3233/jrs-210039", "abstract_or_summary": "The authors surveyed members of an online PSSD support group about the drugs implicated, symptoms experienced on and off treatment, the course of the condition, treatments tried, and effects on quality of life. Among 239 responses, most implicated SSRIs rather than SNRIs or atypical agents. After stopping the drug, symptoms improved in 45% and worsened or stayed the same in 37%. Only 12% recalled being counseled about sexual side effects before starting the antidepressant. Respondents rated the impact on quality of life as severe, underscoring the gap between patient experience and clinical recognition.", "study_type": "survey", "sample_size": "n=239 survey responses", "keywords": [ "PSSD", "survey", "quality of life", "patient experience", "informed consent" ], "relevance": "Largest published PSSD patient survey characterizing symptom course and quality-of-life impact. Direct patient-voice evidence for the corpus.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Self-selected online sample; no clinical verification of cases.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-006", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "34366299" }, { "item_id": "LIT-025", "source_type": "peer-reviewed paper", "title": "Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: A systematic review", "authors": [ "Livio Tarchi", "Giuseppe Pierpaolo Merola", "Ottone Baccaredda-Boy", "Francesca Arganini", "Emanuele Cassioli", "Eleonora Rossi", "Mario Maggi", "David S. Baldwin", "Valdo Ricca", "Giovanni Castellini" ], "journal_or_site": "Pharmacoepidemiology and Drug Safety", "year_or_date": 2023, "doi": "10.1002/pds.5653", "url": "https://doi.org/10.1002/pds.5653", "abstract_or_summary": "The authors systematically reviewed clinical evidence on sexual dysfunction persisting after SSRI discontinuation and on persistent genital arousal disorder (PGAD) linked to SSRIs. Eligible studies comprised two retrospective interventional studies, six observational studies, and eleven case reports. They found the literature insufficient to produce reliable prevalence estimates or to establish a cause-effect relationship, though continued sexual disturbance after stopping could not be entirely ruled out and persisting dysfunction may be linked to relapse of depression or anxiety; they stated that their findings support the EMA's caution about possible continued sexual disturbance after discontinuation. PGAD was reported in 6 of the 19 studies, and the authors described post-SSRI PGAD only in women and only in case reports. The review cataloged reported symptoms and the treatments that have been attempted, highlighted how thin the evidence base remains, and cautioned against routine early SSRI discontinuation.", "study_type": "systematic review", "sample_size": "19 eligible studies (2 interventional, 6 observational, 11 case reports)", "keywords": [ "PSSD", "systematic review", "persistent genital arousal disorder", "prevalence", "SSRI discontinuation" ], "relevance": "A 2023 systematic review of post-treatment sexual dysfunction evidence, covering literature to December 2022; documents exactly how sparse the literature is. Good \"state of the evidence\" anchor.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed, reputable pharmacoepidemiology journal. Concludes evidence is insufficient for prevalence/causality — an honest negative finding.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-007", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pds.5653", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc-nd", "pmid": "37294623", "plain": { "summary": "Researchers searched three medical databases, up to December 2022, for reports of sexual problems that carried on, or began, after people stopped taking an SSRI antidepressant. They found 19: two small treatment studies with no comparison group, six studies such as surveys and collections of reports, and 11 reports on single patients or small groups. Most described problems that began while people were on the drug and did not go away after stopping; unwanted, persistent genital arousal (PGAD) after stopping was described only in women. The researchers concluded the evidence was too weak to say how common these problems are or to show the drug caused them, though lasting problems could not be ruled out.", "caveat": "It can't say how common these problems are, what causes them or what helps: the 19 reports were few, small and mostly without comparison groups, and the review did not combine their numbers." }, "evidence": { "design": "Systematic review following PRISMA 2020, with a protocol registered in advance (PROSPERO CRD42021273886); narrative synthesis, no meta-analysis", "design_class": "systematic-review", "setting": "PubMed, Embase and Google Scholar; English-language papers only; last search December 2022", "population": "Published clinical data (observational or experimental studies, case series and case reports) on SSRI use with sexual dysfunction persisting, or first appearing, after treatment stopped, and on PGAD after SSRI discontinuation. Reviews, meta-analyses, opinion articles, animal studies and methods papers were excluded.", "n": 19, "n_note": "19 studies (2 retrospective interventional, 6 observational, 11 case reports) from 859 records; 73 duplicates removed, 571 excluded on title and abstract, 196 on full text (193 on criteria, 3 not in English)", "exposure": "SSRIs; included reports also covered SNRIs (venlafaxine, desvenlafaxine, duloxetine) and tricyclics (clomipramine, amitriptyline)", "comparator": "None (narrative synthesis); both interventional studies were uncontrolled", "outcome": "Prevalence or incidence, timing of onset relative to SSRI treatment, reported symptoms and attempted treatments, for PSSD and for post-SSRI PGAD. Risk of bias rated with JBI checklists, ROBINS-I and RoB 2.", "follow_up": "Not applicable (review). Included case reports followed patients for up to 2 years; the longest illness duration reported was 23 years", "results": [ { "text": "No reliable estimate of the prevalence of PSSD or post-SSRI PGAD could be made, and a cause-effect relationship between SSRI exposure and persistent sexual impairment could not be ascertained; continued disturbance after stopping \"could not be entirely ruled out\"", "where": "pp. 1053, 1056, 1064" }, { "text": "Average risk-of-bias score at least medium or higher; the authors judge most included reports at high risk of bias", "where": "pp. 1056, 1064" }, { "text": "In most studies, sexual dysfunction arose during SSRI treatment and did not recede after stopping. Reported symptoms ranged widely (e.g. penile anaesthesia, pleasureless orgasm, loss of libido, emotional blunting, loss of nocturnal erections, reduced semen volume, reduced taste and smell); most overlap with on-treatment side effects or with depression, except nipple and genital anaesthesia", "where": "pp. 1056–1057, 1063" }, { "text": "PGAD was reported in 6 of the 19 studies. In the text, post-SSRI PGAD was described only in women and only in case reports, with onset after stopping slightly more frequent than during treatment; no prevalence could be derived", "where": "pp. 1057, 1063" }, { "text": "Treatment evidence was limited to two uncontrolled retrospective studies (13 men, IIEF improvement after 12 months; 12 men, improvement at a 6-month follow-up) and single case reports (e.g. low-power laser, a dietary supplement). No guidelines exist, and the evidence was not sufficient to suggest a single approach", "where": "p. 1058, Table 2; p. 1060" }, { "text": "The authors found insufficient evidence to justify limiting SSRI prescriptions or stopping them early, and caution against routine early discontinuation; they note reports of improvement after SSRIs were restarted. They also state their findings support the EMA's caution about possible continued sexual disturbance after stopping", "where": "pp. 1054, 1063–1064" } ], "limitations_stated": [ "Restricted to English-language articles with full text available", "Some discrepancies with previous reviews, even allowing for publication dates", "High risk of bias in most included reports, so caution is needed in generalising to clinical practice", "Included studies had uncertain sampling criteria and little control for psychopathology and comorbidities; online surveys risk selection bias toward higher prevalence and lack clinical detail" ], "design_notes": [ "Narrative synthesis only; no numbers were pooled, and per-study risk-of-bias scores are given only in the online supplement (eContent-1)", "Two of the six \"observational studies\" (Healy 2018; Hogan 2014) are, per Table 3, the same dataset (Hogan being a less complete version, 120 accounts), so there are five separate observational datasets", "The text says post-SSRI PGAD was described only in women, only in case reports, and that there are no data on it in men, but Table 3 lists PGAD among symptoms reported by both men and women in the Healy 2018 website accounts", "The only prevalence-style figure in the tables, 12.6% (17 of 135; recomputed 12.6%) in Patacchini 2021, comes from a self-selected online survey", "On Embase and Google Scholar the search required the term \"PSSD\", so reports there not using it could be missed", "The two interventional studies are both in this corpus: \"De Luca 2022\" (LIT-029) and \"Reisman 2021\" (ref. 44, Reisman, Jannini TB and Jannini EA, J Mens Health 2022; LIT-030)", "The review reads the uncontrolled vortioxetine study as favouring an interplay between PSSD and depressive or anxious symptoms; that is the authors' interpretation" ], "funding": "No specific grant from any funding agency in the public, commercial or not-for-profit sectors", "interests": "None declared", "supports": "That, as of a December 2022 search, the clinical evidence on sexual dysfunction persisting after SSRIs (and on post-SSRI PGAD) consisted of a few small uncontrolled studies, surveys, pharmacovigilance reports and case reports at high risk of bias. It cannot support any estimate of how common the condition is, of causation, or of treatment effect.", "extracted_from": "fulltexts/LIT-025-Selective-serotonin-reuptake-inhibitors-post-treat.pdf (publisher PDF, CC BY-NC-ND, 15 pp.; page refs are the journal's printed page numbers 1053–1067, so PDF page 1 is p. 1053)", "extracted": "2026-10-10" } }, { "item_id": "LIT-026", "source_type": "peer-reviewed paper", "title": "Penile anesthesia in Post SSRI Sexual Dysfunction (PSSD) responds to low-power laser irradiation: A case study and hypothesis about the role of transient receptor potential (TRP) ion channels", "authors": [ "Marcel D. Waldinger", "Ruben S. van Coevorden", "Dave H. Schweitzer", "Janniko R. Georgiadis" ], "journal_or_site": "European Journal of Pharmacology", "year_or_date": 2015, "doi": "10.1016/j.ejphar.2014.11.031", "url": "https://doi.org/10.1016/j.ejphar.2014.11.031", "abstract_or_summary": "A man who developed penile anesthesia and scrotal hypesthesia on paroxetine, persisting two years after stopping the drug, received 20 sessions of low-power laser irradiation to the glans penis, the nerve branches at the base of the penis and the lower back over the spinal nerve roots. Tactile and temperature sensitivity partially returned (by the patient's own estimate, a 20-40% improvement compared with his sensitivity before paroxetine), though erectile difficulties and anejaculation did not improve. The authors propose that SSRIs may disturb transient receptor potential (TRP) ion channels in mechano-, thermo-, and chemosensitive nerve endings, offering a peripheral-nerve hypothesis for PSSD genital anesthesia and suggesting two PSSD phenotypes, including one with very early onset during treatment.", "study_type": "case report", "sample_size": "n=1", "keywords": [ "PSSD", "genital anesthesia", "paroxetine", "low-power laser irradiation", "TRP channels", "peripheral neuropathy", "mechanism hypothesis" ], "relevance": "Proposes a mechanistic hypothesis locating PSSD genital anesthesia in peripheral sensory nerves (TRP channels), and by its own account is the first report of low-power laser treatment for genital sensitivity loss in PSSD. Key pathophysiology citation.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Single case; mechanistic claim is speculative and untested in larger samples.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-008", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://dspace.library.uu.nl/handle/1874/331003", "fulltext_source": "publisher OA", "oa_status": "green", "oa_license": "", "pmid": "25483212", "plain": { "summary": "This paper describes one man who, within a week of starting the antidepressant paroxetine, lost much of the feeling in his skin, including his penis and scrotum, and had erection and ejaculation problems. Feeling elsewhere came back, but his genitals were still numb about two years after he stopped. After an experimental course of low-power laser light on his penis and lower back, he said some feeling for touch and for warm and cold had returned, though far less than before the medicine; his erection and ejaculation problems did not change. The authors suggest an untested explanation involving tiny sensors in nerve endings.", "caveat": "It can't show that the laser caused the improvement or would help anyone else: it is one person's own account, with no comparison or sham treatment, and the authors say a placebo effect can't be ruled out." }, "evidence": { "design": "Single case report of persistent genital anaesthesia after paroxetine, with an uncontrolled experimental treatment (low-power laser irradiation) and a mechanistic hypothesis", "design_class": "case-report", "setting": "The Netherlands, 2012–2014; referred to the first author (Utrecht University and a private psychiatry and neurosexology practice, Amstelveen), laser treatment by the second author (Medisch Centrum Buitenveldert, Amsterdam)", "population": "One 43-year-old man with a master's degree, treated with paroxetine for depression after a divorce. Lifelong premature ejaculation before treatment; no other particular disease or disorder recorded.", "n": 1, "n_note": "Single patient (\"Mr. A.\")", "exposure": "Paroxetine 20 mg/day for about 2.5 years (May 2008 to November 2010). From October 2012, low-power laser irradiation, 20 sessions of 15 minutes, applied to the glans, the nerve branches at the base of the penis and the lower back over the spinal nerve roots (device settings on p. 264). Bupropion was added afterwards (April 2013).", "comparator": "None (no placebo or sham); improvement was judged against the patient's recalled sensitivity before paroxetine", "outcome": "Patient-reported penile touch and temperature sensation (his own percentage estimates against his recalled pre-paroxetine sensitivity), ejaculation and erection; hormone levels measured twice in 2013.", "follow_up": "From first consultation (September 2012) to July 2014", "results": [ { "text": "Within 7 days of starting paroxetine, loss of smell and taste and reduced skin sensitivity over much of the body, including penis and scrotum, with anejaculation and erectile difficulties; smell and taste returned after 2 months, and skin sensitivity outside the genitals gradually returned", "where": "p. 264" }, { "text": "In September 2012, about two years after stopping, penile anaesthesia, reduced scrotal sensation, anejaculation and erectile difficulties were unchanged, with normal sexual desire; general blood tests in May 2012 were normal (testosterone not measured)", "where": "p. 264" }, { "text": "After the first 5 laser sessions (October 2012), slight tingling at the glans lasting about two hours; after 20 sessions (January 2013), a self-reported 10–15% improvement in glans sensitivity, with touch felt and warm and cold told apart again", "where": "p. 264" }, { "text": "In April 2013, after the sessions ended, he estimated a 20% improvement compared with his erect penis before paroxetine and 40% compared with his flaccid penis; anejaculation and erectile difficulties were unchanged, also after bupropion (May 2013), and his state was unchanged from August 2013 to July 2014", "where": "p. 265" }, { "text": "Hypothesis: SSRIs disturb transient receptor potential (TRP) ion channels in nerve endings that sense touch, temperature and chemicals; there may be two PSSD subtypes, one starting early in treatment with severe genital anaesthesia and one worsening after stopping. Seven of the eight PSSD case reports then published described genital anaesthesia, reduced touch sensation or numbness", "where": "pp. 266–267" } ], "limitations_stated": [ "No comparison with a placebo treatment", "More patients with PSSD-related genital anaesthesia are needed to evaluate the treatment", "Little is known about his sexual function in the first months of paroxetine, as he had no sexual contact then", "A placebo effect or other central mechanism cannot be excluded", "The laser was applied at three sites, so which site produced the improvement cannot be determined", "The 20–40% improvement is \"subjectively\" perceived" ], "design_notes": [ "One patient; the improvement figures are his own estimates against recalled sensation, and no measured sensory testing is reported", "The laser treatment was given by one of the authors (p. 264)", "Before paroxetine he had lifelong premature ejaculation with unusually quick genital responses (p. 264), the baseline his estimates were compared with", "Testosterone was not measured before the laser course (p. 264); the two values reported, 8.8 and 11.5 nmol/l, are from 2013 (p. 265)", "The TRP mechanism and the two subtypes are hypotheses built on this one case and were not tested (pp. 266–267)", "The authors make recommendations to prescribers on the basis of this case and their hypothesis (pp. 267–268)" ], "funding": "None", "interests": "Not stated", "supports": "One documented case of genital numbness that began early in paroxetine treatment and persisted after stopping, with a partial, self-reported return of sensation after an uncontrolled course of laser treatment, and a hypothesis about nerve-ending ion channels. It cannot show that the laser caused the improvement, that it would help others, or that the hypothesis is right.", "extracted_from": "fulltexts/LIT-026-Penile-anesthesia-in-Post-SSRI-Sexual-Dysfunction.pdf (publisher version via Utrecht University Repository, 7 pp. including a repository cover sheet; page refs are the journal's printed pages 263–268, PDF pages 2–7)", "extracted": "2026-10-10" } }, { "item_id": "LIT-027", "source_type": "peer-reviewed paper", "title": "The pathophysiology of Post SSRI Sexual Dysfunction – Lessons from a case study", "authors": [ "Samantha Klaas", "Jessica Barbut Siva", "Maarten Bak", "Mark Govers", "Rudy Schreiber" ], "journal_or_site": "Biomedicine & Pharmacotherapy", "year_or_date": 2023, "doi": "10.1016/j.biopha.2022.114166", "url": "https://doi.org/10.1016/j.biopha.2022.114166", "abstract_or_summary": "The authors present a detailed PSSD case and use it to walk through candidate biological mechanisms for the syndrome, noting that although regulators now recognize PSSD, it remains poorly understood, underdiagnosed, and undertreated. The discussion surveys serotonergic, dopaminergic, hormonal, and neurosteroid pathways that could plausibly sustain sexual dysfunction after the drug is gone. The paper argues that clinician familiarity with the symptom pattern is a prerequisite for both diagnosis and future mechanistic research.", "study_type": "case report", "sample_size": "n=1 (with mechanistic discussion)", "keywords": [ "PSSD", "pathophysiology", "case study", "neurosteroids", "serotonin", "dopamine" ], "relevance": "A recent, accessible synthesis of hypothesized PSSD mechanisms anchored in a case. Useful as the corpus's pathophysiology overview for non-specialists.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Mechanism discussion is a literature synthesis around a single case, not new experimental data.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-009", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://doi.org/10.1016/j.biopha.2022.114166", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "36898260" }, { "item_id": "LIT-028", "source_type": "peer-reviewed paper", "title": "Towards Improving Post-SSRI Sexual Dysfunction by Using Nutriceuticals: Lessons from a Case Study", "authors": [ "Rocco Salvatore Calabrò", "Rosaria De Luca", "Alfredo Manuli", "Simona Portaro", "Antonino Naro", "Fabrizio Quattrini" ], "journal_or_site": "Journal of Sex & Marital Therapy", "year_or_date": 2019, "doi": "10.1080/0092623X.2018.1556755", "url": "https://doi.org/10.1080/0092623X.2018.1556755", "abstract_or_summary": "The authors describe a PSSD patient — persistent genital hypoesthesia, loss of libido, and erectile dysfunction after SSRI discontinuation — treated with a nutraceutical regimen, and report improvement in sexual function. They review the sparse treatment literature and propose that nutritional/pharmacological strategies targeting neurotransmitter and hormonal balance deserve systematic investigation. The paper frames PSSD as a distinct clinical entity whose lack of proven therapies forces clinicians toward experimental approaches.", "study_type": "case report", "sample_size": "n=1", "keywords": [ "PSSD", "nutraceuticals", "treatment", "case study", "genital hypoesthesia" ], "relevance": "One of very few published treatment attempts for PSSD. Documents the therapeutic vacuum and an early experimental strategy.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Single unblinded case; no control; treatment claim is anecdotal.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-010", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "30640584" }, { "item_id": "LIT-029", "source_type": "peer-reviewed paper", "title": "Cutting the First Turf to Heal Post-SSRI Sexual Dysfunction: A Male Retrospective Cohort Study", "authors": [ "Rosaria De Luca", "Mirjam Bonanno", "Alfredo Manuli", "Rocco Salvatore Calabrò" ], "journal_or_site": "Medicines", "year_or_date": 2022, "doi": "10.3390/medicines9090045", "url": "https://doi.org/10.3390/medicines9090045", "abstract_or_summary": "Thirteen men with PSSD after citalopram, paroxetine, sertraline, fluoxetine, or escitalopram were followed retrospectively after receiving varied individualized treatments, most commonly vortioxetine (alone in five men, with turmeric or nutraceuticals in one each); the other six received bupropion, tadalafil, or nutraceuticals, alone or combined, or pelvic muscle vibration. Erectile-function scores improved significantly in most patients; two did not respond. Onset timing varied — some patients developed enduring dysfunction within weeks of starting the SSRI, others only after stopping it. The authors present this as an early proof-of-concept that active treatment, particularly vortioxetine-based strategies, may help some PSSD patients.", "study_type": "retrospective case series (uncontrolled, open-label)", "sample_size": "n=13 males", "keywords": [ "PSSD", "vortioxetine", "treatment", "retrospective cohort", "IIEF", "male sexual dysfunction" ], "relevance": "A small (13-man) uncontrolled treated PSSD series, suggesting vortioxetine-based regimens may help some patients. Central to the corpus's treatment-evidence section.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed (MDPI). Small, uncontrolled, retrospective; treatment regimens heterogeneous; results are hypothesis-generating.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-011", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.mdpi.com/2305-6320/9/9/45/pdf?version=1662113443", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "36135826", "plain": { "summary": "Doctors at one clinic in Italy looked back at the records of 13 young men diagnosed with lasting sexual problems after taking an SSRI antidepressant. Each man was given a treatment chosen for him, most often another antidepressant called vortioxetine. On a questionnaire about erections and sexual function, scored from 0 to 30, the group's average rose from about 7, in the \"severe\" range, to about 18, in the \"mild\" range, after a year. Eleven of the 13 men scored higher; two did not change.", "caveat": "It can't show that any of the treatments worked: there was no comparison group, each man got a different mix of treatments, and the men's problems might have changed over a year anyway." }, "evidence": { "design": "Retrospective, uncontrolled before-and-after review of men treated for PSSD at one clinic (the authors call it a retrospective cohort study)", "design_class": "case-series", "setting": "Neurobehavioural outpatient clinic, IRCCS Centro Neurolesi \"Bonino-Pulejo\", Messina, Italy; January 2020 to December 2021", "population": "Men diagnosed with PSSD using published criteria (Healy et al. 2022; necessary criteria were prior serotonin reuptake inhibitor treatment and an enduring change in genital sensation after stopping), referred by doctors or self-referred via internet and media. Major depression, bipolar disorder and psychosis were excluded beforehand; the final sample had anxiety and/or adjustment disorders. Mean age 29.53 ± 4.57 years; all Caucasian.", "n": 13, "n_note": "13 men included of 30 referred to the clinic", "exposure": "Treatment chosen for each man: vortioxetine alone (5 men; listed as 10 mg); vortioxetine 20 mg with turmeric (1); vortioxetine 15 mg with nutraceuticals (1); bupropion 300 mg (1); bupropion 150 mg, tadalafil 10 mg and nutraceuticals (1); nutraceuticals with bupropion 150 mg (1); nutraceuticals alone (1); tadalafil 10 mg (1); pelvic muscle vibration (Vibra-Plus) (1).", "comparator": "None; each man's own baseline score", "outcome": "International Index of Erectile Function-15 (IIEF-15) score at baseline (T0) and after 12 months (T1). The paper gives a 0–30 range with severity bands (1–10 severe, 11–16 moderate, 17–25 mild, 26–30 no ED). \"Percentage of therapeutic success\" is not defined; in every row it equals the score change divided by 30.", "follow_up": "12 months", "results": [ { "text": "Mean IIEF-15 score 7.3 (SD 1.84; median 7) at baseline and 17.7 (SD 6.01; median 19) at 12 months; p = 0.003 (Wilcoxon signed-rank). Recomputed from the per-patient scores in Table 3, the means are 7.31 and 17.69, matching", "where": "p. 5, Table 3" }, { "text": "11 of 13 men scored higher at 12 months; two were unchanged (vortioxetine 15 mg with nutraceuticals, 11 to 11; bupropion, tadalafil and nutraceuticals, 5 to 5). The text's \"10/12\" counts the 12 drug-treated men", "where": "pp. 4–5, Table 3" }, { "text": "Vortioxetine alone (5 men): from 5–8 (severe) at baseline to 15–25 at 12 months (four mild, one moderate); \"therapeutic success\" 33.3% to 60%. Vortioxetine with turmeric, 7 to 16 (30%)", "where": "p. 5, Table 3" }, { "text": "Single men on other treatments: bupropion 300 mg, 9 to 12 (10%); nutraceuticals with bupropion, 6 to 19 (43.33%); nutraceuticals alone, 6 to 15 (30%); tadalafil, 8 to 20 (40%); pelvic muscle vibration after no response to earlier drug treatment, 10 to 25 (50%)", "where": "p. 5, Table 3; p. 7" }, { "text": "The enduring sexual effects began 2–4 weeks after starting the SSRI in 8 men and 2–4 weeks after stopping it in 5. The SSRI had been taken for 1–48 months (citalopram, paroxetine, sertraline and escitalopram 3 men each; fluoxetine 1)", "where": "p. 4, Tables 1–2" } ], "limitations_stated": [ "The retrospective design prevented any a priori hypothesis", "Small sample size", "Only a baseline Hamilton depression score; repeated depression and anxiety measures (PHQ-9, GAD-7) would have been more helpful", "Not possible to compare the efficacy of the different compounds, alone or combined", "No pharmacogenetic assessment (e.g. of slow metabolisers)", "Psychiatric diagnoses and stressors were identified by other clinicians, so their role cannot be fully ruled out; including mixed psychiatric diagnoses makes the sample less homogeneous" ], "design_notes": [ "No control group and open-label, so change over 12 months cannot be separated from change that would have happened anyway. How long each man had had PSSD, or had been off the SSRI, at baseline is not reported (Table 2 gives onset only relative to starting or stopping)", "Treatments differed between men (nine regimens for 13 men); the text calls vortioxetine the most common and effective (p. 4) but also states the compounds could not be compared (p. 8)", "Questionnaire reporting is inconsistent: the IIEF-15 is described as 15 items each scored 0–5, which would total 0–75, but a 0–30 range with ED severity bands is used; the abstract refers to the \"IIEF-5\" and to improvement in all domains, but only one score per man is reported", "Statistical reporting is inconsistent: the significance threshold is given as p < 0.005, the text says the score improved significantly \"(p > 0.05)\", the abstract gives p < 0.05, and Table 3 gives p = 0.003", "The exclusion criterion for severe depression is written as a Hamilton score below 17, which reads as the reverse of excluding severe depression", "The outcome measures erectile and sexual function; the necessary diagnostic criterion (changed genital sensation) and the reported improvement in non-sexual symptoms (judged at interview) were not measured with a reported scale. Non-sexual problems at baseline are given only as approximate percentages (about 23% cognitive, 8% emotional, 25% both)", "The corresponding author is a co-author of the diagnostic criteria used (ref. 19) and of an earlier case report of a nutraceutical for PSSD (ref. 34)" ], "funding": "Italian Ministry of Health (\"current research\" funding)", "interests": "None declared", "supports": "That most of 13 men with PSSD at one clinic had higher erectile and sexual-function questionnaire scores a year after individually chosen treatments, most often vortioxetine. It cannot show that any treatment caused the change, or compare treatments.", "extracted_from": "fulltexts/LIT-029-Cutting-the-First-Turf-to-Heal-Post-SSRI-Sexual-Dy.pdf (publisher PDF, CC BY 4.0, 11 pp.; page refs are the printed \"N of 11\" numbers, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-030", "source_type": "peer-reviewed paper", "title": "Post-Selective Serotonin Reuptake Inhibitor Sexual Dysfunctions (PSSD): Clinical Experience with a Multimodal Approach", "authors": [ "Yacov Reisman", "Tommaso Benedetto Jannini", "Emmanuele Angelo Jannini" ], "journal_or_site": "Journal of Men's Health", "year_or_date": 2022, "doi": "10.31083/j.jomh1808165", "url": "https://doi.org/10.31083/j.jomh1808165", "abstract_or_summary": "The authors reported their clinical experience managing 12 men with PSSD (selected from 17 referred) with a six-month multimodal protocol combining lifestyle and exercise advice, L-arginine and L-carnitine supplements, and pharmacological and behavioral interventions given according to each patient's needs. Correcting hormonal abnormalities was part of the protocol, but none of the men's laboratory results required it. They characterized PSSD as a heterogeneous set of disorders that can begin during SSRI/SNRI treatment and persist afterward, commonly accompanied by marked distress and poor quality of life. All IIEF-15 domain scores and the male Orgasmometer score rose from baseline to 6 months, with erectile function on average in the mild-ED range at both points, and no patient dropped out.", "study_type": "case series", "sample_size": "n=12 males (of 17 referred)", "keywords": [ "PSSD", "multimodal treatment", "clinical management", "SSRI", "SNRI" ], "relevance": "A senior sexual-medicine group's treatment framework for PSSD. Complements the De Luca cohort with a clinical-management perspective.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Descriptive clinical experience with standardized outcomes (IIEF-15 and male Orgasmometer at baseline and 6 months) but no control group.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-012", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://oss.jomh.org/files/article/20220926-112/pdf/1875-6859-18-8-165.pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "fulltext_note": "direct PDF on journal file server (oss.jomh.org); verified HTTP 200 2026-10-09", "plain": { "summary": "Researchers looked back at 12 men seen at their clinics in 2019–2020 with sexual problems that began on an antidepressant (mostly SSRIs) and lasted after stopping it. Each man followed a six-month programme combining exercise and lifestyle advice, two dietary supplements and talking therapies, and some also took an erection drug or another medicine called buspirone. On questionnaires about desire, erections, orgasm and satisfaction, the group's average scores were higher after six months than before, and no one dropped out.", "caveat": "It can't show that the programme caused the improvement or which part of it helped: there was no comparison group, and the authors themselves say the problems may have eased on their own or through a placebo effect." }, "evidence": { "design": "Retrospective, uncontrolled before-and-after case series of men treated with a six-month multimodal protocol", "design_class": "case-series", "setting": "The authors' sexual-medicine clinics (affiliations in Amstelveen, the Netherlands, and Rome, Italy); men from 7 European countries, 8 of the 17 referred assessed remotely because of COVID-19; July 2019 to July 2020", "population": "Men aged 18–60 with sexual dysfunction that began while taking one SSRI or SNRI and persisted after stopping it at least 1 month before interview; no sexual dysfunction before treatment; no medical condition, medication or addictive substance use associated with sexual dysfunction; \"high probability\" of PSSD by published criteria. The Beck Depression Inventory-II was used to exclude co-existing depression. Mean age 31.3 ± 6.21 years; mean BMI 25.3 ± 2.18.", "n": 12, "n_note": "12 men selected of 17 referred with suspected PSSD", "exposure": "Six-month protocol: lifestyle advice (no drugs of abuse, no more than 2 alcohol units a day, stopping nicotine); supervised aerobic exercise, 40 minutes 4–5 times a week; L-arginine 3 g/day and L-carnitine 2 g/day for all; correction of hormonal abnormalities if needed (none was); PDE-5 inhibitors (4 men); buspirone 5 mg three times a day (5); mindfulness and cognitive-behavioural therapy (10); sex therapy and sensate focus (2). Visits every 2 weeks.", "comparator": "None; each man's own baseline scores", "outcome": "IIEF-15 domain scores (erectile function, orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction) and the male Orgasmometer (a 0–10 orgasm-intensity scale), at baseline and 6 months. Paired t-tests with bootstrapped 95% confidence intervals (3,000 samples); no p-values are reported.", "follow_up": "6 months; no drop-outs", "results": [ { "text": "Erectile function domain 19.11 (SD 4.76) at baseline and 23.69 (SD 3.12) at 6 months, difference 4.58 (95% CI 1.50–7.51); on average both values fall in the mild-ED band", "where": "p. 3; Table 4, p. 6" }, { "text": "Sexual desire 3.78 to 5.53 (difference 1.75; 95% CI 1.08–2.58); orgasmic function 4.67 to 5.83 (1.16; 0.50–2.17); intercourse satisfaction 5.22 to 7.88 (2.66; 1.83–3.58); overall satisfaction 3.56 to 6.22 (2.66; 2.42–2.83). Table 4 gives the differences as negative (baseline minus follow-up); recomputed differences match", "where": "Table 4, p. 6" }, { "text": "Orgasmometer 3.22 (SD 1.42) at baseline and 4.39 (SD 1.19) at 6 months, difference 1.17 (95% CI 0.09–1.81)", "where": "Table 4, p. 6" }, { "text": "Symptoms at presentation: loss of libido in 11 of 12; reduced sexual activity, pleasureless orgasm and loss of morning erections in 9 each; genital numbness in 8; ED and a brain–genital \"disconnection\" in 6 each; emotional blunting and reduced orgasm intensity in 5 each. Most complaints began on the drug and continued after stopping; pleasureless orgasm (3 men), genital numbness (3), memory impairment (2) and fatigue (2) appeared after withdrawal", "where": "p. 3; Table 3, p. 5" }, { "text": "Antidepressants: escitalopram 5, fluoxetine 2, paroxetine 2, sertraline 1, venlafaxine 1, amitriptyline 1; taken for a median 12 months (range 3–36) and stopped a median 10.5 months (range 3–26) before assessment", "where": "Table 2, p. 4" }, { "text": "All men adhered to the programme and none dropped out; they needed encouragement in the first 2–3 months, when improvement was limited. Hormone and other laboratory values were within normal ranges and none needed treatment", "where": "pp. 3–4; Table 1, p. 3" } ], "limitations_stated": [ "Retrospective, with self-administered outcome measures; recall bias may affect the results", "Small and not randomised", "No control group, so spontaneous remission or a placebo effect cannot be excluded; caution in generalising; no room for causal inference" ], "design_notes": [ "Several components were given together (exercise, alcohol and nicotine limits, supplements, drugs, psychological therapy), so any change cannot be attributed to one of them", "The authors cite the men's adherence as suggesting the treatment was effective; adherence does not measure benefit", "Inclusion required one SSRI or SNRI, but one man had taken amitriptyline, a tricyclic", "IIEF items are answered on whole-number scales, so a mean of 12 men's domain scores should be a multiple of 1/12. All five baseline domain means in Table 4 (e.g. 19.11, 3.78, 3.56) are instead multiples of 1/9, and four of the five follow-up means fit neither; the paper reports no missing questionnaires, so how many men contribute to Table 4 is unclear", "Beck Depression Inventory-II scores, used to exclude depression, are not reported", "Small percentage slip; 2 of 12 men in sex therapy is given as 16.3% (2 of 12 is 16.7%)" ], "funding": "No external funding", "interests": "The authors declare no conflict of interest, but disclose that E. A. Jannini has been a speaker and/or paid consultant for Bayer, Ibsa, Lundbeck, Menarini, Otsuka, Pfizer, Shionogi and Viatris, and Y. Reisman a speaker and/or consultant for Lundbeck, Pfizer, Coloplast, Ohhmed and Besins. Reisman is an editorial board member and guest editor of the journal, with no involvement in this article's peer review.", "supports": "That 12 men meeting PSSD criteria reported higher sexual-function and orgasm-intensity scores after six months of a combined lifestyle, supplement, drug and psychological programme. It cannot show that the programme caused the change, or which part of it helped.", "extracted_from": "fulltexts/LIT-030-Post-Selective-Serotonin-Reuptake-Inhibitor-Sexual.pdf (publisher PDF, CC BY 4.0, 8 pp.; page refs are the article's printed page numbers 1–8, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-031", "source_type": "peer-reviewed paper", "title": "Prolonged Post-Treatment Genital Anesthesia and Sexual Dysfunction Following Discontinuation of Citalopram and the Atypical Antidepressant Nefazodone", "authors": [ "Robert P. Kauffman", "Amanda Murdock" ], "journal_or_site": "The Open Women's Health Journal", "year_or_date": 2007, "doi": "10.2174/1874291200701010001", "url": "https://doi.org/10.2174/1874291200701010001", "abstract_or_summary": "The authors report cases of sustained genital anesthesia and sexual dysfunction persisting after stopping citalopram, including a patient switched to nefazodone — a drug usually considered free of sexual side effects — whose symptoms still did not resolve. They review scattered early reports of persistent post-SSRI sexual effects and argue the phenomenon deserves recognition rather than dismissal as psychogenic. The paper is among the earliest to document prolonged genital anesthesia specifically as a post-treatment entity.", "study_type": "case report", "sample_size": "small case series (exact n not extracted from metadata)", "keywords": [ "PSSD", "genital anesthesia", "citalopram", "nefazodone", "case report" ], "relevance": "Early (2007) documentation of persistent genital anesthesia after SSRI discontinuation. Historical anchor showing the signal predates the PSSD label.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Venue reputation unverified (Bentham Open journal). Early descriptive report; limited detail in metadata.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-013", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "http://benthamopen.com/contents/pdf/TOWHJ/TOWHJ-1-1.pdf", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "" }, { "item_id": "LIT-032", "source_type": "peer-reviewed paper", "title": "Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence", "authors": [ "Audrey S. Bahrick" ], "journal_or_site": "The Open Psychology Journal", "year_or_date": 2008, "doi": "10.2174/1874350100801010042", "url": "https://doi.org/10.2174/1874350100801010042", "abstract_or_summary": "Bahrick argues that the clinical convention — that SSRI/SNRI sexual side effects resolve on discontinuation — rests on an untested assumption rather than evidence. Reviewing post-marketing prevalence data and emerging case reports, she notes that real-world sexual side-effect rates far exceeded pre-marketing trial figures, and that persistent cases were already accumulating in the literature. The paper calls for systematic study of post-discontinuation sexual function and for honest informed-consent discussions with patients starting antidepressants.", "study_type": "review", "sample_size": "n/a", "keywords": [ "PSSD", "review", "informed consent", "prevalence", "post-marketing surveillance" ], "relevance": "An early (2008) call to recognize persistent post-SSRI sexual dysfunction, by a researcher who later co-authored the diagnostic-criteria paper. Shows the argument's lineage.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Venue reputation unverified (Bentham Open journal). Argumentative review rather than systematic.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-014", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://openpsychologyjournal.com/VOLUME/1/PAGE/42/PDF/", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by" }, { "item_id": "LIT-033", "source_type": "peer-reviewed paper", "title": "Post-SSRI Sexual Dysfunction (PSSD): Ten Year Retrospective Chart Review", "authors": [ "Ahad Waraich", "Jessica M. Yih", "Sue W. Goldstein", "Irwin Goldstein" ], "journal_or_site": "The Journal of Sexual Medicine", "year_or_date": 2021, "doi": "10.1016/j.jsxm.2021.01.046", "url": "https://doi.org/10.1016/j.jsxm.2021.01.046", "abstract_or_summary": "From a decade of charts at a sexual-medicine practice, the authors identified 43 young men (mean age 31) meeting PSSD criteria — about 4% of male patients seen — with erectile dysfunction the most common complaint (93%) and a mean erectile-function score in the severe range. Workup included validated questionnaires, Doppler ultrasound during pharmacological erection, and quantitative sensory testing of vibration, warmth, and cold perception. The study provides rare objective clinical data on PSSD, including sensory testing results consistent with a peripheral sensory component.", "study_type": "retrospective chart review", "sample_size": "n=43 males", "keywords": [ "PSSD", "chart review", "quantitative sensory testing", "erectile dysfunction", "Doppler ultrasound" ], "relevance": "Rare clinic-based PSSD series with objective testing (QST, Doppler) — one of the only sources of measured physiological data in PSSD. High value for the corpus's pathophysiology section.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Conference abstract (peer-reviewed for meeting presentation); full paper not in metadata. Single-center, retrospective.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-015", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-034", "source_type": "peer-reviewed paper", "title": "Psychological and sexual functioning of persons suffering from post-SSRI sexual dysfunction – cases study", "authors": [ "Kacper Gargul", "Beata Pastwa-Wojciechowska" ], "journal_or_site": "Current Issues in Personality Psychology", "year_or_date": 2025, "doi": "10.5114/cipp/193244", "url": "https://doi.org/10.5114/cipp/193244", "abstract_or_summary": "While most PSSD research has catalogued somatic symptoms, this case study focuses on the psychological side: the authors described the sexual functioning, and feelings about it, of four young women aged 22-27 before, during and after SSRI treatment, using a written interview of 15 open questions. Two were presented as PSSD cases and two as contrasting cases in which SSRIs seemed to have had a positive effect; the authors noted that personality aspects were not explored sufficiently. They document how these sexual changes interact with identity, mood, and interpersonal functioning, arguing that the psychological dimension is under-studied relative to the physical symptoms. The paper frames PSSD as a biopsychosocial condition requiring psychological as well as medical attention.", "study_type": "case series", "sample_size": "n=4 (two described as PSSD cases, two as contrasting cases in which SSRIs seemed to have a positive effect)", "keywords": [ "PSSD", "psychological functioning", "personality", "quality of life", "case study" ], "relevance": "One of few papers centering the psychological/identity impact of PSSD rather than physiology. Rounds out the corpus's human-impact coverage.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Small sample; primarily descriptive.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-016", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://cipp.ug.edu.pl/pdf-193244-123756?filename=Psychological-and-sexual-.pdf", "fulltext_source": "publisher OA", "oa_status": "diamond", "oa_license": "cc-by-nc-sa", "pmid": "40235557", "plain": { "summary": "Researchers in Poland asked four young women, aged 22 to 27, who had finished a course of SSRI antidepressants (a common type of antidepressant) to answer 15 open questions in writing about their sex lives before, during and after treatment. Two said some problems that began on the medicine, such as weaker orgasms or lower desire, were still there about six months after stopping. The other two described some improvements in their sex lives during or after treatment, although one of them also described much lower desire after stopping.", "caveat": "It can't show how common these problems are or that the medicine caused them: it describes only four people, who recalled the past at a single sitting, with no comparison group." }, "evidence": { "design": "Qualitative study of four cases, using a written interview with 15 open questions, analysed case by case with an approach drawn from thematic analysis", "design_class": "qualitative", "setting": "University of Gdansk, Poland; participants from the Pomeranian region (mainly the Tricity area), autumn 2021", "population": "Four young adults aged 22–27, all described as women, studying for or holding a higher-education degree, who had finished SSRI treatment and noticed changes in their sexuality. Recruited from University of Gdansk students and through psychotherapists. Excluded: people taking other medicines, still on treatment, or with no sexual changes.", "n": 4, "n_note": "4 participants, described as two PSSD cases and two contrasting cases; numbers approached or excluded not reported", "exposure": "SSRIs, sertraline (Zoloft) in cases 1 and 2 (50 mg in case 1), not named in cases 3 and 4; about 6 months to about 2 years of treatment", "comparator": "None; each participant's recalled sexual functioning before treatment", "outcome": "Self-described sexual functioning (desire, arousal, orgasm, pain, satisfaction) and feelings about it, before, during and after treatment, across six question areas.", "follow_up": "One retrospective interview, about 6 months after stopping (cases 1 and 2) or 7 months (case 3); case 4 started about 5 years earlier and took the drug for about 6 months", "results": [ { "text": "Case 1 (aged 23, sertraline for about a year): difficulty reaching orgasm and lower desire from 2–3 weeks into treatment; half a year after stopping, sex life \"almost the same as before\", but orgasm \"weaker than before\"", "where": "p. 38" }, { "text": "Case 2 (aged 27, sertraline for two years): lower desire a few months into treatment; six months after stopping, sexual functioning had not returned to its pre-treatment state, though at interview the problems did not bother her", "where": "pp. 38–39" }, { "text": "Case 3 (aged 23, an SSRI for almost two years, stopped seven months earlier): intercourse less painful and libido higher during treatment; satisfaction rose further after stopping, with no pain on penetration", "where": "p. 39" }, { "text": "Case 4 (aged 22, an SSRI for about six months): libido rose during treatment; after stopping, a \"significant\" fall in libido and stress about sex focused on her; she suggested her gender identity as a possible other cause", "where": "p. 39" }, { "text": "Authors' summary: symptoms persisted after stopping in cases 1 and 2; in the other two, \"treatment alleviated sexual dysfunctions during or after pharmacotherapy\"", "where": "p. 40" } ], "limitations_stated": [ "Small sample limits generalisability, and its size may have increased bias", "Retrospective design; memory is unreliable and tends to be positive, and respondents may have concealed facts", "Results are mainly descriptive case reports, lacking deeper analysis in some areas", "Personality aspects (gender incongruence, mood swings, religious beliefs, guilt) were not explored sufficiently", "The analysis drew on Braun and Clarke's thematic analysis but was not conducted according to that method" ], "design_notes": [ "Only two of the four cases are described as PSSD; the paper cites diagnostic criteria (p. 36) but does not say whether any case met them", "Case 4 is counted among the two contrasting, positive cases (pp. 35, 40) but is described as having a marked fall in desire after stopping (pp. 39–40)", "The summary that all four had good sexual functioning before treatment (p. 40) differs from the descriptions of earlier difficulty reaching orgasm or painful intercourse in cases 2 and 3 (pp. 38–39)", "Data collection is described both as written answers to a paper interview and as a semi-structured interview that was transcribed (p. 37)", "Data were collected in autumn 2021 (p. 37); the ethics approval cited is numbered 1/01/2024, with no date given (p. 41)", "Participants named other possible influences, such as workload, religious guilt and gender identity (p. 39)" ], "funding": "No external funding", "interests": "None declared", "supports": "Descriptions of how four young women experienced sexual changes during and after SSRI treatment, two of whom reported some problems persisting about six months after stopping. It cannot show how common persistent problems are, that the medicine caused them, or what PSSD is like in general.", "extracted_from": "fulltexts/LIT-034-Psychological-and-sexual-functioning-of-persons-su.pdf (publisher PDF, CC BY-NC-SA 4.0, 7 pp.; page refs are the journal's printed pages 35–41)", "extracted": "2026-10-10" } }, { "item_id": "LIT-035", "source_type": "peer-reviewed paper", "title": "“It’s taken away the most fundamental things about being human”: the lived experience and impact of post-SSRI sexual dysfunction", "authors": [ "Seraj Brugi", "Bob Budd", "Craig Mackie", "Sarah Fish" ], "journal_or_site": "International Journal of Qualitative Studies on Health and Well-Being", "year_or_date": 2026, "doi": "10.1080/17482631.2026.2717470", "url": "https://doi.org/10.1080/17482631.2026.2717470", "abstract_or_summary": "This qualitative interview study explores how people living with PSSD experience the condition's effects on identity, relationships, and mental health. Participants describe sexual side effects that long outlasted their antidepressant treatment and a struggle to be believed by clinicians. The analysis highlights grief for a lost sense of self, strain on intimate relationships, and the psychological burden of an iatrogenic, poorly recognized condition. The authors argue that understanding lived experience is essential for humane clinical care and for research priorities that reflect patients' concerns.", "study_type": "qualitative study", "sample_size": "interview study (exact n not extracted from metadata)", "keywords": [ "PSSD", "qualitative research", "lived experience", "identity", "patient experience", "mental health" ], "relevance": "The most recent PSSD paper found in this sweep (2026) and the first dedicated qualitative study of living with PSSD. Strong patient-voice addition to the corpus.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Qualitative design; findings are interpretive, not generalizable estimates.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-017", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://doi.org/10.1080/17482631.2026.2717470", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "42595701" }, { "item_id": "LIT-036", "source_type": "peer-reviewed paper", "title": "Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction: a pharmacovigilance analysis", "authors": [ "Mengting Shen", "Luyao He", "Pei Chen", "Lei Zhang", "Duan Zeng", "Yan Li", "Huafang Li" ], "journal_or_site": "Sexual Medicine", "year_or_date": 2026, "doi": "10.1093/sexmed/qfag008", "url": "https://doi.org/10.1093/sexmed/qfag008", "abstract_or_summary": "Using the FDA Adverse Event Reporting System (FAERS), the authors compared disproportionality signals for sexual-dysfunction adverse events across individual SSRIs and SNRIs (sertraline, citalopram/escitalopram, paroxetine, fluoxetine, venlafaxine, duloxetine), applying Bayesian shrinkage to stabilize estimates. All studied agents showed associations with sexual dysfunction reports, with distinct symptom profiles emerging by drug. The analysis demonstrates how spontaneous-reporting data can differentiate drug-specific sexual adverse-event patterns within the antidepressant class.", "study_type": "pharmacovigilance analysis", "sample_size": "1,144,969 valid FAERS reports (Q1 2021-Q4 2023), 3,021 with sexual dysfunction; 41,793 reports for the six study drugs, 541 with sexual dysfunction", "keywords": [ "pharmacovigilance", "FAERS", "SSRI", "SNRI", "sexual dysfunction", "disproportionality analysis" ], "relevance": "Recent large-scale pharmacovigilance comparison of sexual-dysfunction signals across individual antidepressants, useful for drug-specific risk discussion in the corpus's epidemiology section. It concerns reported sexual side effects in general and does not separate problems during treatment from problems persisting after stopping (therapy-date data were not used), so it is not direct evidence on PSSD.", "verification_status": "verified: matching records in OpenAlex and Crossref", "quality_notes": "Peer-reviewed. Spontaneous reports are subject to reporting bias; signals are associations, not incidence rates.", "sweep_date": "2026-10-07", "axis_id": "LIT-B-018", "sweep_axis": "pssd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://doi.org/10.1093/sexmed/qfag008", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by-nc", "pmid": "41877765", "plain": { "summary": "Researchers looked at about 1.1 million reports of suspected side effects sent to the US medicines regulator from 2021 to 2023. For each of six common antidepressants, reports mentioning a sexual problem made up a bigger share of that drug's reports than across all medicines: for sertraline about 1 in 52 of its reports, compared with about 1 in 380 overall. The kinds of sexual problem reported differed between drugs: sertraline had the widest range, including genital numbness, and duloxetine the narrowest.", "caveat": "It can't show how often these medicines cause sexual problems, or whether problems lasted after stopping: it counted voluntary reports, many side effects are never reported, and the study did not look at whether problems continued once the medicine was stopped." }, "evidence": { "design": "Pharmacovigilance disproportionality (case/non-case) analysis of spontaneous adverse-event reports, comparing each drug with all other drugs in the database, with Bayesian shrinkage", "design_class": "pharmacovigilance", "setting": "US FDA Adverse Event Reporting System (FAERS), reports from Q1 2021 to Q4 2023, mainly from the USA, UK and Canada", "population": "Spontaneous adverse-event reports naming fluoxetine, paroxetine, citalopram/escitalopram, sertraline, venlafaxine or duloxetine as the main suspect drug, after removing duplicates and reports lacking drug information. Fluvoxamine was excluded for too few reports.", "n": 1144969, "n_note": "1,144,969 valid reports (all drugs), 3,021 of them sexual dysfunction; the six drugs account for 41,793 reports, 541 of them sexual dysfunction (summed from p. 3). Units are reports, not people", "exposure": "Each of the six drugs as the main suspect drug", "comparator": "All other reports in FAERS (all other drugs), not other antidepressants", "outcome": "Reports of sexual dysfunction, overall and by MedDRA preferred term (e.g. anorgasmia, erectile dysfunction, loss of libido, genital hypoaesthesia). A signal required IC025 above 0, \"ROR\" above 1 and more than 3 reports.", "follow_up": "Not applicable (reports, not followed patients)", "results": [ { "text": "Share of each drug's reports that were sexual dysfunction (percentages computed here), with the paper's \"ROR\" and IC025: sertraline 195 of 10,114 (1.9%; 7.19; 2.61), paroxetine 53 of 2,917 (1.8%; 6.53; 2.25), fluoxetine 73 of 5,558 (1.3%; 4.85; 1.89), citalopram/escitalopram 86 of 7,203 (1.2%; 4.43; 1.79), venlafaxine 83 of 7,655 (1.1%; 4.03; 1.65), duloxetine 51 of 8,346 (0.6%; 2.29; 0.73), against 3,021 of 1,144,969 (0.26%) for all reports. All six met the signal criteria", "where": "pp. 2–3, Table 1" }, { "text": "The values labelled ROR equal the shrunk observed-to-expected ratio in the formula on p. 2 (2 to the power of the IC), not a reporting odds ratio from the 2×2 table. Conventional RORs computed from the paper's counts are slightly higher, in the same order: sertraline 7.88, paroxetine 7.10, fluoxetine 5.13, citalopram/escitalopram 4.67, venlafaxine 4.23, duloxetine 2.35", "where": "pp. 2–3, Table 1" }, { "text": "Breadth of symptom signals: sertraline widest (the text says 15 signals; Figure 1 shows 16 positive IC025 values, from 1.32 for orgasmic sensation decreased to 3.06 for loss of libido), citalopram/escitalopram 14 positive values in Figure 1, fluoxetine 8, venlafaxine 5, paroxetine 4, duloxetine 1 (sexual dysfunction, IC025 0.64)", "where": "p. 3, Fig. 1 (p. 4)" }, { "text": "Anorgasmia, erectile dysfunction and decreased libido gave signals for every drug except duloxetine; citalopram/escitalopram was the only drug with a female orgasmic disorder signal (IC025 0.57)", "where": "p. 3, Fig. 1 (p. 4)" }, { "text": "Genital hypoaesthesia (genital numbness) gave signals for sertraline (IC025 2.86) and citalopram/escitalopram (1.81) but not venlafaxine (−0.38); persistent genital arousal disorder gave a signal for sertraline (1.35)", "where": "Fig. 1 (p. 4)" }, { "text": "Of the 3,021 sexual-dysfunction reports, 26.02% concerned women and 67.56% men; 1,312 (43.43%) came from the USA, 434 (14.37%) from the UK and 367 (12.15%) from Canada. The text calls these shares \"of the total\" and \"of all valid reports\", but they match the 3,021 sexual-dysfunction reports, not the 1,144,969", "where": "pp. 3–4" } ], "limitations_stated": [ "Voluntary reporting brings data-quality problems (drug mapping, missing data, duplicates) that may bias results", "With no denominator, true incidence cannot be calculated, and disproportionality cannot establish causation", "Possible protopathic bias, as sexual dysfunction may precede antidepressant use in some depressed patients", "Dose and severity of depression could not be assessed against sexual dysfunction", "Genetic differences in susceptibility were not accounted for", "Generalisability is limited by reporting biases and by reports coming mainly from the USA, Canada and the UK" ], "design_notes": [ "The analysis cannot tell whether problems began on the drug or persisted after stopping; the therapy-dates file (THER) was not used (p. 2), so it is not direct evidence on PSSD", "Each drug is compared with all other drugs in FAERS, not with other antidepressants; differences between the six drugs are not tested statistically", "The number of symptom signals per drug partly reflects how many reports each drug has (sertraline has the most sexual-dysfunction reports, 195)", "Table 1's upper limits (IC975) cannot be reproduced. The formula on p. 2 is printed with a minus sign, which would put them below the IC; the standard formula gives 1.53–3.03 against 2.81–4.08 reported. The lower limits (IC025), which define the signals, do reproduce", "The discussion describes duloxetine as \"least likely to produce\" sexual dysfunction (p. 5), which reads reporting ratios as risk" ], "funding": "Shenzhen Medical and Health Three Project (SZSM202011014); Collaborative Innovation Center for Clinical and Translational Science, Ministry of Education & Shanghai (CCTS-202306, CCTS-202409PT); Clinical Research Plan of SHDC (SHDC2020CR2053B); Shanghai clinical research center for mental health (19MC1911100); Shanghai Sailing Program (23YF1438000); Shanghai Mental Health Center (2022024-FX-05).", "interests": "None declared", "supports": "That sexual problems are reported disproportionately often for each of six common SSRIs and SNRIs, with the kinds of problem differing by drug. It cannot give rates, establish causation, or say whether problems persisted after stopping.", "extracted_from": "fulltexts/LIT-036-Selective-serotonin-reuptake-inhibitor-and-seroton.pdf (publisher PDF, CC BY-NC 4.0, 6 pp.; page refs are the printed page numbers 1–6, the same as the PDF pages)", "extracted": "2026-10-10" } }, { "item_id": "LIT-037", "source_type": "peer-reviewed paper", "title": "Sexual dysfunction following retinoid treatment: a systematic review", "authors": [ "Heidi Oi-Yee Li", "Elena Pastukhova", "Olivier Brandts-Longtin", "Adrian Joseph-Michel Bailey", "Marcus G. Tan", "Mark G. Kirchhof" ], "journal_or_site": "British Journal of Dermatology", "year_or_date": 2024, "doi": "10.1093/bjd/ljae361", "url": "https://doi.org/10.1093/bjd/ljae361", "abstract_or_summary": "A short systematic review in a major dermatology journal surveys the evidence on sexual dysfunction after systemic retinoid therapy, in the context of existing product-label warnings for post-retinoid sexual dysfunction and recent regulatory safety decisions. It concludes that the available evidence is conflicting and of low quality, and that causation between retinoids and sexual dysfunction cannot currently be established. The letter uses PRSD for sexual side effects of retinoids in general: most included studies described effects during treatment, and persistence after stopping was not assessed separately. The authors advise dermatologists and patients to be aware of the contradictory data. They also suggest that routine screening for sexual side effects during treatment may be reasonable, since patients are unlikely to volunteer these concerns.", "study_type": "systematic review (brief research letter; pp. 175-177, 14 cited references)", "sample_size": "11 studies from 880 records (6 case reports, 2 case series, 2 cross-sectional, 1 cohort)", "keywords": [ "PRSD", "post-retinoid sexual dysfunction", "isotretinoin", "retinoid", "systematic review", "causality", "screening" ], "relevance": "The most prominent peer-reviewed synthesis to date that directly names PRSD; its \"conflicting, low-quality evidence\" verdict is the key counterweight the corpus needs alongside patient-reported and pharmacovigilance data.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/journal/year match)", "quality_notes": "Legitimate venue (BJD, Oxford University Press); note it is a short research letter rather than a full-length review", "sweep_date": "2026-10-07", "axis_id": "LIT-C-001", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://academic.oup.com/bjd/article-pdf/192/1/175/60001119/ljae361.pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc", "pmid": "39283147", "plain": { "summary": "Researchers searched two large medical databases for studies of sexual problems linked to retinoid medicines taken by mouth, such as isotretinoin for acne. Of 880 records, 11 studies fit: six reports on single patients and five larger studies. The findings disagreed: a database of side-effect reports linked isotretinoin with slightly more reports of erection problems than expected, while a large health-records study found no difference between men with acne who took it and men who did not. The authors concluded the evidence is conflicting and of low quality, and cannot show whether retinoids cause these problems.", "caveat": "It can't settle whether sexual problems last after a retinoid is stopped: most of the studies it found described problems during treatment, it did not look at lasting problems separately, and the studies were too different to combine." }, "evidence": { "design": "Systematic review (research letter), registered on PROSPERO (CRD42023495820), MEDLINE and Embase searched from inception to 26 January 2024 following PRISMA, JBI risk-of-bias appraisal, narrative synthesis without meta-analysis", "design_class": "systematic-review", "setting": "Human studies published 1988–2024, from the USA, Denmark, Ireland, the UK, Italy and Turkey, plus one global online case series", "population": "People treated with systemic retinoids (isotretinoin, etretinate or acitretin) for acne, psoriasis or ichthyosis, in studies of 1 to 13,600 participants.", "n": 11, "n_note": "11 studies from 880 records (6 case reports, 2 case series, 2 cross-sectional, 1 cohort); participants per study 1 to 13,600", "exposure": "Systemic retinoids; isotretinoin in 7 studies, etretinate in 2, acitretin in 2", "comparator": "Only the cohort study had an untreated comparison group (men with acne on no systemic medication); the FAERS study compared against reports for other drugs", "outcome": "Any reported sexual dysfunction or genital side effect (e.g. erectile dysfunction, loss of libido, ejaculation failure, genital anaesthesia, vulvovaginal dryness, painful sex, vaginal bleeding); no included study used a validated scale.", "follow_up": "Not applicable; follow-up in the included studies was mostly unclear", "results": [ { "text": "11 of 880 records included: 6 case reports, 2 case series, 2 cross-sectional studies and 1 cohort study; designs too varied for meta-analysis", "where": "p. 175" }, { "text": "Women: in one cross-sectional study 20 of 50 women (40%) on isotretinoin had vulvovaginal symptoms after more than 3 months of treatment, including vulval dryness in 16 of 50 (32%) and painful sex in 10 of 50 (20%); in a study of acitretin, vaginal dryness in 11 of 160 women (6.9%)", "where": "p. 175, Table 1 (p. 176)" }, { "text": "Men on isotretinoin, conflicting results: a FAERS analysis of 181 men found a weak signal for erectile dysfunction (PRR 1.24, 95% CI 1.03–1.45), while a matched TriNetX cohort of 13,600 found no difference in erectile dysfunction (aRR 1.0, 95% CI 0.55–1.4), sexual dysfunction (0.74, 0.39–1.38), decreased libido (1.0, 0.42–2.4) or PDE5 inhibitor use (1.1, 0.62–1.9)", "where": "p. 175, Table 1 (p. 176)" }, { "text": "RxISK case series of 54 isotretinoin cases (49 men, 5 women): erectile dysfunction in 46 of 49 men (94%), loss of libido in 35 of 49 (71%), genital anaesthesia in 18 of 49 (37%); loss of libido in 5 of 5 women and genital anaesthesia in 3 of 5", "where": "Table 1 (p. 176)" }, { "text": "The text reports more than 300 PRSD cases across the studies (p. 175); the affected people listed in Table 1 sum to about 278 (6 single cases, 54, 181, 20 women in one study and 17 genital or sexual events in another; the cohort gives no case count). The cited RxISK paper's title refers to 300 cases across three drug classes, of which 54 were isotretinoin", "where": "pp. 175–177, Table 1" }, { "text": "Conclusion: the evidence is conflicting and of low quality, and causation between retinoids and PRSD cannot be established; the authors suggest routine screening for sexual side effects during treatment may be reasonable", "where": "p. 175" } ], "limitations_stated": [ "Most included papers were case studies, with small samples, no control groups, and confounding, selection and reporting biases", "The few larger studies relied on administrative or reporting databases; TriNetX is limited by generalisability and under-reporting, and FAERS may over-report because anyone can file", "Confounders such as mental illness, self-esteem, other illnesses and other medicines were not adjusted for", "No included study used validated objective scales to classify PRSD", "Study designs were too varied for a meta-analysis" ], "design_notes": [ "The letter uses PRSD for any sexual side effect of retinoids; most included reports describe effects during treatment, and persistence after stopping is not assessed separately (pp. 175–176)", "A short research letter; only two databases were searched, and the number of reviewers, a flow diagram and reasons for exclusion are not reported", "Canada is listed among the study countries (p. 175), but no included study in Table 1 is from Canada", "For erectile dysfunction in the cohort study, the interval 0.55–1.4 is not centred on the stated aRR of 1.0 on the ratio scale (its midpoint is about 0.88), unlike the other three estimates; the figure may need checking against the original paper", "The letter calls a dose finding from a cross-sectional study a \"causal relationship\" (p. 175), which that design cannot establish" ], "funding": "No specific grant from any funding agency", "interests": "None declared", "supports": "That, as of January 2024, published evidence on sexual dysfunction with systemic retinoids was sparse, conflicting and mostly low quality, and could not establish causation. It does not show that retinoids do not cause lasting sexual problems, and it did not assess persistence after stopping separately.", "extracted_from": "fulltexts/LIT-037-Sexual-dysfunction-following-retinoid-treatment-a.pdf (publisher PDF, research letter, 3 pp.; page refs are the journal's printed pages 175–177)", "extracted": "2026-10-10" } }, { "item_id": "LIT-038", "source_type": "peer-reviewed paper", "title": "Exploring the association between isotretinoin and sexual dysfunction: a comprehensive scoping review", "authors": [ "Eugene Tan", "Harriet Kennedy", "Marius Rademaker" ], "journal_or_site": "Clinical and Experimental Dermatology", "year_or_date": 2024, "doi": "10.1093/ced/llae168", "url": "https://doi.org/10.1093/ced/llae168", "abstract_or_summary": "This scoping review searched for peer-reviewed studies on isotretinoin and sexual dysfunction using a broad set of terms covering erectile, ejaculatory, libido, arousal, orgasmic, fertility, and menstrual outcomes. It included 55 manuscripts (8 animal, 46 human studies with 2,420 patients): 18 case reports/series, 2 case-control, 4 cross-sectional, 6 longitudinal, 3 pharmacovigilance reports, and 13 cohort studies, mostly at 0.5-1.0 mg/kg/day for 1-6 months. More than half of human studies reported beneficial or neutral effects on sexual function, and 89% were Oxford evidence level 4. The authors conclude the evidence for a link is very weak, argue that heterogeneous definitions of sexual dysfunction make studies hard to compare, and call for standardized definitions and a causality framework.", "study_type": "scoping review", "sample_size": "55 manuscripts (46 human studies, 2,420 patients; 8 animal studies)", "keywords": [ "isotretinoin", "sexual dysfunction", "erectile dysfunction", "libido", "scoping review", "evidence quality", "causality" ], "relevance": "The most comprehensive mapping of the isotretinoin-sexual-dysfunction literature (55 papers); documents exactly why this field is stuck — low-level evidence and inconsistent definitions — and is essential context for any PRSD claim in the corpus.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/journal/year match)", "quality_notes": "Legitimate peer-reviewed venue (Oxford Academic dermatology journal); 8 citations in OpenAlex at sweep time", "sweep_date": "2026-10-07", "axis_id": "LIT-C-002", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "38703072" }, { "item_id": "LIT-039", "source_type": "peer-reviewed paper", "title": "Isotretinoin-related adverse sexual and reproductive outcomes: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)", "authors": [ "Cansu Altınöz Güney", "Huriye Aybüke Koç" ], "journal_or_site": "Cutaneous and Ocular Toxicology", "year_or_date": 2025, "doi": "10.1080/15569527.2025.2602768", "url": "https://doi.org/10.1080/15569527.2025.2602768", "abstract_or_summary": "Using FAERS data from 2004-2024 via the public dashboard and OpenVigil 2.1, the authors pulled isotretinoin-related adverse events and ran disproportionality analyses (PRR, ROR with 95% CIs, Evans' criteria) across four MedDRA system organ classes. From 53,017 isotretinoin reports, 1,300 reproductive/sexual events (92 preferred terms) qualified, with analysis on 1,151 reports naming isotretinoin as primary suspect; 59.7% of reports were female. Significant signals included erectile dysfunction (195 reports, PRR ~4.5), decreased libido (76 reports), and loss of libido (64 reports), plus 31 more: genital hypoaesthesia, genital anaesthesia, anorgasmia, decreased orgasmic sensation, sexual dysfunction, vulvovaginal dryness, dyspareunia, infertility, abnormal spermatozoa, testicular pain, and others. The authors stress FAERS limits (underreporting, reporting bias, no causal inference) and urge routine inquiry and patient education about sexual and reproductive effects during isotretinoin therapy.", "study_type": "retrospective pharmacovigilance / disproportionality analysis of spontaneous-report data", "sample_size": "53,017 isotretinoin reports in FAERS (2004-2024); 1,300 reproductive/sexual AE cases analyzed", "keywords": [ "isotretinoin", "FAERS", "pharmacovigilance", "erectile dysfunction", "libido", "genital anaesthesia", "anorgasmia", "infertility", "disproportionality analysis" ], "relevance": "The largest real-world signal-detection study of isotretinoin's sexual/reproductive harms (20 years of FAERS); gives the corpus hard numbers — e.g. significant genital-anaesthesia and decreased-orgasmic-sensation signals — that mirror PSSD/PFS symptom profiles and directly inform PRSD.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/journal match)", "quality_notes": "Peer-reviewed Taylor & Francis journal; Crossref records print year 2026, OpenAlex records online-first 2025 (listed as 2025); spontaneous-report data cannot establish causation", "sweep_date": "2026-10-07", "axis_id": "LIT-C-003", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "41447583" }, { "item_id": "LIT-040", "source_type": "peer-reviewed paper", "title": "Insights into the peripheral nature of persistent sexual dysfunction associated with post-finasteride, post-SSRI and post-accutane syndromes: lessons learned from a case study", "authors": [ "Jackson Stachelek", "Bernadette M. M. Zwaans", "Roni Mintz Shtein", "Kenneth M. Peters" ], "journal_or_site": "International Urology and Nephrology", "year_or_date": 2025, "doi": "10.1007/s11255-025-04373-w", "url": "https://doi.org/10.1007/s11255-025-04373-w", "abstract_or_summary": "The paper frames persistent sexual dysfunction after finasteride/saw palmetto, SSRIs, and retinoids as a single post-drug syndrome of unknown mechanism with no effective treatment, and asks whether targeting the peripheral genital nerves can help. Three men seen in a urology clinic received 16 weeks of high-frequency electrical stimulation plus low-intensity extracorporeal shockwave therapy, assessed by IIEF, Masturbation Erection Index, global response scales, corneal confocal microscopy, nocturnal-erection monitoring, and von Frey filament testing. All three showed mild to moderate improvement in erectile function, mild gains in penile sensitivity and nocturnal erections; corneal microscopy showed peripheral neuropathy in two patients. Central symptoms did not resolve, and patients remained profoundly affected. The authors conclude the syndrome has a treatable peripheral component but stress the urgent need for more research.", "study_type": "case series / retrospective chart review with interventional treatment (3 patients)", "sample_size": "3 male patients with post-drug syndrome (PFS/PSSD/PRSD-type)", "keywords": [ "post-drug syndrome", "PFS", "PSSD", "PRSD", "post-accutane", "peripheral neuropathy", "shockwave therapy", "IIEF", "case series" ], "relevance": "Rare clinical evidence that PFS, PSSD, and PRSD may share a peripheral-neuropathy component amenable to nerve-targeted therapy — a unifying post-drug-syndrome hypothesis paper the corpus currently lacks.", "verification_status": "verified — Crossref + OpenAlex + PubMed (PMID 39934554) all return the work", "quality_notes": "Peer-reviewed Springer journal; very small n (3) and uncontrolled — hypothesis-generating, not efficacy proof", "sweep_date": "2026-10-07", "axis_id": "LIT-C-004", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "39934554" }, { "item_id": "LIT-041", "source_type": "preprint", "title": "Isotretinoin use is associated with persistent alterations in male reproductive function", "authors": [ "Fie Bendix", "Lærke Priskorn", "Niels Jørgensen", "Hanne Winther Frederiksen", "Anne Jørgensen", "Lina Steinrud Mørch", "Hans Christian Ring", "SriDurgaDevi Kolla", "Anna K. Rosenmai", "Terje Svingen", "Anders Juul", "Anders Rehfeld" ], "journal_or_site": "medRxiv", "year_or_date": 2026, "doi": "10.64898/2026.07.22.26356991", "url": "https://doi.org/10.64898/2026.07.22.26356991", "abstract_or_summary": "A multi-model study combined the Danish Young Men Study cohort (semen parameters and reproductive hormones compared between 322 isotretinoin users and 4,065 non-users) with ex vivo human testis tissue exposed to isotretinoin and retinoic acid, plus an in vitro retinoic-acid-receptor-alpha reporter assay. Cohort analysis linked isotretinoin use to lower FSH, a higher inhibin B/FSH ratio, and higher estradiol, with a non-significant trend toward lower sperm counts; associations persisted after stopping use and were absent in men who started isotretinoin a year after examination. Ex vivo tissue showed altered hormone secretion (including higher testosterone) without changes in germ-cell dynamics, and isotretinoin competitively inhibited retinoic-acid-induced RAR-alpha signaling in vitro. The authors suggest isotretinoin may durably influence male reproductive function and call for randomized trials.", "study_type": "preprint: cross-sectional analysis of a population cohort + ex vivo human tissue + in vitro mechanistic assay", "sample_size": "5,217 men in the Danish Young Men Study (322 isotretinoin users, 4,065 non-users, 830 users of other acne medication); ex vivo testis tissue from 8 donors with testicular cancer; cell reporter assay", "keywords": [ "isotretinoin", "male reproductive function", "semen", "FSH", "inhibin B", "estradiol", "RAR-alpha", "persistent effects", "Danish Young Men Study" ], "relevance": "A mechanistic-plus-epidemiology signal on whether post-isotretinoin reproductive changes persist: at a single examination, 124 men whose last prescription was at least 2 years earlier had slightly lower FSH (2.2 vs 2.6 IU/L) and higher estradiol than non-users, within clinical reference ranges, with a plausible RAR-alpha pathway. It measured semen and reproductive hormones, not sexual symptoms, so it bears on PRSD only indirectly.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/year match)", "quality_notes": "Preprint, not peer-reviewed; authors are established Danish reproductive-epidemiology researchers (DYMS/Rigshospitalet/Statens Serum Institut groups); observational cohort cannot prove causation", "sweep_date": "2026-10-07", "axis_id": "LIT-C-005", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.medrxiv.org/content/medrxiv/early/2026/07/27/2026.07.22.26356991.full.pdf", "fulltext_source": "preprint server", "oa_status": "green", "oa_license": "all-rights-reserved", "plain": { "summary": "Researchers in Denmark studied about 5,200 young men who gave semen and blood samples at one hospital visit, using national prescription records to see who had taken the acne drug isotretinoin. The 322 men who had taken it had slightly lower levels of FSH, a hormone that drives sperm production, and slightly higher estradiol, a form of oestrogen, including men who had stopped at least two years before; their sperm counts were a little lower, but not by a clear margin. In lab tests, the drug raised the testosterone made by pieces of human testis tissue and interfered with a vitamin A signal that sperm production relies on. It is a preprint, not yet checked by other scientists.", "caveat": "It can't show that isotretinoin caused these differences or that they affect fertility or sex life: each man was measured only once, the differences were small and stayed within normal ranges, and sexual function was not studied." }, "evidence": { "design": "Preprint (not peer reviewed). Multi-model study: cross-sectional analysis of a population cohort with registry-linked prescription histories, plus ex vivo culture of human testis tissue and an in vitro RARα reporter-cell assay", "design_class": "cross-sectional", "setting": "Danish Young Men Study, Copenhagen University Hospital - Rigshospitalet; men examined 2002–2022 and linked to Danish national patient and prescription registries; testis tissue collected September 2023 to December 2024", "population": "Young Danish men (median age 19) recruited at their compulsory military fitness examination, who attended one examination day with semen and blood sampling; men with no exact examination date or with anabolic steroid use were excluded. Ex vivo: non-tumour testis tissue from 8 men having a testis removed for testicular cancer.", "n": 5217, "n_note": "5,217 men (from 5,307 examined), of whom 322 isotretinoin users, 4,065 non-users and 830 users of other acne medication; overlapping user subgroups of 45 active, 124 prior and 164 later users; ex vivo hormones from 8 donors, germ-cell staining from 4; reporter assay 3 independent experiments", "exposure": "Systemic isotretinoin (ATC D10BA01), at least one redeemed prescription before the examination; dose unknown for 164 of 322 (most common 40 mg/day, n = 112). Ex vivo 10, 15 or 25 µM isotretinoin (and 1 or 10 µM retinoic acid) for 96 hours; in vitro 12, 195 or 1,440 nM isotretinoin.", "comparator": "Men with no isotretinoin before their examination (n = 4,065); users of other acne medication (n = 830) as a check on acne itself; men who first used isotretinoin at least one year after their examination (sensitivity analysis); vehicle (DMSO) controls ex vivo", "outcome": "Semen volume, sperm concentration, total count, motility and morphology; serum LH, FSH, testosterone, free testosterone, SHBG, estradiol and inhibin B, with testosterone/LH and inhibin B/FSH ratios. Ex vivo hormone secretion, germ-cell proliferation and apoptosis; in vitro RARα activation. Sexual function was not assessed.", "follow_up": "None; one examination day per man (cross-sectional), with \"prior\" users defined by a last prescription at least 2 years before that day. Ex vivo culture 96 hours.", "results": [ { "text": "All isotretinoin users (322) vs non-users (4,065), medians: FSH 2.4 vs 2.6 IU/L (p = 0.008), inhibin B/FSH ratio 81 vs 69 (p = 0.027), estradiol 85 vs 81 pmol/L (p = 0.044); LH, testosterone, free testosterone and SHBG did not differ", "where": "p. 12, Table 3" }, { "text": "Semen in users vs non-users: sperm concentration 41 vs 45 million/ml, total sperm count 125 vs 145 million, progressively motile count 74 vs 88 million; none statistically significant (p 0.358, 0.465, 0.521)", "where": "p. 11, Table 3 (p. 12)" }, { "text": "Prior users (last prescription at least 2 years before, n = 124): FSH 2.2 vs 2.6 IU/L (p = 0.014), inhibin B/FSH 83 vs 69 (p = 0.035), estradiol 85 vs 81 pmol/L (p = 0.024). Active users (n = 45): no significant differences (estradiol 88 vs 81 pmol/L, p = 0.068 in Table 4; the text gives P = 0.06)", "where": "pp. 12–13, Table 4" }, { "text": "Later users (first prescription at least 1 year after the examination, n = 164): no significant differences, with FSH 2.8 IU/L, inhibin B/FSH 58 and total sperm count 170 million (p 0.077, 0.061, 0.079), i.e. in the opposite direction to past users", "where": "p. 13, Table 4" }, { "text": "Ex vivo testis tissue (8 donors): testosterone higher than vehicle at every isotretinoin concentration (p < 0.05) and DHT lower (p < 0.001); estradiol unchanged; inhibin B lower only at 25 µM isotretinoin and with 10 µM retinoic acid plus 10 µM isotretinoin; no effect on germ-cell proliferation (4 donors), and apoptosis rose only with 10 µM retinoic acid", "where": "pp. 13–15, Figs 2–3" }, { "text": "Reporter cells: isotretinoin alone activated RARα; with 195 or 1,440 nM isotretinoin, added retinoic acid gave almost no further activation; with 12 nM, retinoic acid's EC50 rose from 2.92 to 7.65 (about 2.6-fold). The text gives these EC50s in µM, but retinoic acid was tested only up to 100 nM and Fig. 4's axis is in nM", "where": "p. 16, Fig. 4; p. 10" } ], "limitations_stated": [ "Dose could not be determined for most users (164 of 322), so all users were analysed as one group", "The ex vivo model does not fully reproduce sperm production, meiosis was not assessed, and results may not reflect the testis in the body", "Germ cells were identified by position and shape, without a germ-cell-specific marker", "All cultured tissue came from men with testicular cancer; 35 of 88 fragments (39.8%) contained GCNIS-positive tubules", "Hormone concentrations and semen parameters stayed within clinical reference ranges", "The proposed mechanism is hypothetical, the ex vivo testosterone rise may involve targets other than RAR, and randomised trials are needed" ], "design_notes": [ "Preprint, not peer reviewed", "Each man was measured once; \"persistence\" is inferred from men whose last prescription was at least 2 years earlier, not from repeat measurements of the same men", "Fifteen semen and hormone measures were compared across four exposure groups with no stated correction for multiple testing; the significant p-values range from 0.008 to 0.044", "Users of other acne medication had the same estradiol median and IQR as isotretinoin users (85 pmol/L, 66–104), which was not significant (p = 0.103, Table 3)", "Hormone assays changed during 2002–2022 (testosterone and SHBG from 2014, LH and FSH from 2021); the stated adjustments do not include assay method or examination year (p. 6, Tables 3–4)", "The 322 + 4,065 + 830 groups sum to the 5,217 included, so the 164 later users must sit within the non-user or other-acne groups; the paper does not say which", "Ex vivo isotretinoin concentrations (10–25 µM) are about 7 to 19 times the plasma Cmax the authors cite (1.34–1.44 µM, p. 18)", "Retinoic acid concentration range is given as 0.015–100 nM in Methods (p. 10) but 0.15 pM–100 nM in the Fig. 4 legend (p. 16)" ], "funding": "Grosses LF Foghts Fund (grant 2026-0047) and King Christian IX and Queen Louise's Jubilee Grant (grant 2025), awarded to F.B. and A.R.", "interests": "Not stated", "supports": "In a preprint, a small cross-sectional association between past isotretinoin use and lower FSH and higher estradiol in young men, including men who had stopped at least two years earlier, plus lab evidence that isotretinoin interferes with retinoic-acid signalling. It cannot establish causation or clinical importance, and says nothing about sexual function.", "extracted_from": "fulltexts/LIT-041-Isotretinoin-use-is-associated-with-persistent-alt.pdf (medRxiv preprint PDF posted 27 July 2026, all rights reserved, 24 pp.; pages cited are the preprint's printed page numbers, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-042", "source_type": "preprint", "title": "Investigating Sexual Dysfunction in Patients on Isotretinoin, and Evaluating Patient Education Practices among Dermatologists: Survey Study (Preprint)", "authors": [ "Elizabeth Tchernogorova", "Eve Golden", "Natalia Correa", "Olnita Martini", "Taylor M. Runion", "Alyssa P Quinn", "Alexandra Ortiz-Jimenez", "Gabriella Vasile", "Amanda Brooks" ], "journal_or_site": "JMIR Preprints", "year_or_date": 2024, "doi": "10.2196/preprints.65329", "url": "https://doi.org/10.2196/preprints.65329", "abstract_or_summary": "A patient survey study set out to measure how common sexual-dysfunction symptoms are among people taking isotretinoin and how often dermatologists counsel patients about them beforehand. Among 144 respondents, 33% of women (n=118) reported vaginal dryness and 34.7% of men (n=23) reported erectile dysfunction while on isotretinoin. Very few had discussed these risks with their prescriber first: 6.8% of women had discussed vaginal dryness and 4.3% of men had discussed erectile dysfunction, ejaculatory failure, or delayed ejaculation. The authors conclude there is a clear opportunity to improve awareness and counseling about isotretinoin's sexual-health effects.", "study_type": "cross-sectional survey study (patients)", "sample_size": "144 respondents (118 female, 23 male, 3 whose sex could not be assigned)", "keywords": [ "isotretinoin", "sexual dysfunction", "erectile dysfunction", "vaginal dryness", "patient counseling", "survey", "dermatology" ], "relevance": "Documents sexual symptoms reported during treatment by respondents to a self-selected online survey (vaginal dryness in 33% of 118 women, erectile dysfunction in 8 of 23 men) and a near-total counseling gap. These are proportions of respondents, not prevalence, and complement the regulatory warnings and pharmacovigilance signals elsewhere in this sweep.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/year match)", "quality_notes": "Preprint, not peer-reviewed; small self-selected survey sample; no published-version DOI found at sweep time", "sweep_date": "2026-10-07", "axis_id": "LIT-C-006", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://preprints.jmir.org/preprint/pdf/65329?version=submitted", "fulltext_source": "preprint server (submitted version)", "oa_status": "gold", "oa_license": "all-rights-reserved", "fulltext_note": "submitted version per author request; verified HTTP 200 2026-10-09", "plain": { "summary": "Researchers ran an anonymous online survey, shared by email and on social media, of 144 adults who had taken isotretinoin for acne. About 1 in 3 of the 118 women said they had vaginal dryness while on the drug, and 8 of the 23 men said they had erection problems. Very few said their dermatologist had mentioned these possible effects beforehand: about 1 in 15 women for vaginal dryness, and 1 of the 23 men for each male sexual symptom.", "caveat": "It can't tell how common these problems are among everyone who takes isotretinoin, whether the drug caused them, or whether they lasted after stopping: the people who answered chose to take part, there was no comparison group, and many were also taking other medicines linked to sexual side effects, such as the contraceptive pill." }, "evidence": { "design": "Preprint (submitted version, not peer reviewed). Cross-sectional anonymous online survey of 14 questions, with no comparison group", "design_class": "cross-sectional", "setting": "Online (Qualtrics) survey run by students at Rocky Vista University College of Osteopathic Medicine, USA, 29 November to 20 December 2023, shared by email, Facebook, Reddit and Instagram", "population": "Adults over 18 with past or present use of isotretinoin for acne who completed the survey. Sex was not asked directly; it was inferred from iPLEDGE answers, and 3 respondents could not be assigned.", "n": 144, "n_note": "144 completed surveys, of whom 118 classified female, 23 male and 3 unassigned (excluded from sex-specific analyses); 110 reported being sexually active", "exposure": "Isotretinoin for acne, past or present; dose, duration and time since stopping are not reported", "comparator": "None", "outcome": "Self-reported symptoms experienced while using isotretinoin, sexual and non-sexual, and whether each was discussed with the prescribing dermatologist before starting", "follow_up": "None; one survey. Only symptoms \"while using\" isotretinoin are reported, and the questionnaire (Appendix 1) is not included in the PDF", "results": [ { "text": "Women (n = 118): vaginal dryness 33.0%, painful intercourse 22.0%, vaginal discomfort 17.8%, more vaginal yeast infections 16.9%, more bacterial vaginosis 9.3% (39, 26, 21, 20 and 11 women)", "where": "p. 6" }, { "text": "Men (n = 23): erectile dysfunction 34.7%, ejaculatory failure 17.3%, delayed ejaculation 8.7%. These correspond to 8, 4 and 2 men (34.8%, 17.4%, 8.7%; the paper truncates rather than rounds). Fig. 1, which adds the 3 unassigned respondents (as its female bars do, e.g. 39 + 3 = 42 for vaginal dryness), shows 9 with erectile dysfunction and 6 with ejaculatory failure (read from the chart), whereas the text implies 8 + 3 = 11 and 4 + 1 = 5", "where": "p. 6, Fig. 1 (p. 13)" }, { "text": "Discussed with the dermatologist before starting, women: vaginal dryness 6.8% (8 of 118), vaginal discomfort 4.2%, painful intercourse 3.4%, bacterial vaginosis 2.5%, yeast infections 1.7%; men: 1 of 23 (4.3%) each for erectile dysfunction, ejaculatory failure and delayed ejaculation. For comparison, of all 144, dry lips was discussed with 90.9%, depression 65.9% and birth defects 52%", "where": "p. 7, Figs 1–2 (pp. 13–14)" }, { "text": "Non-sexual effects among all 144: dry lips 93.7%, headaches 49.3%, joint pain 47.9%, mood swings 40.2%, depression 35.4%, vision changes 27.7%", "where": "p. 6" }, { "text": "Write-in answers under \"other symptoms\" included decreased libido (7 respondents) and genital paresthesia, i.e. altered genital sensation (4); neither was a listed option", "where": "p. 6" } ], "limitations_stated": [ "69% of female respondents were taking oral contraceptives for iPLEDGE, which can themselves cause sexual dysfunction (83 selections among the 121 respondents asked, 68.6%)", "12 respondents were taking an SSRI antidepressant, known to cause sexual dysfunction", "Only 16% of respondents were male", "People aged 12–17 were excluded, although isotretinoin is approved from age 12", "Sex was not asked but inferred from iPLEDGE answers, and 3 respondents could not be assigned" ], "design_notes": [ "Preprint (submitted version), not peer reviewed", "Self-selected respondents recruited through social media, with no response rate, so the percentages are not population frequencies", "No comparison group of people not taking isotretinoin", "Dose, duration, timing of symptoms and whether they resolved after stopping are not reported", "Counselling was reported by patients, not checked against records", "All 3 unassigned respondents reported vaginal dryness, painful intercourse and vaginal discomfort, and all 3 also reported erectile dysfunction (p. 6)", "No statistical tests are described, though discussion of non-sexual effects is called \"significantly\" more frequent (p. 7)", "The introduction says that in a survey of 300 patients with sexual dysfunction \"54% of the patients were taking isotretinoin\" (p. 6); in that series (Healy et al. 2018, LIT-019 in this corpus) isotretinoin accounted for 54 of 300 cases, 18.0% (LIT-019 p. 127, Table 1). Reference numbers in the introduction also appear shifted against the reference list (pp. 5–6, 10)" ], "funding": "Not stated; the acknowledgements say there are no financial disclosures", "interests": "None declared", "supports": "That, in a small self-selected online sample, many isotretinoin users reported sexual symptoms during treatment and few recalled being told about them beforehand. It cannot estimate how common these symptoms are, show that isotretinoin caused them, or say whether they persisted after stopping.", "extracted_from": "fulltexts/LIT-042-Investigating-Sexual-Dysfunction-in-Patients-on-Is.pdf (JMIR Preprints PDF of the version submitted to JMIR Dermatology on 13 August 2024, all rights reserved, 14 pp.; no printed page numbers, so pages cited are the PDF page index, with the manuscript on pp. 5–10 and figures on pp. 13–14)", "extracted": "2026-10-10" } }, { "item_id": "LIT-043", "source_type": "peer-reviewed paper", "title": "Isotretinoin-induced gynecomastia.", "authors": [ "Ernesto Bonifazi" ], "journal_or_site": "European Journal of Pediatric Dermatology", "year_or_date": 2020, "doi": "10.26326/2281-9649.30.1.2086", "url": "https://doi.org/10.26326/2281-9649.30.1.2086", "abstract_or_summary": "This brief report reviews the four published cases of isotretinoin-induced gynecomastia and argues that isotretinoin can, albeit rarely, cause persistent sexual dysfunction in the same manner as finasteride and serotonin-reuptake antidepressants — noting that unlike those drugs, sexual dysfunction is not even mentioned in isotretinoin's data sheet. It cites the 300-case series finding that isotretinoin alone accounted for as many enduring-dysfunction cases as fluoxetine and finasteride combined, and proposes anti-androgenic inhibition (with studies showing lowered testosterone) as the likely mechanism.", "study_type": "case report with literature review of published cases", "sample_size": "4 published gynecomastia cases reviewed (+ index case)", "keywords": [ "isotretinoin", "gynecomastia", "androgen inhibition", "testosterone", "persistent sexual dysfunction", "case report" ], "relevance": "A concise clinical anchor for the anti-androgenic-mechanism hypothesis of PRSD, explicitly linking isotretinoin to the PFS/PSSD paradigm — useful as a citable counterpoint to the \"very weak evidence\" reviews.", "verification_status": "verified — OpenAlex returns the work; Crossref has no record (journal does not deposit there); second signal is the journal's own live article page (ejpd.com/index.php/journal/article/view/2086, crawled 2026-09, abstract matches)", "quality_notes": "Small specialty journal; Crossref absent so metadata is thin; opinionated commentary tone — treat mechanistic claim as hypothesis, not proof", "sweep_date": "2026-10-07", "axis_id": "LIT-C-007", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-044", "source_type": "peer-reviewed paper", "title": "Effect of Acitretin on Penile Erection in Psoriatic Male Patients", "authors": [], "journal_or_site": "The Egyptian Journal of Hospital Medicine", "year_or_date": 2023, "doi": "10.21608/ejhm.2023.322661", "url": "https://doi.org/10.21608/ejhm.2023.322661", "abstract_or_summary": "Noting case reports that retinoids may impair sexual function, this study prospectively assessed penile erection in 31 men with psoriasis treated with the systemic retinoid acitretin for at least two months. Erectile function was measured with the IIEF-5 questionnaire before treatment and again after two months of therapy. The design directly tests whether a retinoid other than isotretinoin affects erectile function in a clinical population, extending the retinoid-sexual dysfunction question beyond acne treatment.", "study_type": "prospective before-after cohort study", "sample_size": "31 male psoriatic patients (IIEF-5 pre-treatment vs after 2 months of acitretin)", "keywords": [ "acitretin", "retinoid", "erectile dysfunction", "IIEF-5", "psoriasis", "prospective study" ], "relevance": "One of the few prospective studies measuring erectile function with a validated instrument under a systemic retinoid — extends PRSD evidence from isotretinoin to the retinoid class as a whole.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/journal/year match; vol. 93, pp. 7275-7278)", "quality_notes": "Legitimate regional journal (Faculty of Medicine, Ain Shams University; ISSN 1687-2002/2090-7125; EBSCO-indexed) but low citation metrics (H-index 3); author list not exposed via Crossref/OpenAlex metadata; small single-center n", "sweep_date": "2026-10-07", "axis_id": "LIT-C-008", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_note": "publisher site unreachable 2026-10-09, re-check" }, { "item_id": "LIT-045", "source_type": "preprint", "title": "PSSD,PFS,PRSD: A perspective for aetiology and treatment", "authors": [ "Spyridon Bourtzalas" ], "journal_or_site": "OSF Preprints", "year_or_date": 2023, "doi": "10.31219/osf.io/jxnbu", "url": "https://doi.org/10.31219/osf.io/jxnbu", "abstract_or_summary": "This theoretical paper treats PSSD, PFS, and PRSD as documented but poorly understood iatrogenic conditions with severe, often permanent effects on quality of life. It argues that developing treatments requires understanding causal pathways, which in turn requires a better grasp of the mechanisms driving sexual behavior in men and women, and notes that no well-supported aetiological proposals or treatments currently exist. The paper aims to supply a new conceptual framework bridging the three syndromes. It is a single-author perspective piece rather than an empirical study.", "study_type": "theoretical / perspective paper", "sample_size": "n/a (no empirical data)", "keywords": [ "PSSD", "PFS", "PRSD", "aetiology", "theoretical framework", "iatrogenic", "perspective" ], "relevance": "An explicit attempt to build a shared aetiological framework across all three post-drug sexual syndromes — the only such theory paper found in this sweep, and directly on the \"unified post-drug syndrome\" axis.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/year match)", "quality_notes": "Preprint, not peer-reviewed; single independent author; no empirical data — include as theory/gray literature, not evidence", "sweep_date": "2026-10-07", "axis_id": "LIT-C-009", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://osf.io/jxnbu/download", "fulltext_source": "preprint server", "oa_status": "gold", "oa_license": "public-domain" }, { "item_id": "LIT-046", "source_type": "policy brief / report (gray literature)", "title": "Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health", "authors": [ "Varun S. Nair" ], "journal_or_site": "Zenodo", "year_or_date": 2025, "doi": "10.5281/zenodo.17999880", "url": "https://doi.org/10.5281/zenodo.17999880", "abstract_or_summary": "This self-published policy brief argues that post-drug syndromes — persistent, multisystem conditions triggered by prescription drugs and continuing long after discontinuation, including PFS, PSSD, and post-retinoid syndromes — are a structurally neglected category of adverse drug reactions. It contends that current pharmacovigilance systems are built to catch acute, temporally proximate events and therefore miss long-latency, persistent harms, despite growing patient-reported evidence and selective regulatory acknowledgments. The brief is framed for public-health and pharmacovigilance audiences rather than as a clinical study.", "study_type": "policy brief / narrative report", "sample_size": "n/a", "keywords": [ "post-drug syndrome", "pharmacovigilance", "PFS", "PSSD", "post-retinoid", "public health", "adverse drug reaction", "policy" ], "relevance": "The only item in this sweep that frames persistent post-drug syndromes as a *systems* problem in pharmacovigilance — directly supports the corpus's \"persistent post-drug syndromes generally\" axis and gives the advocacy/policy angle a citable anchor.", "verification_status": "verified — OpenAlex returns the work; Crossref has no record (Zenodo mints DataCite DOIs); second signal is the Zenodo records API (record 17999880, v4 of concept 10.5281/zenodo.17999879, with deposited PDF)", "quality_notes": "venue reputation unverified — self-published policy brief, single independent author (affiliation listed as 'Independent Public Health Researcher, India'); not peer-reviewed", "sweep_date": "2026-10-07", "axis_id": "LIT-C-010", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-047", "source_type": "conference abstract", "title": "PS01 (P075) A retrospective review of isotretinoin treatment-related psychosexual health side-effects in a tertiary dermatology clinic", "authors": [ "Kyriaki Stefania Mitsaki", "Sumir Chawla", "Eirini Merika" ], "journal_or_site": "British Journal of Dermatology (conference abstract supplement)", "year_or_date": 2024, "doi": "10.1093/bjd/ljae090.372", "url": "https://doi.org/10.1093/bjd/ljae090.372", "abstract_or_summary": "Presented after the UK regulator introduced new monitoring requirements for isotretinoin's psychiatric and sexual side effects, this retrospective review examined 167 consecutive patients who completed isotretinoin treatment at a tertiary dermatology clinic. The primary aim was mental-health outcomes (depressive symptoms, quality of life); the secondary endpoint was the effect of isotretinoin on sexual function. It represents real-world clinic data on psychosexual side effects collected under the new regulatory monitoring regime.", "study_type": "conference abstract: retrospective cohort study", "sample_size": "167 consecutive patients completing isotretinoin treatment", "keywords": [ "isotretinoin", "psychosexual", "sexual function", "depression", "retrospective", "MHRA", "monitoring", "conference abstract" ], "relevance": "The largest single-clinic retrospective cohort on isotretinoin psychosexual effects found in this sweep, and a direct artifact of the 2023 MHRA monitoring requirements — captures how regulators are now forcing this data to be collected.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/journal/year match)", "quality_notes": "Conference abstract only — methods and full results not published as a paper at sweep time; secondary-endpoint sexual-function results not extractable from abstract metadata", "sweep_date": "2026-10-07", "axis_id": "LIT-C-011", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-048", "source_type": "conference abstract", "title": "P046 Investigating sexual side-effects in female patients on isotretinoin via routine screening questionnaires", "authors": [], "journal_or_site": "British Journal of Dermatology (conference abstract supplement)", "year_or_date": 2025, "doi": "10.1093/bjd/ljaf085.074", "url": "https://doi.org/10.1093/bjd/ljaf085.074", "abstract_or_summary": "This conference abstract reports on investigating sexual side effects specifically in female patients taking isotretinoin, using routine screening questionnaires administered in clinical practice. It addresses the under-studied female side of retinoid sexual dysfunction — an area where spontaneous-report data (e.g. the FAERS study in this sweep) suggest most reports come from women, yet the published literature is overwhelmingly male-focused. Full abstract text was not retrievable via API metadata at sweep time.", "study_type": "conference abstract (screening-questionnaire study)", "sample_size": "n/a (cohort size not available from abstract metadata)", "keywords": [ "isotretinoin", "female sexual dysfunction", "screening", "questionnaire", "conference abstract" ], "relevance": "One of very few PRSD-relevant items centered on female patients — fills a gender gap in a corpus otherwise dominated by male erectile-dysfunction data, and shows routine sexual-health screening for isotretinoin entering practice.", "verification_status": "verified — Crossref + OpenAlex both return the work (title/journal/year match)", "quality_notes": "Conference abstract only; author list and full abstract not exposed via API metadata — flag for full-text retrieval before citation", "sweep_date": "2026-10-07", "axis_id": "LIT-C-012", "sweep_axis": "prsd", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-049", "source_type": "peer-reviewed paper", "title": "Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition", "authors": [ "Silvia Diviccaro", "Silvia Giatti", "Francesca Borgo", "Matteo Barcella", "Elisa Borghi", "José Luis Trejo", "Luis Miguel Garcia-Segura", "Roberto Cosimo Melcangi" ], "journal_or_site": "Psychoneuroendocrinology", "year_or_date": "2019", "doi": "10.1016/j.psyneuen.2018.09.021", "url": "https://doi.org/10.1016/j.psyneuen.2018.09.021", "abstract_or_summary": "Male Sprague-Dawley rats were treated with finasteride for 20 days and then followed for one month after withdrawal. At the end of treatment, the dentate gyrus showed more proliferating progenitor cells and higher hippocampal TNF-alpha mRNA, indicating an acute inflammatory-proliferative shift. One month after the drug was stopped, the picture had reversed and worsened: the animals displayed depressive-like behavior, fewer proliferating cells, reduced granule-cell density, and more reactive astrocytes in the dentate gyrus. The gut microbiota was also altered, with different bacterial families enriched at the end of treatment versus at the end of the withdrawal period. Because the behavioral, neurogenic, inflammatory, and microbial changes persisted a full month after the last dose, the work provides one of the closest animal models of the persistence phenomenon seen in post-finasteride patients.", "study_type": "primary-animal", "sample_size": "male Sprague-Dawley rats; 20-day treatment arm plus 1-month withdrawal arm (per-group n not extracted from the record)", "keywords": [ "finasteride", "5-alpha-reductase inhibitor", "withdrawal persistence", "depressive-like behavior", "hippocampal neurogenesis", "neuroinflammation", "gut microbiota", "post-finasteride syndrome" ], "relevance": "Directly addresses the core persistence question of the corpus: finasteride-induced brain and microbiome changes outlasting drug exposure by weeks. Bridges the neurosteroid, neuroinflammation, and gut-brain axes in a single controlled experiment.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 30265917; PubMed abstract checked.", "quality_notes": "Peer-reviewed journal (Elsevier). Melcangi lab — the leading PFS mechanistic research group.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-001", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "30265917" }, { "item_id": "LIT-050", "source_type": "peer-reviewed paper", "title": "Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm", "authors": [ "Abdulmaged M. Traish" ], "journal_or_site": "The World Journal of Men's Health", "year_or_date": "2020", "doi": "10.5534/wjmh.200012", "url": "https://doi.org/10.5534/wjmh.200012", "abstract_or_summary": "Traish argues that dihydrotestosterone (DHT) is far more than a prostate-and-hair hormone, documenting its physiological roles in liver, pancreatic beta-cell function and survival, ocular and lacrimal function, and kidney physiology. Blocking DHT synthesis with finasteride or dutasteride therefore has systemic consequences that extend well beyond the intended targets. The review catalogs health risks associated with long-term 5-alpha-reductase inhibition and contends that the drugs' safety profile has been underappreciated. It is written as a call to clinicians to weigh these broader risks, especially for cosmetic use in young men.", "study_type": "review", "sample_size": "n/a", "keywords": [ "finasteride", "dutasteride", "5-alpha-reductase inhibitor", "dihydrotestosterone", "systemic effects", "drug safety", "post-finasteride syndrome" ], "relevance": "Provides the systemic-physiology counterweight to narrow urologic/dermatologic framing of 5-AR inhibitors — foundational context for why persistent multi-system symptoms after finasteride are biologically plausible.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 32202088.", "quality_notes": "Peer-reviewed society journal (Korean Society for Sexual Medicine and Andrology); Traish is the author of the Fertility and Sterility PFS review already in the corpus.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-003", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "starred": true, "sidefxhub_curated": true, "sidefxhub_article_title": "Long-term finasteride and dutasteride side effects", "fulltext_url": "http://wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-38-323.pdf", "fulltext_source": "publisher OA", "oa_status": "diamond", "oa_license": "cc-by-nc" }, { "item_id": "LIT-051", "source_type": "peer-reviewed paper", "title": "The connection of 5-alpha reductase inhibitors to the development of depression", "authors": [ "Thiraphat Saengmearnuparp", "Bannakij Lojanapiwat", "Nipon Chattipakorn", "Siriporn Chattipakorn" ], "journal_or_site": "Biomedicine & Pharmacotherapy", "year_or_date": "2021", "doi": "10.1016/j.biopha.2021.112100", "url": "https://doi.org/10.1016/j.biopha.2021.112100", "abstract_or_summary": "Clinical studies indicate that former users of 5-alpha-reductase inhibitors carry a higher incidence of depressive symptoms and neuropsychiatric side effects than non-users, yet the mechanisms behind depression in former users — sometimes called post-finasteride syndrome — remain poorly understood. This review pulls together the association between 5-AR inhibitors and depression alongside candidate mechanisms, with emphasis on neurosteroid depletion and downstream effects on GABAergic and neurotrophic signaling. The authors note that the persistence of depressive symptoms after the drug is stopped points to lasting neurobiological changes rather than a transient pharmacologic effect. The paper is a PubMed-based literature synthesis rather than original research.", "study_type": "review", "sample_size": "n/a", "keywords": [ "5-alpha-reductase inhibitor", "finasteride", "depression", "neurosteroids", "allopregnanolone", "post-finasteride syndrome", "neuropsychiatric adverse effects" ], "relevance": "Explicitly centers the depression-withdrawal link that the corpus tags heavily, and frames persistence as a lasting neurobiological change — directly on the neurosteroid/GABA-A axis.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 34479019.", "quality_notes": "Peer-reviewed journal (Elsevier). Literature synthesis; check for predatory concerns — none; venue is established.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-004", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.sciencedirect.com/science/article/pii/S0753332221008842/pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by-nc-nd" }, { "item_id": "LIT-052", "source_type": "peer-reviewed paper", "title": "Studies on Neurosteroids XXV. Influence of a 5.ALPHA.-Reductase Inhibitor, Finasteride, on Rat Brain Neurosteroid Levels and Metabolism", "authors": [ "Yoshiyuki Mukai", "Tatsuya Higashi", "Yukiko Nagura", "Kazutake Shimada" ], "journal_or_site": "Biological and Pharmaceutical Bulletin", "year_or_date": "2008", "doi": "10.1248/bpb.31.1646", "url": "https://doi.org/10.1248/bpb.31.1646", "abstract_or_summary": "Using sensitive LC-ESI-MS/MS methods developed to quantify trace neurosteroids, the authors measured how finasteride alters brain levels and metabolism of allopregnanolone, 3alpha-dihydroprogesterone, progesterone, 20alpha-dihydroprogesterone, and 11-deoxycorticosterone in rats exposed to immobilization stress. The work establishes that 5-alpha-reductase blockade measurably depletes multiple brain neurosteroids, not just peripheral DHT. It is primarily an analytical-pharmacology study: the method development was a prerequisite for showing the drug's central neurosteroid effects. The findings supply the direct experimental link between finasteride administration and reduced brain allopregnanolone.", "study_type": "primary-animal", "sample_size": "rats under immobilization stress (per-group n not extracted from the record)", "keywords": [ "finasteride", "5-alpha-reductase inhibitor", "brain neurosteroids", "allopregnanolone", "LC-MS/MS", "neurosteroidogenesis" ], "relevance": "One of the earliest direct demonstrations that finasteride depletes brain neurosteroids — the foundational 5AR-neurosteroid mechanism paper for the corpus's mechanistic axis.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 18758053.", "quality_notes": "Peer-reviewed journal (Pharmaceutical Society of Japan). Open access.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-005", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.jstage.jst.go.jp/article/bpb/31/9/31_9_1646/_pdf", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "" }, { "item_id": "LIT-053", "source_type": "peer-reviewed paper", "title": "Revisiting the roles of progesterone and allopregnanolone in the nervous system: Resurgence of the progesterone receptors", "authors": [ "M. Schumacher", "C. Mattern", "A. Ghoumari", "J.P. Oudinet", "P. Liere", "F. Labombarda", "R. Sitruk-Ware", "A.F. De Nicola" ], "journal_or_site": "Progress in Neurobiology", "year_or_date": "2014", "doi": "10.1016/j.pneurobio.2013.09.004", "url": "https://doi.org/10.1016/j.pneurobio.2013.09.004", "abstract_or_summary": "This major review reconsiders progesterone and its 5-alpha-reduced metabolite allopregnanolone as central nervous system signaling molecules rather than mere reproductive hormones. It covers their synthesis in the brain, their potentiation of GABA-A receptor function, and their roles in neuroprotection, myelination, and mood regulation. A distinctive thread is the resurgence of classical progesterone receptors as active players alongside the rapid membrane/GABA-A effects, arguing for a dual mechanism of neurosteroid action. The synthesis draws on decades of neuroendocrinology to explain how disrupting this pathway could produce broad neuropsychiatric consequences.", "study_type": "review", "sample_size": "n/a", "keywords": [ "progesterone", "allopregnanolone", "neurosteroids", "GABA-A receptor", "progesterone receptors", "neuroprotection", "mood regulation" ], "relevance": "Canonical neurosteroid review (362+ citations) that details exactly the signaling pathway 5-AR inhibitors disrupt in the brain — essential background for the allopregnanolone/GABA-A pillar.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 24172649.", "quality_notes": "Peer-reviewed journal (Elsevier, Progress in Neurobiology). Highly cited.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-006", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "http://hdl.handle.net/11336/6678", "fulltext_source": "publisher OA", "oa_status": "green", "oa_license": "" }, { "item_id": "LIT-054", "source_type": "peer-reviewed paper", "title": "Allopregnanolone: State of the art", "authors": [ "Roberto Cosimo Melcangi", "Gian Carlo Panzica" ], "journal_or_site": "Progress in Neurobiology", "year_or_date": "2014", "doi": "10.1016/j.pneurobio.2013.09.005", "url": "https://doi.org/10.1016/j.pneurobio.2013.09.005", "abstract_or_summary": "Melcangi and Panzica consolidate the state of knowledge on allopregnanolone: its enzymatic synthesis via 5-alpha-reductase and 3alpha-hydroxysteroid dehydrogenase, its distribution in brain and periphery, and its potent modulation of GABA-A receptors. The review spans the molecule's roles in stress regulation, mood, sexual behavior, neuroprotection, and neuroinflammation, and flags how pharmacological blockade of its synthesis can disturb each of these domains. Written by the group that leads PFS mechanistic research, it explicitly connects allopregnanolone biology to the consequences of 5-alpha-reductase inhibition. It serves as the definitive short synthesis of why allopregnanolone matters to the post-drug syndrome question.", "study_type": "review", "sample_size": "n/a", "keywords": [ "allopregnanolone", "neurosteroids", "GABA-A receptor", "5-alpha-reductase", "neuroprotection", "stress", "finasteride" ], "relevance": "The allopregnanolone review from the PFS research group itself — directly bridges the neurosteroid mechanism to 5-AR inhibitor effects and anchors the GABA-A pillar of the corpus.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 24121112.", "quality_notes": "Peer-reviewed journal (Elsevier, Progress in Neurobiology).", "sweep_date": "2026-10-07", "axis_id": "LIT-D-007", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://iris.unito.it/retrieve/e27ce428-7820-2581-e053-d805fe0acbaa/Progress%20in%20Neurobiology_2014_OA.pdf", "fulltext_source": "repository", "oa_status": "green", "oa_license": "", "pmid": "24121112", "fulltext_note": "Link updated 2026-10-09: the free copy is the University of Turin repository version" }, { "item_id": "LIT-055", "source_type": "peer-reviewed paper", "title": "Tolerance to allopregnanolone with focus on the GABA-A receptor", "authors": [ "Sahruh Turkmen", "Torbjorn Backstrom", "Goran Wahlstrom", "Lotta Andreen", "Inga-Maj Johansson" ], "journal_or_site": "British Journal of Pharmacology", "year_or_date": "2011", "doi": "10.1111/j.1476-5381.2010.01059.x", "url": "https://doi.org/10.1111/j.1476-5381.2010.01059.x", "abstract_or_summary": "Allopregnanolone is among the most potent endogenous modulators of the GABA-A receptor, and fluctuations in its levels create vulnerability to mood and emotional pathology. This review focuses on how the GABA-A receptor adapts — developing tolerance — under conditions of changing allopregnanolone exposure, such as stress, the menstrual cycle, and pregnancy. The authors describe receptor-level adaptations, including subunit changes, that alter sensitivity to neurosteroids and to GABAergic drugs. The tolerance concept is directly relevant to what happens when allopregnanolone is chronically depleted by 5-alpha-reductase inhibition and then the system must readapt after the drug is withdrawn.", "study_type": "review", "sample_size": "n/a", "keywords": [ "allopregnanolone", "GABA-A receptor", "tolerance", "neuroactive steroids", "mood disorders", "receptor plasticity" ], "relevance": "Supplies the receptor-plasticity mechanism that could explain why symptoms persist after allopregnanolone depletion ends — tolerance/readaptation dynamics are a prime candidate for the persistence mechanism the corpus seeks.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 20883478.", "quality_notes": "Peer-reviewed journal (British Pharmacological Society).", "sweep_date": "2026-10-07", "axis_id": "LIT-D-008", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/3031054", "fulltext_source": "publisher OA", "oa_status": "green", "oa_license": "", "pmid": "20883478" }, { "item_id": "LIT-056", "source_type": "peer-reviewed paper", "title": "Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective", "authors": [ "Steven M. Paul", "Graziano Pinna", "Alessandro Guidotti" ], "journal_or_site": "Neurobiology of Stress", "year_or_date": "2020", "doi": "10.1016/j.ynstr.2020.100215", "url": "https://doi.org/10.1016/j.ynstr.2020.100215", "abstract_or_summary": "Tracing three decades of research, the authors describe how allopregnanolone — synthesized in the CNS from cholesterol or from progesterone and pregnenolone — came to be recognized as a rapid, non-genomic modulator of GABA-A receptors. Shifts in brain allopregnanolone during pregnancy, the postpartum period, and protracted stress are linked to the pathophysiology of mood disorders. The review then follows the molecule's path into therapeutics, culminating in the development of allopregnanolone-based treatments for postpartum depression. It is both a history and a mechanistic synthesis, showing how central this single neurosteroid is to affective regulation.", "study_type": "review", "sample_size": "n/a", "keywords": [ "allopregnanolone", "GABA-A receptor", "mood disorders", "postpartum depression", "brexanolone", "neurosteroid therapeutics" ], "relevance": "Shows the therapeutic flip side of the mechanism: if allopregnanolone deficiency drives mood pathology and its replacement treats it, then 5-AR-inhibitor-induced depletion is a coherent causal story for PFS neuropsychiatric symptoms.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 32435665.", "quality_notes": "Peer-reviewed journal (Elsevier, Neurobiology of Stress). Authors include the discoverers of key neurosteroid biology.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-009", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.sciencedirect.com/science/article/pii/S2352289520300059/pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by-nc-nd", "pmid": "32435665" }, { "item_id": "LIT-057", "source_type": "peer-reviewed paper", "title": "Steroid 5α-reductase isozymes in the adult female rat brain: central role of dihydrotestosterone", "authors": [ "J. M. Torres", "E. Ortega" ], "journal_or_site": "Journal of Molecular Endocrinology", "year_or_date": "2006", "doi": "10.1677/jme.1.01907", "url": "https://doi.org/10.1677/jme.1.01907", "abstract_or_summary": "5-alpha-reductase exists as two isoforms, type 1 associated with catabolic functions and type 2 with sexually dimorphic functions, and the authors had previously shown both are present and oppositely regulated by androgens in the adult male rat brain. This study extends that mapping to the adult female rat brain, examining the distribution and regulation of both isozymes in the central nervous system. The work demonstrates that the brain expresses its own 5-alpha-reductase machinery independent of gonadal status, with regional specificity. It establishes the anatomical and regulatory foundation for understanding how systemic 5-AR inhibitors reach and act on brain neurosteroid synthesis.", "study_type": "primary-animal", "sample_size": "adult female rats (per-group n not extracted from the record)", "keywords": [ "5-alpha-reductase", "SRD5A1", "SRD5A2", "brain", "dihydrotestosterone", "neurosteroidogenesis", "isozyme distribution" ], "relevance": "Maps the brain's own 5-AR isozyme machinery — the direct anatomical substrate that finasteride acts on centrally, grounding the neurosteroid-synthesis pillar.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 16595696.", "quality_notes": "Peer-reviewed journal (Society for Endocrinology).", "sweep_date": "2026-10-07", "axis_id": "LIT-D-010", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://jme.bioscientifica.com/downloadpdf/journals/jme/36/2/0360239.pdf", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "", "pmid": "16595696" }, { "item_id": "LIT-058", "source_type": "peer-reviewed paper", "title": "Epigenetic regulation of 5α reductase-1 underlies adaptive plasticity of reproductive function and pubertal timing", "authors": [ "Ben Bar-Sadeh", "Or E. Amichai", "Lilach Pnueli", "Khurshida Begum", "Gregory Leeman", "Richard D. Emes", "Reinhard Stöger", "Gillian R. Bentley" ], "journal_or_site": "BMC Biology", "year_or_date": "2022", "doi": "10.1186/s12915-021-01219-6", "url": "https://doi.org/10.1186/s12915-021-01219-6", "abstract_or_summary": "Women who experienced high energetic demands in childhood show altered adult ovarian function and shorter reproductive lifespan, suggesting early-life programming of reproduction. Combining a mouse model with methylation analysis of proxy-tissue DNA from a well-characterized cohort of Bangladeshi migrants in the UK, the authors trace this programming to epigenetic regulation of 5-alpha-reductase-1. Methylation changes at the SRD5A1 locus are linked to later pubertal onset and altered reproductive function, showing that the gene encoding a key neurosteroidogenic enzyme is itself subject to lasting epigenetic control. The study demonstrates adaptive plasticity of 5-AR expression through DNA methylation in both animal and human data.", "study_type": "primary-animal/primary-human", "sample_size": "mouse model plus human Bangladeshi-migrant cohort in the UK (cohort sizes not extracted from the record)", "keywords": [ "SRD5A1", "5-alpha-reductase", "epigenetics", "DNA methylation", "early-life programming", "reproductive function", "adaptive plasticity" ], "relevance": "Proof of principle that 5-alpha-reductase expression is epigenetically tunable with lasting phenotypic consequences — a direct precedent for the epigenetic persistence hypothesis in post-drug syndromes.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 34996447.", "quality_notes": "Peer-reviewed journal (BMC/Springer Nature). Human + animal converging evidence.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-011", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://bmcbiol.biomedcentral.com/counter/pdf/10.1186/s12915-021-01219-6", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "34996447" }, { "item_id": "LIT-059", "source_type": "peer-reviewed paper", "title": "Neurosteroids Involvement in the Epigenetic Control of Memory Formation and Storage", "authors": [ "Alessandra Colciago", "Valerio Magnaghi" ], "journal_or_site": "Neural Plasticity", "year_or_date": "2016", "doi": "10.1155/2016/5985021", "url": "https://doi.org/10.1155/2016/5985021", "abstract_or_summary": "Memory formation depends on strengthening synaptic connections in areas like the hippocampus, and the proteins involved are tightly regulated by DNA methylation and histone modifications. This review argues that neurosteroids participate in this epigenetic control of memory, influencing the transcriptional programs that consolidate synaptic plasticity. Steroid-driven epigenetic remodeling is presented as a mechanism by which transient hormonal signals are converted into durable changes in neuronal circuitry. The authors integrate evidence on how neurosteroid signaling converges on chromatin-modifying machinery during memory formation and storage.", "study_type": "review", "sample_size": "n/a", "keywords": [ "neurosteroids", "epigenetics", "memory", "hippocampus", "DNA methylation", "histone modification", "synaptic plasticity" ], "relevance": "Directly couples the two corpus axes — neurosteroids and epigenetics — and offers a mechanism by which neurosteroid disruption could produce lasting cognitive symptoms (brain fog, memory complaints) in post-drug syndromes.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 28090360.", "quality_notes": "Peer-reviewed journal (Hindawi, Neural Plasticity). Venue reputation acceptable; peer-reviewed.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-012", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/2016/5985021", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "28090360", "fulltext_note": "Link updated 2026-10-09: Hindawi journals moved to Wiley" }, { "item_id": "LIT-060", "source_type": "peer-reviewed paper", "title": "Influence of Androgen Receptor CAG Polymorphism on Sexual Function Recovery after Testosterone Therapy in Late-Onset Hypogonadism", "authors": [ "Giacomo Tirabassi", "Giovanni Corona", "Andrea Biagioli", "Eddi Buldreghini", "Nicola delli Muti", "Mario Maggi", "Giancarlo Balercia" ], "journal_or_site": "The Journal of Sexual Medicine", "year_or_date": "2015", "doi": "10.1111/jsm.12790", "url": "https://doi.org/10.1111/jsm.12790", "abstract_or_summary": "Seventy-three men with late-onset hypogonadism were evaluated with the IIEF questionnaire and hormone panels before testosterone replacement therapy and again before their sixth testosterone injection. All sexual function domains improved with therapy, but the number of CAG repeats in the androgen receptor gene was negatively correlated with the degree of improvement in nearly every domain. In multivariable models, longer CAG tracts independently predicted smaller gains in erectile function and overall sexual function. The study is the first in a large cohort to show that this common AR polymorphism conditions how well sexual function recovers when androgen signaling is restored.", "study_type": "primary-human", "sample_size": "73 men with late-onset hypogonadism", "keywords": [ "androgen receptor", "CAG repeat polymorphism", "sexual function", "testosterone therapy", "late-onset hypogonadism", "IIEF", "pharmacogenetics" ], "relevance": "Shows that androgen-receptor genetics determine the capacity for sexual-function recovery — a key genetic axis for explaining why some finasteride users recover and others develop persistent PFS.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 25443437; PubMed abstract checked.", "quality_notes": "Peer-reviewed journal (International Society for Sexual Medicine). Human clinical study.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-013", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "pmid": "25443437" }, { "item_id": "LIT-061", "source_type": "peer-reviewed paper", "title": "Influence of CAG Repeat Polymorphism on the Targets of Testosterone Action", "authors": [ "Giacomo Tirabassi", "Angelo Cignarelli", "Sebastio Perrini", "Nicola delli Muti", "Giorgio Furlani", "Mariagrazia Gallo", "Francesco Pallotti", "Donatella Paoli" ], "journal_or_site": "International Journal of Endocrinology", "year_or_date": "2015", "doi": "10.1155/2015/298107", "url": "https://doi.org/10.1155/2015/298107", "abstract_or_summary": "A decade of evidence shows that the androgen receptor CAG repeat polymorphism conditions the peripheral effects of testosterone across many tissues. Longer repeat tracts blunt receptor transactivation and thereby influence male sexual function and fertility, body composition, bone metabolism, cardiovascular risk, cancer risk, psychiatric status, and neurodegenerative vulnerability. This review surveys the literature and assigns the polymorphism a central role in modulating systemic androgen action. It provides the broad physiological map against which AR-signaling disruptions in post-drug syndromes can be interpreted.", "study_type": "review", "sample_size": "n/a", "keywords": [ "androgen receptor", "CAG repeat polymorphism", "testosterone", "sexual function", "androgen signaling", "genetic variation" ], "relevance": "Companion review to LIT-D-013: lays out the full systemic reach of AR CAG-length variation, grounding the androgen-receptor-signaling pillar of the corpus.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 26421011.", "quality_notes": "Peer-reviewed journal (Hindawi). Venue reputation acceptable; peer-reviewed.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-014", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/2015/298107", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "26421011", "fulltext_note": "Link updated 2026-10-09: Hindawi journals moved to Wiley" }, { "item_id": "LIT-062", "source_type": "peer-reviewed paper", "title": "The gut-microbiota-brain axis: Focus on gut steroids", "authors": [ "Silvia Diviccaro", "Silvia Giatti", "Lucia Cioffi", "Gabriela Chrostek", "Roberto Cosimo Melcangi" ], "journal_or_site": "Journal of Neuroendocrinology", "year_or_date": "2024", "doi": "10.1111/jne.13471", "url": "https://doi.org/10.1111/jne.13471", "abstract_or_summary": "Beyond the gonads, adrenals, and brain, the gastrointestinal tract itself performs steroidogenesis, producing an extensive repertoire of gut steroids. This review focuses on how those intestinal steroids communicate with the gut microbiota — which functions almost like a virtual endocrine organ — and how the resulting gut-brain signaling influences neuroendocrine and behavioral outcomes. The authors detail bidirectional crosstalk: microbial communities shape steroid metabolism and vice versa. Because finasteride alters both neurosteroid levels and gut microbial composition, this axis is proposed as an underappreciated contributor to persistent post-drug symptoms.", "study_type": "review", "sample_size": "n/a", "keywords": [ "gut-brain axis", "gut microbiota", "gut steroids", "steroidogenesis", "neurosteroids", "finasteride", "post-finasteride syndrome" ], "relevance": "From the Melcangi PFS group: the first synthesis centering gut steroids in the microbiota-brain axis — directly extends LIT-D-001's rat microbiota findings into a mechanistic framework for persistent symptoms.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 39575839.", "quality_notes": "Peer-reviewed journal (British Society for Neuroendocrinology).", "sweep_date": "2026-10-07", "axis_id": "LIT-D-015", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jne.13471", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "39575839" }, { "item_id": "LIT-063", "source_type": "peer-reviewed paper", "title": "Neurosteroids as regulators of neuroinflammation", "authors": [ "Canelif Yilmaz", "Kanelina Karali", "Georgia Fodelianaki", "Achille Gravanis", "Triantafyllos Chavakis", "Ioannis Charalampopoulos", "Vasileia Ismini Alexaki" ], "journal_or_site": "Frontiers in Neuroendocrinology", "year_or_date": "2019", "doi": "10.1016/j.yfrne.2019.100788", "url": "https://doi.org/10.1016/j.yfrne.2019.100788", "abstract_or_summary": "Neuroinflammation is protective in acute injury but drives neurodegeneration when chronic, with microglial and astrocytic activation seen across multiple sclerosis, Alzheimer's, Parkinson's, and traumatic brain injury. This review shows that the CNS is itself a highly steroidogenic environment and that locally synthesized neurosteroids regulate the inflammatory activation of glia. Neurosteroid synthesis can shift under pathological conditions, and restoring it dampens chronic neuroinflammation in several models. The paper positions neurosteroid signaling as a master regulator that determines whether glial responses resolve or become self-perpetuating.", "study_type": "review", "sample_size": "n/a", "keywords": [ "neurosteroids", "neuroinflammation", "microglia", "astrocytes", "allopregnanolone", "neurodegeneration", "GABA-A" ], "relevance": "Mechanistic bridge: chronic neuroinflammation is a leading candidate for why PFS neuropsychiatric symptoms persist, and this review shows neurosteroid depletion is a plausible driver of that chronicity.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 31513776.", "quality_notes": "Peer-reviewed journal (Elsevier, Frontiers in Neuroendocrinology).", "sweep_date": "2026-10-07", "axis_id": "LIT-D-016", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.sciencedirect.com/science/article/pii/S0091302219300500/pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc-nd", "pmid": "31513776" }, { "item_id": "LIT-064", "source_type": "peer-reviewed paper", "title": "Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study", "authors": [ "Hyo Young Choi", "Kathleen C. Torkko", "M. Scott Lucia", "Khyobeni Mozhui", "Won-Young Choi", "Peter E. Clark", "Jay H. Fowke" ], "journal_or_site": "Scientific Reports", "year_or_date": "2024", "doi": "10.1038/s41598-024-69301-x", "url": "https://doi.org/10.1038/s41598-024-69301-x", "abstract_or_summary": "To understand why some patients' symptoms persist despite treatment, the authors profiled gene expression in prostate transition-zone biopsies from 108 MTOPS trial participants before and after treatment. Finasteride produced a distinctive transcriptional signature: 398 genes changed expression relative to placebo (FDR < 0.05), broadly suppressing androgen-response, estrogen-response, and fatty-acid and amino-acid metabolic pathways, while doxazosin altered almost nothing. Crucially, the patients whose gene expression shifted (a definable molecular subgroup) were the ones most likely to respond clinically — nearly all finasteride responders showed the shift, versus only half of non-responders. The study demonstrates in humans that finasteride rewires tissue-level gene expression in a drug-specific way.", "study_type": "nested case-control study within a randomized trial (paired prostate biopsies, RNA-seq)", "sample_size": "108 MTOPS trial participants with paired pre/post prostate biopsies", "keywords": [ "finasteride", "gene expression", "transcriptome", "MTOPS", "androgen response", "doxazosin", "treatment resistance" ], "relevance": "Human evidence that finasteride, unlike doxazosin, changes gene expression in the prostate tissue of men with BPH during treatment, a transcriptional effect relevant to mechanism hypotheses for post-drug syndromes. It has no samples taken after stopping and no epigenetic measurements, so it does not show persistence, and its \"resistance\" means BPH progression, not adverse effects.", "verification_status": "Crossref + OpenAlex records retrieved 2026-10-07; PMID 39160179.", "quality_notes": "Peer-reviewed journal (Nature Portfolio, Scientific Reports). Randomized-trial biospecimen analysis.", "sweep_date": "2026-10-07", "axis_id": "LIT-D-017", "sweep_axis": "mechanisms", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep", "fulltext_url": "https://www.nature.com/articles/s41598-024-69301-x.pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by-nc-nd", "pmid": "39160179", "plain": { "summary": "In a large US trial of drugs for an enlarged prostate, some men gave small prostate tissue samples before starting treatment and again later on. Researchers measured which genes were more or less active in these samples for 108 of the men. Compared with a dummy pill, finasteride changed the activity of about 400 genes, mostly turning down genes that respond to male hormones, while doxazosin, a different type of prostate drug, changed almost none. Among men on finasteride, 14 of the 15 whose symptoms stayed under control showed these gene changes, compared with 7 of the 13 whose symptoms got worse.", "caveat": "It can't show whether these gene changes last after finasteride is stopped or happen anywhere other than the prostate: the samples came from older men with enlarged prostates during the trial, and the groups were small." }, "evidence": { "design": "Nested case-control study within the MTOPS randomised, double-blind, placebo-controlled trial, using RNA sequencing of paired baseline and follow-up prostate biopsies", "design_class": "case-control", "setting": "MTOPS trial (17 US clinical centres) and its NIDDK tissue biorepository; analysis led from the University of Tennessee Health Science Center", "population": "Men aged 50 or over with moderate to severe urinary symptoms of benign prostatic hyperplasia (AUA score 8–30, low urine flow) in the MTOPS biopsy sub-study (1,198 consented). Within each arm, men whose condition progressed (\"resistant\" cases) were sampled 1:1 with men who did not (\"responsive\" controls) of similar age and symptom score. Mean age 62.7.", "n": 108, "n_note": "108 men with paired RNA-seq (finasteride 28, of whom 15 responsive and 13 resistant; doxazosin 28; combination 15; placebo 37), from 3,047 randomised in MTOPS", "exposure": "Finasteride 5 mg/day, doxazosin up to 8 mg/day, or both, by random assignment", "comparator": "Placebo arm for drug effects on gene expression; responsive vs resistant men within each arm", "outcome": "Within-person change in gene expression (log2 follow-up/baseline) across 16,781 protein-coding genes in transition-zone biopsies; clinical progression as defined by MTOPS (a rise of 4 or more points in AUA score, acute urinary retention, recurrent urinary infection, renal insufficiency or incontinence)", "follow_up": "Baseline and post-treatment biopsies; the paper does not state when the follow-up biopsy was taken (it cites MTOPS Year 5 tissue for an earlier analysis) and gives the trial duration as 5.5 years", "results": [ { "text": "Versus placebo (FDR < 0.05), 398 genes changed with finasteride, 4 with doxazosin and 28 with the combination; 70% of the finasteride genes went down. The Discussion instead gives 416 genes for finasteride and 5 for doxazosin (p. 10); 416 is the union across the three drug arms (398 + 4 + 28 - 11 - 3, p. 3), and 5 is the doxazosin count at FDR < 0.1 (Fig. 1a)", "where": "p. 3, Fig. 1 (p. 4), p. 10" }, { "text": "Finasteride-changed genes were most enriched for the androgen-response hallmark (FDR = 2.4 × 10⁻¹⁶), then early oestrogen response, and for fatty-acid and amino-acid metabolism pathways, mostly down-regulated", "where": "p. 3" }, { "text": "Clustering on the 416 genes split patients into SC1 (clear changes, mostly finasteride or combination) and SC2 (little change, mostly placebo or doxazosin). In the finasteride arm, 14 of 15 responsive men (93.3%) vs 7 of 13 resistant men (53.8%) were SC1 (Fisher p = 0.02); in the combination arm all 5 SC2 men were responsive", "where": "pp. 3, 5, Fig. 2" }, { "text": "Using an 84% response rate from MTOPS, the paper estimates 86.8% of finasteride-treated men would be SC1, and that 90.1% of SC1 and 44.5% of SC2 would respond. Recomputing from 14/15, 7/13 and 0.84 gives 87.0%, 90.1% and 43.1%; the paper's values follow from the rounded inputs 0.93 and 0.54 (86.8%, 90.0%, 44.4%). The Discussion says 44.5% of SC2 men \"developed clinical resistance\" (p. 11), the reverse of p. 6", "where": "pp. 5–6, Fig. 3, p. 11" }, { "text": "Within SC1 finasteride and combination patients (n = 31), larger baseline transition-zone volume was linked to resistance (Wilcoxon p = 0.007; 3.4 times the odds per 23 ml); top genes differing in change between resistant and responsive men were FKBP5 and SLC1A4 (28 genes at unadjusted p < 0.05)", "where": "pp. 8–10, Figs 5–6" } ], "limitations_stated": [ "Sample size was too small across treatment and response groups to support all subanalyses", "Newer BPH drugs could not be considered", "Bulk RNA-seq may mask differences between cell types", "Responsive vs resistant differences were not significant at FDR < 0.1, so a permissive p < 0.01 screen was used, and changes may be confounded by unknown factors", "Few non-white patients, and the association of race with resistance is unexplained", "Response in the combination arm may reflect doxazosin rather than finasteride", "Results are initial and need confirmation" ], "design_notes": [ "Participants were older men with BPH taking 5 mg/day; \"resistance\" means progression of urinary disease, not adverse effects", "No tissue was sampled after finasteride was stopped and no epigenetic marks were measured, so persistence after stopping cannot be assessed", "Case-control sampling over-represents progression (13 of 28 in the finasteride arm against an assumed 16% in the trial, p. 5), so within-sample proportions are not trial rates; the combination arm ended with 10 responsive and 5 resistant despite 1:1 sampling (Table 1)", "SC1 and SC2 were found by clustering on genes selected from the same patients, with no independent validation set", "Internal inconsistencies include 497 (p. 7, Fig. 4) vs 470 (p. 11) genes differing at baseline between SC1 and SC2, and FKBP5 and SLC1A4 described as both increasing and decreasing in responsive men (p. 8)", "Combination-arm estimates (53.3%, 86.1%, 98.2%; the Fig. 3b legend also says 9.1% resistant in SC2) do not follow from the stated inputs 0.5, 1 and 0.92, which give 54.0%, 85.2% and 100% (p. 6)" ], "funding": "Not stated (MTOPS itself was NIDDK-sponsored, and tissue was used with NIDDK approval)", "interests": "None declared", "supports": "That finasteride, unlike doxazosin, changes gene activity in the prostate transition zone of men with BPH during treatment, and that this change tracks clinical response. It cannot show whether such changes persist after stopping, occur in other tissues, or relate to adverse effects.", "extracted_from": "fulltexts/LIT-064-Change-in-prostate-tissue-gene-expression-followin.pdf (publisher PDF, Scientific Reports 14, 19164, CC BY-NC-ND 4.0, 15 pp.; pages cited are the journal's printed page numbers, which match the PDF page index)", "extracted": "2026-10-10" } }, { "item_id": "LIT-065", "source_type": "regulatory document", "title": "Finasteride-dutasteride Article 31 referral — PRAC assessment report (EMA/PRAC/55203/2025)", "authors": "European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC)", "journal_or_site": "EMA (ema.europa.eu)", "year_or_date": "2025-05", "doi": null, "url": "https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-assessment-report_en.pdf", "abstract_or_summary": "The full PRAC assessment behind the 2025 EU-wide review of finasteride and dutasteride, triggered by France's ANSM over suicidal ideation. The report evaluates 325 EudraVigilance cases of suicidal ideation (313 finasteride, 13 dutasteride) against roughly 270 and 82 million patient-years of exposure. It documents a large burden of co-reported sexual adverse effects (erectile dysfunction, loss of libido, ejaculation disorders) and notes that a pattern of combined sexual and psychiatric effects persisting despite drug withdrawal appeared in 187 of the cases. The report also discusses cases in patients under 18 and the absence of an identifiable common risk factor among completed suicides.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "EMA", "PRAC", "Article 31 referral", "finasteride", "dutasteride", "suicidal ideation", "sexual dysfunction persistence", "EudraVigilance", "pharmacovigilance" ], "relevance": "The primary technical document of the biggest EU regulatory action on finasteride to date. Its case-level discussion of sexual dysfunction persisting alongside psychiatric effects after withdrawal is directly on axis for the corpus and cites the exact case counts the corpus can quote.\n", "verification_status": "verified — official EMA PDF URL from search index; corroborated by the EMA referral announcement page (LIT-E-002) and the HMA/CMDh June 2025 press release", "quality_notes": "Primary regulatory source; 23-page PDF. Does not itself establish persistence of sexual dysfunction as a labelled outcome — it is primarily about suicidal ideation — but it is the key source for the regulator's current stance and case data.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-001", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-066", "source_type": "regulatory document", "title": "Finasteride- and dutasteride-containing medicinal products — referral", "authors": "European Medicines Agency (EMA)", "journal_or_site": "EMA (ema.europa.eu)", "year_or_date": "2025-06-19", "doi": null, "url": "https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products", "abstract_or_summary": "EMA's public announcement that the CMDh endorsed PRAC's Article 31 referral outcome on finasteride and dutasteride. Suicidal ideation was confirmed as a side effect of finasteride 1 mg and 5 mg tablets, with frequency unknown. The announcement states that product information for finasteride 1 mg will warn patients to seek medical advice for sexual function problems such as decreased sex drive or erectile dysfunction, which are known side effects and may contribute to mood changes, and that a patient card will be added to 1 mg packs. Dutasteride gets precautionary class-effect wording on mood changes despite insufficient evidence of a direct link.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "EMA", "PRAC", "CMDh", "Article 31", "finasteride", "dutasteride", "suicidal ideation", "sexual dysfunction", "patient card", "label update" ], "relevance": "The citable public face of the 2025 EU action: explicit regulatory text linking sexual dysfunction to mood changes on finasteride, plus the patient-card measure. High-value for any timeline of regulatory responses.\n", "verification_status": "verified — page text fetched and read on ema.europa.eu", "quality_notes": "Primary regulatory source. Benefits still judged to outweigh risks; the persistence of sexual dysfunction per se is not ruled on here.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-002", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-067", "source_type": "regulatory document", "title": "Finasteride and dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction", "authors": "Medicines and Healthcare products Regulatory Agency (MHRA)", "journal_or_site": "GOV.UK — Drug Safety Update, volume 19, issue 10", "year_or_date": "2026-05", "doi": null, "url": "https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction", "abstract_or_summary": "The UK regulator's May 2026 Drug Safety Update following the EU Article 31 review, building on its April 2024 finasteride review and the patient alert cards introduced in 2024. Its advice for health professionals states plainly that finasteride is associated with depression, suicidal ideation and sexual dysfunction which may persist after treatment is stopped. It updates finasteride 1 mg product information with a warning that sexual dysfunction may contribute to mood disorders (and can occur without them), adds precautionary class-effect wording for dutasteride, and publishes Yellow Card counts: 170 suicidal-ideation reports for finasteride, 19 of them fatal, plus 5 for dutasteride, in data to 31 May 2025.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "MHRA", "Drug Safety Update", "finasteride", "dutasteride", "sexual dysfunction persistence", "suicidal ideation", "patient alert card", "Yellow Card" ], "relevance": "The first UK regulatory statement to use \"may persist after treatment is stopped\" for finasteride sexual dysfunction, with concrete Yellow Card numbers. Very recent (May 2026) — likely the newest item in the corpus.\n", "verification_status": "verified — page text fetched and read on gov.uk; corroborated by the MHRA gov.uk press release of the same month", "quality_notes": "Primary regulatory source. Note the date: May 2026, later than earlier trade-press framing suggested (2025). MHRA describes the evidence on persistence as mixed.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-003", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-068", "source_type": "regulatory document", "title": "Finasteride, dutasteride – New measures to minimise the risk of suicidal ideation (Direct Healthcare Professional Communication)", "authors": "Marketing authorisation holders, in agreement with EMA and the Health Products Regulatory Authority (HPRA, Ireland)", "journal_or_site": "HPRA (assets.hpra.ie)", "year_or_date": "2025-09-12", "doi": null, "url": "https://assets.hpra.ie/data/docs/default-source/product-updates/dhpc/human-medicines/finasteride-dutasteride---direct-healthcare-professional-communication.pdf?sfvrsn=a41b7532_5", "abstract_or_summary": "The Irish implementation letter sent to health professionals following the 2025 EU referral. It states that suicidal ideation is an adverse reaction of oral finasteride, seen mainly in men treated for androgenetic alopecia, and asks doctors to advise such patients to stop and seek help if mood symptoms appear. It explicitly flags that sexual dysfunction which may contribute to mood alterations, including suicidal ideation, has been reported in some alopecia patients, and instructs prescribers to counsel patients about sexual dysfunction and consider discontinuation. A patient card for finasteride 1 mg packs is announced, and precautionary class-effect wording is added for dutasteride.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "HPRA", "Ireland", "DHPC", "finasteride", "dutasteride", "suicidal ideation", "sexual dysfunction", "patient card", "Article 31 implementation" ], "relevance": "Shows how the EU Article 31 outcome translated into national prescriber-level communications — a distinct, citable document type (DHPC) for the corpus's regulatory set, with the sexual-dysfunction-to-mood pathway stated in prescriber instructions.\n", "verification_status": "verified — full PDF text fetched and read on assets.hpra.ie", "quality_notes": "Primary regulatory document (Irish national implementation of the EU referral). Dated 12 September 2025; distinct from the June 2025 EMA announcement.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-004", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-069", "source_type": "regulatory document", "title": "Finasteride 1 mg (Propecia and generics): added warning statements on boxes to reinforce information on adverse effects", "authors": "French Agency for the Safety of Health Products (ANSM)", "journal_or_site": "ANSM (ansm.sante.fr) — English translation hosted on pfsfoundation.org", "year_or_date": "2022-11-30", "doi": null, "url": "https://www.pfsfoundation.org/wp-content/uploads/2022/12/01-ANSM-revised-finasteride-PI-10-22-ENGLISH-5.pdf", "abstract_or_summary": "France's medicines agency announced that manufacturers must affix a red warning box and a QR code to every finasteride 1 mg pack, stating that sexual and/or psychiatric adverse reactions may occur during and after treatment. The measure was to be on all boxes by 28 April 2023 at the latest, alongside an updated patient information sheet. The document explains that the step extends earlier French efforts to strengthen patient awareness of finasteride's psychiatric and sexual effects, and reminds readers that reporting side effects directly is encouraged. It was this French regulatory pressure that later triggered the 2025 EU-wide Article 31 review.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "ANSM", "France", "finasteride", "red-box warning", "psychiatric adverse effects", "sexual dysfunction", "patient information", "QR code" ], "relevance": "The strongest single-country packaging intervention on finasteride — an on-box red warning covering effects \"during and after treatment\" — and the origin of the Article 31 referral. Essential context for the EMA 2025 items.\n", "verification_status": "verified — PDF text fetched and read; corroborated by PFS Foundation coverage and the EMA referral background noting the French request", "quality_notes": "The URL is an English translation hosted by the PFS Foundation, not the original French on ansm.sante.fr; type and content are ANSM's. A later 2025 French measure (annual signed attestation for finasteride 1 mg) was reported in French media but no official ANSM document was locatable, so it is not included.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-005", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-070", "source_type": "regulatory document", "title": "Post-Finasteride Syndrome", "authors": "Medsafe (New Zealand Medicines and Medical Devices Safety Authority)", "journal_or_site": "Prescriber Update 37(1): 8–9 (medsafe.govt.nz)", "year_or_date": "2016-03", "doi": null, "url": "https://medsafe.govt.nz/profs/puarticles/march2016/postfinasteridesyndrome.htm", "abstract_or_summary": "New Zealand's regulator published one of the earliest official clinical briefings to use the term \"post-finasteride syndrome\" outright. It states that PFS can occur in some men who took finasteride and that sexual, physical, and mental/neurological symptoms often persist after stopping. It tabulates reported symptoms across those three domains, notes the syndrome was newly listed in NIH's rare-diseases database, warns that suicidal ideation and depression can appear after stopping treatment, and reports 10 New Zealand CARM reports linking finasteride to at least one listed symptom, with only three patients recovered at the time of report.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "Medsafe", "New Zealand", "Prescriber Update", "post-finasteride syndrome", "persistent symptoms", "CARM", "pharmacovigilance" ], "relevance": "One of the first regulators anywhere to publish a named-PFS prescriber briefing — a 2016 anchor for the regulatory timeline, with a rare official symptom table and national case counts.\n", "verification_status": "verified — full page text fetched and read on medsafe.govt.nz", "quality_notes": "Primary regulatory source. Medsafe flags the article as over five years old; keep as historical regulatory evidence, not current guidance.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-006", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-071", "source_type": "regulatory document", "title": "Summary Safety Review — Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-norepinephrine Reuptake Inhibitors (SNRIs): Assessing the Potential Risk of Sexual Dysfunction despite Treatment Discontinuation", "authors": "Health Canada", "journal_or_site": "Health Canada Drug Product Vigilance (dhpp.hpfb-dgpsa.ca), resource SSR00254", "year_or_date": "2021-01", "doi": null, "url": "https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00254", "abstract_or_summary": "Health Canada's published review of whether SSRI/SNRI sexual dysfunction can persist, worsen, or newly appear after stopping treatment. Its case review found 58 sexual-dysfunction reports, of which 43 (16 Canadian, 27 international) were judged possibly linked to prior SSRI/SNRI use and discontinuation, with symptoms lasting weeks to years in some cases. The review could neither confirm nor rule out a causal link, but Health Canada committed to work with manufacturers so that all SSRI/SNRI product monographs advise informing patients about the potential risk of long-lasting sexual symptoms persisting after stopping treatment, and published a Health Product InfoWatch label-update notice in December 2021.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "Health Canada", "Summary Safety Review", "SSRIs", "SNRIs", "persistent sexual dysfunction", "PSSD", "product monograph", "labelling" ], "relevance": "Canada's counterpart to the EMA 2019 action and the document behind the Canadian label warnings. Distinct from the corpus's existing timeline event noting its publication — this is the review itself, with the 43 possibly-linked cases and the exact \"weeks to years\" wording.\n", "verification_status": "verified — official Health Canada URL identified via search index (direct fetch timed out); content corroborated by the official House of Commons petition-response page (ourcommons.ca, Petition 441-00192) which reproduces the review's conclusions and actions", "quality_notes": "The review's conclusion is deliberately non-committal on causality; the labelling action is the substantive outcome. Note the corpus already has a timeline event about this publication — keep both, document vs. event.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-007", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-072", "source_type": "regulatory document", "title": "Re: Docket No. FDA-2017-P-5787 — Response to the Post-Finasteride Syndrome Foundation citizen petition", "authors": "U.S. Food and Drug Administration (FDA)", "journal_or_site": "FDA (letter to PFS Foundation, hosted as PDF on citizen.org)", "year_or_date": "2022-06-08", "doi": null, "url": "https://www.citizen.org/wp-content/uploads/Response-to-PFSF-CP-FDA-2017-P-5787-002.pdf", "abstract_or_summary": "FDA's 2022 decision letter on the PFS Foundation's 2017 citizen petition asking for withdrawal of Propecia 1 mg or stronger labelling. The agency denied the petition in part and granted it in part. It recounts the 2010–2012 labelling history (depression added 2011; post-discontinuation erectile dysfunction 2011/2012; infertility/seminal-quality language 2012; Proscar update 2013), declines to find the evidence sufficient to establish causality between finasteride and persistent sexual problems, depression, or suicide, but requires \"suicidal ideation and behavior\" to be added to the adverse reactions of all finasteride 1 mg products — the labelling win that came out of the petition. It also explains why no boxed warning, REMS, or market withdrawal was ordered.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "FDA", "citizen petition", "PFS Foundation", "Propecia", "finasteride", "labelling", "suicidal ideation", "persistent sexual dysfunction", "docket FDA-2017-P-5787" ], "relevance": "The definitive US regulatory document on finasteride safety: it is both the ruling on the patient-led petition and the complete official history of every FDA finasteride label change, with citations to the approval packages. Pairs with LIT-E-009.\n", "verification_status": "verified — full 3,364-line PDF text fetched and read (FDA letter hosted on citizen.org)", "quality_notes": "Hosted copy is on Public Citizen's site; document is the official FDA response letter. FDA explicitly states the evidence did not meet the bar for a causal link with persistent sexual problems — important for balanced citation.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-008", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-073", "source_type": "gray literature", "title": "Citizen Petition to the FDA regarding Propecia (finasteride 1 mg) and Proscar (finasteride 5 mg) safety labelling", "authors": "Post-Finasteride Syndrome Foundation (PFS Foundation)", "journal_or_site": "PFS Foundation — FDA docket FDA-2017-P-5787 (mirror at georgesdebled.org)", "year_or_date": "2017-09-18", "doi": null, "url": "http://georgesdebled.org/Citizen_Petition_Post-_Finasteride_Syndrome_Foundation.pdf", "abstract_or_summary": "The patient advocacy group's formal petition asking FDA to withdraw approval of Propecia 1 mg for hair loss, or alternatively to overhaul its labelling. The petition requests boxed warnings for persistent erectile dysfunction, depression and suicidal ideation said to continue for years after discontinuation, contraindications for patients with sexual dysfunction or depression, a REMS, and rewritten mechanism-of-action and clinical-trial sections. Its statement of grounds argues that post-finasteride syndrome is a life-changing condition of sexual and psychoneurocognitive symptoms beginning on the drug and continuing after stopping, and lays out claims about 5-alpha-reductase inhibition affecting neurosteroid pathways beyond androgen metabolism.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "PFS Foundation", "citizen petition", "FDA", "Propecia", "finasteride", "boxed warning", "REMS", "persistent sexual dysfunction", "neurosteroids" ], "relevance": "The patient-org filing that forced the 2022 FDA ruling (LIT-E-008); its \"statement of grounds\" is the most detailed single statement of the PFS case from the advocacy side, and it directly caused the suicidal-ideation label addition.\n", "verification_status": "verified — full 7,714-line PDF text fetched and read; petition's receipt and contents corroborated by the FDA response letter (LIT-E-008)", "quality_notes": "Advocacy document, not an impartial source — type honestly. Mirror copy on georgesdebled.org; the official record is FDA docket FDA-2017-P-5787.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-009", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-074", "source_type": "gray literature", "title": "EMA Acknowledges Persistent Sexual Dysfunction After SSRIs & SNRIs", "authors": "RxISK (Dr David Healy group)", "journal_or_site": "rxisk.org", "year_or_date": "2019-06", "doi": null, "url": "https://rxisk.org/ema-acknowledges-persistent-sexual-dysfunction-after-ssris-snris/", "abstract_or_summary": "RxISK's account of how its 2018 petition on PSSD and PGAD led to the EMA/PRAC review of sexual dysfunction after SSRI/SNRI discontinuation. It describes the 22 signatories, the submission of 82 named patient reports (32 with supporting letters from health professionals), and reproduces the EMA letters of May 2019 in which PRAC concluded that sexual dysfunction can be long-lasting in some patients even after treatment withdrawal. It also notes parallel outreach: the FDA petition remaining undecided, Health Canada requesting the named reports in January 2019, and no separate MHRA response being expected.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "RxISK", "David Healy", "EMA", "PRAC", "PSSD", "PGAD", "named patient reports", "2019 review", "petition" ], "relevance": "The primary historical record of the patient-research campaign behind the 2019 EMA decision — how named (non-anonymous) reports were used to overcome the credibility problem of spontaneous reports. Pairs with the corpus's existing EMA-2019 event entry.\n", "verification_status": "verified — full page text fetched and read on rxisk.org; corroborated by the Mad in America and propeciahelp.com reproductions of the same EMA letters", "quality_notes": "Advocacy/patient-research source; the reproduced EMA letters are the key primary material. The rxisk.org PSSD reference page is already in the corpus — this article is distinct.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-010", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-075", "source_type": "gray literature", "title": "PSSD Network — Scientific Research program", "authors": "PSSD Network (patient advocacy and research funding organisation)", "journal_or_site": "pssdnetwork.org", "year_or_date": "2026 (page current; research support expanded February 2025)", "doi": null, "url": "https://www.pssdnetwork.org/", "abstract_or_summary": "The PSSD Network's main hub describes its patient-led research program: ongoing support for Dr Roberto Cosimo Melcangi's neuroendocrine work at the University of Milan, and, since February 2025, new support for Dr Ashley Monks (University of Toronto) and Dr Antonei Csoka (Howard University), plus a research-participant and matched-control database. Its linked research-fundraiser page details three funded efforts: the DAWN Study with the Florey Institute of Neuroscience and Mental Health in Melbourne (a population-based study of PSSD mechanisms, phase 1 funded), a joint Csoka/Monks study of PSSD as iatrogenic epigenetic damage affecting neural reward circuitry, and the long-running Melcangi collaboration. The site also maintains a curated literature collection and expert statements.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "PSSD Network", "DAWN Study", "Florey Institute", "Melcangi", "Csoka", "Monks", "research funding", "patient registry", "epigenetics" ], "relevance": "The current map of active patient-funded PSSD science — names the labs, the hypotheses (neuroendocrine mechanisms, iatrogenic epigenetic damage), and the participant database any future cohort work would draw on. High-value gray literature for the corpus's research landscape.\n", "verification_status": "verified — main page text fetched and read on pssdnetwork.org; research-fundraiser detail corroborated via search-indexed page snippets", "quality_notes": "Advocacy/fundraising source; research descriptions are self-reported by the organisation. Funding figures on the linked fundraiser page may change; verify before quoting amounts.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-011", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-076", "source_type": "gray literature", "title": "Seven drug regulators, including the EU, UK, and Canada, have warned since 2019 that antidepressant-linked sexual side effects can persist for years after the drug is stopped. The US hasn't.", "authors": "ScienceBlog (Lab Report column)", "journal_or_site": "scienceblog.com", "year_or_date": "2026-08", "doi": null, "url": "https://scienceblog.com/n-pssd-antidepressant-fda-warning-gap/", "abstract_or_summary": "A 2026 news-analysis piece mapping how seven regulators addressed persistent post-antidepressant sexual dysfunction between 2019 and 2025: the EMA's 2019 PRAC conclusion and label changes, the UK's 2019 label-level implementation, Health Canada's 2021 safety review, the TGA's 2024 product-information update, Malaysia's 2025 alert, and reported but poorly documented actions in Ireland and Hong Kong. It then documents the US gap: the FDA has no equivalent antidepressant label language, a 2018 citizen petition remains undecided, and a 2024 Public Citizen lawsuit over the delay was dismissed in 2025 on standing grounds. The piece also explains why incidence remains unknown and notes that patient leaflets in the UK were still under expert-group review as recently as 2025.\n", "study_type": "n/a — regulatory", "sample_size": "n/a", "keywords": [ "ScienceBlog", "regulators", "EMA", "Health Canada", "TGA", "FDA", "labelling gap", "citizen petition", "Public Citizen", "PSSD" ], "relevance": "A one-stop, up-to-date comparative survey of every national PSSD label action — useful as a secondary source and as a cross-check list for the corpus's regulatory entries, plus documentation of the unresolved FDA petition and the 2024–2025 litigation.\n", "verification_status": "verified — full article fetched and read; its regulatory claims cross-checked against the official EMA, Health Canada, and MHRA documents in this sweep", "quality_notes": "Journalism/analysis, not a primary source; written with an advocacy-adjacent stance. Two companion ScienceBlog pieces cover the same ground — this is the more comprehensive.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-012", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "LIT-077", "source_type": "peer-reviewed paper", "title": "Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of VigiBase", "authors": "Nguyen, David-Dan; et al.", "journal_or_site": "Journal of the American Academy of Dermatology (research letter)", "year_or_date": "2022-03", "doi": null, "url": "https://www.jaad.org/article/S0190-9622(22)00527-8/abstract", "abstract_or_summary": "A WHO VigiBase case/non-case disproportionality study focused on finasteride and sexual dysfunction in young men treated for hair loss. Building on the same group's JAMA Dermatology work on finasteride and suicidality/depression, it identified about 7,700 sexual-dysfunction reports linked to finasteride and found disproportional reporting concentrated in younger alopecia patients, with the signal markedly stronger than for dutasteride or minoxidil and stronger after 2012. The authors discuss stimulated reporting and nocebo as possible biases while concluding the pattern is unlikely to be fully explained by bias alone, and note the plausibility link between sexual dysfunction and the depression signals seen earlier.\n", "study_type": "pharmacovigilance disproportionality (case/non-case) study using WHO VigiBase", "sample_size": "n/a (spontaneous-report database; ~7,700 sexual-dysfunction reports with finasteride)", "keywords": [ "VigiBase", "WHO", "pharmacovigilance", "finasteride", "sexual dysfunction", "young men", "androgenetic alopecia", "disproportionality", "reporting odds ratio", "stimulated reporting" ], "relevance": "The most rigorous global-database evidence on finasteride-associated sexual dysfunction reporting — the WHO-side counterpart to the EMA/EudraVigilance data in LIT-E-001, and the key citation behind regulators' attention to the young alopecia-patient subgroup.\n", "verification_status": "verified — jaad.org abstract URL confirmed via search index; authors, journal, date corroborated by tressless.com research index, singerderm.com review, and the MedicalResearch.com author interview with Naeem Bhojani and David-Dan Nguyen", "quality_notes": "Published as a research letter ('To the Editor'), not a full article; spontaneous-report data cannot establish incidence or causality. The group's fuller conference abstract (J Sex Med 2022) covers the same analysis and is intentionally not listed separately.", "sweep_date": "2026-10-07", "axis_id": "LIT-E-014", "sweep_axis": "regulatory", "collection_tag": "literature-sweep-2026-10", "_source_file": "literature_sweep" }, { "item_id": "EPI-001", "source_type": "peer-reviewed paper", "title": "Finasteride Induces Epigenetic Alteration of TMPRss2 Gene Expression: A Potential role in Severe Acute Respiratory Syndrome-Corona Virus-2 Inhibition", "authors": "Churchill Jonadab Ihentuge, Antonei Benjamin Csoka", "journal_or_site": "Journal of Pharmacology and Experimental Therapeutics", "year_or_date": 2023, "doi": "10.1124/jpet.122.524570", "url": "https://doi.org/10.1124/jpet.122.524570", "abstract_or_summary": "Reports that finasteride induces epigenetic alteration of TMPRSS2 gene expression. The paper's framing concerns SARS-CoV-2 (TMPRSS2 is an androgen-regulated host protease), but the mechanistic finding is the point for this corpus: a 5-alpha-reductase inhibitor producing a measurable epigenetic change at an androgen-responsive locus — a direct precedent for lasting drug-induced epigenetic remodeling at androgen-signaling genes.", "study_type": "primary", "sample_size": "not extracted from record", "keywords": [ "finasteride", "epigenetics", "TMPRSS2", "androgen-regulated gene expression", "5-alpha-reductase inhibitor" ], "relevance": "Direct precedent that finasteride alters the epigenetic state of an androgen-regulated gene — the same class of locus (cf. SRD5A2 methylation, DISC-025) implicated in PFS persistence.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed ASPET journal. COVID framing is incidental to the corpus; the epigenetic-alteration finding is what earns inclusion.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-001", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_note": "No free full text: paywalled at the publisher (checked 2026-10-09)" }, { "item_id": "EPI-002", "source_type": "peer-reviewed paper", "title": "Methylated CpG dinucleotides in the 5-alpha reductase 2 gene may explain finasteride resistance in benign prostatic enlargement patients", "authors": "Zhemin Lin, Dongdong Fan, Song Jin, Zhanliang Liu, Yi-Nong Niu", "journal_or_site": "Asian Journal of Andrology", "year_or_date": 2021, "doi": "10.4103/aja.aja_63_20", "url": "https://doi.org/10.4103/aja.aja_63_20", "abstract_or_summary": "Finds methylated CpG dinucleotides in the SRD5A2 gene and proposes that methylation status of the 5-alpha-reductase-2 gene explains variable finasteride response in benign prostatic enlargement patients. DNA methylation at the very locus encoding finasteride's drug target modulates pharmacodynamics.", "study_type": "primary-human", "sample_size": "not extracted from record", "keywords": [ "SRD5A2", "DNA methylation", "CpG", "finasteride resistance", "5-alpha-reductase inhibitor", "pharmacodynamics" ], "relevance": "Ties DNA methylation at SRD5A2 to 5-ARI action in humans — complements the Melcangi 2019 finding of altered SRD5A2 methylation in PFS cerebrospinal fluid (DISC-025) and the SRD5A1 epigenetic-regulation precedent (LIT-058). Methylation at the drug-target locus is a candidate persistence mechanism.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed andrology journal; human clinical population. Year: Crossref records print 2021 (vol. 23); online-first 2020 — using print year.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-002", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_url": "https://doi.org/10.4103/aja.aja_63_20", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by-nc-sa", "pmid": "33243958" }, { "item_id": "EPI-003", "source_type": "peer-reviewed paper", "title": "Large-Scale Integrative Analysis of Epigenetic Modifications Induced by Isotretinoin, Doxycycline and Metronidazole in Murine Colonic Intestinal Epithelial Cells", "authors": "Eugenia Becker, Susan Bengs, Sirisha Aluri, Lennart Opitz, Kirstin Atrott, Felix Rost", "journal_or_site": "Epigenomes", "year_or_date": 2017, "doi": "10.3390/epigenomes1030024", "url": "https://doi.org/10.3390/epigenomes1030024", "abstract_or_summary": "Large-scale integrative analysis of genome-wide epigenetic modifications induced by isotretinoin (alongside doxycycline and metronidazole) in murine colonic intestinal epithelial cells, in the context of inflammatory bowel disease models. Demonstrates broad epigenetic remodeling following isotretinoin exposure.", "study_type": "primary-animal", "sample_size": "not extracted from record (murine cell/tissue model)", "keywords": [ "isotretinoin", "epigenetics", "epigenetic modifications", "post-retinoid syndrome", "murine model" ], "relevance": "The only genome-wide epigenetics data on isotretinoin exposure found in this sweep — extends the epigenetic-persistence question to the post-retinoid axis, which had essentially no epigenetics coverage in v1.5. IBD-model context noted; the exposure-to-epigenetic-change link is the transferable finding.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed MDPI journal (Epigenomes); murine colonic model — tissue context differs from neurosteroid axes, noted for the user.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-003", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_url": "https://www.mdpi.com/2075-4655/1/3/24/pdf?version=1513839998", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by" }, { "item_id": "EPI-004", "source_type": "peer-reviewed paper", "title": "Doxycycline, metronidazole and isotretinoin: Do they modify microRNA/mRNA expression profiles and function in murine T-cells?", "authors": "Eugenia Becker, Susan Bengs, Sirisha Aluri, Lennart Opitz, Kirstin Atrott, Claudia Stanzel", "journal_or_site": "Scientific Reports", "year_or_date": 2016, "doi": "10.1038/srep37082", "url": "https://doi.org/10.1038/srep37082", "abstract_or_summary": "Examines whether doxycycline, metronidazole and isotretinoin modify microRNA and mRNA expression profiles and function in murine T-cells. Reports drug-induced changes in microRNA/mRNA regulatory networks — a microRNA-mediated (epigenetic-adjacent) layer of isotretinoin action.", "study_type": "primary-animal", "sample_size": "not extracted from record (murine T-cell model)", "keywords": [ "isotretinoin", "microRNA", "mRNA expression", "epigenetic regulation", "post-retinoid syndrome" ], "relevance": "microRNA-mediated regulation is one arm of epigenetic control; shows isotretinoin rewires small-RNA regulatory networks — supporting the post-retinoid persistence hypothesis alongside EPI-003.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Nature Portfolio journal; murine immune-cell model.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-004", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_url": "https://www.nature.com/articles/srep37082.pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "27853192" }, { "item_id": "EPI-005", "source_type": "peer-reviewed paper", "title": "Genotoxicity and DNA Damage in Long-Term SSRI Therapy: A Review Across SSRIs With Citalopram as a Case Study", "authors": "Emadeldin M. Kamel, Sally Mostafa Khadrawy, Nour Y. S. Yassin, Noha A. Ahmed", "journal_or_site": "Journal of Applied Toxicology", "year_or_date": 2026, "doi": "10.1002/jat.70099", "url": "https://doi.org/10.1002/jat.70099", "abstract_or_summary": "Review of genotoxicity and DNA damage reported across SSRIs in long-term therapy, with citalopram as a detailed case study. Surveys the evidence that chronic SSRI exposure produces DNA-level damage.", "study_type": "review", "sample_size": "n/a (narrative review)", "keywords": [ "SSRI", "genotoxicity", "DNA damage", "citalopram", "long-term therapy", "PSSD" ], "relevance": "DNA damage is a persistence-adjacent mechanism on the PSSD axis: if chronic SSRI exposure damages DNA, downstream epigenetic/repair landscapes change with it. Newest item in this supplement (2026) — postdates the main sweep's PSSD axis.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Wiley toxicology journal. Note: genotoxicity is adjacent to, not identical with, epigenetic persistence — framed accordingly.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-005", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "pmid": "41672035", "fulltext_note": "No free full text: paywalled at the publisher (checked 2026-10-09)" }, { "item_id": "EPI-006", "source_type": "peer-reviewed paper", "title": "Does finasteride treatment for benign prostatic hyperplasia influence sperm DNA integrity in dogs?", "authors": "Daniel de Souza Ramos Angrimani, Luana de Cássia Bicudo, Núria Llamas Luceño, Bruno Rogério Rui, Matheus F. Silva, João Diego de Agostini Losano", "journal_or_site": "Basic and Clinical Andrology", "year_or_date": 2020, "doi": "10.1186/s12610-020-00108-2", "url": "https://doi.org/10.1186/s12610-020-00108-2", "abstract_or_summary": "Canine study asking whether finasteride treatment for benign prostatic hyperplasia alters sperm DNA integrity in dogs. Tests 5-ARI effects on germline DNA — the transgenerational-persistence angle.", "study_type": "primary-animal", "sample_size": "not extracted from record (canine model)", "keywords": [ "finasteride", "sperm DNA integrity", "germline", "transgenerational", "canine model", "5-alpha-reductase inhibitor" ], "relevance": "Germline DNA-integrity effects would be the strongest form of \"persistence\" (transgenerational). Animal model and DNA integrity rather than methylation — included as a boundary datapoint for the epigenetics question, not as core evidence.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed BMC/Springer andrology journal; canine model, DNA integrity (not methylation) — framed as adjacent.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-006", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_url": "https://bacandrology.biomedcentral.com/track/pdf/10.1186/s12610-020-00108-2", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "32695403" }, { "item_id": "EPI-007", "source_type": "conference abstract", "title": "Epigenetic Effects of Finasteride on Human Leydig Cells", "authors": "Churchill Jonadab Ihentuge, Antonei Benjamin Csoka", "journal_or_site": "The FASEB Journal (Experimental Biology meeting abstract)", "year_or_date": 2020, "doi": "10.1096/fasebj.2020.34.s1.03823", "url": "https://doi.org/10.1096/fasebj.2020.34.s1.03823", "abstract_or_summary": "Conference abstract reporting epigenetic effects of finasteride on human Leydig cells — the steroidogenic cells of the testis. Epigenetic remodeling at the site of androgen synthesis.", "study_type": "conference-abstract", "sample_size": "not extracted from record", "keywords": [ "finasteride", "epigenetics", "Leydig cells", "steroidogenesis" ], "relevance": "Epigenetic effects at the androgen-synthesis site itself (Leydig cells) — if persistent, this is a direct route to lasting androgen/neurosteroid disruption. Author throughline: Csoka co-authored the 2008 PSSD paper and the 2009 epigenetic-side-effects paper already in the corpus.", "verification_status": "verified-crossref-openalex", "quality_notes": "Conference abstract, not a full paper — abstract-level evidence only, peer review limited to meeting selection.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-007", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement" }, { "item_id": "EPI-008", "source_type": "conference abstract", "title": "Finasteride induces Epigenetic Modulation of LSP1: A Gene implicated in Neutrophil Actin Dysfunction disease", "authors": "Churchill Jonadab Ihentuge, Antonei Benjamin Csoka", "journal_or_site": "The FASEB Journal (Experimental Biology meeting abstract)", "year_or_date": 2022, "doi": "10.1096/fasebj.2022.36.s1.r4708", "url": "https://doi.org/10.1096/fasebj.2022.36.s1.r4708", "abstract_or_summary": "Conference abstract reporting finasteride-induced epigenetic modulation of LSP1, a gene implicated in neutrophil actin dysfunction. A second locus showing 5-ARI epigenetic effects beyond the primary steroidogenic targets.", "study_type": "conference-abstract", "sample_size": "not extracted from record", "keywords": [ "finasteride", "epigenetics", "LSP1", "gene modulation" ], "relevance": "Shows finasteride's epigenetic footprint extends beyond steroid genes (LSP1/immune locus) — breadth-of-effect datapoint for the persistence hypothesis.", "verification_status": "verified-crossref-openalex", "quality_notes": "Conference abstract — abstract-level evidence only.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-008", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement" }, { "item_id": "EPI-009", "source_type": "conference abstract", "title": "Epigenetic Effects of Finasteride on Dopaminergic Signaling Pathways: A potential contributor to Post-Finasteride Syndrome", "authors": "Churchill Jonadab Ihentuge, Antonei Benjamin Csoka", "journal_or_site": "Physiology (Physiology Summit meeting abstract)", "year_or_date": 2024, "doi": "10.1152/physiol.2024.39.s1.1269", "url": "https://doi.org/10.1152/physiol.2024.39.s1.1269", "abstract_or_summary": "Conference abstract explicitly linking finasteride's epigenetic effects on dopaminergic signaling pathways to post-finasteride syndrome — the only abstract in this series that names PFS directly, tying the epigenetic mechanism to the clinical syndrome.", "study_type": "conference-abstract", "sample_size": "not extracted from record", "keywords": [ "finasteride", "epigenetics", "dopaminergic signaling", "post-finasteride syndrome" ], "relevance": "Directly connects the epigenetic mechanism to PFS (dopaminergic pathways — relevant to anhedonia/motivation symptoms Powers reports persisting after his relugolix trial). Bridges the epigenetics axis to the neuropsychiatric symptom cluster.", "verification_status": "verified-crossref-openalex", "quality_notes": "Conference abstract — abstract-level evidence only.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-009", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement" }, { "item_id": "EPI-010", "source_type": "conference abstract", "title": "Epigenetic Modulation of ESR1 and DNMT3A Following Finasteride Exposure: Implications for Female Reproductive Function", "authors": "Churchill Jonadab Ihentuge", "journal_or_site": "Physiology (Physiology Summit meeting abstract)", "year_or_date": 2026, "doi": "10.1152/physiol.2026.41.s1.2301385", "url": "https://doi.org/10.1152/physiol.2026.41.s1.2301385", "abstract_or_summary": "Conference abstract reporting epigenetic modulation of ESR1 (estrogen receptor alpha) and DNMT3A (DNA methyltransferase 3A — part of the epigenetic machinery itself) following finasteride exposure, framed around female reproductive function. Finasteride perturbing a DNA methyltransferase implies second-order epigenetic effects.", "study_type": "conference-abstract", "sample_size": "not extracted from record", "keywords": [ "finasteride", "epigenetics", "ESR1", "DNMT3A", "DNA methyltransferase", "estrogen receptor" ], "relevance": "DNMT3A modulation is the most mechanistically suggestive item here: if a 5-ARI alters a DNA methyltransferase, the epigenetic footprint can propagate beyond the initial exposure. Also the only female-reproduction framing in the epigenetics set — relevant to post-drug syndromes beyond the male PFS literature.", "verification_status": "verified-crossref-openalex", "quality_notes": "Conference abstract — abstract-level evidence only; newest item in the Ihentuge series.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-010", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement" }, { "item_id": "EPI-011", "source_type": "peer-reviewed paper", "title": "Epigenetic Mechanisms of Depression and Antidepressant Action", "authors": "Vincent Vialou, Jian Feng, Alfred Jay Robison, Eric J. Nestler", "journal_or_site": "Annual Review of Pharmacology and Toxicology", "year_or_date": 2013, "doi": "10.1146/annurev-pharmtox-010611-134540", "url": "https://doi.org/10.1146/annurev-pharmtox-010611-134540", "abstract_or_summary": "Landmark review (Nestler lab) establishing that antidepressants act through epigenetic mechanisms — histone modifications and DNA methylation in reward and mood circuitry — producing lasting changes in gene expression. The foundational plausibility argument that psychiatric drugs routinely remodel the brain epigenome.", "study_type": "review", "sample_size": "n/a (narrative review)", "keywords": [ "antidepressants", "epigenetics", "histone modification", "DNA methylation", "depression", "Nestler" ], "relevance": "The plausibility backbone for epigenetic persistence on the PSSD axis: if therapeutic antidepressant action itself requires lasting epigenetic remodeling, persistent epigenetic side-effects after discontinuation are mechanistically unsurprising.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Annual Reviews; highly cited Nestler-lab review. Year: Crossref records 2013 (vol. 53); OpenAlex shows 2011 — using Crossref.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-011", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/3711377", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "23020296", "pmcid": "PMC3711377" }, { "item_id": "EPI-012", "source_type": "peer-reviewed paper", "title": "Epigenetics of the Depressed Brain: Role of Histone Acetylation and Methylation", "authors": "HaoSheng Sun, Pamela Kennedy, Eric J. Nestler", "journal_or_site": "Neuropsychopharmacology", "year_or_date": 2013, "doi": "10.1038/npp.2012.73", "url": "https://doi.org/10.1038/npp.2012.73", "abstract_or_summary": "Review of histone acetylation and methylation mechanisms in the depressed brain (Nestler lab). Covers HDAC-dependent and histone-methylation-dependent regulation of mood-relevant gene expression — the chromatin-level mechanisms antidepressants engage.", "study_type": "review", "sample_size": "n/a (narrative review)", "keywords": [ "histone acetylation", "histone methylation", "HDAC", "depression", "antidepressants", "Nestler" ], "relevance": "Chromatin-mechanism background for the PSSD axis: histone-level regulation is the other half (besides DNA methylation) of the epigenetic persistence story, and HDAC pathways are pharmacologically targetable — a treatment-research pointer.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Nature Portfolio journal (ACNP). Year: Crossref 2013 (print); DOI registered 2012 — using Crossref.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-012", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_url": "https://www.nature.com/articles/npp201273.pdf", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "", "pmid": "22692567" }, { "item_id": "EPI-013", "source_type": "peer-reviewed paper", "title": "Epigenetic Neuropharmacology: Drugs Affecting the Epigenome in the Brain", "authors": "Miklós Tóth", "journal_or_site": "Annual Review of Pharmacology and Toxicology", "year_or_date": 2021, "doi": "10.1146/annurev-pharmtox-030220-022920", "url": "https://doi.org/10.1146/annurev-pharmtox-030220-022920", "abstract_or_summary": "Review of how CNS-active drugs alter the brain epigenome — covering antidepressants among other drug classes. Generalizes the \"psychiatric drugs remodel brain epigenetics\" thesis beyond depression to neuropharmacology at large.", "study_type": "review", "sample_size": "n/a (narrative review)", "keywords": [ "neuropharmacology", "epigenome", "antidepressants", "brain", "epigenetics" ], "relevance": "Generalizes EPI-011's thesis: brain-epigenome remodeling is a routine drug effect, not an edge case — the broadest plausibility support for persistent post-drug epigenetic states across all three syndrome axes.", "verification_status": "verified-crossref-openalex", "quality_notes": "Peer-reviewed Annual Reviews. Year: Crossref 2021; OpenAlex 2020 — using Crossref.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-013", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_url": "https://www.annualreviews.org/doi/pdf/10.1146/annurev-pharmtox-030220-022920", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "", "pmid": "32997604" }, { "item_id": "EPI-014", "source_type": "peer-reviewed paper", "title": "Trazodone by epigenetic mechanism can reverse the post finasteride syndrome", "authors": "Eric Almeida Xavier", "journal_or_site": "Magna Scientia Advanced Research and Reviews", "year_or_date": 2023, "doi": "10.30574/msarr.2023.9.2.0149", "url": "https://doi.org/10.30574/msarr.2023.9.2.0149", "abstract_or_summary": "Single-author paper claiming trazodone can reverse post finasteride syndrome through an epigenetic mechanism. Included for completeness of the epigenetics-of-PFS record, not as vetted evidence.", "study_type": "primary-hypothesis", "sample_size": "not extracted from record", "keywords": [ "trazodone", "post-finasteride syndrome", "epigenetics", "reversal" ], "relevance": "Only item in the sweep proposing an epigenetic *reversal* of PFS — a treatment-direction datapoint. Evidentiary weight is low; included so the claim is visible and flagged, not buried.", "verification_status": "verified-crossref-openalex", "quality_notes": "FLAGGED — venue reputation unverified: single-author paper in a journal the sweep could not vouch for (Magna Scientia Advanced Research and Reviews). Treat as hypothesis, not evidence.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-014", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement", "fulltext_url": "https://magnascientiapub.com/journals/msarr/sites/default/files/MSARR-2023-0149.pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc-sa" }, { "item_id": "EPI-015", "source_type": "editorial", "title": "Notes from the Editor Emeritus: Coincidental Epigenetics or Post-Finasteride Syndrome (PFS)?", "authors": "Dow B. Stough", "journal_or_site": "International Society of Hair Restoration Surgery (journal)", "year_or_date": 2016, "doi": "10.33589/26.6.0246", "url": "https://doi.org/10.33589/26.6.0246", "abstract_or_summary": "2016 editorial from the hair-restoration surgery community raising the epigenetics question for post-finasteride syndrome — an early datapoint showing the drug-induced-epigenetics framing of PFS was in the air two years before Traish's 2018 review (PFS-002).", "study_type": "editorial", "sample_size": "n/a", "keywords": [ "post-finasteride syndrome", "epigenetics", "editorial", "hair restoration" ], "relevance": "Historical framing datapoint: the epigenetics hypothesis for PFS predates the peer-reviewed reviews. Useful for the corpus's intellectual- history layer, not as mechanistic evidence.", "verification_status": "verified-crossref-openalex", "quality_notes": "Editorial/opinion — no original data; included as historical context only.", "sweep_date": "2026-10-07", "axis_id": "EPI-A-015", "sweep_axis": "epigenetics-supplement", "proposed_collection_tag": "epigenetics-supplement-2026-10", "collection_tag": "epigenetics-supplement-2026-10", "_source_file": "epigenetics_supplement" }, { "item_id": "SIDE-001", "source_type": "interview", "title": "Dr. Will Powers on the Genetics of Post-Drug Syndromes", "authors": "Robb (SIDEfxHUB, interviewer); Dr. Will Powers (interviewee)", "journal_or_site": "SIDEfxHUB", "year_or_date": "2026-08-21", "doi": null, "url": "https://sidefxhub.com/articles/dr-will-powers-pfs-pssd-summit-2026/", "abstract_or_summary": "SIDEfxHUB editorial interview write-up with Dr. Will Powers at the April 2026 PFS/PSSD/PAS Summit. Powers describes several years spent collecting genome data one patient at a time from people affected by post-drug syndromes, initially through transitioning patients who were also taking finasteride and later from people affected by PFS specifically, and reports finding patterns consistent with patients' accounts. Per RxISK's first-hand summit account, the findings do not currently point to a cure or something broken that can be repaired; they may instead help identify who could run into problems before starting one of these drugs or before stopping, and which options to avoid. Powers reportedly sees a different pattern in PSSD than in PFS, and is seeking data from post-isotretinoin cases where he has far less to work from. The work is explicitly framed as early-stage, non-peer-reviewed pattern-finding presented at a research meeting, not a result; the summit group was working toward a consensus statement due before the end of 2026.\n", "study_type": "interview", "keywords": [ "Will Powers", "genetics", "whole-genome sequencing", "post-drug syndromes", "PFS", "PSSD", "PAS", "risk prediction", "summit 2026" ], "relevance": "Primary-commentary record from a clinician-researcher actively collecting PFS/PSSD genomes. Distinct editorial record from the YouTube summit interview (iWFDBRTgT3g) already in the corpus; corroborated by RxISK's independent first-hand summit write-up.\n", "verification_status": "verified — page live 2026-10-07; corroborated by RxISK's Summit account (Dr. David Healy) linked from the article", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Dr. Will Powers on the Genetics of Post-Drug Syndromes", "sidefxhub_article_url": "https://sidefxhub.com/articles/dr-will-powers-pfs-pssd-summit-2026/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub" }, { "item_id": "SIDE-002", "source_type": "interview", "title": "Dr. Kenneth Peters on the First PFS/PSSD/PAS Summit", "authors": "Robb (SIDEfxHUB, interviewer); Dr. Kenneth Peters (interviewee)", "journal_or_site": "SIDEfxHUB", "year_or_date": "2026-08-21", "doi": null, "url": "https://sidefxhub.com/articles/pfs-pssd-pas-summit-2026/", "abstract_or_summary": "Interview with Dr. Kenneth Peters, Chair of Urology at Corewell Health William Beaumont University Hospital, organizer of the first medical conference dedicated to PFS, PSSD and PAS together (late April 2026). Peters recounts stopping finasteride prescribing entirely after a single severe patient case roughly a decade ago. A cluster of four young patients presenting within two weeks with near-identical acute-onset genital numbness, anhedonia and brain fog after finasteride, SSRIs, or isotretinoin motivated him to act. His team ran a small case series with corneal confocal microscopy showing nerve damage suggestive of small-fibre neuropathy, then an IRB-approved anonymous online survey drawing over 1,100 responses across all three conditions, with very high reported suicidal ideation. Peters is first author on a SUFU February 2026 conference abstract (\"Post-Drug Syndrome: Urgent Need For Clinician Education and Research\", Neurourology and Urodynamics Vol. 45, Issue S1), with a further paper submitted and two more in progress; the summit group is writing an extended congress manuscript with a follow-up meeting scheduled. His closing assessment: one cannot sit through the meeting and deny the post-drug syndromes, while being clear the meeting produced far more questions than answers and nothing discussed is a treatment recommendation.\n", "study_type": "interview", "keywords": [ "Kenneth Peters", "PFS/PSSD/PAS Summit 2026", "urology", "small-fibre neuropathy", "corneal confocal microscopy", "clinician advocacy", "post-drug syndromes" ], "relevance": "Firsthand account of the first PFS/PSSD/PAS medical conference from its organizer — a new clinician voice not previously in the corpus — documenting summit-scale survey data, a small-fibre neuropathy hypothesis, and the emergence of a post-drug-syndrome research consortium.\n", "verification_status": "verified — page live 2026-10-07; corroborated by the SUFU 2026 abstract link and RxISK's first-hand summit report", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Dr. Kenneth Peters on the First PFS/PSSD/PAS Summit", "sidefxhub_article_url": "https://sidefxhub.com/articles/pfs-pssd-pas-summit-2026/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub" }, { "item_id": "SIDE-003", "source_type": "peer-reviewed paper", "title": "A curvilinear relationship between hair loss and mental rotation and neuroticism: a possible influence of sustained dihydrotestosterone production", "authors": "John R. Beech", "journal_or_site": "Personality and Individual Differences, 31(2):185-192", "year_or_date": 2001, "doi": "10.1016/S0191-8869(00)00127-6", "url": "https://doi.org/10.1016/S0191-8869(00)00127-6", "abstract_or_summary": "Observational psychology study using hair loss as a proxy for sustained DHT exposure over time. Reported an inverted-U (curvilinear) relationship between cumulative DHT levels and mental-rotation performance, peaking at moderate DHT and declining at both high and low extremes, plus a similar curvilinear pattern for neuroticism — suggesting both very high and very low DHT production could relate to emotional stability. Small, closed-access paper with few citations; an indirect but suggestive data point on lifelong DHT exposure and cognition.\n", "study_type": "observational study", "keywords": [ "DHT", "androgen", "mental rotation", "neuroticism", "spatial cognition" ], "relevance": "One of few papers probing links between sustained DHT exposure and cognition/mood — provides background mechanistic context for the cognitive and emotional effects reported with finasteride's DHT suppression.\n", "verification_status": "verified — OpenAlex and Crossref both resolve the DOI with matching title, author, journal, and year", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "The Connection Between DHT Levels and Mental Health", "sidefxhub_article_url": "https://sidefxhub.com/articles/the-connection-between-dht-levels-and-mental-health/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub" }, { "item_id": "SIDE-004", "source_type": "peer-reviewed paper", "title": "Macular Abnormalities Associated With 5α-Reductase Inhibitor", "authors": "Yong Kyun Shin; Geun Woo Lee; Se Woong Kang; Sang Jin Kim; A. Young Kim", "journal_or_site": "JAMA Ophthalmology, 138(7):732", "year_or_date": 2020, "doi": "10.1001/jamaophthalmol.2020.1279", "url": "https://doi.org/10.1001/jamaophthalmol.2020.1279", "abstract_or_summary": "Short research letter from Samsung Medical Center (Sungkyunkwan University) reporting macular abnormalities associated with 5α-reductase inhibitor use. The SideFXHub article that surfaced it additionally leans on an unpublished South Bay Retina clinic investigation (Dr. Lynnette Nguyen) reviewing 28 finasteride users, in which most showed visual abnormalities including cystoid macular edema and optic nerve dysfunction — but that clinical investigation has no peer-reviewed citation; Shin et al. 2020 is the named, verified peer-reviewed source linking the drug class to macular findings.\n", "study_type": "case series / observational (research letter)", "keywords": [ "finasteride", "5ARI", "ocular toxicity", "macula", "cystoid macular edema" ], "relevance": "Documents a rarely discussed harm category (ocular) for 5ARI use, expanding the corpus's adverse-effect coverage beyond sexual/neuropsychiatric domains.\n", "verification_status": "verified — OpenAlex and Crossref both resolve the DOI with matching title, authors, journal, and year", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Finasteride-Induced Eye Toxicity: Serious Risks for Patients", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/finasteride-induced-eye-toxicity-serious-risks-for-patients/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub", "fulltext_url": "https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2765649/jamaophthalmology_shin_2020_oi_200034.pdf", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "", "pmid": "32379286" }, { "item_id": "SIDE-005", "source_type": "peer-reviewed paper", "title": "Advancing human gut microbiota research by considering gut transit time", "authors": "Nicola Procházková; Gwen Falony; Lars Ove Dragsted; Tine Rask Licht; Jeroen Raes; Henrik M. Roager", "journal_or_site": "Gut, 72(1):180-191", "year_or_date": 2023, "doi": "10.1136/gutjnl-2022-328166", "url": "https://doi.org/10.1136/gutjnl-2022-328166", "abstract_or_summary": "Review arguing that gut transit time is a top covariate driving interindividual variation in gut microbiota composition and activity, yet is rarely accounted for in microbiome research. Faster transit favors carbohydrate fermentation and beneficial short-chain fatty acids; slower transit favors protein fermentation and less favorable by-products. The authors describe bidirectional links between transit time and microbiota and urge incorporating transit-time measures into microbiome study design to avoid confounded disease signatures.\n", "study_type": "review", "keywords": [ "gut transit time", "gut microbiota", "gut-brain axis", "microbiome", "neuroinflammation" ], "relevance": "Mechanistic background for gut-brain axis discussion in PFS/PSSD; complements corpus PFS gut-microbiota papers (DISC-008/009/010). No direct PFS/PSSD link — background mechanism only.\n", "verification_status": "verified — OpenAlex and Crossref both resolve the DOI with matching title, authors, journal, and year", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Gut Transit Time and Its Effect on Health", "sidefxhub_article_url": "https://sidefxhub.com/articles/gut-transit-time-a-key-factor-in-shaping-health-and-wellness/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub", "fulltext_url": "https://gut.bmj.com/content/gutjnl/72/1/180.full.pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc", "pmid": "36171079" }, { "item_id": "SIDE-006", "source_type": "peer-reviewed paper", "title": "The Effect of Citalopram on Genome-Wide DNA Methylation of Human Cells", "authors": [ "Riya R. Kanherkar", "Bruk Getachew", "Joseph Ben-Sheetrit", "Sudhir Varma", "Thomas Heinbockel", "Yousef Tizabi", "Antonei B. Csoka" ], "journal_or_site": "International Journal of Genomics", "year_or_date": "2018-07-25", "doi": "10.1155/2018/8929057", "url": "https://doi.org/10.1155/2018/8929057", "abstract_or_summary": "Human embryonic kidney (HEK-293) cells were cultured in 50 micromolar citalopram for 30 days and then profiled genome-wide for DNA methylation changes. Of roughly 25,000 gene promoters assayed, 626 showed significant differential methylation versus controls (272 hypomethylated, 354 hypermethylated). Pathway analysis flagged nervous-system development and function, cellular growth and proliferation, and depression-related gene networks as the most affected systems, with BDNF, FSH, and NF-kappaB predicted as upstream regulators from their methylated targets. The authors present this as a first proof of concept that common prescription drugs can exert persistent off-target epigenetic effects.", "study_type": "in-vitro experimental (cell line)", "keywords": [ "citalopram", "DNA methylation", "epigenetics", "pharmacoepigenetics", "SSRI", "HEK-293" ], "relevance": "First genome-wide demonstration that citalopram reprograms DNA methylation across hundreds of promoters, directly supporting the epigenetic-persistence hypothesis for post-drug syndromes. Co-author Csoka is also the author of the corpus's foundational pharmacoepigenomics paper (PSSD-005), making this a mechanistic bridge between them.", "verification_status": "verified — Crossref + OpenAlex (independent signals); PMID 30148158; gold open access (CC-BY)", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Epigenetic Effects of Citalopram", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/epigenetic-effects-of-citalopram/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub", "fulltext_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/2018/8929057", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "30148158", "fulltext_note": "Link updated 2026-10-09: Hindawi journals moved to Wiley" }, { "item_id": "SIDE-007", "source_type": "peer-reviewed paper", "title": "The potential involvement of cholinergic system in finasteride induced cognitive dysfunction", "authors": [ "Ashutosh Ahire", "Kala P. Nair", "B. S. Shankaranarayana Rao", "B. N. Srikumar" ], "journal_or_site": "Psychoneuroendocrinology", "year_or_date": 2021, "doi": "10.1016/j.psyneuen.2020.105066", "url": "https://doi.org/10.1016/j.psyneuen.2020.105066", "abstract_or_summary": "Adult male Wistar rats trained on a partially baited radial-arm maze then received finasteride (30 or 100 mg/kg) or vehicle for seven days. The high dose produced clear spatial-memory deficits on retention testing and reduced sociability with loss of social-novelty preference. Biochemical analysis showed decreased acetylcholinesterase activity in frontal cortex, hippocampus, and septum. The authors interpret this as finasteride-driven disruption of central cholinergic signaling, offering a candidate mechanism for the cognitive complaints reported by finasteride users.", "study_type": "preclinical animal study (rats)", "keywords": [ "finasteride", "cognitive dysfunction", "cholinergic system", "acetylcholinesterase", "neurosteroids", "5-alpha-reductase" ], "relevance": "One of the few mechanistic studies linking 5-alpha-reductase inhibition to cognitive impairment via the cholinergic system, filling a neurocognitive gap in the corpus's PFS coverage. Connects neurosteroid depletion to measurable brain-enzyme changes.", "verification_status": "verified — Crossref + OpenAlex (independent signals); PMID 33249331", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "The Dark Side of Finasteride", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/the-dark-side-of-finasteride-uncovering-cognitive-risks-and-cholinergic-disruption/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub", "pmid": "33249331" }, { "item_id": "SIDE-008", "source_type": "peer-reviewed paper", "title": "Androgen Levels and Semen Parameters Among Former Users of Finasteride With Persistent Sexual Adverse Effects", "authors": "Michael S. Irwig", "journal_or_site": "JAMA Dermatology", "year_or_date": 2014, "doi": "10.1001/jamadermatol.2014.1830", "url": "https://doi.org/10.1001/jamadermatol.2014.1830", "abstract_or_summary": "Irwig studied 24 otherwise healthy young men who had taken low-dose finasteride for hair loss and developed persistent sexual side effects, measuring their hormone levels and semen quality against reference populations. Although average testosterone and DHT fell within normal ranges, 13% had confirmed low levels of both androgens, above the roughly 5% expected in the general population. Semen analysis showed a striking fertility signal: 16% had severe oligospermia, 44% low sperm motility, and 50% abnormal morphology. The author concluded that serum androgens alone do not fully explain persistent sexual dysfunction, but the reproductive impact warrants attention. Limitations include the small sample and no pre-treatment baseline hormone or semen data.", "study_type": "observational case series", "keywords": [ "finasteride", "post-finasteride syndrome", "semen parameters", "oligospermia", "androgen levels", "male fertility" ], "relevance": "One of the few studies to document objective semen abnormalities in men with persistent sexual side effects after finasteride, linking PFS to measurable reproductive harm beyond self-reported symptoms.", "verification_status": "verified-crossref-openalex", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Androgen Levels and Semen Parameters After a 5-ARI", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/androgen-levels-and-semen-parameters-in-men-with-persistent-sexual-adverse-effects-after-using-a-5alpha-reductase-inhibitor/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub", "pmid": "25229565" }, { "item_id": "SIDE-009", "source_type": "peer-reviewed paper", "title": "Differential Gene Expression in Post-Finasteride Syndrome Patients", "authors": "Skyler Howell; Weitao Song; Alexander W. Pastuszak; Mohit Khera", "journal_or_site": "The Journal of Sexual Medicine", "year_or_date": 2021, "doi": "10.1016/j.jsxm.2021.05.009", "url": "https://doi.org/10.1016/j.jsxm.2021.05.009", "abstract_or_summary": "This Baylor-affiliated team compared gene expression in penile skin cells from 26 men with post-finasteride syndrome against 26 healthy controls. They found 1,446 genes over-expressed and 2,318 under-expressed in the PFS group, with the androgen receptor gene notably more active despite no corresponding rise in circulating androgen levels. The authors interpret the pattern as evidence that PFS has a real, tissue-localized biological basis rather than a purely psychological one. The work is limited to penile skin tissue, so it may not capture systemic effects. It remains a landmark molecular study in a field short on mechanistic data.", "study_type": "case-control gene expression study", "keywords": [ "post-finasteride syndrome", "gene expression", "androgen receptor", "transcriptomics", "penile tissue" ], "relevance": "Key molecular evidence for a biological basis of PFS, showing thousands of differentially expressed genes and elevated androgen receptor activity in affected tissue.", "verification_status": "verified-crossref-openalex", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Gene expression changes in PFS: a 2021 study", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/understanding-the-genetic-basis-of-post-finasteride-syndrome-pfs/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub", "pmid": "34247957", "note": "Published version of the conference report recorded as PFS-008." }, { "item_id": "SIDE-010", "source_type": "peer-reviewed paper", "title": "Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss", "authors": "Shehzad Basaria; Ravi Jasuja; Grace Huang; Whitney Wharton; Hong Pan; Karol Pencina; Zhuoying Li; Thomas Travison; Jag Bhawan; Renaud Gonthier; Fernand Labrie; Alain Dury; Carlo Serra; Allen Papazian; Michael O'Leary; Sami Amr; Thomas Storer; Emily Stern; Shalender Bhasin", "journal_or_site": "The Journal of Clinical Endocrinology & Metabolism", "year_or_date": 2016, "doi": "10.1210/jc.2016-2726", "url": "https://doi.org/10.1210/jc.2016-2726", "abstract_or_summary": "Basaria's group compared three groups of men: 25 finasteride users with persistent sexual symptoms, 13 asymptomatic finasteride users, and 18 men who never used the drug. Assessments covered hormones, body composition, cognition, and brain activity via fMRI. Men with persistent symptoms had normal testosterone and DHT and no explanatory variants in the androgen receptor or SRD5A genes, yet showed markedly worse sexual function and higher depression scores. In small fMRI subsets (6 symptomatic men in the erotic-image task, 7 per group in the emotional-word task), worse symptom scores among finasteride users correlated with activity in brain regions tied to sexual arousal and mood. The authors concluded the symptoms are unlikely to reflect simple androgen deficiency and may instead involve neurobiological changes. They suggested treatment focus on mood and sexual function rather than testosterone replacement.", "study_type": "case-control study with neuroimaging", "keywords": [ "finasteride", "persistent sexual symptoms", "fMRI", "depression", "androgen deficiency", "neurobiology" ], "relevance": "Three-group cross-sectional study (symptomatic users, asymptomatic users, never-users) arguing persistent post-finasteride sexual symptoms are not explained by androgen deficiency, pointing instead to central neurobiological mechanisms. The groups differed in race and education and were recruited by different routes.", "verification_status": "verified-crossref-openalex", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Persistent Sexual Symptoms After Finasteride Use", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/characteristics-of-men-who-report-persistent-sexual-symptoms-after-finasteride-use-for-hair-loss/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/5155688", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "27662439", "pmcid": "PMC5155688", "plain": { "summary": "Researchers in Boston compared 25 men who had ongoing sexual problems after stopping finasteride for hair loss with 13 men who had taken it without such problems and 18 men who had never taken it. The men with ongoing problems had much poorer sexual function and higher depression scores. But their testosterone, DHT (a stronger form of testosterone) and other hormone levels were similar to the other groups, and no relevant gene differences were found. In brain scans of a small number of the men, activity in some areas linked to sexual arousal and mood rose or fell with how severe their symptoms were.", "caveat": "It can't show that finasteride caused the symptoms or the low mood: everyone was measured once, after the fact, the groups were small, and each brain-scan task included only about 20 men." }, "evidence": { "design": "Case-control comparison at a single visit of three groups (symptomatic former finasteride users, asymptomatic former users, never-users): hormones, genes, skin androgen markers, body composition, sexual function, mood, cognition and functional MRI", "design_class": "case-control", "setting": "Brigham and Women's Hospital, Boston, USA; enrolment June 2013 to October 2014", "population": "Men aged 18–50. Group 1: used finasteride for hair loss for at least 7 days, none in the preceding 4 months, with erectile dysfunction (IIEF erectile function score of 25 or less) but normal blood tests and examination. Group 2: former finasteride users without sexual symptoms after stopping. Group 3: healthy men who never used finasteride. Excluded: depression before finasteride, recent androgens or related drugs, cancer, diabetes, BMI over 40.", "n": 56, "n_note": "25 symptomatic users, 13 asymptomatic users and 18 never-users, from 282 men screened by telephone and 132 in person. fMRI in subsets only: erotic-image task 6 symptomatic, 4 asymptomatic and 10 never-users; emotional-word task 7 per group", "exposure": "Finasteride for hair loss, median 1.0 mg/day; median 1.7 years (IQR 0.5–6.0) in group 1 vs 1.0 (0.7–2.0) in group 2; median 3.5 vs 3.0 years since the last dose", "comparator": "Asymptomatic former users and never-users", "outcome": "Serum hormones by LC-MS/MS (testosterone, DHT, estradiol, glucuronide metabolites as markers of 5α-reductase activity); sequences of the AR, SRD5A1 and SRD5A2 genes; skin androgen markers; IIEF and Male Sexual Health Questionnaire; PHQ-9, Beck Depression Inventory, Hamilton Depression Scale; Positive and Negative Affect Scale; cognitive tests; body composition by DXA; fMRI during erotic images and emotional words.", "follow_up": "None; a single assessment, a median 3.5 years after the last dose in group 1", "results": [ { "text": "Total and free testosterone, DHT, LH, FSH, estradiol and SHBG did not differ among groups (P > .1) and were in the normal range for young men; the testosterone-to-DHT ratio, 3α-diol glucuronides and the ADT-G to ETIO-G ratio were also similar", "where": "p. 8; Fig. 1, p. 9" }, { "text": "No potentially harmful variants in the AR, SRD5A1 or SRD5A2 genes; AR CAG repeat length 22.2, 21.8 and 21.0 (P = .236)", "where": "p. 10" }, { "text": "IIEF composite score median 30.0 (IQR 23.0–35.0) vs 67.0 (65.0–68.0) vs 68.5 (67.0–71.0), P < .001; not related to treatment duration (r = 0.059, P = .725) or time since stopping (r = −0.215, P = .194)", "where": "p. 10" }, { "text": "PHQ-9 depression score median 11.0 (7.0–17.0) vs 1.0 (1.0–2.0) vs 1.0 (0–2.0), P < .001, in the moderate range for group 1; Beck and Hamilton scores also higher, more negative and less positive affect. Objective cognitive tests did not differ; memory complaints were higher (MAC-Q 20.8 vs 18.4 vs 16.9, education-adjusted overall P = .02, no significant pairwise difference)", "where": "pp. 12, 14; Table 2, p. 15" }, { "text": "fMRI, correlations across finasteride users in small subsets: lower IIEF scores went with more activity in the hypothalamus and thalamus and less in cingulate and other cortical areas during erotic images; higher Beck negative-attitude subscores went with more activity in the nucleus accumbens, anterior cingulate and other regions linked to depression", "where": "pp. 16–18; Fig. 4, pp. 17–18" } ], "limitations_stated": [ "Cross-sectional design, so a causal link between finasteride and the symptoms, mood changes, cognitive complaints or fMRI findings cannot be inferred", "Low mood may be coincidental, related to hair loss itself or a nocebo effect, or may contribute to the sexual dysfunction", "No control group of profoundly hypogonadal men", "Normal blood DHT does not rule out local 5α-reductase inhibition in specific brain regions", "Variation in other genes, gene expression in other tissues or brain regions, or epigenetic effects cannot be excluded", "Findings need confirmation in larger prospective studies" ], "design_notes": [ "Groups differed in race (white 88%, 61.5%, 50%; Black 4%, 15.4%, 50%; P < .001) and years of education (19.3, 19.3, 16.2; P = .03), and were recruited differently (physician referral for group 1, newspaper advertising and mailing for never-users)", "The fMRI covered only small subsets and was analysed mainly as correlations between symptom scores and brain activity across finasteride users (symptomatic and asymptomatic together), not as a direct comparison of symptomatic men with never-users", "The text says acne and androgen-responsive markers did not differ, but Table 1 shows back acne (P = .02) and haemoglobin (15.4 vs 14.9 vs 14.6 g/dL, P = .02) differing, both highest in group 1", "The asymptomatic group was small (13), and entry required only 7 days of finasteride use", "Hormones were measured in one morning fasting sample" ], "funding": "In part the Post-Finasteride Syndrome Foundation; also Harvard Catalyst and the Center for Clinical Investigation at Brigham and Women's Hospital", "interests": "S. Basaria: grant support from Abbott for unrelated studies, previously consulted for Eli Lilly. S. Bhasin: research grants from AbbVie, Transition Therapeutics, Takeda and Eli Lilly for unrelated research; consultant to AbbVie, Regeneron, Novartis and Eli Lilly; financial interest in Function Promoting Therapies, LLC. Other authors nothing to disclose.", "supports": "That men with persistent sexual symptoms after finasteride, in this sample, had normal circulating androgen levels and markers alongside poorer sexual function and depressed mood. It cannot show that finasteride caused the symptoms, it tested no treatment, and its brain-scan findings come from small subsets.", "extracted_from": "fulltexts/SIDE-010-Characteristics-of-Men-Who-Report-Persistent-Sexua.pdf (PMC article page printed to PDF, PMC5155688, 24 pp.; page refs are PDF page indices)", "extracted": "2026-10-10" } }, { "item_id": "SIDE-011", "source_type": "peer-reviewed paper", "title": "A Pharmacogenetic Survey of Androgen Receptor (CAG)N and (GGN)N Polymorphisms in Patients Experiencing Long Term Side Effects after Finasteride Discontinuation", "authors": "Erika Cecchin; Elena De Mattia; Giorgio Mazzon; Sabina Cauci; Carlo Trombetta; Giuseppe Toffoli", "journal_or_site": "The International Journal of Biological Markers", "year_or_date": 2014, "doi": "10.5301/jbm.5000095", "url": "https://doi.org/10.5301/jbm.5000095", "abstract_or_summary": "The team compared the prevalence of two androgen receptor polymorphisms, CAG-rs4045402 and GGN-rs3138869, across 69 men with androgenetic alopecia who developed persistent side effects after finasteride, 91 untreated men with alopecia, and 76 untreated men without alopecia. Extreme-length alleles of both polymorphisms were markedly more common in the PFS and alopecia groups than in controls, with odds ratios around 5.9 for the PFS group versus controls. The authors concluded these repeat lengths predict alopecia development and may flag susceptibility to persistent finasteride side effects. They called for prospective trials in other ethnicities to confirm the findings and identify further predictive markers.", "study_type": "genetic association study", "keywords": [ "androgen receptor", "pharmacogenetics", "CAG repeat", "GGN repeat", "post-finasteride syndrome", "androgenetic alopecia" ], "relevance": "Foundational pharmacogenetic study suggesting AR repeat-length variants predispose men both to hair loss and to persistent side effects from finasteride.", "verification_status": "verified-crossref-openalex", "crosscheck_source": "SIDEfxHUB research-and-insights (2026-10-07)", "sidefxhub_article_title": "Androgen receptor gene length in PFS and hair loss", "sidefxhub_article_url": "https://sidefxhub.com/articles/scientific-research/understanding-the-genetic-factors-behind-post-finasteride-syndrome-pfs/", "starred": true, "curated_source": "SIDEfxHUB", "collection_tag": "sidefxhub", "fulltext_url": "https://journals.sagepub.com/doi/pdf/10.5301/jbm.5000095", "fulltext_source": "publisher OA", "oa_license": "cc-by-sa", "pmid": "24855036", "fulltext_note": "Link updated 2026-10-09: the earlier link was a DOAJ listing, not the article", "note": "From the same Trieste group as PFS-007 (2017, 66 PFS patients); the cohorts may overlap." }, { "item_id": "MECH-001", "source_type": "peer-reviewed journal (review)", "title": "Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions?", "authors": [ "Doodipala S. Reddy" ], "journal_or_site": "Trends in Pharmacological Sciences", "year_or_date": 2003, "doi": "10.1016/S0165-6147(03)00023-3", "url": "https://doi.org/10.1016/S0165-6147(03)00023-3", "abstract_or_summary": "This review argues that THDOC (allotetrahydrodeoxycorticosterone), the adrenal-derived 5α-reduced metabolite of deoxycorticosterone, is a genuine physiological signal rather than a pharmacological curiosity. During acute stress, THDOC rises several-fold to concentrations capable of potentiating GABA-A receptors, particularly extrasynaptic subtypes mediating tonic inhibition. The author surveys evidence linking this surge to seizure protection, restraint of HPA-axis activity, and mood regulation, and proposes that dysregulated THDOC signaling could underlie stress-sensitive conditions including epilepsy, PTSD, and depression. Antidepressants, the review notes, normalize neurosteroid disturbances, suggesting the pathway is tractable.", "system_classification": "neurosteroid signaling", "justification": "Powers' current theorizing centers on THDOC/allopregnanolone excess held in place by feedback loops; this review is the canonical statement that THDOC reaches physiologically active levels during stress and modulates the HPA circuits implicated in post-drug depressive phenotypes. It also documents that 5α-reductase inhibition blocks the DOC-to-THDOC conversion — the exact enzymatic step his model implicates. Any causal-pathway search for a neurosteroid-excess syndrome must start from the evidence base this review consolidates.", "keywords": [ "THDOC", "tetrahydrodeoxycorticosterone", "GABA-A receptor", "stress", "depression", "neurosteroid", "HPA axis" ], "relevance": "high", "verification_status": "verified: Crossref + OpenAlex + PubMed (PMID 12628349)", "quality_notes": "Peer-reviewed review in high-impact pharmacology journal; 103 citations per Crossref; single-author expert review.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "12628349" }, { "item_id": "MECH-002", "source_type": "peer-reviewed journal (original research)", "title": "Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain.", "authors": [ "Robert H. Purdy", "A. Leslie Morrow", "Perry H. Moore", "Steven M. Paul" ], "journal_or_site": "Proceedings of the National Academy of Sciences", "year_or_date": 1991, "doi": "10.1073/pnas.88.10.4553", "url": "https://doi.org/10.1073/pnas.88.10.4553", "abstract_or_summary": "This foundational study demonstrated that acute stress sharply elevates GABA-A receptor-active steroids — including THDOC and allopregnanolone — in the rat brain. Using swim stress with biochemical quantification, the authors showed that the brain's inhibitory neurosteroid tone is dynamically coupled to stress exposure. The work established the core observation the entire stress-neurosteroid-GABA literature rests on: stress co-releases GABAergic neurosteroids alongside glucocorticoids. It remains among the most-cited empirical anchors for all later THDOC physiology.", "system_classification": "neurosteroid signaling", "justification": "This is the empirical root of the stress–THDOC story Powers leans on: without stress-induced neurosteroid surges, there is no substrate for an \"excess held in place by feedback loops\" model. It serves as the founding observation that later work (Reddy 2003; Cadeddu 2025) builds on, and it defines the normal physiology that any pathological-excess hypothesis must be measured against.", "keywords": [ "THDOC", "allopregnanolone", "stress", "GABA-A receptor", "rat brain", "foundational" ], "relevance": "high", "verification_status": "verified: OpenAlex + Crossref (cited as reference in Reddy 2003 Crossref record)", "quality_notes": "Peer-reviewed PNAS article; heavily cited foundational work (1991).", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/51699", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "1852011", "pmcid": "PMC51699" }, { "item_id": "MECH-003", "source_type": "peer-reviewed journal (original research)", "title": "Reversal of neurosteroid effects at α4β2δ GABAA receptors triggers anxiety at puberty", "authors": [ "Hui Shen", "Qi Hua Gong", "Chiye Aoki", "Maoli Yuan", "Yevgeniy Ruderman", "Michael Dattilo", "Keith Williams", "Sheryl S. Smith" ], "journal_or_site": "Nature Neuroscience", "year_or_date": 2007, "doi": "10.1038/nn1868", "url": "https://doi.org/10.1038/nn1868", "abstract_or_summary": "In pubertal female mice, the stress-released neurosteroid allopregnanolone paradoxically increases anxiety rather than reducing it. The authors trace this to α4β2δ GABA-A receptors, which are upregulated in hippocampal CA1 at puberty: allopregnanolone inhibits these receptors, reducing tonic inhibition of pyramidal cells and raising excitability. The effect depends on a chloride-modulation site (arginine 353) in the α4 subunit. The study is the clearest mechanistic proof that a GABA-A-positive neurosteroid can flip sign — anxiogenic instead of anxiolytic — when receptor subunit composition changes.", "system_classification": "neurosteroid signaling", "justification": "Powers' reversal from a deficiency to an excess theory requires a mechanism by which more GABAergic neurosteroid produces worse outcomes; this paper supplies exactly that — a sign-flip at α4β2δ receptors driven by subunit composition. It explains how elevated allopregnanolone/THDOC could be anxiogenic rather than calming, mapping onto anxiety phenotypes in PFS/PSSD. It also implicates receptor plasticity as a candidate mechanism for persistence after drug withdrawal.", "keywords": [ "allopregnanolone", "paradoxical effect", "alpha4beta2delta", "GABA-A receptor", "anxiety", "puberty", "tonic inhibition" ], "relevance": "high", "verification_status": "verified: OpenAlex + PubMed (PMID 17351635, PMCID PMC1858651)", "quality_notes": "Peer-reviewed Nature Neuroscience article; mechanistic electrophysiology plus behavior.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/1858651", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "17351635", "pmcid": "PMC1858651" }, { "item_id": "MECH-004", "source_type": "peer-reviewed journal (original research)", "title": "Tolerance development to Morris water maze test impairments induced by acute allopregnanolone", "authors": [ "Şahruh Türkmen", "Mats Löfgren", "Vita Birzniece", "Torbjörn Bäckström", "Inga-Maj Johansson" ], "journal_or_site": "Neuroscience", "year_or_date": 2006, "doi": "10.1016/j.neuroscience.2005.12.031", "url": "https://doi.org/10.1016/j.neuroscience.2005.12.031", "abstract_or_summary": "Rats given repeated acute allopregnanolone develop rapid tolerance to its impairment of spatial memory in the Morris water maze, requiring escalating doses to maintain the effect. The tolerance persists for about a day after induction and is accompanied by reduced GABA-A receptor α4-subunit mRNA in the thalamic ventral-posteromedial nucleus. The work shows tolerance is a receptor-level adaptation rather than altered drug kinetics. For an excess-neurosteroid model, it documents that sustained high neurosteroid exposure remodels the very receptors it acts on.", "system_classification": "neurosteroid signaling", "justification": "A neurosteroid-excess model needs evidence that sustained high neurosteroid exposure produces lasting adaptation rather than just acute sedation; this tolerance study provides it at the behavioral level. The persistence of tolerance beyond drug clearance parallels the clinical puzzle of symptoms outlasting exposure. It motivates the receptor-level studies (MECH-005) that reveal the adaptation's substrate.", "keywords": [ "allopregnanolone", "tolerance", "Morris water maze", "GABA-A receptor", "alpha4 subunit", "thalamus" ], "relevance": "high", "verification_status": "verified: OpenAlex + PubMed (PMID 16457954)", "quality_notes": "Peer-reviewed Neuroscience article; Umeå Neurosteroid Research Centre group.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "16457954" }, { "item_id": "MECH-005", "source_type": "peer-reviewed journal (original research)", "title": "GABAA receptor changes in acute allopregnanolone tolerance", "authors": [ "Vita Birzniece", "Şahruh Türkmen", "Charlotte Lindblad", "Di Zhu", "Inga-Maj Johansson", "Torbjörn Bäckström", "Göran Wahlström" ], "journal_or_site": "European Journal of Pharmacology", "year_or_date": 2006, "doi": "10.1016/j.ejphar.2006.01.059", "url": "https://doi.org/10.1016/j.ejphar.2006.01.059", "abstract_or_summary": "This companion mechanistic study links acute allopregnanolone tolerance to concrete GABA-A receptor plasticity: after tolerance induction, α4 subunit abundance and mRNA fall in thalamic relay nuclei, correlating with the dose escalation needed to sustain the neurosteroid's effects. It provides the molecular substrate for the behavioral tolerance seen in the Morris water maze experiments. The message is that chronic neurosteroid elevation rewires inhibitory circuitry — a template for how a persistent excess state could become self-sustaining even after the inducing exposure ends.", "system_classification": "neurosteroid signaling", "justification": "This paper gives the molecular face of neurosteroid tolerance — downregulated α4 subunits — which is the kind of self-sustaining receptor remodeling Powers' feedback-loop theorizing invokes. If chronic excess remodels GABA-A composition, then removing the drug does not restore the original circuit, offering a persistence mechanism independent of continued exposure. It is the strongest preclinical precedent for \"the system does not reset.\"", "keywords": [ "allopregnanolone", "tolerance", "GABA-A receptor", "alpha4 subunit", "receptor plasticity", "thalamus" ], "relevance": "high", "verification_status": "verified: OpenAlex + PubMed (PMID 16513107)", "quality_notes": "Peer-reviewed Eur J Pharmacol article; same Umeå group as MECH-004; note: an incorrect DOI for this paper (10.1016/j.ejphar.2006.02.001) circulates — the correct DOI was confirmed via PubMed.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "16513107" }, { "item_id": "MECH-006", "source_type": "peer-reviewed journal (original research)", "title": "3β-20β-dihydroxy-5α-pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone.", "authors": [ "Şahruh Turkmen", "Per Lundgren", "Vita Birzniece", "Ewa Zingmark", "Torbjörn Backstrom", "Inga-Maj Johansson" ], "journal_or_site": "European Journal of Neuroscience", "year_or_date": 2004, "doi": "10.1111/j.1460-9568.2004.03610.x", "url": "https://doi.org/10.1111/j.1460-9568.2004.03610.x", "abstract_or_summary": "The 3β-steroid UC1011 blocks both the GABA-potentiating and the learning-impairing effects of allopregnanolone in rats. As a functional antagonist of allopregnanolone at the GABA-A receptor, it demonstrates that neurosteroid signaling can be pharmacologically opposed without blocking GABA itself. The compound is the direct conceptual ancestor of isoallopregnanolone (sepranolone), later developed for premenstrual dysphoric disorder. Included here strictly as a mechanistic research record, it is the founding preclinical demonstration of a neurosteroid-antagonist strategy.", "system_classification": "neurosteroid signaling", "justification": "If excess neurosteroid signaling is causal, then blocking it is the logical therapeutic probe; UC1011 is the founding demonstration that allopregnanolone's effects can be selectively antagonized. Its lineage runs to isoallopregnanolone/sepranolone, the clinical-stage neurosteroid antagonist — a genuine treatment-candidate anchor recorded here as mechanistic research only. It also shows the field already accepts that allopregnanolone excess can be pathogenic (in PMDD), a precedent for extending the logic to post-drug syndromes.", "keywords": [ "UC1011", "allopregnanolone antagonist", "sepranolone", "GABA-A receptor", "PMDD", "treatment candidate (mechanistic)" ], "relevance": "high", "verification_status": "verified: OpenAlex + PubMed (PMID 15355327)", "quality_notes": "Peer-reviewed Eur J Neurosci article; note: DOI 10.1111/j.1460-9568.2004.03629.x is a different (dopamine) paper — correct DOI confirmed via PubMed.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "15355327", "fulltext_note": "No free full text: paywalled at the publisher (checked 2026-10-09)" }, { "item_id": "MECH-007", "source_type": "peer-reviewed journal (original research)", "title": "Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis", "authors": [ "Roberto C. Agís-Balboa", "Graziano Pinna", "Adrian Zhubi", "Ekrem Maloku", "Marin Veldic", "Erminio Costa", "Alessandro Guidotti" ], "journal_or_site": "Proceedings of the National Academy of Sciences", "year_or_date": 2006, "doi": "10.1073/pnas.0606544103", "url": "https://doi.org/10.1073/pnas.0606544103", "abstract_or_summary": "Using in situ hybridization combined with neuronal and glial markers, the authors mapped 5α-reductase type I and 3α-hydroxysteroid dehydrogenase — the two enzymes that convert progesterone and deoxycorticosterone into allopregnanolone and THDOC — across mouse and rat brain. Both enzymes colocalize in glutamatergic principal neurons of cortex, hippocampus, and olfactory bulb, and in major GABAergic output neurons, but are absent from glia and cortical interneurons. The study proves the brain manufactures these neurosteroids locally via the type I isoenzyme, independent of peripheral glands.", "system_classification": "neurosteroid signaling", "justification": "Powers' model and the Melcangi group's CSF findings both turn on where neurosteroids are made; this study proves the brain synthesizes allopregnanolone and THDOC locally via 5α-reductase type I, independent of gonads or adrenals. That means finasteride's CNS effects cannot be dismissed as secondary to peripheral DHT loss — and it explains how neurosteroid disruption could survive castration, a specific claim in Powers' theorizing. The type I anatomical map is the essential background for the isoenzyme division of labor shown in MECH-008.", "keywords": [ "5alpha-reductase type I", "SRD5A1", "3alpha-HSD", "neurosteroid biosynthesis", "brain", "allopregnanolone", "THDOC" ], "relevance": "high", "verification_status": "verified: Crossref + OpenAlex", "quality_notes": "Peer-reviewed PNAS article; 341 citations per Crossref; includes Pinna (neurosteroid/PTSD researcher).", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/1600006", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "16984997", "pmcid": "PMC1600006" }, { "item_id": "MECH-008", "source_type": "peer-reviewed journal (original research)", "title": "Prefrontal 5α-reductase 2 mediates male-specific acute stress response", "authors": [ "Roberto Cadeddu", "Giulia Braccagni", "Gabriele Floris", "Caterina Branca", "Eleonora Corridori", "Sara Salviati", "Pilar Sánchez", "Luca Spiro Santovito", "Jesus M. Torres", "Esperanza Ortega", "Graziano Pinna", "Philip J. Moos", "Simona Scheggi", "Marco Bortolato" ], "journal_or_site": "Science Advances", "year_or_date": 2025, "doi": "10.1126/sciadv.adr0563", "url": "https://doi.org/10.1126/sciadv.adr0563", "abstract_or_summary": "Acute stress selectively raises 5α-reductase type 2 — not type 1 — in the medial prefrontal cortex of male rats, and 5αR2 knockdown or knockout blunts the hormonal and behavioral stress response in males only. The authors demonstrate a division of labor: 5αR1 sustains baseline allopregnanolone, while 5αR2 is recruited to boost production under stress; exogenous allopregnanolone rescues the knockdown phenotype. Single-nucleus transcriptomics ties 5αR2 to stress-induced protein translation in neurons and glia. The work reframes the two isoenzymes as functionally distinct rather than redundant in brain.", "system_classification": "neurosteroid signaling", "justification": "This is among the most PFS-relevant isoenzyme papers in recent years: it shows 5αR2 — finasteride's primary target — is the stress-recruited, male-specific driver of prefrontal allopregnanolone synthesis, while 5αR1 maintains baseline. That division maps directly onto what finasteride does and does not disrupt in brain neurosteroidogenesis, and why effects might be sex-specific and stress-gated. Any causal-pathway model involving 5α-reductase inhibition must reckon with this 2025 result.", "keywords": [ "5alpha-reductase type 2", "SRD5A2", "5alpha-reductase type 1", "SRD5A1", "prefrontal cortex", "stress", "allopregnanolone", "sex differences" ], "relevance": "high", "verification_status": "verified: Crossref + OpenAlex (open access, CC-BY-NC)", "quality_notes": "Peer-reviewed Science Advances article (Jan 2025); includes Graziano Pinna; has a bioRxiv preprint (10.1101/2024.05.07.593076).", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.science.org/doi/pdf/10.1126/sciadv.adr0563?download=true", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by-nc", "pmid": "39841836" }, { "item_id": "MECH-009", "source_type": "peer-reviewed journal (review)", "title": "The GABAergic deficit hypothesis of major depressive disorder", "authors": [ "Bernhard Lüscher", "Qiuying Shen", "Nadia Sahir" ], "journal_or_site": "Molecular Psychiatry", "year_or_date": 2011, "doi": "10.1038/mp.2010.120", "url": "https://doi.org/10.1038/mp.2010.120", "abstract_or_summary": "This major review argues that deficits in GABAergic transmission — reduced GABA levels and altered GABA-A receptor subunit expression — play a causal role in major depressive disorder rather than being downstream epiphenomena. It integrates clinical imaging, postmortem, and genetic evidence, and proposes that monoaminergic antidepressants ultimately work by restoring GABAergic function, including via neurosteroid pathways. A dedicated section covers neurosteroid modulation of GABA-A receptors, including stress-induced THDOC/allopregnanolone dynamics and the high-affinity extrasynaptic α4βδ receptors. It provides the clinical depression framework into which THDOC/allopregnanolone dysregulation fits.", "system_classification": "neurosteroid signaling", "justification": "Post-drug syndromes present with prominent depressive and anhedonic features; this review provides the best-supported framework linking those symptoms to GABAergic and neurosteroid dysfunction rather than monoamine deficiency. It legitimizes searching the causal pathway in GABA-A plasticity and neurosteroid tone instead of serotonin, and Powers' excess model is in effect a special case of the dysregulated-inhibition story told here.", "keywords": [ "GABAergic deficit", "major depressive disorder", "GABA-A receptor", "neurosteroid", "THDOC", "allopregnanolone", "alpha4betadelta" ], "relevance": "high", "verification_status": "verified: OpenAlex + PubMed (PMID 21079608) + PMC (PMC3412149)", "quality_notes": "Peer-reviewed Mol Psychiatry review; open via PMC (NIHMS394968); published online 2010, in print Apr 2011.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/3412149", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "21079608", "pmcid": "PMC3412149" }, { "item_id": "MECH-010", "source_type": "peer-reviewed journal (review)", "title": "Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans?", "authors": [ "Shannon K. Crowley", "Susan S. Girdler" ], "journal_or_site": "Psychopharmacology", "year_or_date": 2014, "doi": "10.1007/s00213-014-3572-8", "url": "https://doi.org/10.1007/s00213-014-3572-8", "abstract_or_summary": "Focused on human data, this review surveys how neurosteroids, GABAergic signaling, and the HPA axis regulate each other: allopregnanolone and allo-THDOC act as an allostatic brake that terminates stress-induced HPA activation, and chronic stress degrades this brake. The authors link disrupted neurosteroid–GABA–HPA coupling to vulnerability for depression and stress-related disorders in people, and review what is known about neurosteroid measurements in human plasma, CSF, and brain. It is the human-translation counterpart to the rodent THDOC literature.", "system_classification": "neurosteroid signaling", "justification": "The human-focused counterpart to the rodent THDOC literature: it documents that allopregnanolone/allo-THDOC normally brake the HPA axis and that chronic stress degrades this brake — the feedback-loop architecture Powers' model invokes. For a corpus built partly on patient-reported phenotypes, having the human regulatory physiology in the record matters more than another rodent study. It ties neurosteroid dysregulation to the exact mood-disorder outcomes the corpus tracks.", "keywords": [ "neurosteroid", "HPA axis", "GABA", "allopregnanolone", "THDOC", "human", "depression", "stress" ], "relevance": "high", "verification_status": "verified: Crossref + OpenAlex", "quality_notes": "Peer-reviewed Psychopharmacology review; 105 citations per Crossref; 203 references.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/4135030", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "24756763", "pmcid": "PMC4135030" }, { "item_id": "MECH-011", "source_type": "peer-reviewed journal (original research)", "title": "17β-Hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties", "authors": [ "Angelika Friedel", "Hans Geyer", "Matthias Kamber", "Ute Laudenbach-Leschowsky", "Wilhelm Schänzer", "Mario Thevis", "Günter Vollmer", "Oliver Zierau", "Patrick Diel" ], "journal_or_site": "Toxicology Letters", "year_or_date": 2006, "doi": "10.1016/j.toxlet.2006.03.001", "url": "https://doi.org/10.1016/j.toxlet.2006.03.001", "abstract_or_summary": "The only controlled pharmacology study of dihydroboldenone (1-testosterone, DHB): in castrated rats, equimolar 1-testosterone matched testosterone propionate in stimulating levator ani, ventral prostate, and seminal vesicle growth, with an anabolic/androgenic profile comparable to the reference androgen, while also increasing liver weight. In a yeast androgen-receptor transactivation assay it proved a potent AR agonist without requiring metabolic activation. The authors flag it as a fully active, non-aromatizing anabolic steroid with hepatic effects. Almost nothing else in the peer-reviewed literature characterizes this compound.", "system_classification": "neurosteroid signaling", "justification": "Community members inject DHB, and Powers theorizes it stacks as glucuronidated metabolites when UGT2BXX function is defective; this paper is the only rigorous pharmacology of the parent compound — potency, tissue effects, hepatic activity, AR agonism without metabolic activation. Without it, the corpus would discuss DHB entirely from forum anecdote. It also establishes DHB as a powerful non-aromatizing androgen, relevant to androgen-trapping hypotheses.", "keywords": [ "dihydroboldenone", "DHB", "1-testosterone", "anabolic steroid", "androgen receptor", "Hershberger assay", "pharmacology" ], "relevance": "high", "verification_status": "verified: Crossref + OpenAlex", "quality_notes": "Peer-reviewed Toxicology Letters article; Cologne doping-research group (Schänzer/Thevis); 25 citations per Crossref.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "16621347" }, { "item_id": "MECH-012", "source_type": "peer-reviewed journal (original research)", "title": "Metabolism of boldenone in man: Gas chromatographic/mass spectrometric identification of urinary excreted metabolites and determination of excretion rates", "authors": [ "Wilhelm Schänzer", "Manfred Donike" ], "journal_or_site": "Biological Mass Spectrometry", "year_or_date": 1992, "doi": "10.1002/bms.1200210104", "url": "https://doi.org/10.1002/bms.1200210104", "abstract_or_summary": "The foundational human metabolism study of boldenone: using GC/MS, the authors identified the urinary metabolites of boldenone administration, quantified excretion rates, and characterized the 5α- and 5β-reduced metabolites — the pathways through which dihydroboldenone arises and is cleared as conjugates. It establishes that boldenone-series steroids undergo extensive reductive metabolism with urinary excretion as conjugated metabolites. For Powers' model, it documents the metabolic plumbing: DHB is cleared not as parent drug but as reduced, conjugated metabolites — exactly the pool his glucuronidation-defect hypothesis concerns.", "system_classification": "neurosteroid signaling", "justification": "Powers' glucuronidation-defect model is specifically about metabolite clearance: DHB \"stacks as metabolites\" only if reductive metabolism plus conjugation is the clearance route, and this study proves exactly that for the boldenone series in humans. It identifies which reduced metabolites form and how they are excreted, giving the corpus a concrete metabolic map against which UGT2BXX-deletion claims can be evaluated. It is the metabolic companion to Friedel 2006's pharmacology.", "keywords": [ "boldenone", "dihydroboldenone", "metabolism", "glucuronidation", "GC-MS", "urinary metabolites", "doping" ], "relevance": "medium", "verification_status": "verified: Crossref + OpenAlex", "quality_notes": "Peer-reviewed Biol Mass Spectrom article (1992); 60 citations per Crossref; classic doping-metabolism paper. Note: an incorrect year/DOI (1996, 10.1002/(SICI)...) circulates for this citation — correct DOI confirmed via Crossref.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "1591280" }, { "item_id": "MECH-013", "source_type": "peer-reviewed article", "title": "Major glucuronide metabolites of testosterone are primarily transported by MRP2 and MRP3 in human liver, intestine and kidney", "authors": [ "Cindy Yanfei Li", "Abdul Basit", "Anshul Gupta", "Zsuzsanna Gáborik", "Emese Kis", "Bhagwat Prasad" ], "journal_or_site": "The Journal of Steroid Biochemistry and Molecular Biology", "year_or_date": 2019, "doi": "10.1016/j.jsbmb.2019.03.027", "url": "https://doi.org/10.1016/j.jsbmb.2019.03.027", "abstract_or_summary": "The authors quantified how the four major testosterone glucuronides (testosterone glucuronide, DHT glucuronide, androsterone glucuronide, etiocholanolone glucuronide) are cleared from human liver, intestine, and kidney. Using recombinant transporter vesicles plus quantitative proteomics, they showed MRP2 and MRP3 are the dominant efflux transporters, with MRP2 preferentially handling the glucuronides of active androgens and MRP3 those of inactive ones. Because these glucuronides are excreted into bile, they reach the gut lumen where they can be deconjugated back to active androgen, implicating transporter-driven biliary efflux as a control point for enterohepatic recirculation of androgens.\n", "system_classification": "steroid clearance / glucuronidation", "justification": "Powers' model hinges on how much androgen is actually eliminated versus trapped or recycled, yet clearance is usually discussed only at the UGT-conjugation step. This study fills the missing next step: the transporters that move androgen glucuronides into bile, which is the direct precondition for gut deconjugation and reabsorption. It belongs in the causal-pathway search as the mechanistic bridge between glucuronidation and enterohepatic androgen recycling.\n", "keywords": [ "testosterone glucuronide", "MRP2", "MRP3", "enterohepatic recirculation", "androgen clearance", "biliary excretion" ], "relevance": "high", "verification_status": "verified (OpenAlex + PubMed PMID 30959153; PMC7075494)", "quality_notes": "Peer-reviewed original research; 73 citations; LC-MS/MS proteomics plus vesicular transport assays. Cited in the top 10% percentile for its field.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/7075494", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "30959153", "pmcid": "PMC7075494" }, { "item_id": "MECH-014", "source_type": "peer-reviewed conference abstract", "title": "Novel mechanisms of testosterone detoxification in UGT2B17 gene deletion carriers and androgen activation by gut microbiome", "authors": [ "Abdul Basit", "John Amory", "Cindy Li", "Vijay Mettu", "Scott Heyward", "Parth B. Jariwala", "Matthew R. Redinbo", "Bhagwat Prasad" ], "journal_or_site": "The FASEB Journal (Experimental Biology meeting abstract)", "year_or_date": 2021, "doi": "10.1096/fasebj.2021.35.S1.02546", "url": "https://doi.org/10.1096/fasebj.2021.35.S1.02546", "abstract_or_summary": "Proteomic comparison of human livers from UGT2B17 deletion carriers versus high expressors found upregulation of alternative steroid-metabolizing pathways (AKR1D1, AKR1C4, and related dehydrogenases/alcohol dehydrogenases) in deletion carriers, redirecting testosterone toward inactive 5beta metabolites whose glucuronidation depends on UGT2B7. Separately, incubating testosterone glucuronide with purified bacterial beta-glucuronidases and human fecal extracts showed ready but variable deconjugation back to active testosterone. The work identifies compensatory detoxification routes in deletion carriers and directly demonstrates microbial reactivation of a conjugated androgen.\n", "system_classification": "steroid clearance / glucuronidation", "justification": "This is the closest published work to Powers' UGT2BXX-as-risk-modifier theorizing: it asks what the body does differently when UGT2B17 is absent and finds a metabolic rerouting strategy rather than collapse. The same study then shows the gut microbiome can undo that clearance by regenerating testosterone from its glucuronide. It belongs in the corpus because it simultaneously advances the \"risk modifier\" genetics angle and the gut-deconjugation angle Powers threads together.\n", "keywords": [ "UGT2B17", "gene deletion", "AKR1D1", "AKR1C4", "bacterial beta-glucuronidase", "testosterone reactivation" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref DOI record; Wiley/FASEB listing)", "quality_notes": "Meeting abstract, not a full paper — brief methods and no peer-review at full-paper depth. Authors overlap with the Li 2019 study and include Matthew Redinbo (estrobolome group). Flag as abstract-level evidence.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review" }, { "item_id": "MECH-015", "source_type": "peer-reviewed review", "title": "The testobolome in microbial testosterone metabolism and human health", "authors": [ "Liisa Veerus", "Anushka Subrahmanian", "Martin J. Blaser" ], "journal_or_site": "npj Biofilms and Microbiomes", "year_or_date": 2026, "doi": "10.1038/s41522-025-00861-0", "url": "https://doi.org/10.1038/s41522-025-00861-0", "abstract_or_summary": "This review proposes the \"testobolome\" — the collection of gut microbial genes and pathways that metabolize testosterone — as the androgen counterpart of the estrobolome. It traces testosterone from endogenous and exogenous sources through hepatic phase I/II metabolism to bile, then describes how luminal microbes deconjugate and structurally modify conjugated hormones, reactivating bioactive steroids that are reabsorbed into enterohepatic recirculation. The authors argue that only liver and intestine meaningfully contribute to testosterone reabsorption and map how microbial processes can raise or lower systemic sex-steroid levels.\n", "system_classification": "gut-brain axis", "justification": "The corpus has the estrobolome concept for estrogens; this 2026 review is the androgen-side counterpart and therefore the more relevant term for PFS, which centers on androgen signaling. It gives the corpus a single citable anchor for \"gut microbes recycle testosterone,\" a mechanism Powers' metabolite-pileup framing implicitly requires. Open-access (CC-BY).\n", "keywords": [ "testobolome", "testosterone", "enterohepatic recirculation", "gut microbiota", "deconjugation", "microbial steroid metabolism" ], "relevance": "high", "verification_status": "verified (OpenAlex + nature.com record; open-access full text)", "quality_notes": "Peer-reviewed review, open-access, from the Blaser group. 2026 publication means citation history is short, but the synthesis is current and directly on-axis.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.nature.com/articles/s41522-025-00861-0.pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "41513699" }, { "item_id": "MECH-016", "source_type": "peer-reviewed article", "title": "Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens", "authors": [ "Samantha M. Ervin", "Hao Li", "Lauren Lim", "Lee R. Roberts", "Xue Liang", "Sridhar Mani", "Matthew R. Redinbo" ], "journal_or_site": "Journal of Biological Chemistry", "year_or_date": 2019, "doi": "10.1074/jbc.ra119.010950", "url": "https://doi.org/10.1074/jbc.ra119.010950", "abstract_or_summary": "The authors isolated and characterized beta-glucuronidase enzymes from human gut bacteria and tested their ability to deconjugate estrone-3-glucuronide and estradiol-17-glucuronide. Several gut microbial glucuronidases efficiently cleaved these conjugates, regenerating free estrone and estradiol capable of re-entering circulation. The study provided the first enzyme-level evidence for the estrobolome concept: that specific microbial enzymes, not just bulk fecal activity, determine how much estrogen the host excretes versus reabsorbs.\n", "system_classification": "gut-brain axis", "justification": "This is the primary-data paper behind the estrobolome claim that the corpus's reviews cite. Powers' background model asserts that gut bacterial enzymes \"undo hormone clearance\" — this study is the concrete experimental demonstration of exactly that, at the enzyme level, for estrogen glucuronides. It earns its place as the mechanistic anchor for all enterohepatic-recycling claims in the corpus. Open-access (CC-BY).\n", "keywords": [ "estrobolome", "beta-glucuronidase", "estrogen reactivation", "deconjugation", "enterohepatic recirculation" ], "relevance": "high", "verification_status": "verified (OpenAlex + jbc.org/PMC full text, PMC6901331)", "quality_notes": "Peer-reviewed original research, widely cited, open-access. Experimental enzymology with human gut-derived enzymes — strong mechanistic evidence.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "http://www.jbc.org/article/S0021925820304130/pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "31636122" }, { "item_id": "MECH-017", "source_type": "peer-reviewed article", "title": "Industrialization increases the estrogen-recycling capacity of the gut microbiome", "authors": [ "Rebecca S. A. Brittain", "Richard G. Bribiescas", "Grażyna Jasienska" ], "journal_or_site": "Proceedings of the National Academy of Sciences", "year_or_date": 2026, "doi": "10.1073/pnas.2523589123", "url": "https://doi.org/10.1073/pnas.2523589123", "abstract_or_summary": "Comparing gut metagenomes across industrialized and non-industrialized populations, the authors found that industrialization is associated with a higher microbial capacity to recycle estrogens — more bacterial beta-glucuronidase genes and greater predicted estrogen reactivation. They note that up to 65% of estradiol and 48% of estrone are excreted in bile while only 10–15% of estrogens are recovered in feces, implying substantial host reabsorption. Formula feeding and industrialized lifestyles emerged as factors shaping this recycling capacity, with implications for estrogen exposure, reproductive biology, and estrogen-linked disease risk.\n", "system_classification": "gut-brain axis", "justification": "This paper quantifies the recycling loop in human populations and shows that the gut's deconjugation capacity is a variable trait — one that differs between people by lifestyle history. For a corpus concerned with individual susceptibility in post-drug syndromes, that variability matters: the same biliary steroid load can yield different systemic exposure depending on a person's microbiome. It also supplies the bile-versus-feces recovery numbers that make the recycling argument quantitative. Open-access (CC-BY-NC-ND).\n", "keywords": [ "estrobolome", "industrialization", "estrogen recycling", "beta-glucuronidase", "biliary excretion", "enterohepatic circulation" ], "relevance": "medium-high", "verification_status": "verified (OpenAlex + pnas.org record; open-access full text)", "quality_notes": "Peer-reviewed, 2026 PNAS article; metagenomic analysis across populations. Causal claims about lifestyle factors remain correlational.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.pnas.org/doi/pdf/10.1073/pnas.2523589123", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc-nd", "pmid": "41973926" }, { "item_id": "MECH-018", "source_type": "peer-reviewed review", "title": "Potential use of d-glucaric acid derivatives in cancer prevention", "authors": [ "Z. Walaszek" ], "journal_or_site": "Cancer Letters", "year_or_date": 1990, "doi": "10.1016/0304-3835(90)90083-a", "url": "https://doi.org/10.1016/0304-3835(90)90083-a", "abstract_or_summary": "This review summarizes the Walaszek group's research program on D-glucaric acid (calcium D-glucarate) as a chemopreventive agent. The central mechanism is that D-glucaro-1,4-lactone, the active metabolite, inhibits beta-glucuronidase, the enzyme that deconjugates glucuronidated compounds in the gut and liver and thereby allows their reabsorption. Animal work reviewed here showed that dietary glucarate reduced serum estradiol and 17-ketosteroid precursors (androgen metabolites), consistent with increased excretion of conjugated steroid hormones rather than their recycling.\n", "system_classification": "steroid clearance / glucuronidation", "justification": "Calcium-D-glucarate is the treatment candidate Powers threads through his beta-glucuronidase theory: block the enzyme, and glucuronidated steroids get excreted instead of deconjugated and reabsorbed. This review is the canonical peer-reviewed summary of that mechanism, including the animal evidence that glucarate administration lowers circulating estradiol and androgen-derived steroid precursors. Recorded here strictly as a mechanistic research record, not a recommendation.\n", "keywords": [ "calcium D-glucarate", "D-glucaro-1,4-lactone", "beta-glucuronidase inhibition", "steroid excretion", "estradiol", "17-ketosteroids" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref record; Medline-indexed)", "quality_notes": "Peer-reviewed review of a sustained research program. Human data remain limited (the review's steroid data are animal and in-vitro); later reviews (e.g., Alternative Medicine Review 2002 monograph) repeat the 23% rat estradiol figure without new human trials.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "2208084" }, { "item_id": "MECH-019", "source_type": "peer-reviewed article", "title": "SULT2A1 Gene Copy Number Variation is Associated with Urinary Excretion Rate of Steroid Sulfates", "authors": [ "Jenny Jakobsson Schulze", "Maria Johansson", "John-Olof Thörngren", "Mats Garle", "Anders Rane", "Lena Ekström" ], "journal_or_site": "Frontiers in Endocrinology", "year_or_date": 2013, "doi": "10.3389/fendo.2013.00088", "url": "https://doi.org/10.3389/fendo.2013.00088", "abstract_or_summary": "In healthy volunteers given exogenous testosterone, the authors tested whether copy-number variation in sulfotransferase genes predicted urinary excretion of steroid sulfates. SULT2A1 copy number was significantly associated with excretion rates of sulfate metabolites: carriers of fewer gene copies excreted less of the sulfated androgens, and testosterone-sulfate and DHEA-sulfate levels tracked genotype even at the low concentrations seen after exogenous testosterone dosing. The study provides in-vivo evidence that SULT2A1 gene dosage controls androgen clearance through the sulfation route.\n", "system_classification": "steroid clearance / glucuronidation", "justification": "Powers' glucuronidation discussion tends to center on UGT enzymes, but sulfation (SULT2A1) is the parallel clearance route for androgens — and it too varies by gene copy number. This human in-vivo study is the exact counterpart of the UGT2B17-deletion logic in the corpus: clearance genotype predicts how fast steroid metabolites leave the body. It belongs here because a complete causal-pathway map must include both conjugation systems, and it surfaces another genetically variable clearance node.\n", "keywords": [ "SULT2A1", "copy number variation", "sulfation", "testosterone sulfate", "DHEA sulfate", "urinary excretion", "androgen clearance" ], "relevance": "high", "verification_status": "verified (OpenAlex + frontiersin.org record; open-access full text)", "quality_notes": "Peer-reviewed original human study, open-access. Small sample (only seven individuals with one gene copy), so the genotype association for some metabolites lacked statistical power; authors flag this explicitly.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.frontiersin.org/articles/10.3389/fendo.2013.00088/pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "23874324" }, { "item_id": "MECH-020", "source_type": "peer-reviewed article", "title": "Gut bacteria convert glucocorticoids into progestins in the presence of hydrogen gas", "authors": [ "Megan D. McCurry", "Gabriel D. D'Agostino", "Jasmine T. Walsh", "Jordan E. Bisanz", "María Inés Zalosnik", "Xueyang Dong", "David J. Morris", "Joshua R. Korzenik", "Andrea G. Edlow", "Emily P. Balskus", "Peter James Turnbaugh", "Jun R. Huh", "A. Sloan Devlin" ], "journal_or_site": "Cell", "year_or_date": 2024, "doi": "10.1016/j.cell.2024.05.005", "url": "https://doi.org/10.1016/j.cell.2024.05.005", "abstract_or_summary": "Two human gut bacteria, Gordonibacter pamelaeae and Eggerthella lenta, were found to convert abundant biliary corticoids into progestins via 21-dehydroxylation — the chemical reverse of how human cells make steroids. The responsible bacterial gene cluster was identified by comparative and functional genomics, and commensal hydrogen-gas production was shown to promote the reaction. In pregnant human fecal samples, levels of bacterial progestins including allopregnanolone were substantially elevated. The authors propose the microbiome functions as an additional endocrine organ interconverting steroid classes.\n", "system_classification": "gut-brain axis", "justification": "This is the strongest primary-data paper for the microbiome–neurosteroid link in the corpus: gut bacteria were shown to manufacture allopregnanolone, the same neurosteroid the Melcangi group has repeatedly implicated in finasteride's long-term CNS effects. It reframes the gut not merely as a steroid recycler but as a net producer of neuroactive steroids, which belongs in both the causal-pathway search (a second neurosteroid source that finasteride withdrawal might perturb) and the treatment-candidate landscape.\n", "keywords": [ "allopregnanolone", "21-dehydroxylation", "Gordonibacter pamelaeae", "Eggerthella lenta", "progestins", "neurosteroids", "hydrogen gas" ], "relevance": "high", "verification_status": "verified (OpenAlex + sciencedirect.com listing; Cell publication)", "quality_notes": "Peer-reviewed original research in Cell; gene-cluster identification plus human pregnancy fecal data. Human quantitative relevance of the bacterial contribution outside pregnancy is not yet established.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "http://www.cell.com/article/S0092867424005142/pdf", "fulltext_source": "publisher OA", "oa_status": "bronze", "oa_license": "", "pmid": "38795705" }, { "item_id": "MECH-021", "source_type": "peer-reviewed article", "title": "Lower serum oestrogen concentrations associated with faster intestinal transit", "authors": [ "S. J. Lewis", "K. W. Heaton", "R. E. Oakey", "H. H. G. McGarrigle" ], "journal_or_site": "British Journal of Cancer", "year_or_date": 1997, "doi": "10.1038/bjc.1997.397", "url": "https://doi.org/10.1038/bjc.1997.397", "abstract_or_summary": "Forty healthy premenopausal volunteers were randomized to senna, loperamide, or wheat bran across menstrual cycles while whole-gut transit time, fecal beta-glucuronidase activity, stool pH, and serum estrogens were measured. Speeding transit with senna lowered serum oestrone sulphate and total and non-protein-bound oestrone, with wheat bran showing a similar trend; slowing transit with loperamide produced no significant change. The authors concluded that faster intestinal transit reduces serum estrogen concentrations, consistent with less time for colonic reabsorption of deconjugated estrogens.\n", "system_classification": "gut-brain axis", "justification": "Powers' background material treats transit time as a lever on steroid exposure, and the corpus already holds a transit-time review — this 1997 human intervention is the primary study behind it and makes the link experimental rather than theoretical. It earns its place because it shows that a mundane gut parameter (transit speed) measurably changes circulating steroid levels, exactly the kind of individually variable exposure factor the causal-pathway search needs.\n", "keywords": [ "intestinal transit time", "serum oestrogen", "reabsorption", "beta-glucuronidase", "senna", "constipation" ], "relevance": "medium-high", "verification_status": "verified (OpenAlex + nature.com record; open-access PDF available)", "quality_notes": "Peer-reviewed human intervention study, small sample (n=40). Fecal beta-glucuronidase activity did not change significantly, so the mechanism is inferred from transit-time effects rather than demonstrated directly.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://europepmc.org/articles/PMC2224051", "fulltext_source": "PMC", "oa_license": "", "pmid": "9252210", "fulltext_note": "Link updated 2026-10-09: the publisher PDF is not free; a scanned copy is free on Europe PMC" }, { "item_id": "MECH-022", "source_type": "peer-reviewed article", "title": "Exploring the Impact of the Microbiome on Neuroactive Steroid Levels in Germ-Free Animals", "authors": [ "Silvia Diviccaro", "Valentina Caputi", "Lucia Cioffi", "Silvia Giatti", "Joshua M. Lyte", "Donatella Caruso", "Siobhain M. O'Mahony", "Roberto Cosimo Melcangi" ], "journal_or_site": "International Journal of Molecular Sciences", "year_or_date": 2021, "doi": "10.3390/ijms222212551", "url": "https://doi.org/10.3390/ijms222212551", "abstract_or_summary": "Using LC-MS/MS, the authors measured neuroactive steroids in brain regions and plasma of germ-free male mice versus conventionally colonized controls. The absence of microbes shifted neuroactive steroid profiles in both compartments: plasma allopregnanolone rose while 3alpha-diol fell, hippocampal DHT and 3alpha-diol changed, hypothalamic DHEA rose as testosterone fell, and several brain regions showed altered dihydroprogesterone and isoallopregnanolone levels. The findings demonstrate that gut microbes modulate the neuroendocrine pathways that maintain neuroactive steroid levels in the brain, not just in the periphery.\n", "system_classification": "gut-brain axis", "justification": "The Melcangi group is the corpus's central PFS neurosteroid laboratory; this paper extends their work from drug effects to the microbiome itself, showing that removing gut microbes reshapes brain allopregnanolone, DHT, and 3alpha-diol — the exact steroids implicated in PFS and PSSD. It is the in-corpus group's own evidence that the gut-brain axis is a neurosteroid axis, tying the axis to the corpus's existing Melcangi cluster. Open-access.\n", "keywords": [ "germ-free mice", "neuroactive steroids", "allopregnanolone", "dihydrotestosterone", "3alpha-diol", "gut-brain axis", "Melcangi" ], "relevance": "high", "verification_status": "verified (OpenAlex + mdpi.com record; open-access full text)", "quality_notes": "Peer-reviewed original research from the Melcangi group (author overlap with corpus's existing PFS neurosteroid studies). Animal study (germ-free mice); human translation not established.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.mdpi.com/1422-0067/22/22/12551/pdf?version=1637568751", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "34830433" }, { "item_id": "MECH-025", "source_type": "journal article", "title": "Central 5-alpha reduction of testosterone is required for testosterone's inhibition of the hypothalamo-pituitary–adrenal axis response to restraint stress in adult male rats", "authors": [ "Handa RJ", "Kudwa AE", "Donner NC", "McGivern RF", "Brown R" ], "journal_or_site": "Brain Research", "year_or_date": 2013, "doi": "10.1016/j.brainres.2013.07.021", "url": "https://doi.org/10.1016/j.brainres.2013.07.021", "abstract_or_summary": "In adult male rats, removal of the gonads amplified both ACTH and corticosterone responses to restraint stress within 48 hours, and testosterone replacement restored the normal stress response. Treating intact males with finasteride for 48 hours produced the same exaggerated stress-hormone response as gonadectomy, showing that blocking 5α-reduction disinhibits the HPA axis. Testosterone's calming effect on the stress response was abolished when finasteride was delivered directly into the brain's third ventricle, whereas the non-aromatizable androgen DHT still suppressed stress responses regardless. The findings indicate that testosterone must be converted to DHT inside the central nervous system to restrain HPA reactivity.", "system_classification": "hormonal axes", "justification": "This is the most direct mechanistic bridge between finasteride and HPA-axis dysregulation: central 5α-reductase blockade is sufficient to disinhibit the stress axis in a mammalian brain. It gives the hormonal-axes axis a concrete published mechanism for how 5AR inhibition can leave a lasting neuroendocrine scar — the kind of axis-level injury consistent with Powers' HPA-shutdown protocol theorizing and with Melcangi-group reports of persistent neurosteroid disruption after drug withdrawal. It also explains why restoring circulating testosterone alone might not normalize a stress axis whose central DHT-dependent brake has been altered.", "keywords": [ "HPA axis", "5-alpha reductase", "finasteride", "testosterone", "DHT", "stress response", "ACTH", "corticosterone" ], "relevance": "high", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed journal article (Brain Research, vol 1529, pp 74-82). Indexed in PubMed (PMID 23880372). Animal model (male rat) — mechanistic, not clinical.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/3970437", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "23880372", "pmcid": "PMC3970437" }, { "item_id": "MECH-026", "source_type": "journal article", "title": "Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer", "authors": [ "Branigan GL", "Torrandell-Haro G", "Soto M", "Gelmann EP", "Vitali F", "Rodgers KE", "Diaz Brinton R" ], "journal_or_site": "Cancer Medicine", "year_or_date": 2022, "doi": "10.1002/cam4.4650", "url": "https://doi.org/10.1002/cam4.4650", "abstract_or_summary": "A retrospective cohort analysis of roughly 1.8 million men with prostate cancer in a US claims database (about 210,000 meeting inclusion criteria, ~6.4 years mean follow-up) examined how different classes of androgen-targeting drugs related to neurodegenerative disease risk. GnRH agonist monotherapy was linked to a substantially elevated risk of any neurodegenerative disease (relative risk about 1.47), while co-treatment with abiraterone lowered the Alzheimer's and Parkinson's risk conferred by GnRH agonists, and androgen receptor inhibitors reduced ALS risk. The authors propose that GnRH analogs cross the blood–brain barrier and disturb stage-specific GnRH/LH signaling in the brain, making the GnRH-axis disruption itself — not just low testosterone — a driver of neurological risk.", "system_classification": "hormonal axes", "justification": "Powers' unpublished theorizing places GnRH-axis manipulation (relugolix as an oral GnRH antagonist \"castration trial,\" HPA-shutdown protocol) at the center of his current model, and this paper gives that move published company: it argues GnRH analogs act directly in the brain via GnRH/LH receptor signaling, with cognitive consequences beyond testosterone suppression. That is the closest peer-reviewed analog to the claim that manipulating the HPG axis is itself a neurological intervention. It also predicts the relugolix-trial pattern Powers describes — restoring androgenic signaling may not rescue symptoms if the GnRH/LH signaling disruption is a separate pathogenic axis.", "keywords": [ "GnRH agonist", "GnRH antagonist", "neurodegenerative disease", "androgen deprivation therapy", "LH signaling", "blood-brain barrier", "Alzheimer", "Parkinson" ], "relevance": "high", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed journal article (Cancer Medicine, vol 11, pp 2687-2698). Large retrospective claims cohort with propensity-score matching; observational, so residual confounding possible. Open access (CC-BY).", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://europepmc.org/articles/PMC9249980", "fulltext_source": "PMC", "oa_status": "gold", "oa_license": "cc-by", "pmid": "35293700", "pmcid": "PMC9249980" }, { "item_id": "MECH-027", "source_type": "review", "title": "Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood", "authors": [ "Reiss AB", "Gulkarov S", "Pinkhasov A", "Sheehan KM", "Srivastava A", "De Leon J", "Katz AE" ], "journal_or_site": "Medicina", "year_or_date": "2023-12-30", "doi": "10.3390/medicina60010077", "url": "https://doi.org/10.3390/medicina60010077", "abstract_or_summary": "This review surveys how androgen deprivation therapy affects cognition, mood, and quality of life in prostate cancer patients. It reports physiological correlates of ADT including reduced white-matter integrity and impaired hypothalamic function from testosterone lowering or androgen-receptor blockade, and notes that comparative gene analysis found more than 30 genes shared between ADT-treated prostate cancer patients and Alzheimer's patients, suggesting overlapping mechanistic ground. The authors walk through neurocognitive testing evidence and call for deeper study of the links between hormonal disruption, cognitive deficits, and mood disturbance.", "system_classification": "hormonal axes", "justification": "ADT is the cleanest human parallel to pharmacologic androgen silencing, and this review documents its central phenotype: cognitive decline plus mood disturbance, with structural and molecular correlates — a direct precedent for treating PFS/PSSD brain fog and anhedonia as consequences of androgen signaling loss rather than as separate psychiatric entities. The shared-gene signal with Alzheimer's disease also gives the corpus a mechanistic hook for why androgen-axis disruption converges on neurocognitive pathology. It is the anchor record for the \"androgen-silencing parallel\" in this axis.", "keywords": [ "androgen deprivation therapy", "cognitive function", "mood", "depression", "Alzheimer", "white matter", "hypothalamus", "androgen receptor" ], "relevance": "high", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed review (Medicina, vol 60, p 77). Open access (MDPI). Narrative review rather than systematic; gene-overlap analysis is comparative and hypothesis-generating.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.mdpi.com/1648-9144/60/1/77/pdf?version=1703921780", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "38256338" }, { "item_id": "MECH-028", "source_type": "journal article", "title": "Effects of Androgen Deprivation on Cerebral Morphometry in Prostate Cancer Patients – An Exploratory Study", "authors": [ "Chao HH", "Hu S", "Ide JS", "Uchio E", "Zhang S", "Rose M", "Concato J", "Li CS R" ], "journal_or_site": "PLoS ONE", "year_or_date": 2013, "doi": "10.1371/journal.pone.0072032", "url": "https://doi.org/10.1371/journal.pone.0072032", "abstract_or_summary": "This exploratory neuroimaging study compared brain morphometry in prostate cancer patients receiving androgen deprivation therapy against matched controls. ADT was associated with reduced gray-matter volumes in frontal and prefrontal cortical structures, and shrinkage of the primary motor cortex tracked with slower response times on an N-back target-detection task. The authors conclude that androgen deprivation can measurably remodel cerebral structures involved in cognitive control and motor processing, even when standard behavioral tests show only variable effects.", "system_classification": "hormonal axes", "justification": "This is the structural-brain counterpart to the ADT cognitive review: it shows androgen silencing producing gray-matter loss in prefrontal regions — a physical substrate for the brain-fog/cognitive-slowing phenotype. It directly supports the task's framing that central symptoms demand a central explanation, and it gives the corpus an imaging-level precedent for androgen signaling as a maintenance factor for adult cortical structure. Exploratory and small, but the morphometry-behavior correlation (motor cortex volume vs. response time) is the kind of objective finding the post-drug-syndrome field lacks.", "keywords": [ "androgen deprivation therapy", "cerebral morphometry", "gray matter", "prefrontal cortex", "N-back", "neuroimaging", "cognitive control" ], "relevance": "moderate", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed journal article (PLoS ONE, vol 8, e72032). Exploratory design, small sample; open access. Findings are correlational and need replication.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0072032&type=printable", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "23977199" }, { "item_id": "MECH-029", "source_type": "journal article", "title": "Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy", "authors": [ "Dai B", "Qu YY", "Kong YY", "Ye DW", "Yao XD", "Zhang SL", "Zhang HL", "Yang WY" ], "journal_or_site": "Asian Journal of Andrology", "year_or_date": 2013, "doi": "10.1038/aja.2012.169", "url": "https://doi.org/10.1038/aja.2012.169", "abstract_or_summary": "Ninety-five men with localized prostate cancer who completed 9 months of adjuvant androgen deprivation after prostatectomy had testosterone measured at cessation and at 1, 3, 6, 9, and 12 months afterward. Nearly all patients (97.9%) had recovered past castrate levels by 3 months, but only 36.9% had reached normal testosterone at that point; the proportion reaching normal levels rose to 66.3% at 6 months, 86.3% at 9 months, and 92.6% at 12 months. A higher baseline testosterone (≥300 ng/dL) predicted faster normalization. The study establishes that HPG-axis restart after medical castration is a slow, months-long process rather than an immediate rebound.", "system_classification": "hormonal axes", "justification": "This is the canonical quantitative record of HPG-axis restart kinetics after medical castration: even with only 9 months of ADT, a meaningful fraction of men took a full year to normalize testosterone. It sets the recovery timeline against which post-drug-syndrome persistence can be judged — symptoms that outlast this restart window point to something beyond simple testosterone recovery, which is exactly the logic of Powers' theorizing that persistent central symptoms survive restored peripheral androgen signaling. It also documents baseline testosterone as a recovery predictor, relevant to any treatment-candidate protocol that involves HPG-axis restart.", "keywords": [ "HPG axis restart", "testosterone recovery", "androgen deprivation therapy", "medical castration", "kinetics", "baseline testosterone" ], "relevance": "high", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed journal article (Asian Journal of Andrology, vol 15, pp 466-470). Prospective cohort design; single-center (China), 95 patients.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "http://www.asiaandro.com/news/upload/20130913-aja2012169a.pdf", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by-nc-sa", "pmid": "23708460" }, { "item_id": "MECH-030", "source_type": "review", "title": "Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients", "authors": [ "Wu LM", "Amidi A" ], "journal_or_site": "Current Opinion in Supportive & Palliative Care", "year_or_date": 2017, "doi": "10.1097/spc.0000000000000251", "url": "https://doi.org/10.1097/spc.0000000000000251", "abstract_or_summary": "This review compares cognitive effects of hormone therapy in breast cancer (estrogen blockade) and prostate cancer (androgen blockade) populations. It emphasizes that estrogen and androgen receptors are densely distributed in memory-relevant brain regions such as the hippocampus and cortex, and that testosterone reaches the brain both directly and via local conversion — 5α-reduction to DHT or aromatization to estradiol, which is itself neuroprotective and regulates synaptic plasticity and neurogenesis. The authors argue that disrupting sex-steroid signaling in either sex can impair cognition, and they flag shortcomings in the existing literature while proposing research directions.", "system_classification": "hormonal axes", "justification": "This is the axis's receptor-level record: androgen and estrogen receptors in the hippocampus and cortex make the brain a direct target of androgen-axis disruption, not just a downstream casualty of low circulating testosterone. Its explicit discussion of testosterone's dual brain fate — conversion to DHT by 5α-reductase or to estradiol by aromatase — ties the hormonal-axes axis back to 5AR (the finasteride target) and to the Melcangi-group theme of altered neuroactive-steroid signaling in the brain. It also provides the rationale for why manipulating steroid synthesis enzymes, not just replacing testosterone, is the mechanistically interesting treatment-candidate space.", "keywords": [ "androgen receptor", "estrogen receptor", "brain", "hippocampus", "cognition", "aromatase", "5-alpha reductase", "hormone therapy", "neuroprotection" ], "relevance": "moderate", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed review (Current Opinion in Supportive & Palliative Care, vol 11, pp 38-45). Concise opinion-style review; only two authors.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/5297865", "fulltext_source": "PMC", "oa_status": "gold", "oa_license": "other-oa", "pmid": "27926544", "pmcid": "PMC5297865" }, { "item_id": "MECH-031", "source_type": "journal article", "title": "A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β", "authors": [ "Iliff JJ", "Wang M", "Liao Y", "Plogg BA", "Peng W", "Gundersen GA", "Benveniste H", "Vates GE", "Deane R", "Goldman SA", "Nagelhus EA", "Nedergaard M" ], "journal_or_site": "Science Translational Medicine", "year_or_date": 2012, "doi": "10.1126/scitranslmed.3003748", "url": "https://doi.org/10.1126/scitranslmed.3003748", "abstract_or_summary": "Using in vivo two-photon imaging in mice, the authors traced cerebrospinal fluid entering the brain along channels surrounding penetrating arteries, bounded by astrocytic endfeet, and exchanging with interstitial fluid to carry solutes — including amyloid-β — out through perivenous routes. This convective exchange was shown to depend on aquaporin-4 water channels on astrocytes; genetic deletion of AQP4 markedly slowed solute clearance. The paper named this brain-wide waste-clearance network the glymphatic system and positioned it as the brain's missing lymphatic equivalent.", "system_classification": "glymphatic / brain clearance", "justification": "The foundational record for the entire brain-clearance axis: without the glymphatic discovery, the hypothesis that central symptoms persist because of failed brain waste clearance has no mechanism. It identifies AQP4 — an astrocyte protein — as the molecular linchpin of clearance, which makes astroglial dysfunction a legitimate causal-pathway candidate for persistent brain fog and anhedonia after drug withdrawal. Every downstream glymphatic claim in this axis rests on this paper.", "keywords": [ "glymphatic system", "AQP4", "cerebrospinal fluid", "interstitial fluid", "amyloid-beta", "astrocytes", "brain waste clearance" ], "relevance": "high", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed journal article (Science Translational Medicine, vol 4, issue 147). Landmark paper; very highly cited (~5,700 citations per OpenAlex). Mouse model — mechanistic foundation.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/3551275", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "22896675", "pmcid": "PMC3551275" }, { "item_id": "MECH-032", "source_type": "journal article", "title": "Sleep Drives Metabolite Clearance from the Adult Brain", "authors": [ "Xie L", "Kang H", "Xu Q", "Chen MJ", "Liao Y", "Thiyagarajan M", "O'Donnell J", "Christensen DJ", "Nicholson C", "Iliff JJ", "Takano T", "Deane R", "Nedergaard M" ], "journal_or_site": "Science", "year_or_date": 2013, "doi": "10.1126/science.1241224", "url": "https://doi.org/10.1126/science.1241224", "abstract_or_summary": "Comparing awake and sleeping states in the same mice with two-photon imaging, the authors found that the brain's interstitial space expands by roughly 60% during sleep, enabling a sharp increase in convective exchange between cerebrospinal fluid and interstitial fluid. Metabolic waste products of neural activity — including β-amyloid — were cleared about twice as fast in the sleeping brain as in the awake brain. The study supplied a mechanistic explanation for sleep's restorative function beyond memory consolidation.", "system_classification": "glymphatic / brain clearance", "justification": "Sleep disturbance is a near-universal feature of post-drug syndromes, and this paper turns that complaint into a clearance-failure mechanism: poor sleep means the brain's interstitial space never opens for its nightly waste wash. If glymphatic failure is a persistence mechanism for brain fog and anhedonia, then the sleep disruption seen in PFS/PSSD is not just a symptom but part of the causal loop — which also makes sleep quality a mechanistically grounded treatment-candidate target (research-only framing). It is the second pillar of the axis alongside Iliff 2012.", "keywords": [ "sleep", "metabolite clearance", "interstitial space", "glymphatic system", "beta-amyloid", "brain fog", "anhedonia" ], "relevance": "high", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed journal article (Science, vol 342, pp 373-377). Landmark; very highly cited (~5,000 citations per Crossref/OpenAlex). Mouse model.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/3880190", "fulltext_source": "PMC", "oa_status": "green", "oa_license": "", "pmid": "24136970", "pmcid": "PMC3880190" }, { "item_id": "MECH-033", "source_type": "review", "title": "The Glymphatic System (En)during Inflammation", "authors": [ "Mogensen FL", "Delle C", "Nedergaard M" ], "journal_or_site": "International Journal of Molecular Sciences", "year_or_date": 2021, "doi": "10.3390/ijms22147491", "url": "https://doi.org/10.3390/ijms22147491", "abstract_or_summary": "This review maps the two-way relationship between neuroinflammation and the glymphatic system. Inflammatory states impair glymphatic flow through perivascular immune-cell accumulation, mislocalization of AQP4 away from astrocytic endfeet (loss of vascular polarity), and reactive changes in astrocytes and microglia. In turn, the resulting buildup of waste and cytokines further drives inflammation, suppresses glymphatic transport, and promotes tissue swelling — a self-reinforcing vicious cycle. The authors highlight astrocytic AQP4 polarization as a dynamic, potentially reversible control point rather than fixed structural damage.", "system_classification": "glymphatic / brain clearance", "justification": "This paper supplies the persistence mechanism the axis needs: a self-sustaining neuroinflammation–glymphatic loop that can keep running after the triggering drug is long gone, producing exactly the chronic central symptoms (brain fog, anhedonia) that outlast hormonal recovery. It dovetails with Powers' unpublished theorizing that persistent central symptoms require a central explanation beyond circulating hormone levels, and with the Melcangi-group theme of chronic neuroinflammation as a PFS/PSSD feature. The emphasis on AQP4 polarization as reversible also keeps a therapeutic door open (research-only) for clearance-restoring interventions.", "keywords": [ "glymphatic system", "neuroinflammation", "AQP4 polarization", "astrocytes", "microglia", "perivascular space", "vicious cycle" ], "relevance": "high", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed review (Int J Mol Sci, vol 22, p 7491). From the Nedergaard group that discovered the glymphatic system. Open access.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://europepmc.org/articles/PMC8305763", "fulltext_source": "PMC", "oa_status": "gold", "oa_license": "cc-by", "pmid": "34299111", "pmcid": "PMC8305763" }, { "item_id": "MECH-034", "source_type": "review", "title": "Glymphatic System Dysfunction in Central Nervous System Diseases", "authors": [ "Zahran A", "Abu-Khazneh O", "Bdair M", "Hajjeh O", "AbuBaha M", "Shehadeh W", "Awashra A", "Alazizi I", "Fuqha R", "Saife S", "Fuqha H", "Milhem F", "Hamshary H", "Abuzahra D", "Shuaib U" ], "journal_or_site": "CNS Neuroscience & Therapeutics", "year_or_date": "2026-03-06", "doi": "10.1002/cns.70810", "url": "https://doi.org/10.1002/cns.70810", "abstract_or_summary": "This 2026 review synthesizes mechanistic and clinical evidence for glymphatic impairment across acute brain injury and chronic neurological disorders (including Alzheimer's, Parkinson's, small-vessel disease, and multiple sclerosis). It organizes dysfunction into five mechanisms: AQP4 depolarization at astrocytic endfeet, perivascular-space compression or obstruction, loss of arterial pulsatility and vascular stiffening, blood–brain barrier disruption with neuroinflammation, and sleep/autonomic dysregulation (altered noradrenergic tone). The authors note emerging clinical probes of glymphatic function (DTI-ALPS, contrast MRI, enlarged perivascular spaces), their associations with cognition and mood, and translational strategies — sleep and circadian optimization, vascular risk control, anti-inflammatory approaches, AQP4/TRPV4 targets, and neuromodulation.", "system_classification": "glymphatic / brain clearance", "justification": "The most current synthesis available, and the axis's only record that links glymphatic dysfunction explicitly to mood and cognition outcomes — the two symptom domains (brain fog, anhedonia) the axis is meant to explain. It also catalogues the measurable biomarkers (DTI-ALPS, enlarged perivascular spaces) and the clearance-restoring strategy space, giving the corpus both a way to test the brain-clearance hypothesis in post-drug patients and a set of mechanistically grounded treatment-candidate directions to track. It closes the axis from discovery (Iliff, Xie) through mechanism (Mogensen) to clinical translation.", "keywords": [ "glymphatic dysfunction", "AQP4", "DTI-ALPS", "cognition", "mood", "neuroinflammation", "sleep", "TRPV4" ], "relevance": "high", "verification_status": "verified (Crossref + OpenAlex)", "quality_notes": "Peer-reviewed review (CNS Neurosci Ther, vol 32, 2026). Recent synthesis (March 2026); already cited ~20 times. Large author team from An-Najah National University / Cleveland Clinic. Open access (CC-BY).", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://europepmc.org/articles/PMC12965907", "fulltext_source": "PMC", "oa_status": "gold", "oa_license": "cc-by", "pmid": "41792880", "pmcid": "PMC12965907" }, { "item_id": "MECH-035", "source_type": "peer-reviewed paper", "title": "Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study", "authors": "Farhana Islam, Leen Magarbeh, Samar S. M. Elsheikh, Stefan M. Kloiber, Caroline Wanderley Espinola, Venkat Bhat, Benicio Noronha Frey, Roumen V. Milev, Claudio N. Soares, Sagar V. Parikh, et al.", "journal_or_site": "The Canadian Journal of Psychiatry", "year_or_date": "2023 (epub Oct 2023)", "doi": "10.1177/07067437231203433", "url": "https://doi.org/10.1177/07067437231203433", "abstract_or_summary": "In 178 adults with major depressive disorder treated with escitalopram (weeks 0-8), nonresponders were augmented with aripiprazole while responders continued escitalopram alone (weeks 8-16), with sexual function and satisfaction tracked on the SexFX scale. CYP2C19 intermediate and poor metabolizers showed treatment-related improvement in sexual arousal during weeks 8-16, whereas normal metabolizers showed a decline (F(2,54) = 8.00, p < 0.001, q = 0.048). No significant associations were found for CYP2D6 or ABCB1 variants, and the CYP2C19 effect ran opposite to the authors' initial hypothesis, which they attribute partly to serum drug and metabolite (S-DCT) exposure patterns. The authors note this is the first study of treatment-emergent sexual dysfunction genetics under escitalopram with aripiprazole augmentation, and that findings need replication in a larger independent sample.", "study_type": "prospective pharmacogenetic cohort (clinical trial substudy)", "sample_size": "n=178 (Phase I); n=91 ESC+ARI, n=80 ESC-only (Phase II)", "system_classification": "pharmacogenomics / genetic markers", "justification": "This is the most directly on-point susceptibility-marker study for the PSSD axis yet found outside the corpus: it links measured CYP2C19 metabolizer status to on-treatment changes in sexual arousal, with serum drug levels as an exposure bridge. It complements the corpus's CYP2D6-focused Discord records by adding CYP2C19 and the blood-brain-barrier transporter ABCB1 to the candidate susceptibility panel, and its unexpected direction of effect is a cautionary data point for any treatment-candidate search that would stratify patients by metabolizer status.", "keywords": [ "CYP2C19", "CYP2D6", "ABCB1", "escitalopram", "treatment-emergent sexual dysfunction", "pharmacogenomics", "CAN-BIND" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 37796764)", "quality_notes": "Peer-reviewed (SAGE); prospective design with measured serum drug levels; ~72% European ancestry limits generalizability; only 2 CYP2D6 ultrarapid metabolizers so that group was excluded; authors explicitly call for replication.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://europepmc.org/articles/PMC10874600", "fulltext_source": "PMC", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "37796764", "pmcid": "PMC10874600" }, { "item_id": "MECH-036", "source_type": "peer-reviewed paper", "title": "ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder", "authors": "Onno L. de Klerk, Ilja Maria Nolte, Pierre M. Bet, Fokko J. Bosker, Harold Snieder, Johan A. den Boer, Richard Bruggeman, Witte J.G. Hoogendijk, Brenda W.J.H. Penninx, et al.", "journal_or_site": "The Pharmacogenomics Journal", "year_or_date": "2013 (epub May 2012)", "doi": "10.1038/tpj.2012.16", "url": "https://doi.org/10.1038/tpj.2012.16", "abstract_or_summary": "P-glycoprotein, the ABCB1-encoded efflux pump at the blood-brain barrier, controls how much of an SSRI substrate reaches the brain. In 424 patients with major depressive disorder from the Netherlands Study of Depression and Anxiety (NESDA), six ABCB1 variants were tested for association with antidepressant adverse effects. The number of SSRI-related adverse effects was significantly associated with rs2032583 (p=0.001) and rs2235040 (p=0.002) and with a haplotype (p=0.002). Serotonergic effects in particular — sleeplessness, gastrointestinal complaints, and sexual effects — were significantly predicted by these variants and the haplotype. The authors conclude that two common ABCB1 polymorphisms predict adverse drug effects of SSRI treatment, especially serotonergic ones.", "study_type": "candidate-gene association study (clinical cohort)", "sample_size": "n=424", "system_classification": "pharmacogenomics / genetic markers", "justification": "ABCB1 sits squarely in the causal-pathway logic Powers applies to drug clearance: a transporter variant that changes brain exposure to an SSRI is a mechanistically credible susceptibility factor for who develops severe or persistent serotonergic side effects, sexual effects included. It extends the corpus's pharmacogenomic coverage beyond metabolizing enzymes (CYPs) to the blood-brain-barrier efflux step, and pairs naturally with MECH-035, which tested the same gene in the same phenotype.", "keywords": [ "ABCB1", "P-glycoprotein", "SSRI", "adverse drug effects", "sexual side effects", "blood-brain barrier", "NESDA" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 22641028)", "quality_notes": "Peer-reviewed (Nature Portfolio journal); large well-phenotyped Dutch cohort; SSRI-substrate-specific hypothesis pre-registered in design; observational — association, not causal proof of brain concentrations.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "22641028" }, { "item_id": "MECH-037", "source_type": "peer-reviewed paper", "title": "Serotonin 2A -1438 G/A and G-Protein Beta3 Subunit C825T Polymorphisms in Patients with Depression and SSRI-Associated Sexual Side-Effects", "authors": "Jeffrey R. Bishop, Jessica Moline, Vicki L. Ellingrod, Susan K. Schultz, Anita H. Clayton", "journal_or_site": "Neuropsychopharmacology", "year_or_date": 2006, "doi": "10.1038/sj.npp.1301090", "url": "https://doi.org/10.1038/sj.npp.1301090", "abstract_or_summary": "In 81 outpatients treated with citalopram, escitalopram, fluoxetine, paroxetine, or sertraline, sexual dysfunction was measured with the Changes in Sexual Function Questionnaire as a primary outcome. The HTR2A -1438 G/G genotype was associated with SSRI-associated sexual dysfunction both unadjusted and after controlling for age, gender, and anxiety/depression scores. In women, G/G carriers had significantly lower arousal and desire/frequency subscores; the association was not significant in men. A follow-up analysis by the same group suggested oral contraceptive use may mediate the HTR2A-sexual adverse reaction association. The authors propose that lower baseline 5-HT2A expression may heighten susceptibility to receptor saturation under SSRI exposure.", "study_type": "candidate-gene association study (clinical cohort)", "sample_size": "n=81", "system_classification": "pharmacogenomics / genetic markers", "justification": "HTR2A is the receptor most directly implicated in the serotonin-brake model of SSRI sexual dysfunction — the same model invoked in PSSD discussions — and this is the primary-outcome study tying its promoter variant to the phenotype, with a sex-specific pattern that echoes the corpus's interest in hormonal context (oral contraceptives as mediator). Together with MECH-035 and MECH-036 it builds a three-gene pharmacodynamic plus pharmacokinetic susceptibility panel (HTR2A/GNB3, CYP2C19, ABCB1) for the treatment-candidate search.", "keywords": [ "HTR2A", "rs6311", "GNB3", "SSRI", "sexual side effects", "pharmacogenetics", "serotonin 2A receptor" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 16710319)", "quality_notes": "Peer-reviewed; small sample (n=81); a larger STAR*D analysis (Perlis et al.) did not replicate the HTR2A association — possible phenotype-measure or population differences, flagged as unresolved.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "16710319" }, { "item_id": "MECH-038", "source_type": "peer-reviewed paper", "title": "Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate", "authors": "A-H Karypidis, M Olsson, S-O Andersson, Anders Rane, Lena Ekstrom", "journal_or_site": "The Pharmacogenomics Journal", "year_or_date": "2008 (online Mar 2007)", "doi": "10.1038/sj.tpj.6500449", "url": "https://doi.org/10.1038/sj.tpj.6500449", "abstract_or_summary": "UGT2B17 is a highly prostate-abundant UDP- glucuronosyltransferase with strong activity against androgens, and its deletion had previously been linked to low or undetectable urinary testosterone. The authors quantified UGT2B17 mRNA in normal prostate tissue by genotype and tested the deletion in a Swedish population-based case-control study (176 prostate cancer cases, 161 controls). Insertion-allele homozygotes expressed roughly 30 times more UGT2B17 mRNA in prostate tissue than heterozygotes, and deletion carriers had significantly increased prostate cancer risk (OR 2.07, 95% CI 1.32-3.25). The authors conclude the deletion polymorphism shapes androgen glucuronidation capacity in target tissue and associates with prostate cancer risk.", "study_type": "case-control genetic association + tissue expression", "sample_size": "n=176 cases, n=161 controls", "system_classification": "pharmacogenomics / genetic markers", "justification": "UGT2B17 is the single gene Powers names most prominently — his theorized \"base, core defect,\" later reframed as a risk modifier — and this is human association data showing that its deletion changes androgen handling inside a steroid target tissue and tracks with an androgen-driven disease outcome. It is the natural companion to the corpus's Yang 2008 (UGT2B17 copy number and circulating testosterone/estradiol) and belongs in any causal-pathway diagram of how impaired steroid clearance could leave a vulnerable endocrine milieu after 5-ARI exposure.", "keywords": [ "UGT2B17", "deletion polymorphism", "androgen glucuronidation", "prostate cancer", "steroid clearance", "copy number variation" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 17387331)", "quality_notes": "Peer-reviewed; tissue-expression plus case-control design is a strength; a subsequent Arkansas Caucasian case-control study (Gallagher et al. 2008) found no association — population or ascertainment differences unresolved; cancer endpoint, not PFS, so relevance is mechanistic.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "17387331" }, { "item_id": "MECH-039", "collection_tag": "systems-review-2026-10", "title": "SULT2A1 Gene Copy Number Variation is Associated with Urinary Excretion Rate of Steroid Sulfates", "doi": "10.3389/fendo.2013.00088", "url": "https://doi.org/10.3389/fendo.2013.00088", "status": "duplicate-tombstone", "duplicate_of": "MECH-019", "tombstone_note": "Deduplicated in corpus v1.10: this record described the same paper as MECH-019 (DOI 10.3389/fendo.2013.00088, SULT2A1 copy-number variation and urinary steroid sulfate excretion). MECH-019 is the canonical record; its PMID (23874324) was recovered from this duplicate. Kept as a tombstone per the no-silent-deletions policy — do not count as a separate paper.", "_source_file": "systems_review" }, { "item_id": "MECH-040", "source_type": "peer-reviewed paper", "title": "Eight Common Genetic Variants Associated with Serum DHEAS Levels Suggest a Key Role in Ageing Mechanisms", "authors": "Guangju Zhai, Alexander Teumer, Lisette Stolk, John R. B. Perry, Liesbeth Vandenput, Andrea D. Coviello, Annemarie Koster, Jordana T. Bell, Shalender Bhasin, Joel Eriksson, et al.", "journal_or_site": "PLoS Genetics", "year_or_date": 2011, "doi": "10.1371/journal.pgen.1002025", "url": "https://doi.org/10.1371/journal.pgen.1002025", "abstract_or_summary": "DHEA sulfate is the most abundant circulating adrenal steroid and declines markedly with age, prompting speculation that relative deficiency contributes to age-related disease. A meta-analysis of genome-wide association data in 14,846 individuals identified eight independent common SNPs associated with serum DHEAS. The implicated loci include SULT2A1 (rs2637125, p = 2.61e-19), CYP2C9 (rs2185570, p = 2.29e-8), ZKSCAN5, ARPC1A, TRIM4, BMF, HHEX, and BCL2L11. Several SNPs tracked with gene-expression changes, and the genes connect to pathways linking DHEAS with ageing. The authors present this as the first robust genetic map of DHEAS regulation.", "study_type": "genome-wide association meta-analysis", "sample_size": "n=14,846", "system_classification": "pharmacogenomics / genetic markers", "justification": "DHEA/DHEAS sits at the top of the neurosteroid cascade that the Melcangi group places at the center of PFS pathophysiology, and this GWAS pins two corpus-relevant genes — SULT2A1 (Powers-named) and CYP2C9 (a drug/xenobiotic-metabolizing CYP) — to circulating DHEAS in humans at genome-wide significance. It gives the corpus its first genome-wide (hypothesis-free) anchor for the sulfation axis and adds CYP2C9, relevant to retinoid and drug metabolism, to the marker list.", "keywords": [ "DHEAS", "GWAS", "SULT2A1", "CYP2C9", "adrenal androgens", "ageing" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 21533175)", "quality_notes": "Peer-reviewed (PLOS); large discovery sample with replication across cohorts; effect sizes per SNP are small, as expected for GWAS; DHEAS function itself remains debated, which the authors acknowledge.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://journals.plos.org/plosgenetics/article/file?id=10.1371/journal.pgen.1002025&type=printable", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "public-domain", "pmid": "21533175" }, { "item_id": "MECH-041", "source_type": "peer-reviewed paper", "title": "Association between MTHFR C677T polymorphism and depression: An updated meta-analysis of 26 studies", "authors": "Yile Wu, Xiuxiu Ding, Yehuan Sun, Huiyun Yang, Jian Chen, Xue Yan Zhao, Yuhong Jiang, Xiaoling Lv, Zhenqiang Wu", "journal_or_site": "Progress in Neuro-Psychopharmacology and Biological Psychiatry", "year_or_date": 2013, "doi": "10.1016/j.pnpbp.2013.06.015", "url": "https://doi.org/10.1016/j.pnpbp.2013.06.015", "abstract_or_summary": "Prior studies of the MTHFR C677T polymorphism and depression had given inconclusive results, so the authors pooled 26 studies comprising 4,992 depression cases and 17,082 controls. The T allele was associated with increased depression risk overall (TT vs CC odds ratio 1.42, 95% CI 1.16-1.75). Subgroup analysis showed a stronger signal in Asian populations (TT vs CC OR 1.88) and only a marginal association in White populations, with no association in the elderly. The authors conclude the C677T variant contributes to depression susceptibility, most clearly in Asian samples.", "study_type": "meta-analysis of genetic association studies", "sample_size": "26 studies; 4,992 cases / 17,082 controls", "system_classification": "pharmacogenomics / genetic markers", "justification": "MTHFR is Powers-named and one-carbon metabolism is his recurring explanatory thread for persistent neuropsychiatric symptoms; this meta-analysis supplies the human association data — modest but real — that a susceptibility model needs. It also motivates the treatment-candidate side of the search: if impaired folate-pathway function raises depression risk, then folate-pathway interventions (e.g., the L-methylfolate augmentation RCT of Papakostas et al. 2012) become testable candidates rather than speculation.", "keywords": [ "MTHFR", "C677T", "depression", "meta-analysis", "one-carbon metabolism", "folate" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 23831680)", "quality_notes": "Peer-reviewed; effect is modest and ethnicity-dependent, and absent in the elderly — consistent with a small risk modifier, not a determinant; no individual-level prediction is warranted.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "23831680" }, { "item_id": "MECH-042", "source_type": "peer-reviewed paper", "title": "Influence of Androgen Receptor Gene CAG and GGC Polymorphisms on Male Sexual Function: A Cross-Sectional Study", "authors": "Giacomo Tirabassi, Giovanni Corona, Sara Falzetti, Nicola delli Muti, Mario Maggi, Giancarlo Balercia", "journal_or_site": "International Journal of Endocrinology", "year_or_date": 2016, "doi": "10.1155/2016/5083569", "url": "https://doi.org/10.1155/2016/5083569", "abstract_or_summary": "No prior study had assessed the AR GGC repeat in sexual function. In 85 male outpatients evaluated with the IIEF-15, longer CAG repeats correlated inversely with erectile function, orgasmic function, and total IIEF score, while GGC tracts showed no correlation. The CAG relationship held only in eugonadal men, not in hypogonadal men, and in eugonadal subjects logistic regression linked higher CAG number to worse erectile function, orgasmic function, desire, and satisfaction scores independently of confounders including metabolic status. The authors conclude CAG length affects sexual parameters in eugonadal men, while GGC appears uninvolved.", "study_type": "cross-sectional association study (clinical)", "sample_size": "n=85", "system_classification": "pharmacogenomics / genetic markers", "justification": "The corpus already covers AR repeats in PFS patients (Cauci 2017, Cecchin 2014); this adds the general-population complement — AR CAG length tracking sexual function in eugonadal men, which is exactly the hormonal context of most PFS/PSSD patients (normal testosterone, persistent symptoms). It sharpens the androgen-sensitivity node of the causal model: the same androgen level can mean different receptor signaling depending on CAG length, a candidate explanation for why only a subset of exposed men develop persistent dysfunction.", "keywords": [ "androgen receptor", "CAG repeat", "GGC repeat", "erectile function", "IIEF", "eugonadal", "sexual function" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 28243253)", "quality_notes": "Peer-reviewed; modest sample (n=85), retrospective, cross-sectional — direction of causality not established; consistent with earlier smaller studies (Pastuszak, Liu) but conflicting with one population survey (Andersen 2011), so the literature is mixed.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/2016/5083569", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "cc-by", "pmid": "28243253", "fulltext_note": "Link updated 2026-10-09: Hindawi journals moved to Wiley" }, { "item_id": "MECH-043", "source_type": "peer-reviewed paper", "title": "Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial", "authors": "Cindy H. Chau, Douglas K. Price, Cathee Till, Phyllis J. Goodman, Xiaohong Chen, Robin J. Leach, Teresa L. Johnson-Pais, Ann Wu Hsing, Ashraful M. Hoque, Catherine M. Tangen, et al.", "journal_or_site": "PLoS ONE", "year_or_date": 2015, "doi": "10.1371/journal.pone.0126672", "url": "https://doi.org/10.1371/journal.pone.0126672", "abstract_or_summary": "Using a nested case-control design inside the Prostate Cancer Prevention Trial, the authors measured serum finasteride by validated LC-MS and tested 27 SNPs in finasteride target and metabolism genes for association with drug concentrations. Five SNPs in CYP3A4 (rs2242480, rs4646437, rs4986910) and CYP3A5 (rs776746, rs15524) were associated with finasteride levels: variant alleles at three SNPs raised mean concentrations more than 1.5-fold, while homozygous variants at the other two halved them. No SRD5A2 or SRD5A3 variants associated with concentrations, and finasteride concentration itself showed no concentration-dependent association with prostate cancer risk. The authors conclude CYP3A4/5 genetics substantially modify systemic finasteride exposure.", "study_type": "nested case-control pharmacogenetic study (trial substudy)", "sample_size": "PCPT treatment-arm subset (cases + matched controls)", "system_classification": "pharmacogenomics / genetic markers", "justification": "This is the only human study found that directly ties common genetic variants to finasteride blood levels — the exposure variable at the very start of any PFS causal chain — with effect sizes large enough to matter (halving to 1.5x-plus). It converts \"CYP3A4 metabolizes finasteride\" from textbook fact into a quantified susceptibility factor and belongs at the intake end of the corpus's causal-pathway map, upstream of the neurosteroid and epigenetic findings.", "keywords": [ "finasteride", "CYP3A4", "CYP3A5", "drug concentrations", "pharmacogenomics", "Prostate Cancer Prevention Trial", "SRD5A2" ], "relevance": "high", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 25955319)", "quality_notes": "Peer-reviewed (PLOS); large trial-embedded sample with validated LC-MS assay; endpoint was prostate cancer, not adverse effects — the exposure-genetics finding is what transfers to PFS; no SRD5A2 signal found.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0126672&type=printable", "fulltext_source": "publisher OA", "oa_status": "gold", "oa_license": "public-domain", "pmid": "25955319" }, { "item_id": "MECH-044", "source_type": "peer-reviewed paper", "title": "LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription", "authors": "Eric Metzger, Melanie Wissmann, Na Yin, Judith M. Muller, Robert Schneider, Antoine H.F.M. Peters, Thomas Gunther, Reinhard Buettner, Roland Schule", "journal_or_site": "Nature", "year_or_date": 2005, "doi": "10.1038/nature04020", "url": "https://doi.org/10.1038/nature04020", "abstract_or_summary": "LSD1 (KDM1A) was known as a transcriptional corepressor that demethylates histone H3 lysine 4. The authors show it also functions as a coactivator of the androgen receptor: when complexed with AR, LSD1 demethylates repressive H3K9 marks at androgen-responsive promoters, thereby promoting AR-dependent transcription. This established histone demethylation as a direct, ligand-gated control point for androgen signaling — the same enzyme can repress or activate depending on its binding partners and histone context.", "study_type": "mechanistic molecular biology (cell-line)", "sample_size": "n/a (in vitro)", "system_classification": "epigenetic persistence", "justification": "The corpus's epigenetic supplement (EPI-001...015) covers DNA methylation and miRNA but has no histone-modifier entry; this landmark paper supplies the missing mechanism by which chromatin state directly gates AR output. It is the conceptual bridge for the epigenetic-persistence hypothesis: if histone-modifying enzymes set the transcriptional competence of androgen-responsive genes, then a drug-induced shift in their activity could lock in altered AR signaling after the drug is gone — exactly the kind of durable state change the Traish epigenetic model of PFS proposes.", "keywords": [ "LSD1", "KDM1A", "histone demethylation", "androgen receptor", "H3K9", "chromatin", "epigenetic regulation" ], "relevance": "medium", "verification_status": "verified (OpenAlex + Crossref + PubMed PMID 16079795)", "quality_notes": "Landmark, highly cited Nature paper — but mechanistic and in vitro (prostate cancer cell lines), not human association data and not a persistence study; included as the foundational histone-AR mechanism, with that limitation explicit.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "16079795" }, { "item_id": "MECH-045", "source_type": "peer-reviewed journal article (history of medicine / sociology of science)", "title": "Divergence and convergence of commercial and scientific priorities in drug development: The case of Zelmid, the first SSRI antidepressant", "authors": [ "Shai Mulinari" ], "journal_or_site": "Social Science & Medicine", "year_or_date": 2015, "doi": "10.1016/j.socscimed.2015.06.020", "url": "https://pubmed.ncbi.nlm.nih.gov/26123880/", "abstract_or_summary": "Drawing on interviews with industry and academic scientists involved in the Zelmid project plus textual sources, the paper reconstructs the development of the first SSRI to reach the market. Zelmid (zimelidine) was synthesized in 1971, launched by the Swedish firm Astra in 1982, and withdrawn the following year because of adverse neurological effects. The author uses the case to show how commercial and scientific priorities converged and diverged across the experimental, preclinical, and clinical phases of a mechanism-based (\"rational\") drug-discovery program.", "system_classification": "drug safety history", "justification": "The corpus's PSSD-recognition arc (EMA 2019, FDA labeling, class-wide signal reviews) needs its historical bookend: the SSRI class has already had a member pulled from the market for severe post-marketing harms. A peer-reviewed history of Zelmid's rise and fall supplies exactly that precedent and documents how early post-marketing neurological toxicity was handled by the manufacturer and regulators, giving readers a baseline for judging whether PSSD recognition has been proportionate. It also anchors the androgen-clearance axis: Zelmid's Astra/Carlsson lineage is the same pharmacological era Powers discusses.", "keywords": [ "zimelidine", "Zelmid", "SSRI", "drug withdrawal", "Guillain-Barré syndrome", "post-marketing safety", "regulatory history" ], "relevance": "foundational precedent for SSRI-class severe post-marketing harms and withdrawal", "verification_status": "verified (OpenAlex/Crossref metadata + PubMed record match; DOI, PMID 26123880, venue, year all agree)", "quality_notes": "Peer-reviewed history article in an Elsevier sociology-of-medicine journal. Realist-interview methodology; not a regulatory document — withdrawal facts corroborated by Fagius 1985 (MECH-046).", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://www.sciencedirect.com/science/article/pii/S0277953615003524/pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by-nc-nd", "pmid": "26123880" }, { "item_id": "MECH-046", "source_type": "peer-reviewed journal article (case series)", "title": "Guillain-Barre syndrome following zimeldine treatment", "authors": [ "Jan Fagius", "Per Olof Osterman", "Åke Sidén", "B.-E. Wiholm" ], "journal_or_site": "Journal of Neurology, Neurosurgery & Psychiatry", "year_or_date": 1985, "doi": "10.1136/jnnp.48.1.65", "url": "https://pubmed.ncbi.nlm.nih.gov/3156214/", "abstract_or_summary": "The authors review thirteen cases of Guillain-Barré syndrome, all with a similar temporal relationship to recent commencement of the antidepressant zimelidine. They estimate the risk of developing the syndrome was increased about 25-fold among patients receiving the drug compared with the disorder's natural incidence. They conclude the case series provides strong evidence that the syndrome can occur as a specific, probably immunologically mediated complication of zimelidine therapy.", "system_classification": "drug safety history", "justification": "This is the primary clinical evidence behind the only SSRI-market withdrawal in history, so it earns its place as the documented anchor of the corpus's drug-safety-history strand. The ~25-fold risk estimate and the explicitly immunological framing matter for the user's stated interest in immune-system-related mechanisms of post-drug syndromes. It also illustrates the corpus's honest-status ethos: rare, severe, mechanistically unexplained harms were what ended Zelmid, and the paper is explicit about the immunological inference being probable rather than proven.", "keywords": [ "zimelidine", "Guillain-Barré syndrome", "SSRI adverse effects", "immunologically mediated neuropathy", "pharmacovigilance" ], "relevance": "primary evidence for the GBS signal that withdrew the first SSRI", "verification_status": "verified (OpenAlex abstract + PubMed record match; DOI, PMID 3156214, venue, year, authors all agree)", "quality_notes": "Peer-reviewed case series, JNNP. Small N (13 cases); risk estimate based on natural-incidence comparison, not a controlled cohort. PMC1028185 open access.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1028185/", "fulltext_source": "PMC", "oa_license": "", "pmid": "3156214", "fulltext_note": "Link updated 2026-10-09: a scanned copy is free on PubMed Central" }, { "item_id": "MECH-047", "source_type": "peer-reviewed journal article (adverse-reaction review)", "title": "Adverse reactions in connection with zimeldine treatment—a review", "authors": [ "B. S. Nilsson" ], "journal_or_site": "Acta Psychiatrica Scandinavica. Supplementum", "year_or_date": 1983, "doi": "10.1111/j.1600-0447.1983.tb11110.x", "url": "https://pubmed.ncbi.nlm.nih.gov/6230884/", "abstract_or_summary": "Reviewing clinical-trial and ordinary-use data from Sweden and the UK, the author reports that zimelidine's general side-effect level was substantially lower than that of tricyclic antidepressants. A hypersensitivity reaction characterized by fever, muscle and/or joint pain, and transient increases in transaminases occurred in approximately 1.5% of patients. Rare, potentially serious neuropathies were also reported in connection with treatment.", "system_classification": "drug safety history", "justification": "This is the peer-reviewed source for the hypersensitivity/liver signal the user asked to verify rather than assume. It shows the corpus's immune-related adverse-event thread for SSRIs is grounded in contemporary clinical-use data, not hindsight. Paired with MECH-046, it gives the axis a complete safety-profile picture: a frequent immune-type hypersensitivity reaction plus a rare immune-type neuropathy, matching the two immune-system-related claims the user wanted checked.", "keywords": [ "zimelidine", "hypersensitivity reaction", "transaminases", "liver effects", "adverse drug reactions", "neuropathy" ], "relevance": "verifies the hypersensitivity (~1.5%) and liver-enzyme component of zimelidine's adverse profile", "verification_status": "verified (OpenAlex abstract + PubMed record match; DOI, PMID 6230884, venue, year agree)", "quality_notes": "Peer-reviewed 1983 supplement review; contemporary to the withdrawal. \"1.5%\" figure is from ordinary-use (not trial) data; neuropathy mention is brief — GBS detail lives in MECH-046.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "6230884" }, { "item_id": "MECH-048", "source_type": "peer-reviewed journal article (experimental)", "title": "Anticonvulsant activity of androsterone and etiocholanolone", "authors": [ "Rafal Marian Kaminski", "Herbert Ryan Marini", "Won-Joo Kim", "Michael A. Rogawski" ], "journal_or_site": "Epilepsia", "year_or_date": 2005, "doi": "10.1111/j.1528-1167.2005.00705.x", "url": "https://pubmed.ncbi.nlm.nih.gov/15946323/", "abstract_or_summary": "Men with epilepsy often show sexual or reproductive abnormalities attributed to altered androgen levels, including subnormal free testosterone, and the testosterone metabolites androsterone (5α-androstan-3α-ol-17-one) and its 5β-epimer etiocholanolone may also be reduced. Androsterone is a neurosteroid that acts as a positive allosteric modulator of GABA-A receptors; it is found in adult brain, and both metabolites circulate in substantial quantities along with their glucuronide and sulfate conjugates. The study tested whether these endogenous steroids protect against seizures, establishing that androsterone has genuine CNS bioactivity rather than being a mere excretory byproduct.", "system_classification": "hormonal axes", "justification": "Powers' androsterone-buildup thread treats androsterone as pharmacologically meaningful, not inert waste. This paper is the peer-reviewed anchor for that claim: androsterone is a GABA-A positive allosteric modulator with demonstrated anticonvulsant activity, so its accumulation or depletion has plausible neuropsychiatric consequences. That turns androsterone from a clearance-pathway footnote into a candidate mediator in the causal-pathway search, and it links the steroid-clearance axis (MECH-049) to functional CNS effects.", "keywords": [ "androsterone", "etiocholanolone", "GABA-A receptor", "neurosteroid", "positive allosteric modulator", "anticonvulsant", "androgen metabolites" ], "relevance": "establishes androsterone's own GABA-A bioactivity — the mechanistic basis of the buildup hypothesis", "verification_status": "verified (OpenAlex abstract + PubMed record match; DOI, PMID 15946323, venue, year, authors all agree)", "quality_notes": "Peer-reviewed experimental paper, Epilepsia. Rogawski lab; mouse seizure models — translational caveat applies. Does not address accumulation or glucuronidation defects directly.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "https://ir.ymlib.yonsei.ac.kr/handle/22282913/151381", "fulltext_source": "repository", "oa_status": "green", "oa_license": "cc-by-nc-nd", "pmid": "15946323" }, { "item_id": "MECH-049", "source_type": "peer-reviewed journal article (experimental)", "title": "UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response", "authors": [ "Sarah Chouinard", "Olivier Barbier", "Alain Bélanger" ], "journal_or_site": "Journal of Biological Chemistry", "year_or_date": 2007, "doi": "10.1074/jbc.m703370200", "url": "https://pubmed.ncbi.nlm.nih.gov/17848572/", "abstract_or_summary": "The UGT2B15 and UGT2B17 enzymes conjugate dihydrotestosterone and its metabolites androstane-3α,17β-diol and androsterone. Both enzymes are present in epithelial cells of the human prostate, where significant concentrations of the corresponding glucuronides were detected. Using RNA interference in the androgen-dependent LNCaP cell line, the authors showed that knocking down these two enzymes markedly alters androgen inactivation, establishing them as major determinants of local androgen termination.", "system_classification": "steroid clearance / glucuronidation", "justification": "This is the clearance-focused core of the axis: it identifies the exact enzymes (UGT2B15/UGT2B17) that terminate androsterone signaling by glucuronidation, which is precisely the pathway Powers theorizes is defective in the buildup model (and the gene family of his hypothesized UGT2B17 \"risk modifier\" deletion). It makes the mechanistic chain explicit — defective UGT2B17 → reduced androsterone glucuronidation → androsterone accumulation — and gives the treatment-candidate search a concrete enzymatic target. Classification is \"steroid clearance / glucuronidation\" because the paper is about termination of signaling, not systemic hormone levels.", "keywords": [ "UGT2B15", "UGT2B17", "glucuronidation", "androsterone", "dihydrotestosterone", "androgen inactivation", "LNCaP" ], "relevance": "names the enzymes whose deficiency would produce androsterone buildup", "verification_status": "verified (OpenAlex abstract + PubMed record match; DOI, PMID 17848572, venue, year, authors all agree)", "quality_notes": "Peer-reviewed, JBC. Prostate/LNCaP model system; tissue distribution beyond prostate is not covered here. Complements the corpus's 564-entry gene library (UGT2B17 card).", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "fulltext_url": "http://www.jbc.org/article/S0021925820716819/pdf", "fulltext_source": "publisher OA", "oa_status": "hybrid", "oa_license": "cc-by", "pmid": "17848572" }, { "item_id": "MECH-050", "source_type": "peer-reviewed journal article (clinical study / review-style)", "title": "Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women", "authors": [ "Fernand Labrie", "Alain Bélanger", "Patrick Bélanger", "René Bérubé", "Céline Martel", "Leonello Cusan", "José Gomez", "Bernard Candas", "Isabelle Castiel", "Véronique Chaussade", "Claire Deloche", "Jacques Leclaire" ], "journal_or_site": "The Journal of Steroid Biochemistry and Molecular Biology", "year_or_date": 2006, "doi": "10.1016/j.jsbmb.2006.02.004", "url": "https://pubmed.ncbi.nlm.nih.gov/16621522/", "abstract_or_summary": "Serum testosterone has correlated poorly with clinical androgen status in women because much androgen is made locally in peripheral tissues from DHEA and never reaches the circulation in active form. The authors measured androsterone glucuronide (ADT-G) and 3α-diol glucuronide — the obligatory end-products of total androgen elimination — by LC-MS/MS in 377 healthy postmenopausal and 47 premenopausal women, finding no correlation with serum testosterone. They conclude ADT-G and 3α-diol-G reflect the total androgen pool and are superior markers of androgenic activity, potentially identifying true androgen deficiency relevant to osteoporosis, metabolic, and sexual dysfunction.", "system_classification": "hormonal axes", "justification": "This paper reframes androsterone glucuronide from waste product to the field's best window on total androgen exposure — exactly the quantity the buildup hypothesis claims is disturbed when glucuronidation fails. For the causal-pathway search it supplies the biomarker logic: if UGT-mediated clearance is defective, ADT-G dynamics are where the lesion shows up, and serum testosterone will miss it. It also connects the corpus's hormonal-axes records to measurable clinical chemistry (LC-MS/MS ADT-G), which is what a future treatment-candidate evaluation would need to monitor.", "keywords": [ "androsterone glucuronide", "ADT-G", "androgen markers", "intracrinology", "DHEA", "LC-MS/MS", "androgen deficiency" ], "relevance": "establishes ADT-G as the marker of total androgen activity — the read-out for a clearance-defect model", "verification_status": "verified (Crossref metadata + PubMed record/abstract match; DOI, PMID 16621522, venue, year, authors all agree)", "quality_notes": "Peer-reviewed, JSBMB. Labrie group has commercial ties to DHEA/prasterone (Endorecherche/EndoCeutics) — the ADT-G chemistry is solid, therapeutic extensions should be discounted. Women-only cohort.", "collection_tag": "systems-review-2026-10", "_source_file": "systems_review", "pmid": "16621522" }, { "item_id": "PRH-1494", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1fyc1mg/list_of_treatments_for_post_finasteride_syndrome/oedpxgx/", "date_raw": "2026-04-05T04:43:28Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who edited their comment to acknowledge that their framing of the androgen-receptor over/underexpression theory had been incorrect, and that Powers' correction — glucuronidation failure leading to metabolite accumulation, androgen-signaling nullification and gene methylation — had clarified things, while stressing that the post was written with respect and gratitude.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1495", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1s1hd56/pssd_and_desperate/ocvg5wz/", "date_raw": "2026-03-28T00:28:54Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], the author of the \"Pssd and desperate\" post (20 years on Zoloft, PSSD after a slow taper), who theorized that his penile shrinkage began when TRT injections shut down his natural production in week two, and asked whether going back on TRT/HCG could reverse it.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1496", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sbm8xq/i_collect_more_and_more_labsgenomedutch_tests/oemr11q/", "date_raw": "~6 months ago", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked supportive follow-up questions: whether 5AR enzymes can regenerate after suicide inhibition, and whether clearing the accumulated metabolites is the key therapeutic step.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1497", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1rwnt0l/you_know_pssd_and_pfs_may_actually_be_the_same/of73ei1/", "date_raw": "2026-04-09T14:39:58Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to a now-deleted comment by u/Drwillpowers himself in his \"PSSD and PFS may actually be the same thing\" data-request thread; the parent comment's text is unrecoverable.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1498", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sbm8xq/i_collect_more_and_more_labsgenomedutch_tests/oewgpt8/", "date_raw": "2026-04-07T23:53:27Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who posted blood and DUTCH results (519 ng/dL total T, near-zero urinary androgens) and asked which of several past exposures — ashwagandha, saw palmetto, Zoloft, Cymbalta, but never finasteride — could explain his symptom collection.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1499", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1qx24yu/_/ofe4ao0/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1sg3yin/if_you_have_pfs_do_not_panic_if_you_dont_end_up/ofdvmqb/", "date_raw": "2026-04-10T14:51:53Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked whether the hypermasculinity-selection idea works in reverse for someone who was not physically or socially masculine before finasteride/dutasteride, and who is pursuing testing.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1500", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sht3ak/_/og4miig/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1skv97m/repost_dutch_test_results/og4irqr/", "date_raw": "2026-04-14T13:22:58Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked how the model reconciles very common UGT2B17 deletion in East Asian populations with the low severe-side-effect rates in large regional finasteride/dutasteride trials — if reduced glucuronidation makes 5α-reductase a critical escape pathway, adverse events should be far more common there.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1501", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sobtzu/questions_regarding_current_pfs_theory/ogv6zrb/", "date_raw": "2026-04-18T08:57:02Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to the original post \"Questions regarding current PFS theory\" by [username removed], who asked about delayed onset, why symptoms often appear only after quitting finasteride, and how non-responders fit the model.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1502", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1smu0ol/cis_male_experienced_insane_side_effects_from/ogmfaj1/", "date_raw": "2026-04-17T00:12:45Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to the original post by [username removed], a cis male reporting severe side effects (dissociation, focus loss, worsened sciatica, dry eyes, prostatitis) from oral/topical dutasteride and finasteride without developing PFS, asking about hormonal options for hair loss.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1503", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/tressless", "permalink": "https://www.reddit.com/r/tressless/comments/1ua4tsx/the_general_population_is_so_severely/osyydyp/", "date_raw": "~3 months ago", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked whether breaking the feedback loop by flushing androgen metabolites would let skin, muscles, nerves and penile tissue normalize once DHT signaling resumes, or whether the damage done is irreversible. The OP ([username removed]) had complained about misinformation downplaying finasteride's rare side effects.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1504", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sht3ak/im_going_to_be_taking_the_week_off_next_week_to/ogznk6m/", "date_raw": "2026-04-19T00:13:31Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who described Klinefelter syndrome (47,XXY) with bilateral orchiectomy on testosterone replacement, developing the full PFS-identical symptom cluster — loss of sexual desire, mind-body dissociation, emotional blunting — persisting five years after six months of letrozole, and offered the case as potentially valuable for the research.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1505", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1t034l8/anyone_want_to_analyse_my_test_results/ojjxpic/", "date_raw": "2026-05-02T19:04:19Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked about common denominators — possibly GSK3β inhibition — among disparate self-reported PSSD recoveries (SSRI reinstatement/switching, inositol, cyproheptadine rebound, etc.), in a thread where the OP posted test results after 20 years of Zoloft and PSSD onset during taper.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1506", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1uctydw/dutasteride_still_a_decent_option/oxw4n9k/", "date_raw": "2026-07-16T14:12:07Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked about specificity: whether asymptomatic finasteride users show the same genetic patterns, and whether pursuing genome testing would merely set up nocebo given how common some of these variants are. (The OP, since deleted, had asked whether dutasteride remains a decent option.)\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1507", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1rwnt0l/you_know_pssd_and_pfs_may_actually_be_the_same/ochiq81/", "date_raw": "2026-03-25T23:31:59Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to a now-deleted comment by u/Drwillpowers himself in the \"PSSD and PFS may actually be the same thing\" data-request thread; the parent comment's text is unrecoverable.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1508", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1ty3sps/_/oqcmvb6/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1tw4lis/very_scared_pfs/oqcmepk/", "date_raw": "2026-06-07T22:45:26Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who flagged that CYP2D6 slow-metabolism variants appear overrepresented in PSSD genomes the community has been reading (against ~14% population prevalence), in the \"Genes from your list (PSSD)\" thread where the OP posted gene results after Zoloft-taper PSSD onset.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1509", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1u3f83t/im_starting_to_see_trends_in_pssd_genomes_this_is/orfmudk/", "date_raw": "2026-06-13T15:48:20Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked whether DHEA is still used alongside progesterone/pregnenolone for neurosteroid types, in Powers' DBH genome-trend thread (low dopamine metabolite HVA as the common PSSD DUTCH finding).\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1510", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/autism", "permalink": "https://www.reddit.com/r/autism/comments/1vuryyy/_/p54bnp3/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1sg3yin/if_you_have_pfs_do_not_panic_if_you_dont_end_up/p41gofw/", "date_raw": "2026-08-21T23:00:14Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to the original post \"New Mental Clarity on HRT is Amazing\" by [username removed] (r/autism), who described dramatic mental clarity and serenity in the first two weeks of MTF HRT, with improved decisiveness and energy.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1511", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1vhy373/post_accutane_syndromepas_experience_and_markers/p367cz0/", "date_raw": "2026-08-12T03:31:49Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked what tests would be useful for PAS — symptoms worsening since stopping isotretinoin (flushing, skin sensitivity, joint/muscle issues, fatigue, brain fog, gut issues) — and volunteered as a test subject, in the \"Post Accutane Syndrome (PAS) Experience and Markers\" thread by [username removed].\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1512", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/PSSD", "permalink": "https://www.reddit.com/r/PSSD/comments/1rx9hbg/_/obkctmj/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1ry4ea3/la_gaht_a_lo_largo_de_la_historia/objn5dp/", "date_raw": "2026-03-20T21:56:02Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked how long-lasting epigenetic changes square with the fact that some people do recover, in the r/PSSD awareness thread (by [username removed]) spreading word of Powers' PFS/PSSD-sameness hypothesis and his request for PSSD patient data.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1513", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sbm8xq/i_collect_more_and_more_labsgenomedutch_tests/oew81jr/", "date_raw": "2026-04-07T23:08:11Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], a PSSD and long-COVID sufferer who asked whether he has tested many PSSD or long-COVID patients and praised the genetic-effect framing, in Powers' labs/genomes/DUTCH theory thread.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1514", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1rwnt0l/you_know_pssd_and_pfs_may_actually_be_the_same/oc49uqe/", "date_raw": "2026-03-24T00:22:39Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who reported near-total windows on corticosteroids and ACTH analogs (anhedonia, emotional numbness, blank mind all lifting) and megadose potassium iodide improving PFS-group members, in the PFS/PSSD-sameness data thread.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1515", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1rwnt0l/you_know_pssd_and_pfs_may_actually_be_the_same/ochizn2/", "date_raw": "2026-03-25T23:33:21Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who reported that an arginine/ornithine experience genuinely reduced symptoms — not a placebo effect, not a cure — in the PFS/PSSD-sameness data thread.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1516", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1u8y875/_/oso1imm/", "permalink_export_verbatim": "https://www.reddit.com/r/whatisit/comments/1u7sbzp/found_this_metallic_rock_in_backyard/oso05qj/", "date_raw": "2026-06-19T23:06:28Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who proposed 3α-HSD oxidation inhibition (citing a fluoxetine/RoDH-4 paper) as the junction point causing metabolite accumulation and asked whether this matches the angle Powers is pursuing, in the \"3α-HSD oxidation inhibition as the junction point\" thread.\n\n_Note: the export's permalink for this entry resolves to an unrelated comment; the curated comment was located by text match on its true thread (see backfill log)._\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1517", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1uu1arm/pssd_an_odd_signal_can_pssd_people_keep_an_eye/oxp2h9l/", "date_raw": "2026-07-15T15:17:25Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who pushed back on the high-neurosteroid framing — citing Melcangi's low-neurosteroid findings and community reports of benefit (not harm) from allopregnanolone-raising interventions such as pregnenolone and zuranolone — in Powers' \"PSSD: An odd signal\" lab-request thread.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1518", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/PSSD", "permalink": "https://www.reddit.com/r/PSSD/comments/1nfcmy2/im_a_doctor_who_treats_both_pfs_and_pssd_im/owssh0h/", "date_raw": "2026-07-10T23:35:35Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who clarified they had misread his statement as claiming fluvoxamine was neutral/negative on allopregnanolone; Powers confirmed the correction. The thread OP (Powers himself) had asked the PSSD community about SSRI options that raise allopregnanolone without worsening PSSD.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1519", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1vk4jlf/_/p2up2np/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1vk4jlf/important_3adiol_plasma_and_csf_findings/p2qnzl4/", "date_raw": "2026-08-10T15:28:42Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who argued the specific numbness pattern in PSSD/PFS remains unexplained and linked a genital-sensory-loss research thread, in the \"Important 3a-diol Plasma and CSF Findings\" gallery thread by [username removed].\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1520", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1skv97m/_/og7vazp/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1skv97m/repost_dutch_test_results/og7s6kn/", "date_raw": "2026-04-14T22:12:28Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who proposed shutting down the HPTA, waiting for testosterone to clear, then adding bypass hormones to route around the UGT2B17 clearance bridge — noting they personally crash testosterone and get massive windows — in the \"REPOST DUTCH test results\" thread.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1521", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sg3yin/_/of46f30/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1sg3yin/if_you_have_pfs_do_not_panic_if_you_dont_end_up/of2bovt/", "date_raw": "2026-04-09T02:31:06Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to a removed comment in his \"If you have PFS do not panic if you don't end up having abnormal urinary androgens\" gallery post (a mild sulfation/glucuronidation-failure case: normal estrogen, low estrone sulfate).\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1522", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/PSSD", "permalink": "https://www.reddit.com/r/PSSD/comments/1sz96pz/_/ojctzl7/", "permalink_export_verbatim": "https://www.reddit.com/r/PSSD/comments/1sz96pz/dr_will_powers_interview_pfs_pas_pssd_summit_2026/ojct0ud/", "date_raw": "2026-05-01T17:29:38Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who objected that TRT/anabolic-steroid cures contradict his theory (which predicts temporary improvement then crash) and asked about HPTA-reboot success stories, in the PFS/PAS/PSSD Summit 2026 interview thread.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1523", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1sg3yin/_/ofh3vwx/", "permalink_export_verbatim": "https://www.reddit.com/r/DrWillPowers/comments/1sdhm5n/tried_to_repost_dr_powers_post_about_pssdpfs_in/ofh2mzf/", "date_raw": "2026-04-10T23:18:11Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07 (export entry merges several comments; parent context anchored on the located 'states, not conditions' comment)", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who relayed a friend's question asking how androgen-clearance issues could translate into anhedonia and inability to feel pleasure, in Powers' \"abnormal urinary androgens\" gallery thread.\n\n_Note: the export entry merges several comments; the parent context above is anchored on the located \"states, not conditions\" comment. The cAMP-pointer and atrophy remarks come from comments whose exact parents were not recoverable from the mirror's truncated thread renders (see backfill log)._\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1524", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/AccutaneRecovery/comments/1whe0jr/dalla_comunit%C3%A0_drwillpowers_su_reddit_post/pbzlre7/", "date_raw": "2026-09-25T15:23:08Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], the cross-poster, who thanked him, described the subreddit's year-long admin vacuum and the new r/AccutaneSyndrome, and asked about MMP-9 testing specifics and the theory that isotretinoin is stored in the liver with impaired bile flow keeping it in circulation.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1525", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1shdmvr/why_do_people_feel_better_on_anti_androgens_in_pfs/off3mub/", "date_raw": "2026-04-10T17:28:59Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked whether Powers has said anything about post-accutane syndrome, in the thread \"Why do people feel better on anti androgens in PFS?\" (OP [username removed]: UGT mutation, feels better on anti-androgens but crashes on them).\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1526", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1shdmvr/why_do_people_feel_better_on_anti_androgens_in_pfs/ofm7tzy/", "date_raw": "2026-04-11T18:46:15Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who wrote in Spanish (41 years old, lifelong acne, high homocysteine, low iron) thanking him and linking their case to his acne–androgen framing, in the anti-androgens thread.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1527", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1va42ar/pssd_question_for_the_peanut_gallery_how_many_of/p0xb69f/", "date_raw": "2026-07-31T18:27:19Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed] (Middle East, five years of PFS), who shared an unusual onset story: stinging nettle tea days before varicocele surgery, with full PFS symptoms emerging after the surgery — without ever taking finasteride.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1528", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1vc13m7/castration_trial_on_post_anastrazole_syndrome/p1y7898/", "date_raw": "2026-08-05T22:38:08Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who asked about anhedonia and cognitive symptoms persisting despite castration and whether NMDA-antagonist-type treatments are being trialed, in the \"Castration trial on Post anastrazole syndrome\" thread ([username removed]'s relugolix self-trial).\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1529", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1v3m1gi/anyone_out_there_with_pfspssdpostdrug_who_has/p39j318/", "date_raw": "2026-08-12T16:00:55Z", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who described severe soft-tissue issues and lower lumbar arthritis with declining quality of life and an upcoming MRI, and worried the theory and treatment could be dangerous for their case, in Powers' osteoporosis/hypermobility survey thread.\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1530", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/PSSD", "permalink": "https://www.reddit.com/r/PSSD/comments/1uvrxag/_/oy6s6ie/", "permalink_export_verbatim": "https://www.reddit.com/r/PSSD/comments/1uv0t88/sult1a1_homozygous_deletion_bam_variants_pssd/oy65c95/", "date_raw": "~2 months ago", "verification_status": "parent context recovered via r.genit.al mirror 2026-10-09; text from John's user-provided export dated 2026-10-07", "starred": true, "curated_source": "Powers Reddit history (John-provided export)", "parent_context": "Powers' comment replies to [username removed], who thanked him, apologized for repeated questions, and said it sometimes feels like \"the end of the road,\" in the \"What is 'melty skin' in pssd/pfs\" thread (OP [username removed], r/PSSD).\n\n(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1531", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1x02eow/something_is_rotten_in_the_state_of_pfsmark/peknc6h/", "date_raw": "2026-10-08T04:14:27Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-09 (post-dates John's 2026-10-07 export)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-08)", "parent_context": "Powers' comment replies to [username removed] (\"PFS-mark\"), who objected that Powers' public characterization of his case — a rectal progesterone/pregnenolone/DHEA crash with height and shoe-size changes — was incomplete, omitting his fuller symptom list (muscle loss, brain fog, anhedonia, gut problems, tachycardia, hard flaccid, worsened ED, chronic fatigue, burning skin, hair loss; off-the-scale cortisol DUTCH) and his years as a special-education teacher now on disability — while maintaining he had been fair about Powers publicly. Powers' OP had framed the week as subreddit drama over attacks on his theories.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-09; this comment post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "PRH-1532", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wy05fo/is_progesterone_therapy_still_used_for_some_pfs/pegejwd/", "date_raw": "2026-10-07T16:05:27Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-09 (post-dates John's 2026-10-07 export)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-08)", "parent_context": "Powers' comment replies to [username removed], who posed a hypothetical: a post-anastrozole patient with genital numbness and sensation loss, broken sleep and an eyelid twitch — should the workup be a pelvic-floor MRI or a trial of estradiol valerate? The OP ([username removed]) had asked whether progesterone therapy is still used for some PFS patients.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-09; this comment post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche2" }, { "item_id": "RES-001", "collection_tag": "researcher-list-2026-10", "title": "Neuroactive Steroid Levels are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology", "doi": "10.1111/jsm.12269", "url": "https://doi.org/10.1111/jsm.12269", "status": "duplicate-tombstone", "duplicate_of": "PFS-004", "tombstone_note": "Deduplicated in corpus v1.14: this record described the same paper as PFS-004 (same title, authors, journal and year (J Sex Med 2013)). PFS-004 is the canonical record; this record's doi, pmid, abstract_or_summary, relevance, keywords, verification_status, study_type moved there, and its listing in researcher-list-2026-10 is now PFS-004's also_listed_in. Kept as a tombstone per the no-silent-deletions policy; do not count as a separate paper." }, { "item_id": "RES-002", "collection_tag": "researcher-list-2026-10", "title": "Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma", "doi": "10.1016/j.jsbmb.2014.03.012", "url": "https://doi.org/10.1016/j.jsbmb.2014.03.012", "status": "duplicate-tombstone", "duplicate_of": "PFS-005", "tombstone_note": "Deduplicated in corpus v1.14: this record described the same paper as PFS-005 (same PMID 24717976 and title). PFS-005 is the canonical record; this record's doi, abstract_or_summary, relevance, keywords, verification_status, study_type moved there, and its listing in researcher-list-2026-10 is now PFS-005's also_listed_in. Kept as a tombstone per the no-silent-deletions policy; do not count as a separate paper." }, { "item_id": "RES-003", "source_type": "peer-reviewed paper", "title": "Effects of Subchronic Finasteride Treatment and Withdrawal on Neuroactive Steroid Levels and Their Receptors in the Male Rat Brain", "authors": "Giatti S, Foglio B, Romano S, Pesaresi M, Panzica G, Garcia-Segura LM, Caruso D, Melcangi RC", "journal_or_site": "Neuroendocrinology", "year_or_date": "2016 (epub 2015)", "doi": "10.1159/000442982", "url": "https://doi.org/10.1159/000442982", "pmid": "26646518", "abstract_or_summary": "Adult male rats received low-dose finasteride (3 mg/kg/day) for 20 days, with neuroactive-steroid levels and steroid-receptor expression measured in plasma, CSF and brain regions both at end of treatment and one month after withdrawal. Treatment altered neurosteroid levels in a region-dependent way and upregulated the androgen receptor in cerebral cortex and the GABA-A receptor β3 subunit in cerebellum. One month after the last dose, several changes persisted or newly appeared: cortical androgen-receptor upregulation, cerebellar dihydroprogesterone elevation, plasma dihydrotestosterone reduction, a shifted cortical estrogen-receptor α/β balance, and reduced GABA-A α4/β3 mRNA in cortex. The authors argue finasteride has broad, lasting consequences for brain steroid signaling beyond simple DHT suppression.", "study_type": "animal study (male rats, treatment + 1-month withdrawal)", "keywords": [ "finasteride withdrawal", "neuroactive steroids", "androgen receptor", "GABA-A receptor", "rat brain", "persistence" ], "relevance": "Preclinical proof that finasteride remodels steroid-receptor expression and GABA-A subunits with effects that outlast exposure by a month — the mechanistic bridge between the human CSF findings (RES-001/002) and persistent neuropsychiatric symptoms.", "verification_status": "verified — OpenAlex + Crossref-indexed + EuropePMC record (title/authors/year/PMID match)", "fulltext_url": "http://hdl.handle.net/2318/1616906", "collection_tag": "researcher-list-2026-10", "_source_file": "researcher_list" }, { "item_id": "RES-004", "collection_tag": "researcher-list-2026-10", "title": "Finasteride withdrawal induces anxiety-like behavior and novelty avoidance in adult male rats", "doi": "10.1111/jne.70150", "url": "https://doi.org/10.1111/jne.70150", "status": "duplicate-tombstone", "duplicate_of": "LIT-015", "tombstone_note": "Deduplicated in corpus v1.14: this record described the same paper as LIT-015 (same DOI 10.1111/jne.70150, PMID 41761643 and title). LIT-015 is the canonical record; this record's pmcid, fulltext_url (PMC), summary details moved there, and its listing in researcher-list-2026-10 is now LIT-015's also_listed_in. Kept as a tombstone per the no-silent-deletions policy; do not count as a separate paper." }, { "item_id": "PRH-1533", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wz74vq/my_reply_to_extension_shift/penw4yu/", "date_raw": "2026-10-08T16:05:34Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-09 (post-dates John's 2026-10-07 export)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-09)", "parent_context": "Replies to [username removed] in the \"My reply to Extension Shift\" thread, who argued the subreddit's post was defending Powers rather than criticizing the Melcangi group — while adding their own criticism that the Melcangi group's direction (rat work, then dopamine mapping) was low-return given that forum members had been \"on the nose\" about the mechanism over a decade earlier, whereas Powers rebuilt the model from scratch.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-09; post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche3" }, { "item_id": "PRH-1534", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wz74vq/my_reply_to_extension_shift/pej5kke/", "date_raw": "2026-10-07T23:16:50Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-09 (post-dates John's 2026-10-07 export)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-09)", "parent_context": "Same thread as PRH-1533 — the twelve-year-old propeciahelp comment surfaced by [username removed], in a thread defending Powers against criticism of his engagement with the Melcangi group.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-09; post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche3" }, { "item_id": "PRH-1535", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wzvlcx/cdg/pesetxa/", "date_raw": "2026-10-09T05:08:38Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-09 (post-dates John's 2026-10-07 export)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-09)", "parent_context": "Top-level reply to the CDG thread OP ([username removed]): five months of PSSD, took CDG two days at 250 mg about 25 days prior, then saw tanked T/E labs off-TRT — reporting total bodily numbness, blank mind, partial cognition recovery, anhedonia, no libido, and asking for advice.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-09; post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche3" }, { "item_id": "PRH-1536", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wzvlcx/cdg/pewrzn4/", "date_raw": "2026-10-09T19:25:10Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-09 (post-dates John's 2026-10-07 export)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-09)", "parent_context": "Replies to a commenter proposing a \"broken, fragile equilibrium\" model — that even long-cleared substances might knock an unstable equilibrium around, with peppermint and ginger cited as mild triggers, and asking whether that is biochemically feasible.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-09; post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche3" }, { "item_id": "PRH-1537", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wzvlcx/cdg/pewtinl/", "date_raw": "2026-10-09T19:31:47Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-09 (post-dates John's 2026-10-07 export)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-09)", "parent_context": "Replies to a commenter noting PFS patients report crashing off mild triggers (ginger cited) and arguing that disrupting the gut in a sensitized state can cause a crash without deepening the syndrome in the typical anti-androgen pattern — expecting the OP to return to baseline in weeks.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-09; post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche3" }, { "item_id": "PRH-1538", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1x1tr8x/menstrual_cessation_in_afab_trans_w_cah/pewujv0/", "date_raw": "2026-10-09T19:36:19Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-10 (post-dates John's 2026-10-07 export and the tranche-3 intake)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-10)", "parent_context": "Replies to the OP of the \"Menstrual cessation in afab trans w/ CAH\" thread. The OP\nreports severe PMDD with painful heavy periods lasting over a week, years of dismissive\nresponses from other doctors (\"periods will eventually stop on T,\" repeated birth-control\ntrials, hysto suggestion), and recent discovery of very low natural estrogen — estradiol\npatches helped PMDD and pain significantly but did not change bleeding. A reply from\nu/Electronic_Loan_8802 (Oct 9 20:03 UTC) asks Powers whether he has tried this protocol\non trans women who experience odd monthly cycling; Powers has not replied as of the\ncheck.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-10; post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche4" }, { "item_id": "PRH-1539", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1wzvlcx/cdg/pf3wly1/", "date_raw": "2026-10-10T19:48:29Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-10 (post-dates John's 2026-10-07 export and the v1.12 intake)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-10)", "parent_context": "Replies to [username removed] (Oct 9 21:08 UTC) in the \"CDG\" thread, a self-report of a\nsix-day CDG trial ending in sexual-function deterioration, with the user unsure\nwhether it was psychosomatic. Powers' reply supplies the causal story for the\n\"CDG crash\" pattern — the third CDG-thread entry after the tranche-3 dose-debunk\nthread (PRH-1535–1537).\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-10; post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche5" }, { "item_id": "PRH-1540", "source_type": "reddit-comment", "author": "u/drwillpowers", "subreddit": "r/DrWillPowers", "permalink": "https://www.reddit.com/r/DrWillPowers/comments/1x1tr8x/menstrual_cessation_in_afab_trans_w_cah/pf3y3if/", "date_raw": "2026-10-10T19:55:20Z", "verification_status": "comment text and parent context recovered via r.genit.al mirror 2026-10-10 (post-dates John's 2026-10-07 export and the v1.12 intake)", "starred": true, "curated_source": "Powers Reddit (mirror, post-export 2026-10-10)", "parent_context": "Sits in the \"Menstrual cessation in AFAB trans w/ CAH\" thread: pewujv0 (PRH-1538,\ntranche-4) → pex0ozz ([username removed]'s question) → pf3y3if. This resolves\ntranche-4's open watch item — Powers has now seen the question and is engaging it.\n\n(Comment text and parent context recovered from the r.genit.al mirror on 2026-10-10; post-dates John's 2026-10-07 export.)", "collection_tag": "powers-reddit-history", "_source_file": "powers_tranche5" }, { "term": "Binary Alignment Map (BAM)", "category": "genomics", "definition": "A compressed, machine-readable file format used in bioinformatics to store DNA or RNA sequencing reads aligned to a reference genome. It is the binary, highly compressed equivalent of a SAM (Sequence Alignment Map) text file, allowing for drastically smaller file sizes and faster data processing.", "used_in": [ "PRH-1330", "PRH-0178", "PRH-1495" ], "related_terms": [ "SAM file (Sequence Alignment Map)", "Variant Call Format (VCF)", "Integrative Genomics Viewer (IGV)" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "Deletion (genetics)", "category": "genomics", "definition": "In genetics, a deletion is a mutation where a section of DNA is lost or removed during replication. It can range from the loss of a single nucleotide base to an entire piece of a chromosome, severely altering genetic code and protein function.", "used_in": [ "PRH-0117", "PRH-0127", "PRH-0124", "PRH-1330", "PRH-0915", "PRH-0235", "PRH-0560", "PRH-1255", "PRH-1493", "MECH-012", "MECH-014", "MECH-019", "MECH-031", "MECH-038", "MECH-049", "PRH-1500", "PRH-1506" ], "related_terms": [ "War Powers", "Binary Alignment Map (BAM)" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "Integrative Genomics Viewer (IGV)", "category": "genomics", "definition": "A high-performance, easy-to-use, interactive tool for the visual exploration of genomic data.", "url": "https://igv.org/", "used_in": [], "related_terms": [ "Binary Alignment Map (BAM)", "Variant Call Format (VCF)" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "PharmCAT (Pharmacogenomics Clinical Annotation Tool)", "category": "genomics", "definition": "A bioinformatics tool that analyzes genetic variants to predict drug response and tailor medical treatment to an individual patient's genetic profile.", "used_in": [], "related_terms": [ "Variant Call Format (VCF)", "War Cat" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "Post-finasteride syndrome (PFS)", "category": "clinical", "definition": "A condition describing persistent sexual, mental, and physical side effects that continue long after stopping finasteride (Propecia or Proscar). Finasteride is widely used to treat hair loss and enlarged prostates. While most users tolerate the drug well, a small subset of individuals report debilitating, long-lasting symptoms.", "used_in": [ "PFS-001", "PFS-002", "PFS-003", "PFS-004", "PFS-005", "PFS-006", "PFS-007", "PFS-008", "PFS-009", "PFS-010", "PFS-011", "PFS-012" ], "related_terms": [ "5-alpha-reductase inhibitor (5ARI)", "Post-SSRI sexual dysfunction (PSSD)", "Post-drug syndrome" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "Post-SSRI sexual dysfunction (PSSD)", "category": "clinical", "definition": "A condition where sexual side effects (like genital numbness, loss of libido, and erectile dysfunction) persist long after stopping SSRIs. Though the exact cause is unknown, these symptoms can significantly impact quality of life and relationships.", "used_in": [ "PSSD-001", "PSSD-002", "PSSD-003", "PSSD-004", "PSSD-005", "PSSD-006", "PSSD-007", "PSSD-008", "PSSD-009", "PSSD-010", "PSSD-011", "PSSD-012", "PSSD-013" ], "related_terms": [ "Genital anesthesia", "Post-finasteride syndrome (PFS)", "Post-drug syndrome" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "SAM file (Sequence Alignment Map)", "category": "genomics", "definition": "A standard, tab-delimited text format used in bioinformatics to store biological sequence data, like DNA or RNA reads, that have been mapped to a reference sequence. It is the universal language for processing genome sequencing data.", "used_in": [], "related_terms": [ "Binary Alignment Map (BAM)", "Variant Call Format (VCF)" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "Variant Call Format (VCF)", "category": "genomics", "definition": "A standard text file used in bioinformatics to store DNA sequence variations. Instead of writing out an entire genome, it only lists where an individual's DNA differs from a standard reference genome.", "used_in": [ "PRH-1330", "PRH-1495" ], "related_terms": [ "Binary Alignment Map (BAM)", "SAM file (Sequence Alignment Map)", "PharmCAT (Pharmacogenomics Clinical Annotation Tool)" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "War Cat", "category": "genomics", "definition": "A tool to predict pharmacogenomic reactions, shared on r/DrWillPowers.", "url": "https://www.reddit.com/r/DrWillPowers/comments/1uwnzir/comment/oxkt1wd/", "used_in": [], "related_terms": [ "PharmCAT (Pharmacogenomics Clinical Annotation Tool)", "War Powers" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "term": "War Powers", "category": "genomics", "definition": "A tool to check for genetic duplications and deletions, shared on r/DrWillPowers.", "url": "https://www.reddit.com/r/DrWillPowers/comments/1uuvp1u/i_am_proud_to_present_war_powers_the_automated/", "used_in": [], "related_terms": [ "Deletion (genetics)", "War Cat" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.14 from the curator's glossary (2026-10-10)." }, { "item_id": "CUR-001", "collection_tag": "curator-additions", "source_type": "video (C-SPAN; event panel)", "title": "Drug Safety Advocates on Mental Health Care", "channel": "C-SPAN", "event_name": "MAHA Institute, Mental Health and Overmedicalization Summit (opening \"lived experience\" panel), Washington, DC", "date": "2026-05", "url": "https://www.c-span.org/program/public-affairs-event/drug-safety-advocates-on-mental-health-care/678538", "speaker": [ "Cooper Davis (executive director, Inner Compass Initiative), introduction", "Rep. Glenn Grothman (R-WI), opening remarks", "Kim Witczak (drug safety advocate), moderator", "Danielle Gansky", "Cameron LaBarre", "Lauren Friedman", "Nick Taber" ], "transcript_status": "not republished (C-SPAN's transcript)", "summary": "C-SPAN recorded the opening panel of the MAHA Institute's Mental Health and Overmedicalization Summit in Washington, DC (May 2026), where four young adults described harms they attribute to psychiatric drugs taken from childhood or adolescence. Cooper Davis of the Inner Compass Initiative, which organised the panel, said the group is not against medication but for fully informed choice, and that the administration and HHS agencies had consulted it on mental health reform over the past year. Rep. Glenn Grothman (R-WI) said psychiatric drug use had doubled in 20 years without matching education or regulation, blamed the pharmaceutical industry's influence in Congress, referred to the House Oversight forum he had just chaired, and said he hoped to introduce legislation within five or six weeks. The moderator, drug safety advocate Kim Witczak, said her husband died by suicide five weeks after being prescribed an antidepressant for insomnia some 22 years earlier, and that she had campaigned for the boxed suicide warnings.\n\nThe post-SSRI sexual dysfunction account came from Lauren Friedman, 23, who said she developed PSSD after taking sertraline in 2022. Describing it as an injury to the nervous system rather than low libido, she reported lasting genital numbness, loss of orgasm, and a loss of libido that came on suddenly, together with emotional blunting severe enough that, years later, she says she cannot feel love for her family and friends or pleasure in music. She said sexual side effects affect 50 to 70% of people taking SSRIs; that persistence after stopping is not on US labels; and that a 2018 citizen petition asking the FDA to add it went unanswered (the library has the petition as LIT-020, and its unresolved status in LIT-076). She also said that Eli Lilly knew of permanent sexual and emotional effects and withheld them, that sexual medicine specialists are finding genital fibrosis in people who took SSRIs, that PSSD may be reversible with intervention, and that some people with PSSD have died by suicide: these are her claims, not assessed here. She said her psychiatrist told her afterwards that he knew of PSSD but thought it rare and had not mentioned it, and she called for recognition of the condition, research funding, and written informed consent before psychiatric prescribing, pointing to efforts in Tennessee.\n\nTwo panelists described withdrawal. Danielle Gansky, 30, said she was medicated at 7 after a school-prompted ADHD evaluation and was on stimulants, antidepressants, benzodiazepines, mood stabilisers and antipsychotics before 10. At 23 her doctor tapered her SSRI over six weeks, following standard guidance; she described a severe neurological reaction that did not resolve when the drug was reinstated, years of disability, and a current hyperbolic taper in reductions of under 1% at a time. Cameron LaBarre, 35, said he has taken SSRIs for about 26 years, since a diagnosis of anxiety, OCD and Tourette's at 9 (paroxetine for two decades, later escitalopram). He said no one discussed an end point, that attempts to stop as a teenager and in college brought severe panic that was read as relapse, and that a video by the psychiatrist Mark Horowitz led him to see it as withdrawal; he has been tapering for three years and now attributes years of numbness and indifference to the drug. Nick Taber argued that psychiatric labels recast children's reactions to difficult family and school environments as brain disorders, citing a CDC estimate that about 21% of children have a psychiatric diagnosis.\n\nIn questions, a urologist in the audience said SSRIs had been promoted to urologists at low doses for premature ejaculation 15 to 20 years earlier, which he took as a sign their sexual effects were known. Asked what government should do, panelists called for boxed warnings on persistent sexual effects and withdrawal, federal evidence-based tapering guidance, written informed consent and research funding.", "key_points": [ "[00:00:08] Cooper Davis (Inner Compass Initiative) opens: the group argues for informed choice rather than against medication, says about 65 million Americans take a psychiatric drug, and that HHS agencies have consulted it; he frames patients' accounts as evidence.", "Rep. Glenn Grothman (R-WI): psychiatric drug use has doubled in 20 years; blames industry influence in Congress; has just chaired a House Oversight forum on the subject; expects to introduce legislation within five or six weeks.", "[00:07:51] Moderator Kim Witczak: her husband died by suicide five weeks after an antidepressant prescribed for insomnia, about 22 years ago; she campaigned for the boxed suicide warnings.", "Danielle Gansky: medicated from age 7 after a school-prompted ADHD evaluation; a six-week doctor-directed SSRI taper at 23 was followed by a severe, prolonged reaction that persisted after reinstatement; now on a hyperbolic taper after seven years of protracted withdrawal.", "Cameron LaBarre: about 26 years on SSRIs since age 9; earlier attempts to stop were treated as relapse; recognised withdrawal through Mark Horowitz's work; tapering for three years, now on about 7.5 mg escitalopram.", "Lauren Friedman (PSSD): onset after sertraline in 2022; genital numbness, anorgasmia, sudden loss of libido and emotional blunting persisting for years; persistence is not on US labels; the 2018 FDA citizen petition is unanswered (LIT-020, LIT-076).", "Lauren Friedman's further claims, not assessed here: that Eli Lilly knew of and withheld permanent effects; that specialists find genital fibrosis after SSRIs; that PSSD may be reversible with intervention (compare LIT-026, LIT-040); that people with PSSD have died by suicide.", "Nick Taber: psychiatric labelling of children (about 21% diagnosed, per a CDC estimate he cited) treats reactions to family and school environments as disorders.", "Q&A: a urologist says SSRIs were promoted for premature ejaculation 15 to 20 years ago; one panelist recalls being given clonazepam after a single panic attack; the panel's asks are boxed warnings, tapering guidance, written informed consent and research funding." ], "keywords": [ "PSSD", "post-SSRI sexual dysfunction", "genital anesthesia", "anorgasmia", "emotional blunting", "antidepressant withdrawal", "protracted withdrawal", "hyperbolic tapering", "sertraline", "paroxetine", "escitalopram", "informed consent", "boxed warning", "citizen petition", "FDA", "MAHA", "overmedicalization", "pediatric prescribing", "patient testimony", "C-SPAN" ], "relevance": "On-the-record patient testimony on PSSD and protracted antidepressant withdrawal at a US policy event with a member of Congress and the HHS-linked reform movement, broadcast by C-SPAN. Friedman's account describes the core PSSD picture in the diagnostic criteria (CROSS-002) and case series (CROSS-001): genital anaesthesia (compare LIT-026), anorgasmia, libido loss and emotional blunting persisting after the drug is stopped. Her description of a nervous system injury lines up with the library's small but growing peripheral-nerve evidence: corneal confocal microscopy suggesting small-fibre neuropathy (LIT-040, SIDE-002), abnormal genital sensory testing (LIT-033) and pudendal evoked potentials (DISC-013), and the TRP-channel hypothesis (LIT-026); the Queen Square series (CUR-003) argues instead for a central mechanism, having found normal large-fibre neurophysiology in 8 of 9 patients. The panel documents the policy demands (labelling, tapering guidance, informed consent) and the US regulatory gap the library records in LIT-020 and LIT-076. It is testimony: it shows how the condition is described and argued for in public, not how common it is or what causes it.", "claims_flagged": [ { "claim": "Sexual side effects affect 50-70% of SSRI users", "by": "Lauren Friedman", "library": "Reported rates vary widely by study and method; not checked against a specific record." }, { "claim": "A 2018 citizen petition asking the FDA to label persistent sexual dysfunction was ignored", "by": "Lauren Friedman", "library": "LIT-020 (the petition), LIT-076 (still undecided in 2026; a 2024 lawsuit over the delay was dismissed in 2025 on standing)." }, { "claim": "Eli Lilly knew Prozac could cause permanent sexual dysfunction and emotional numbness and withheld it", "by": "Lauren Friedman", "library": "No record in the library." }, { "claim": "PSSD is a nervous system injury, not low libido", "by": "Lauren Friedman", "library": "Small studies point to a peripheral-nerve component: corneal confocal microscopy showed peripheral neuropathy in 2 of 3 patients (LIT-040) and nerve damage suggestive of small-fibre neuropathy in Peters' case series (SIDE-002); abnormal quantitative sensory testing (LIT-033); abnormal pudendal evoked potentials in 4 of 16 PFS patients (DISC-013); TRP-channel hypothesis (LIT-026). Against: the Queen Square series found normal pelvic neurophysiology in 8 of 9 PSSD patients and proposes a central mechanism (CUR-003), though its tests don't assess small fibres. No controlled skin-biopsy study yet." }, { "claim": "PSSD may be reversible with intervention", "by": "Lauren Friedman", "library": "Partial improvements only, in single cases or tiny series: laser therapy (LIT-026), electrical stimulation plus shockwave therapy, with central symptoms unchanged (LIT-040)." }, { "claim": "Sexual medicine specialists are finding genital fibrosis after SSRIs", "by": "Lauren Friedman", "library": "No record in the library." }, { "claim": "SSRIs were promoted to urologists at low doses for premature ejaculation", "by": "an audience member (urologist)", "library": "CROSS-001 and LIT-026 mention SSRI use for premature ejaculation; promotion to urologists is not documented in the library." } ], "_source_file": "curator_additions" }, { "item_id": "CUR-002", "collection_tag": "curator-additions", "source_type": "peer-reviewed paper (narrative review)", "title": "Failing Public Health Again? Analytical Review of Depression and Suicidality From Finasteride", "authors": [ "Mayer Brezis" ], "journal_or_site": "The Journal of Clinical Psychiatry", "year_or_date": "2025-09-22", "volume": "86(4)", "pages": "25nr15862", "doi": "10.4088/JCP.25nr15862", "pmid": "41004169", "url": "https://doi.org/10.4088/JCP.25nr15862", "abstract_or_summary": "A narrative review by Mayer Brezis (Braun School of Public Health, Hadassah-Hebrew University) arguing that finasteride can cause depression, anxiety and suicidality, including after it is stopped, and analysing why recognition took two decades. Concerns appeared in studies from 2002; between 2017 and 2023, four analyses of adverse event reporting systems and four studies mining health records found a raised risk. Comparing the suicides reported to the FDA's adverse event system by 2024 (320) with the number he calculates would be expected over 30 years of use (19,320), the author argues for gross underreporting, and by an extrapolation he calls speculative estimates that over 20 years hundreds of thousands of users may have had depression and hundreds to thousands may have died by suicide. He attributes the delay to the manufacturer not running or publishing simple database pharmacovigilance studies and to regulators not requiring them, invokes the precautionary principle for a drug with a cosmetic indication, and concludes that regulators should require, and enforce, ongoing post-approval analytical studies.", "keywords": [ "finasteride", "depression", "suicidality", "post-finasteride syndrome", "pharmacovigilance", "FAERS", "underreporting", "drug regulation", "precautionary principle", "narrative review" ], "relevance": "A single argument that pulls the finasteride depression and suicidality signals together and makes the case that regulators were slow; eight of its references are already in the library (among them DISC-013, LIT-049, LIT-010 and PFS-003). It is an analytical narrative review, not new data, and its harm estimates are the author's own extrapolations. Read alongside the FDA's 2022 response to the PFS Foundation petition (LIT-072) and the EMA's 2025 finasteride review (LIT-065).", "note": "Interests, as declared: no funding; the author served as an expert witness at a trial over a suicide after finasteride for hair loss, which he says prompted the review. Correction (3 Oct 2026): in Table 1, the Lyakhovitsky study's odds ratio for depression was corrected to 1.44.", "curated_note": "News scout, 2026-10-10 (web search misdated it as October 2026 news; it was published 22 Sep 2025)", "_source_file": "curator_additions" }, { "item_id": "CUR-003", "collection_tag": "curator-additions", "source_type": "conference abstract", "title": "Genital sensory loss in persistent sexual dysfunction following SSRI exposure", "authors": [ "I Valnarov-Boulter", "A Noronha", "P Malladi", "S Simeoni", "S Wright", "J Panicker" ], "journal_or_site": "Continence (ICS 2026 Maastricht abstracts, no. 302)", "year_or_date": 2026, "volume": "19S", "pages": "102779", "doi": "10.1016/j.cont.2026.102779", "url": "https://doi.org/10.1016/j.cont.2026.102779", "study_type": "cross-sectional review of consecutive referrals (May 2019 to May 2024)", "sample_size": "55 referred with genital sensory impairment; 9 met PSSD criteria", "abstract_or_summary": "The uro-neurology unit at the National Hospital for Neurology and Neurosurgery, Queen Square, reviewed 55 consecutive patients referred with genital sensory impairment between 2019 and 2024; nine (mean age 35, eight men) met the published PSSD criteria (CROSS-002). All nine had abnormal sensory examination with von Frey hairs or a Neurotip, with loss greatest over the glans and the distal and mid shaft, symmetrical and more marked on the ventral surface. Rates of abnormal examination did not differ significantly from patients with other causes, but PSSD patients more often reported ejaculatory dysfunction (75% vs 20%) and sexual dysfunction (100% vs 65%). Pelvic neurophysiology (tibial, S2 and S3 dermatomal, and pudendal somatosensory evoked potentials) was normal in eight of the nine. The authors read this mismatch as excluding a significant large-fibre neuropathy or dorsal-column dysfunction, and propose that PSSD's genital sensory loss reflects a central disturbance in how erogenous sensation is processed (possibly lasting serotonergic dysregulation of reward circuits) rather than peripheral nerve damage. They suggest ejaculatory dysfunction as a clinical marker separating PSSD from other causes of genital numbness.", "keywords": [ "PSSD", "genital anesthesia", "genital sensory loss", "von Frey", "somatosensory evoked potentials", "pudendal", "pelvic neurophysiology", "ejaculatory dysfunction", "central mechanism", "Queen Square", "conference abstract" ], "relevance": "The first detailed neurological phenotyping of PSSD genital numbness, from a specialist uro-neurology unit. Its central interpretation stands against the peripheral-nerve reading of other small studies: the TRP-channel hypothesis (LIT-026), corneal confocal microscopy suggesting small-fibre neuropathy (LIT-040, SIDE-002), abnormal sensory testing (LIT-033) and pudendal evoked potentials (DISC-013). The two are not necessarily in conflict: the evoked-potential tests used here assess large fibres and central pathways, and small fibres were not tested. Nine patients, abstract only; replace with the full paper when it appears.", "note": "Conference abstract, not a full paper. Ethics: data from standard clinical care in a pelvic neurophysiology database reviewed by an institutional review board; no funding declared.", "curated_note": "User submission via Discord, 2026-10-10", "_source_file": "curator_additions" }, { "term": "Small fiber neuropathy (SFN)", "category": "clinical", "definition": "Nerve damage limited to the small nerve fibres (thinly myelinated A-delta and unmyelinated C fibres) that carry pain, temperature and some touch sensation and serve autonomic functions; it can cause numbness, burning or tingling. It is usually shown by skin biopsy, corneal confocal microscopy or thermal threshold testing; nerve conduction studies and somatosensory evoked potentials test large fibres and central pathways, so they can be normal in SFN. In the post-drug syndromes it is proposed as one explanation for genital numbness, and the corpus's evidence is small and mixed: corneal microscopy findings in tiny mixed series (LIT-040, SIDE-002), thermal sensory testing in PSSD (LIT-033), and normal large-fibre tests at Queen Square, where small fibres were not tested (CUR-003). The corpus holds no skin-biopsy study in these syndromes.", "used_in": [ "LIT-040", "SIDE-002", "LIT-033", "CUR-003", "DISC-013" ], "related_terms": [ "Pudendal neuropathy", "Genital anesthesia" ], "_source_file": "glossary", "collection_tag": "core", "source_note": "Added in v1.17 from the curator's glossary (2026-10-11)." } ] }